PCT -  World Patents in Skin Care Actives Published from 1990 to 2006

Thank you for visiting FormulaScan . Please click on the WO Patent No to study the full patent document

WORLD PATENTS IN SKIN CARE ACTIVES PUBLISHED FROM 1990 TO 2006


GEL COMPOSITIONS FOR TOPICAL ADMINISTRATION

(WO2006138735) 28.12.2006 A61K 9/06 WARNER CHILCOTT COMPANY, INC.
Pharmaceutical gel compositions containing pharmacologically active agent for topical administration, as well as a method of making the same, are disclosed.
---------------------------------- ----------------------------------------------

PHARMACEUTICAL COMPOSITION COMPRISING A MAHONIA AQUIFOLIUM EXTRACT FOR THE TREATMENT OF PSORIASIS

(WO2006138056) 28.12.2006 A61P 17/00 APOLLO PHARMACEUTICAL, INC.
Pharmaceutical compositions for the treatment of skin disorders such as psoriasis, acne and eczema, methods of making the compositions and methods of use thereof are described herein. The composition comprises psorberine, an alcohol-water extract isolated from the Mahonia aquifolium plant, and one or more additional active agents. In a preferred embodiment, the one or more active agents is a vitamin D3 analog, such as calcipotriol. The compositions may also contain excipients such as emollients, surfactants, emulsiflers and buffers. The compositions are formulated into a cream, lotion or ointment for topical administration.
---------- ----------------------------------------------------------------------

IMMUNE DISEASE MEDICAMENT COMPRISING A MODULATOR OF THE BINDING BETWEEN A HEPARIN BINDING DOMAIN OF THROMBOSPONDIN-1 AND A BETA1 INTEGRIN

(WO2006137060) 28.12.2006 A61K 38/39 HADASIT MEDICAL RESEARCH SERVICES AND DEVELOPMENT LTD.
An article of manufacture comprising packaging material and a pharmaceutical composition is disclosed, the article of manufacture being identified in print in or on the packaging material for treatment of an immunity-related disease in a subject in need thereof. The pharmaceutical composition comprises a pharmaceutically acceptable carrier and, as an active ingredient, a compound being capable of modulating an interaction between a heparin-binding domain of a thrombospondin and a receptor of the heparin-binding domain.
---------------------------------- ----------------------------------------------

LOW-RESIDUE DEODORANT OR ANTIPERSPIRANT STICK BASED ON AN ETHANOL-CONTAINING OIL-IN-WATER DISPERSION/EMULSION

(WO2006136330) 28.12.2006 A61Q 15/00 HENKEL KOMMANDITGESELLSCHAFT AUF AKTIEN
The invention relates to deodorant or antiperspirant sticks based on an ethanol- containing oil-in-water dispersion/emulsion for application on the skin. The composition acts as a suitable carrier for active ingrediends, and permits the rapid release of the active agent on the skin, leaving behind as little sticky or visible residue as possible.
---------------------------------- ----------------------------------------------

NOVEL USE 25- HYDROXYCHOLECALCIFEROL IN COMBINATION WITH UV-B SCREENING AGENTS

(WO2006133828) 21.12.2006 A61Q 19/00 DSM IP ASSETS B.V.
The present invention relates to the use of 25-hydroxycholecalcif erol as an active ingredient in the manufacture of topical compositions which contain a UV-B screening agent for the prevention of vitamin D deficiencies caused by the topical application of such UV-B screening agents, and for increased skin regeneration and cosmetic treatment of skin damages caused by environmentally-induced noxious impact.
---------------------------------- ----------------------------------------------

WATER-BASED ANTIPERSPIRANT AND AEROSOL DISPENSER THEREFOR

(WO2006133725) 21.12.2006 A45D 34/00 SARA LEE
The present invention relates to an antiperspirant system comprising a water-based antiperspirant which feels comfortable on the skin and a capillary aerosol dispenser therefore. An antiperspirant system of the present invention comprises: a pressurized container (51) in which a water-based antiperspirant composition comprising one or more astringent active salt, and a propellant are present, a valved outlet (41) on the surface of the container through which antiperspirant is ejected into an inlet port (111) of a capillary tube (11), a capillary tube (11) having one inlet port (111) and one exit port through which antiperspirant is dispensed from the system, and a coupling means (12) to closely couple the inlet port of the capillary tube (1...
---------- ----------------------------------------------------------------------

TOPICAL OLIGOPEPTIDE DELIVERY SYSTEM

(WO2006132867) 14.12.2006 A61K 38/08 ELC MANAGEMENT LLC
The invention relates to a delivery system for biologically active oligopeptides. The delivery system comprises an electrochemical cell and a skin-beneficial amount of one or more oligopeptides. In a preferred embodiment the electrochemical cell and the peptide are contained in a dermal patch. The invention also relates to a topically acceptable hydrogel that comprises a hydrophilic polymer, an aqueous or aqueous alcoholic carrier, at least one skin-beneficial oligopeptide, and a salt, wherein at least a portion of the carrier is a structured water.
------------------------------------------ --------------------------------------

VITAMIN FORMULATION

(WO2006129161) 07.12.2006 A61P 17/06 CONNETICS AUSTRALIA PTY LTD.
A pharmaceutical aerosol foam composition, comprising an effective amount of a pharmaceutically active ingredient, wherein said pharmaceutically active ingredient is a vitamin or analogue thereof; an occlusive agent; an aqueous solvent; an organic co-solvent; wherein the pharmaceutically active ingredient is insoluble in both water and the occlusive agent; and the occlusive agent being present in an amount sufficient to form an occlusive layer on the skin, in use. The pharmaceutically active ingredient can be selected from vitamin D3 and vitamin A and/or their analogues such as calcipotriene, tretinoin, acitretin, etc. In a second embodiment, an oil-in-water emulsion having a vitamin; an occlusive agent; an aqueous solvent; and an organic c...
------------------------------------------------------------------ --------------

METHOD AND COMPOSITION FOR TRANSDERMAL DRUG DELIVERY

(WO2006128255) 07.12.2006 A61K 31/568 ACRUX DDS PTY LTD
The invention is a transdermal drug delivery composition of at least one physiologically active agent (e.g. buspirone or fentanyl or androgens such as testosterone), at least one volatile solvent (e.g. isopropanol or ethanol), and at least one viscosity modulating agent (e.g. PVP), preferably with a penetration enhancer (such as octisalate), which is preferably applied to the axilla.
-- ------------------------------------------------------------------------------

LIGUSTILIDE DERIVATIVES FOR THE TREATMENT OF INFLAMMATORY DISORDERS

(WO2006125651) 30.11.2006 A61P 19/06 DSM IP ASSETS B.V.
The present invention relates to the use of compounds of the formula (I) wherein the clotted line is an optional bond; R1 is butyl or butyryl if R2 is hydroxyl but is butyl if R2 is hydrogen; or R1 and R2 taken together are 1-butylidene optionally substituted by hydroxyl, methyl, or 3- (?,?-dimethylacrylyloxy)-pentylidenyl; X is a residue selected from the group consisting of X1 , X2, X3, X4, and X5; wherein X is X2, X3or X5 if the dotted line in formula (I) is absent ;and X is X1 , X4 or X5 if the dotted line signifies a bond in formula (I) above; R3 is hydroxyl or butyryl; and n is 1 or 2, as agents for the prevention, control and treatment of conditions requiring modulation of inflammation in mammals. In another aspect, the prese...
-- ------------------------------------------------------------------------------

A PHARMACEUTICAL PRODUCT COMPRISING A CONTAINER

(WO2006125442) 30.11.2006 A61M 35/00 LEO PHARMA A/S
A pharmaceutical product (100) comprises a container (102; 104) with a high-viscosity liquid pharmaceutical composition (122) comprising a therapeutically active agent contained therein, e.g. for the treatment of a dermatological disorder, such as psoriasis on the human scalp. The container has a tapered dispensing section (108) having a length of at least 25 mm. A lid (104) is provided for protecting the dispensing section, the lid defining a liquid tight seal when engaging a tip (110) of the dispensing section. An inner bottom portion of the container is curved for facilitating emptying of the container. The liquid may comprise at least 75% oil, and the container may be made essentially from high-density polyethylene to reduce penetration...
------------------ --------------------------------------------------------------

REGULATION OF MAMMALIAN KERATINOUS TISSUE USING PERSONAL CARE COMPOSITIONS COMPRISING CETYL PYRIDINIUM CHLORIDE

(WO2006124990) 23.11.2006 A61K 8/37 THE PROCTER &GAMBLE COMPANY
Personal care composition including a first skin and/or hair care active cetyl pyridinium chloride; and at least one additional skin and/or hair care active selected from the group consisting of tetrahydrocurcumin, sugar amine, vitamin B3, retinoids, hydroquinone, peptides, phytosterol, dialkanoyl hydroxyproline, hexamidine, salicylic acid, n-acyl amino acid compounds, sunscreen actives, water soluble vitamins, oil soluble vitamins, hesperedin, mustard seed extract, glycyrrhizic acid, glycyrrhetinic acid, carnosine, Butylated Hydroxytoluene (BHT) and Butylated Hydroxyanisole (BHA), ergothioneine, vanillin or its derivatives, diethylhexyl syrinylidene malonate, melanostatine, sterol esters, idebenone, dehydroacetic acid, Licohalcone A, creat...
------------------------------------------------------------------ --------------

LOW DOSE ADMINISTRATION OF A TOPICAL COMPOSITION

(WO2006124275) 23.11.2006 A61K 31/573 MACROCHEM CORPORATION
Unexpectedly, the therapeutically required amount of active ingredient in a topical drug delivery product may be significantly reduced by applying the product in a delivery vehicle containing a SEPA® penetration enhancer to the upper arms and shoulders of an individual in need of the active ingredient rather than to the abdomen of the individual.
-------------------------------------------------- ------------------------------

GELATIN-CONTAINING TOPICAL COMPOSITION

(WO2006123173) 23.11.2006 A61K 8/73 KILDA BIOLINK AS
This invention provides a topical pharmaceutical or cosmetic composition comprising a pharmaceutically or cosmetically active agent and a gelling agent, characterized in that said gelling agent comprises a fish gelatin and a polysaccharide.
-- ------------------------------------------------------------------------------

SEQUENCE ENABLED REASSEMBLY (SEER) - A NOVEL METHOD FOR VISUALIZING SPECIFIC DNA SEQUENCES

(WO2006121866) 16.11.2006 C12Q 1/68 THE ARIZONA BOARD OF REGENTS ON BEHALF OF THE UNIVERSITY OF ARIZONA
The present invention provides a nucleotide sequence detection system in which a reporter enzyme is split into two halves each half of which is associated with at least one zinc finger domain. Upon DNA binding to the specific sequence defined by the zinc finger domains associated with the respective halves, the split-protein reassembles to reconstitute a functional enzyme. As such, the present invention provides methods of using the nucleotide sequence detection system for various diagnostic and identification purposes.
-------------------------------------------------- ------------------------------

SKIN CARE COMPOSITIONS CONTAINING IDEBENONE

(WO2006121717) 16.11.2006 A61Q 19/00 THE PROCTER &GAMBLE COMPANY
A stable skin care composition, comprising an effective amount of idebenone, at least one additional skin care active, and a dermatologically acceptable carrier. The composition is substantially colorless.
---------------------------------- ----------------------------------------------

TOPICAL USE OF TEPRENONE

(WO2006120646) 16.11.2006 A61K 8/35 SEDERMA
Topical use of teprenone in a cosmetic or dermopharmaceutical composition as an active preventing and/or limiting the skin cells sénescence and /or protecting the general state of the skin.
------------------------------------------------------------------ --------------

SUNLESS TANNING COMPOSITION AND METHODS FOR USING

(WO2006118638) 09.11.2006 A61Q 19/04 SKINVISIBLE PHARMACEUTICALS, INC.
A sunless tanning composition is provided according to the invention. The sunless tanning composition includes an effective amount of a tanning active component to provide a darkening effect of skin tissue after exposure to the skin tissue, a polymer component, water, an effective amount of an acidifying agent to provide the composition with a pH of less than about 5, and wherein the composition has the viscosity of at least about 3,000 cSt. The polymer component can be characterized as a skin bonding polymer component to hold the tanning active component in exposure to the skin tissue when applied to the skin tissue. The polymer component can be characterized as a polymer having an average molecular weight of about 2,000 to about 500,000. ...
------------------ --------------------------------------------------------------

HYDROXAMIC ACID DERIVATIVES AND THE PREPARATION METHOD THEREOF

(WO2006118380) 09.11.2006 C07C 239/18 AMOREPACIFIC CORPORATION
The present invention provides hydroxamic acid derivatives represented by the formula (I), having antioxidation, collagen biosynthesis promotion and skin pore contraction effects, and a method for preparation thereof. Further, the present invention provides skin-care external compositions for preventing skin aging, containing said hydroxamic acid derivatives represented by the formula (I) as an active ingredient.
------------------ --------------------------------------------------------------

COSMECEUTICAL COMPOSITION

(WO2006117132) 09.11.2006 A61K 8/34 NOVARTIS AG
Topical compositions comprising: - a physiologically acceptable alkanediol, ether diol or diether alcohol containing up to (8) carbon atoms; - water; and - optionally an unsaturated fatty alcohol; and optionally further conventional excipients, for use as a cosmeceutical, in particular for use in the repair or maintenance of skin barrier function. They are indicated for use in e.g. moisturizing skin, nail and mucosa and, when an optional pharmaceutically active agent is present, additionally in the treatment of various skin, nail and mucosal diseases. Also disclosed are compositions suitable for topical application to infants and babies for treating dry skin, and soothing skin irritated from diaper rash and scrapes.
---------------------------------------------------------- ----------------------

COMPOSITION AND METHOD FOR REDUCING THE APPEARANCE FOR CELLULITE

(WO2006116486) 02.11.2006 A61K 6/00 P.A. HOLDINGS LLC
A topical composition for controlling the metabolism and/or distribution of subcutaneous fat and/or moderating the appearance of cellulite, comprising, as an active ingredient, phosphatidylcholine together with a solvent operative to maintain the phosphatidylcholine in solution, and a buffer which maintains the composition in the range of pH 7.5-9.0. Typically, the composition includes less than 10% by weight water. The composition may include further active ingredients such as xanthines. Also disclosed are methods for using the composition.
-- ------------------------------------------------------------------------------

POLYURETHANE FOAMS COMPRISING OLIGOMERIC POLYOLS

(WO2006116456) 02.11.2006 C08G 18/36 CARGILL, INCORPORATED
The invention relates to polyurethane foams comprising oligomeric polyols. In embodiments of the invention, the polyurethane foams comprise the reaction product of: (a) a polyisocyanate; and (b) an active- hydrogen containing composition comprising an oligomeric polyol having a hydroxyl number of about 45 to about 65 mg KOH/g, a number average hydroxyl functionality (Fn) of less than about 2.7, and about 40% weight or greater oligomers. The polyurethane foams of the invention may be slabstock foams or molded foams. Also disclosed are low odor polyols and polyurethane compositions.
---------- ----------------------------------------------------------------------

MICROBIAL CELLULOSE MATERIALS FOR USE IN TRANSDERMAL DRUG DELIVERY SYSTEM

(WO2006113796) 26.10.2006 A61L 15/16 XYLOS CORPORATION
A method for transdermally delivering a biologically active agent to a subject in need thereof, comprising topically applying a composition comprising insoluble microbial cellulose, water, and a therapeutically effective amount of the biologically active agent, wherein the biologically active agent penetrates through the subject's stratum corneum at a substantially constant rate.
-------------------------- ------------------------------------------------------

COMPOSITIONS FOR TREATING ALOPECIA OR PROMOTING HAIR GROWTH

(WO2006112619) 26.10.2006 A61K 8/98 MEDIGENES CO., LTD.
The present invention relats to a composition for treating alopecia or promoting hair growth, which contains the blood plasma or serum as an active ingredient. The inventive composition is effective in hair growth, hair growth promotion and hair loss prevention.
-- ------------------------------------------------------------------------------

A PHARMACEUTICAL COMPOSITION FOR THE TREATMENT OF ATOPIC DERMATITIS CONTAINING 4-HYDROXY-5-METHOXY-4-[2-METHYL-3-(3-METHYL-2-BUTENYL)-2-OXIRANYL]-1- OXASPIRO [2,5]OCTAN-6-ONE

(WO2006107184) 12.10.2006 A61K 31/336 MYCOPLUS CO., LTD.
The present invention relates to a pharmaceutical composition comprising the compound, 4 -hydroxy- 5 -met hoxy- 4- [2-methyl-3- (3-methyl-2- butenyl) -2-oxiranyl] -1- oxaspiro [2, 5] octan-6-one, as an active ingredient with a pharmaceutically effective amount for preventing and treating atopic dermatitis, which is caused by a complicated correlation between genetic, environmental and immune factors .
---------------------------------------------------------- ----------------------

METHOD FOR IMPROVING SENSORY CHARACTERISTICS OF SEMISOLID PREDOMINANTLY ANHYDROUS LIPIDS

(WO2006106398) 12.10.2006 A61K 8/81 SUESS, Hans, R.
A composition comprises amphiphobic halocarbon particles, and amphiphilic lipids having at least 2 hydroxyl groups. Tliis composition maybe used in methods of decreasing oiliness, greasiness, stickiness and tackiness of anhydrous semisolid lipids, methods of delivering pharmaceutical active ingredients, methods of preventing or treating sunburn or ultraviolet radiation, methods of preventing or treating skin disorders and methods of delivering cosmetics.
-------------------------------------------------- ------------------------------

DELAYING SKIN AGEING AND DISORDERS CAUSED BY SKIN AGEING BY SUPPRESSION OF ANGIOTENSIN II PRODUCTION OR ACTIVITY

(WO2006105805) 12.10.2006 A61K 8 49 SABOVIC, Miso
The present invention relates to the field of ageing of the skin, particularly to the prevention and/or treatment of skin ageing and disorders caused by skin -ageing. The use of a topical applicable composition is envisaged, which comprises three or more active ingredients to reduce or suppress skin ageing and disorders associated with ageing and their symptoms, such as wrinkles.
-------------------------------------------------- ------------------------------

BUCCAL DELIVERY SYSTEM

(WO2006105615) 12.10.2006 A61K 9/20 OZPHARMA PTY LTD
A buccal delivery system capable of being blended in a normal dry powder process and compressed using a standard tabletting machine, said buccal delivery system comprising a matrix of: (a) an effective amount of one or more active ingredients; (b) an amount of one or more polyethylene glycols or derivatives thereof having a molecular weight between 1000 to 8000 sufficient to provide the required hardness and time for dissolution of the matrix; (c) 0.05-2% by weight of the total matrix of one or more suspending agents; (d) 0.05-2% by weight of the total matrix of one or more flowing agents; and (e) 0.05-2% by weight of the total matrix of one or more sweeteners.
---------- ----------------------------------------------------------------------

USE OF COMPOUNDS INDUCING THE SYNTHESIS OF SIRT PROTEINS IN OR FOR THE PREPARATION OF A COSMETIC OR PHARMACEUTICAL COMPOSITION

(WO2006103110) 05.10.2006 A61K 38/08 SOCIETE D'EXTRACTION DES PRINCIPES ACTIFS SA (VINCIENCE)
The present invention concerns a cosmetic, or dermo-pharmaceutical, or dermatological composition comprising, as an active agent in an acceptable cosmetic or pharmaceutical medium, at least one compound able to activate the synthesis of SIRT proteins in skin cells. The present invention also relates to the use of said composition.
---------------------------------------------------------- ----------------------

TOPICAL FORMULATIONS OF BORINIC ACID ANTIBODIES AND THEIR METHODS OF USE

(WO2006102604) 28.09.2006 A61K 31/69 ANACOR PHARMACEUTICALS, INC.
Disclosed are topical formulations, for example, creams, gels, or lotions, of borinic acid antibiotic compounds active against acne vulgaris or secondarily infected skin conditions.
-------------------------- ------------------------------------------------------

PHARMACEUTICALLY ACTIVE LIPID-BASED FORMULATION OF NUCLEOSIDE-LIPID CONJUGATES

(WO2006102533) 28.09.2006 A61K 31/7072 NEOPHARM, INC.
Novel formulations of nucleoside- lipid conjugates, the methods of preparing them and the methods for administering them are provided. More particularly, methods for making liposomal formulations of nucleoside-cardiolipin and analogues thereof are provided. By encapsulating nucleoside prodrugs, drugs are protected from degradation, thereby extending the drugs' plasma half-life and intracellular release. In addition, compositions that demonstrate greater efficacy and higher cytotoxicity are produced. Accordingly, nucleoside-lipid conjugates that demonstrate greater in-vitro and in-vivo activity are produced.
---------------------------------------------------------- ----------------------

NEW NEURONAL PAIN PATHWAY

(WO2006102267) 28.09.2006 A61K 38/10 THE TRUSTEES OF COLUMBIA UNIVERSITY IN THE CITY OF NEW YORK
The present invention relates to the discovery of a novel molecular pathway involved in long-term hyperexcitability of sensory neurons, which, in higher animals, is associated with persistent pain. It is based on the discovery that, following injury to an axon of a neuron, an increase in nitric oxide synthase activity results in increased nitric oxide production, which, in turn, activates guanylyl cyclase, thereby increasing levels of cGMP. Increased cGMP results in activation of protein kinase G ('PKG'), which then is retrogradely transported along the axon to the neuron cell body, where it phosphorylates MAPKerk.
------------------ --------------------------------------------------------------

METHODS AND COMPOSITIONS FOR PREVENTING AND TREATING AGING OR PHOTODAMAGED SKIN

(WO2006101855) 28.09.2006 A61Q 19/08 PROCYTE CORPORATION
Disclosed are methods for treating aging and photodamaged skin employing topical application of compositions which comprise at least one peptide manganese complex. Also disclosed are methods wherein the composition further comprises retinol, at least one retinol derivative, or a mixture thereof and methods wherein the composition further comprises active agents selected from active drug substances, emollients, sunscreen agents, skin lightening agents, skin protectants, skin conditioning agents, humectants, and mixtures thereof.
------------------------------------------------------------------ --------------

RECOMBINANT ANTIBODIES AGAINST HUMAN TYPE II TRANSGLUTAMINASE AND USES THEREOF

(WO2006100679) 28.09.2006 A61K 39/395 QUARK PHARMACEUTICALS, INC.
The present invention provides specific antibodies that are able to inhibit TGase II enzymatic activity. The present invention further provides a pharmaceutical composition comprising as an active ingredient the antibody of the invention useful in treating or preventing fibrosis diseases, scarring, or fibrosis-related pathologies. The pharmaceutical composition may be useful for treating both acute and chronic forms of fibrosis of organs.
-- ------------------------------------------------------------------------------

A TRANSDERMAL TOPICAL COMPOSITION AND ITS USES

(WO2006100489) 28.09.2006 A61K 9/70 TRANSPHASE LIMITED
At least one silicone is used to modify the release profile of the active compound(s) in a therapeutic composition for topical application the skin that also comprises at least one penetration enhancer and a fugitive solvent base.
-------------------------------------------------- ------------------------------

TRANSDERMAL THERAPEUTIC SYSTEM

(WO2006099946) 28.09.2006 A61K 31/48 NEUROBIOTEC GMBH
The invention concerns a transdermal therapeutic system containing ergoline derivatives, preferably lisuride, with a stabilized ergoline compound. Stabilization of the oxidation sensitive ergoline combination is done through a combination of at least one fat- soluble, radical-trapping antioxidant, preferably Di-tert.-butylmethylphenols, Ditert.-butylmetoxyphenols, tocopherols or ubichinones and a basic polymer. Use of a transdermal therapeutic system (TTS) comprising a pharmaceutical layer containing at least one matrix having an active ingredient and/or an active ingredient reservoir; a diffusion barrier that is permeable to said active ingredient and arranged on the skin side of the active ingredient reservoir; and an ergoline derivative o...
---------------------------------------------------------- ----------------------

BENZOYL PEROXIDE COMPOSITIONS AND METHODS OF USE

(WO2006099187) 21.09.2006 A61K 8/35 JR CHEM, LLC
Solutions of benzoyl peroxide, in one or more solvents are provided that are suitable for direct topical application to the skin of a user or can be formulated into a product that is suitable for topical application to the skin of a user. In embodiments, the solutions include benzoyl peroxide and optionally additional active or inactive ingredients, and a solvent or mixture of solvents in which the benzoyl peroxide is prepared as a clear solution at 25° C. Methods of using the solutions are also described. Product formulations such as emulsion are also described. The solutions and product formulations can increase the efficacy and percutaneous absorption of benzoyl peroxide.
---------------------------------------------------------- ----------------------

THE USE OF A HYDROPHOBIC ZEOLITE, THAT CONTAINS AND GIVES A SLOW RELEASE OF AN ACTIVE ELEMENT, FOR TREATMENT OF SKIN

(WO2006098680) 21.09.2006 B01J 20/18 BENJAMINSON, Håkan
The invention describes the use of a hydrophobic zeolite, that contains an active component, especially a disinfection element, as ethanol, iodine, phenol, cresol or hydrogen peroxide, in a composition for non-medical treatment of the skin, for example as a deodorant. The invention also describes the use of a hydrophobic zeolite, that contains an active component, especially a disinfection element, as ethanol, iodine, phenol, cresol or hydrogen peroxide, for manufacturing of a pharmaceutical preparation for treatment of skin related conditions and diseases, as skin infections. The hydrophobic zeolite is especially selected from that group that comprises silicalite, or hydrophobic ZMS- 5, hydrophobic mordenite and hydrophobic zeolite Y.
-------------------------- ------------------------------------------------------

LIGHT PHARMACEUTICAL WATER AND THERAPEUTIC COMPOSITIONS AND METHODS THEREOF

(WO2006098650) 21.09.2006 A61K 35/02 POMYTKIN, Igor Anatolievich
This invention relates to pharmaceutical water, which comprises from 99.760 to 99.999% of light isotopologue 1H2160 and up to 100% of residual isotopologues 1H2 170, 1H2180, 1H2H160, 1H2H170, 1H2H180,2H2 160,2H2 170, and 2H2180, for the production of finished product, intermediate reagent preparation, and analytical processes in pharmaceutical industry. Further, the invention relates to pharmaceutical compositions comprising a biologically active agent and said pharmaceutical water, wherein said agent is selected from the group consisting of drugs, physiologically active peptides, physiologically active proteins, and nucleic acids. Further, the invention relates to method of administering a biologically active agent to a mammal in need ther...
------------------------------------------------------------------ --------------

HAIR AND/OR EYELASH CARE COMPOSITION CONTAINING AMINEXIL IN COMBINATION WITH AN AGENT FOR PROMOTING THE NO PRODUCTION AND USES THEREOF

(WO2006097359) 21.09.2006 A61K 8/49 L'ORÉAL
The invention relates to a topical composition for caring for and/or for making up human keratin fibres, in a physiologically acceptable medium the combination of aminexil with at least one agent for promoting the NO production. This composition makes it possible to induce and/or stimulate the growth of keratin fibres such as the hair and eyelashes and/or to stop the loss thereof and/or to increase the density thereof.
------------------------------------------------------------------ --------------

VEHICLE FOR TOPICAL DELIVERY OF ANTI-INFLAMMATORY COMPOUNDS

(WO2006096955) 21.09.2006 A61K 31/192 ALPHARX INC.
The present invention relates to a vehicle for topical delivery of a pharmaceutically active ingredient such as anti-inflammatory drugs, comprising a liquid eutectic mixture containing a hydrophobic component. The eutectic mixture comprises, for example, compounds selected from camphor, menthol, thymol, resorcinol, phenol or substituted phenol derivatives. The invention also relates to a method for increasing the solubility of said pharmaceutically active ingredient.
------------------ --------------------------------------------------------------

TOPICAL GELS COMPOSITIONS

(WO2006096360) 14.09.2006 A61K 31/192 ISW GROUP, INC.
Topical alcoholic gel compositions are disclosed that are useful for delivering therapeutic levels of an NSAID to target in and below the skin. The compositions comprise a topically active drug, an alcoholic solvent, a polymeric thickener, and optionally a keratolytic agent. In one embodiment, excellent viscosity for dermal application is attained without the need of a step for neutralizing the pH of the composition. Alcoholic and alcohol-free topical compositions comprising an NSAID prodrug are also disclosed. The compositions are particularly useful for the treatment of pseudo folliculitis barbae.
---------------------------------- ----------------------------------------------

A METHOD OF PREPARING A PORPHYRIN DERIVATIVE, A PORPHYRIN DERIVATIVE, USE OF SAID PORPHYRIN

(WO2006096053) 14.09.2006 C07D 471/22 PHOTOBIOCHEM N.V.
The present invention relates to a method of preparing a porphyrin derivative from a meso-acrylonitrile-substituted porphyrin compound. According to the invention a Vilsmeier reagent carrying an aromatic ring is used, wherein said Vilsmeier reagent is a soft elec- trophile. The use of this Vilsmeier reagent results in a porphyrin derivative having the ring system of the Vilsmeier reagent condensed to its porphyrin macrocycle via two new 6 membered rings. Thus a new class of porphyrin derivatives is provided, wherein said derivatives are photodynamically more active than the starting compound. The invention also relates to a porphyrin derivative, use of said porphyrin derivative and a pharmaceutical composition containing said porphyrin deri...
---------- ----------------------------------------------------------------------

COMPOSITIONS AND METHODS ENHANCING TRANSDERMAL DELIVERY OF DRUGS AND BIOLOGICS

(WO2006091719) 31.08.2006 A61K 9/70 SONTRA MEDICAL CORPORATION
Improved methods for transdermal transport of drug formulations are described herein. Formulations designed to enhance transport of therapeutic levels of topically applied drugs into the systemic circulation, methods of making the formulations are also described herein. The formulations contain at least one active agent to be delivered and at least one skin permeation enhancer in a polymeric hydrogel, and optional additional excipients. Methods for enhancing transport of formulations into and through the skin include: (a) pretreatment of the skin with a hydrating solution, (b) physical permeation of the stratum corneum by low frequency ultrasound (administered by a sono-permeation device, such as SONOPREP®, available from Sontra Medical...
---------------------------------- ----------------------------------------------

BENZO[2,3]AZEPINO [4,5-B]INDOL-6-ONES

(WO2006089874) 31.08.2006 C07D 487/04 GPC BIOTECH AG
The present invention relates to benzo[2,3]azepino[4,5-b]indol-6-ones of the general formula (I): and pharmaceutically acceptable salts thereof, the use of these compounds as pharmaceutically active agents, especially for the prophylaxis and/or treatment of infectious diseases, including opportunistic diseases, prion diseases, immunological diseases, autoimmune diseases, bipolar and clinical disorders, cardiovascular diseases, cell proliferative diseases, diabetes, inflammation, transplant rejections, erectile dysfunction, neurodegenerative diseases and stroke. Furthermore, the present invention is directed towards pharmaceutical composition containing at least one of the benzo[2,3]azepino[4,5-b]indol-6-ones and/or pharmaceutically acceptab...
------------------------------------------ --------------------------------------

APPARATUS AND METHOD FOR TRANSDERMAL DELIVERY OF ERYTHROPOETIN-BASED AGENTS

(WO2006089056) 24.08.2006 A61K 9/28 ALZA CORPORATION
An apparatus and method for transdermally delivering a biologically active agent comprising a delivery system having a microprojection member (or system) that includes a plurality of microprojections (or array thereof) that are adapted to pierce through the stratum corneum into the underlying epidermis layer, or epidermis and dermis layers. In one embodiment, an Epoetin-based agent is contained in a biocompatible coating that is applied to the microprojection member. In a further embodiment, the delivery system includes a gel pack having an Epoetin-based agent-containing hydrogel formulation that is disposed on the microprojection member after application to the skin of a patient. In an alternative embodiment, the Epoetin-based agent is con...
------------------ --------------------------------------------------------------

GRANULYSIN PEPTIDES AND METHODS OF USE THEREOF

(WO2006088945) 24.08.2006 A61K 6/00 THE REGENTS OF THE UNIVERSITY OF CALIFORNIA
Granulysin peptides are small antimicrobial agents with potent activity. A pharmaceutical composition comprising granulysin peptides as an active agent is administered therapeutically to a patient for exfoliation, e.g. for the treatment of skin lesions.
-- ------------------------------------------------------------------------------

NATURAL SUNLIGHT PHOTOSTABLE COMPOSITION

(WO2006086354) 17.08.2006 A61K 8/00 TANNING RESEARCH LABORATORIES, INC.
The present invention relates to photostable compositions that provide protection from ultraviolet radiation ('UVR'). The invention particularly relates to the sunscreens avobenzbne, octocrylene and oxybenzone, forming a triplet combination. Compositions of the present invention are free of diesters or polyesters of naphthalene dicarboxylic acid and also are substantially free of substantial amounts of other sunscreens and substantial amounts of optimizing agents. Sunscreens of the invention may be essentially free of, or free of, lower monohydric alcohol and/or acrylates/C12-22 alkylmethacrylate copolymer in an effective non-pilling amount used to gel a C1-C4 alcohol. The triplet combination surprisingly provides and substantially maintain...
------------------------------------------------------------------ --------------

METHODS AND RELATED COMPOSITIONS FOR REDUCTION OF FAT AND SKIN TIGHTENING

(WO2006086038) 17.08.2006 A61K 9/00 LOS ANGELES BIOMEDICAL RESEARCH INSTITUTE AT HARBOR-UCLA MEDICAL CENTER
Compositions and methods useful in the reduction of localized fat deposits and tightening of loose skin in subjects in need thereof using pharmacologically active detergents are disclosed. The pharmacologically active detergent compositions can additionally include anti-inflammatory agents, analgesics, dispersion or anti-dispersion agents and pharmaceutically acceptable excipients. The pharmacologically active detergent compositions are useful for treating localized accumulations of fat including, for example, lower eyelid fat herniation, lipodystrophy and fat deposits associated with cellulite and do not require surgical procedures such as liposuction.
-- ------------------------------------------------------------------------------

STABILIZED COMPOSITIONS FOR TOPICAL ADMINISTRATION AND METHODS OF MAKING SAME

(WO2006084353) 17.08.2006 A61K 38/39 DPM THERAPEUTICS CORP.
A stabilizing composition that also enhances permeation is provided for the topical or transdermal administration of an active ingredient. The composition preferably comprises collagen, elastin, sphingoside and cerebroside. Also provided are pharmaceutical or cosmetic formulations comprising an effective amount of an active agent and the stabilizing composition as well as methods of administering active agents topically or transdermally.
------------------------------------------ --------------------------------------

COMPOSITION FOR PREVENTION, TREATMENT, AND DIAGNOSIS OF CHRONIC OBSTRUCTIVE PULMONARY DISEASE (COPD)

(WO2006083126) 10.08.2006 G01N 33/53 JEON, Sook-yeong
The present invention provides a pharmaceutical composition for preventing or treating chronic obstructive pulmonary disease (COPD) comprising cytokeratin 18 protein as an active ingredient. The present invention also provides a diagnostic composition and a diagnostic kit for diagnosing COPD comprising cytokeratin 18 protein. The present invention further provides a composition for screening a therapeutic agent for COPD, comprising one or more of cytokeratin 18 protein or autoantibodies to cytokeratin 18 obtained from patients with COPD and a method for screening a therapeutic agent for COPD using this composition. The present invention still further provides methods for diagnosing, preventing or treating COPD using cytokeratin 18 protein.
-- ------------------------------------------------------------------------------

HYDROPHILIC BEADS FOR USE IN TOPICAL FORMULATIONS

(WO2006081313) 03.08.2006 A61K 9/14 INTERNATIONAL FLORA TECHNOLOGIES, LTD
A composition and method for producing hydrophilic beads for use in topical formulations is described as generally including gellan gum, salts of divalent cations and water. Disclosed features and specifications may be variously controlled, adapted or otherwise optionally modified to realize improved production and/or use of hydrophilic beads to achieve a particular desired purpose. Exemplary embodiments of the present invention generally provide hydrophilic beads that may be comixed with cosmetic, cosmeceutical and/or topical preparations for surface abrasion or as carriers for the delivery of other compounds; such as, aloe vera, ascorbic acid, active agents, and/or the like.
---------------------------------------------------------- ----------------------

ANTHELMINTIC COMPOSITION

(WO2006077429) 27.07.2006 A61K 35/74 NORBROOK LABORATORIES LIMITED
A topical formulation comprising as active ingredients, at least one effective agent derived from Streptomyces avermitilis, i.e. a macrocylic lactone e.g. an avermectin or chemically modified or synthetic derivative thereof, e.g. ivermectin, together with another anthelmintic of the sulphonamide type, e.g. clorsulon, in a carrier that facilitates topical administration and delivery of the active ingredients transdermal Iy, e.g. a carrier that is useful for this purpose comprises alcoholic solvents, such as ethanol, and isopropanol, with optional excipients and formulation aids, which may comprise a polymeric species such as PVP or a poloxamer.
------------------ --------------------------------------------------------------

SKIN-CONDITION IMPROVING COMPOSITION COMPRISING VACCINIUM ULIGINOSUM EXTRACT AND METHOD FOR PREPARATION THEREOF

(WO2006075865) 20.07.2006 A61K 8/97 CHUNG, Se Young
The present invention relates to a composition for the improvement of skin conditions, comprising an extract of Vaccinium uliginosum as an active ingredient. The Vaccinium uliginosum extract has the effects of inhibiting and scavenging reactive oxygen species produced in skin tissue as a result of ultraviolet irradiation to the skin, effectively inhibiting tyrosinase activity to inhibit the production of melanin in melanin cells, inhibiting the secretion of cytokines in keratinocytes, promoting the production of procollagen, and inhibiting the decomposition of collagen. Thus, the extract will be useful for the prevention of skin photo aging caused by ultraviolet radiation, the enhancement of skin whitening and the improvement of wrinkles. I...
---------------------------------- ----------------------------------------------

USE OF THE POF1 GENE PRODUCT FOR COSMETIC AND/OR THERAPEUTIC USE OF SKIN ASSOCIATED DISORDERS

(WO2006075350) 20.07.2006 A61K 38/17 FONDAZIONE CENTRO DAN RAFFAELE DEL MONTE TABOR
The present invention relates to the use of the encoded product of the POFlB gene or biologically active fragments thereof for the production of a cosmetic product for skin topic use, for skin regeneration and anti-aging and/or for hair and/or hair- epidermis related disorders.
------------------------------------------ --------------------------------------

ALCOHOL-FREE MICROEMULSION COMPOSITION

(WO2006074177) 13.07.2006 A61K 8/00 MARY KAY INC.
The present invention concerns compositions that comprise alcohol-free microemulsions and methods for their use that include a surfactant, a lipophilic linker, and/or a hydrophilic linker. These compositions can be used, for example, in cosmetic or hair applications, hi certain aspects, compositions of the invention have the ability to rnicroemulsify sebum while providing enhanced cleansing of cosmetic products from the skin or hair, hi addition, the compositions have the ability to enhance the penetration of skin or hair active ingredients, such as emollients, humectants, anti-oxidants, lipids, vitamins, botanicals, dyes, tanning compounds, etc.
------------------------------------------------------------------ --------------

COMPOSITION FOR PREVENTION, TREATMENT AND DIAGNOSIS OF CHRONIC INFLAMMATORY AIRWAY DISEASES

(WO2006073254) 13.07.2006 A61K 38/17 JEON, Sook-yeong
The present invention provides a pharmaceutical composition for preventing or treating chronic inflammatory airway diseases comprising alpha-enolase protein as an active ingredient. The present invention also provides a diagnostic composition and a diagnostic kit for diagnosing chronic inflammatory airway diseases comprising alpha-enolase protein. The present invention further provides a composition for screening a therapeutic agent for chronic inflammatory airway diseases, comprising one or more of alpha-enolase protein or autoantibodies to alpha-enolase obtained from patients with chronic inflammatory airway diseases, and a method for screening a therapeutic agent for chronic inflammatory airway diseases using this composition. The presen...
-- ------------------------------------------------------------------------------

METHOD OF USING LASER INDUCED INJURY TO ACTIVATE TOPICAL PRODRUGS

(WO2006071850) 06.07.2006 A61B 18/20 RELIANT TECHNOLOGIES, INC.
Methods and compositions are disclosed for improving the wound healing process and increasing collagen synthesis following laser induced thermal injury. The method comprises delivering prodrugs to a target site before the target site is injured and taking advantage of those enzymes that are physiologically-expressed to promote wound healing to convert the prodrugs to active drugs. The claimed invention has the advantage of the prodrugs being readily available to immediately participate in the wound healing process, but not have any negative side-effects of the active drug being present before injury occurs.
------------------------------------------ --------------------------------------

COSMETIC COMPOSITION FOR SKIN APPLICATION SUITABLE FOR RELAXING EXPRESSION WRINKLES

(WO2006069608) 06.07.2006 A61K 8/64 LABO COSPROPHAR AG
The present invention relates to a cosmetic composition for skin application suitable for relaxing expression wrinkles which combines a selected active peptide component with a decontracting or relaxing action on the muscular fiber with a micro-element which reduces the muscular contraction level by acting directly or indirectly on a muscular fiber component. The active principles of the cosmetic composition of the invention are conveniently carried by liposomes.
-------------------------------------------------- ------------------------------

COMPOSITIONS AND METHODS OF THEIR USE FOR IMPROVING THE CONDITION AND APPEARANCE OF SKIN

(WO2006068779) 29.06.2006 A61K 9/00 AVON PRODUCTS, INC.
The present invention relates to composition and methods for treating, preventing and improving the condition and/or aesthetic appearance of skin, particularly, treating, preventing, ameliorating, reducing and/or eliminating fine lines and/or wrinkles of skin, where the compositions include active agents which increase expression levels of genes associated with the dermatological signs of aging. The compositions of the invention are topically applied to the skin, or are delivered by directed means to a site in need thereof, once daily in an amount effective in improving the condition and/or aesthetic appearance of skin.
-------------------------- ------------------------------------------------------

PERSONAL CARE AND HOUSEHOLD COMPOSITIONS OF HYDROPHOBICALLY-MODIFIED POLYSACCHARIDES

(WO2006065848) 22.06.2006 A61K 8/73 HERCULES INCORPORATED
A conditioning composition is used in functional systems (personal care and household care compositions) that has a nonionic hydrophobically modified cellulose ether (HMCE) having a weight average molecular weight (Mw) with a lower limit of 400,000 and an upper limit of 2,000,000 and a hydrophobic substitution lower limit of 0.6 wt % and an upper limit amount which renders said cellulose ether insoluble in a 5 wt % solution of surfactant and less than 0.05 % by weight soluble in water and wherein the cellulose ether provides conditioning benefit to the functional system substrate.. This composition has at least one active functional system ingredient.
------------------ --------------------------------------------------------------

METHODS FOR PRODUCING BLOCK COPOLYMER/AMPHIPHILIC PARTICLES

(WO2006060723) 08.06.2006 A61K 9/14 VICAL INCORPORATED
The invention relates to a method for manufacturing cell delivery particles, pharmaceutical component-particle dispersions, composition comprising cell delivery particles and pharmaceutical compositions comprising pharmaceutical component-particle dispersions. The method comprises homogenization of mixtures comprising amphiphilic components and a block copolymer to form stable particles. The invention is also directed to cell delivery particles and pharmaceutical component-particle dispersions produced by the claimed methods and compositions comprising same. In certain embodiments, the cell delivery particles may further comprise co-lipids. The invention further relates to methods of generating an immune response, treating or preventing a d...
---------- ----------------------------------------------------------------------

SYSTEM FOR IMPROVED PERCUTANEOUS ABSORPTION OF SKIN BENEFITING AGENTS

(WO2006060515) 08.06.2006 A61K 9/00 OMP, Inc.
Stable topical compositions containing active ingredients that are prone to oxidation, and methods for improving the percutaneous absorption of an active ingredient are provided.
---------- ----------------------------------------------------------------------

N-(PYRIDIN-3-YL)-2-PHENYLBUTANAMIDES AS ANDROGEN RECEPTOR MODULATORS

(WO2006060108) 08.06.2006 A61K 31/44 MERCK &CO., INC.
Compounds of structural formula (I) are modulators of the androgen receptor (AR) in a tissue selective manner. These compounds are useful in the enhancement of weakened muscle tone and the treatment of conditions caused by androgen deficiency or which can be ameliorated by androgen administration, including osteoporosis, osteopenia, glucocorticoid-induced osteoporosis, periodontal disease, bone fracture, bone damage following bone reconstructive surgery, sarcopenia, frailty, aging skin, male hypogonadism, postmenopausal symptoms in women, atherosclerosis, hypercholesterolemia, hyperlipidemia, obesity, aplastic anemia and other hematopoietic disorders, inflammatory arthritis and joint repair, HIV-wasting, prostate cancer, benign prostatic hy...
---------------------------------------------------------- ----------------------

METHODS AND SOLUTIONS FOR TISSUE PRESERVATION

(WO2006057876) 01.06.2006 A01N 1/00 CEDARS-SINAI MEDICAL CENTER
Described herein are compositions and methods particularly useful in the medical arts. The compositions and methods may be used in connection with the preservation of a portion of a mammal, for example, tissues, organs, appendages, limbs, extremities, stem cells, myocytes, bone marrow, skeletal muscle as well as an array of other medical procedures, such as cardiac surgery, transplantation and/or preservation. In various embodiments, the inventive composition may be hyperoxygenated and be formulated to resemble the biochemistries of natural intracellular fluids. The inventive composition includes active ingredients to reduce ischemic, hypothermic and reperfusion injury during transplantation, thereby resulting in improved post-transplant gr...
---------------------------------- ----------------------------------------------

COMPOSITION COMPRISING A POLYSACCHARIDE WITH BACTERIA BLOCKING ACTION

(WO2006056801) 01.06.2006 A61K 36/886 PASSION FOR LIFE HEALTHCARE LIMITED
A composition of an isotonic or hypertonic formulation or a powder for the preparation thereof is described comprising an active ingredient which is effective in blocking harmful bacteria and is selected from extracts of plant or animal origin and/ or derivatives thereof comprising a combination of polysaccharides comprising 60-100 % of D-mannose, 40-0 % of D-glucose and 0-10 % of other monosaccharides. An active ingredient which is effective in blocking harmful bacteria for use in a spray composition or douche so as to drench the surface tissue of a recipient; use of a composition in blocking adhesion of harmful bacteria to host tissues; and use of a composition in the manufacture of a medicament with this effect are also described.
------------------------------------------------------------------ --------------

COSMETIC COMPOSITIONS CONTAINING SOPHORA ALOPECUROIDES L.EXTRACTS

(WO2006056317) 01.06.2006 A61K 8/97 UNILEVER PLC
Disclosed are extracts of Sophora alopecuroides L. as cosmetic skin lightening agents alone or in combination with other skin benefit agents and together with a cosmetic vehicle. Also disclosed are active ingredients in the extracts, including alopecurone A, alopecurone B, sophoraflavone-G, sophoraflavone-I, sophoraflavone-K, and mixtures thereof. The inventive extracts, compositions and methods have effective skin lightening properties, may be easier to deliver to the skin and are available in nature.
-------------------------------------------------- ------------------------------

UNDERARM COSMETIC METHOD AND COMPOSITIONS

(WO2006056283) 01.06.2006 A61Q 15/00 UNILEVER PLC
A method of inhibiting skin darkening whilst inhibiting perspiration in the underarm which comprises incorporating into a antiperspirant composition comprising an astringent salt comprising an aluminium and/or zirconium salt, a triglyceride oil and optionally an active acid comprising an aliphatic dicarboxylic acid, especially C6 -C12 such as azelaic acid, an unsaturated C18 aliphatic carboxylic acid such as a linoleic acid or an hydroxybenzoic acid such as salicylic acid, at a ratio to said astringent salts, x:y, of 1:<4 in which x represents the weight concentration of said triglyceride oil plus 4 times the weight concentration of active carboxylic acid and y represents the weight concentration of said astringent salts. The composition can...
---------------------------------------------------------- ----------------------

IONTOPHORETIC DEVICE AND METHOD FOR ADMINISTERING IMMUNE RESPONSE-ENHANCING AGENTS AND COMPOSITIONS

(WO2006055729) 26.05.2006 A61K 39/00 TRANSCUTANEOUS TECHNOLOGIES INC.
An iontophoresis device and method delivers an immune response-enhancing agent, or composition thereof via iontophoresis. The device may include an active electrode assembly having a drug solution holding portion, comprising an immune response-enhancing agent, or composition thereof; and a non-active electrode assembly. An iontophoresis device delivers an immune response-enhancing agent via iontophoresis. The device includes an active electrode assembly and a non-active electrode assembly, wherein the active electrode assembly comprises: a first electrode element operable to provide an electrical potential of a first polarity and a drug solution holding portion arranged on a front surface of the first electrode member.
------------------ --------------------------------------------------------------

AMMONIUM COMPOUNDS FOR TREATING PSORIASIS AND ECZEMA

(WO2006054312) 26.05.2006 A61K 31/14 MEDASANI, Munisekhar
Administration of ammonium compounds, as active and effective ingredient which has the properties such as prevention, reduction, relief and treating Psoriasis, Eczema and like other diseases and administration of the same through topical or trans-dermal application.
-- ------------------------------------------------------------------------------

SKIN CARE COMPOSITION COMPRISING FUSION POLYPEPTIDE COMPOSITION

(WO2006053613) 26.05.2006 A61Q 19/00 UNILEVER N.V.
A composition is provided comprising (i) a fusion polypeptide comprising a first binding domain which comprises a complementarity determining region (CDR) which binds specifically to hair and a second binding domain which binds to a cosmetic or dermatologically active agent; and (ii) a cosmetic or dermatologically active agent bound to said second binding domain. The compositions can be used in methods of selectively delivering a cosmetic or dermatologically active agent to the skin.
------------------ --------------------------------------------------------------

BACTERICIDAL FORMULATIONS

(WO2006053458) 26.05.2006 A61K 8/92 GIVAUDAN SA
The invention relates to bactericidal formulations that come into contact with human body, particularly wash formulations including liquid soaps, comprising perfume ingredients active against gram-negative bacteria. Such compositions contact the target site, for example the skin surface, only for a short time, usually not longer than 30 seconds. Therefore the antibacterial action has to be of the bactericidal type and rapid. Furthermore, the bactericidal activity has to be sufficiently high to ensure an effect even when applied to wet substrates that will dilute the bactericidal formulation.
---------------------------------- ----------------------------------------------

TREATMENT ARTICLES CAPABLE OF CONFORMING TO AN UNDERLYING SHAPE

(WO2006053332) 18.05.2006 A61K 8/02 THE PROCTER &GAMBLE COMPANY
Treatment articles capable of conforming to an underlying shape and methods for their use are provided. The articles comprise a water insoluble substrate having at least one elongation zone where at least a portion of the elongation zone has been incrementally stretched. The article also includes a treatment composition which preferably delivers a skin care active. Preferred articles of the present invention comprise facial treatment masks.
------------------------------------------------------------------ --------------

THE USE OF ESTRIOL AND OTHER ESTRANES, ESTROGENS AND ESTROGEN RECEPTOR ACTIVE COMPOSITIONS IN THE TREATMENT OF PSORIASIS AND OTHER AUTOIMMUNE DISEASES

(WO2006053172) 18.05.2006 A61K 31/56 THE REGENTS OF THE UNIVERSITY OF CALIFORNIA
Methods, compositions and kits for treating psoriasis and other autoimmune diseases in human or animal subjects. The disclosed methods generally comprise administering to the subject a therapeutically effective amount of a naturally occurring or synthetic agent comprising estriol or another estrane, estrogen or estrogen receptor-effective composition. The disclosed compositions and kits generally comprise topical preparations and/or combination preparations wherein 2 or more agents are combined for either simultaneous administration or administration at different times and by the same or different route(s) of administration.
---------------------------------------------------------- ----------------------

RETINOID SOLUTIONS AND FORMULATIONS MADE THEREFROM

(WO2006053006) 18.05.2006 A61K 9/12 IMAGINATIVE RESEARCH ASSOCIATES, INC.
Compositions for topical application for treating a skin disorder (e.g., acne) include a retinoid, which is solubilized completely in alcohol only with the aid of cosolvents such as esters (e.g., alkyl benzoate, isopropyl palmitate, isopropyl myristate, diisopropyl adipate and their derivatives). This completely solubilized retinoid can be used to formulate an emulsion system or liquid to powder suspension containing a second active, such as an antibiotic (e.g., clindamycin) or benzoyl peroxide.
---------------------------------- ----------------------------------------------

TOPICAL COMPOSITIONS COMPRISING MYRICA GALE OIL

(WO2006051246) 18.05.2006 A61K 8/04 THE BOOTS COMPANY PLC
The use of Myrica gale oil in the manufacture of a composition for the treatment of the skin or other exposed surfaces of the body is disclosed. Compositons prepared in accordance with the invention are particularly useful as anti-acne and anti-dandruff products. Myrica gale oil may bai used with other active agents which have complementary benefits.
------------------------------------------------------------------ --------------

ANTI-DIABETIC HERBAL FORMULATION COMPRISING GLYCINE MAX

(WO2006048696) 11.05.2006 A61K 36/9068 COUNCIL OF SCIENTIFIC AND INDUSTRIAL RESEARCH
The invention provides a novel herbal preparation comprises of Glycine max active fraction containing 7S globulin protein extract, Curcuma longa and Zingiber officinale Linn. rhizome extract used in treatment of diabetes and diabetic related diseases.
------------------------------------------------------------------ --------------

COSMETIC COMPOSITION COMRISING AN ACTIVE AGENT AND A UREA COMPOUND

(WO2006048339) 11.05.2006 A61K 8/42 L'ORÉAL
The invention relates to a composition comprising a hydroxylated urea compound and an active agent chosen from dermal relaxant active agents, agents that stimu- late the synthesis of dermal or epidermal extracellular matrix fibres or of fibres lo-cated at the dermal-epidermal junction and/or that prevent their degradation, anti- glycation agents, lipolytic active agents or active agents that inhibit lipogenesis, anti-irritants, and mixtures thereof. The invention also relates to a composition comprising a hydroxylated urea compound and an active agent chosen from carotenoids, retinoids, flavanones, flavonols, isoflavones, coumarins, lignans, stilbenoids, sapogenins, pentacyclic triterpenic acids, ß-hydroxy acids, hydroxyphe...
---------------------------------------------------------- ----------------------

USE OF ANDROGENS TO REDUCE THE LIKELIHOOD OF ACQUIRING OR TO TREAT SKIN AGING

(WO2006047859) 11.05.2006 A61K 31/568 ENDORECHERCHE, INC.
Novel methods of treating or reducing the likelihood of acquiring skin diseases due to age-related androgen deficiency, particularly skin atrophy, loss of collagen, loss of elastic fibers, loss of connective tissue, cellulite, and formation of wrinkles, in susceptible warm-blooded animals including humans involving administration of an androgen or/and a sex steroid precursor. Pharmaceutical compositions for delivery of active ingredient(s) useful to the invention are also disclosed.
------------------------------------------ --------------------------------------

COMPOSITIONS OF LACTOFERRIN RELATED PEPTIDES AND USES THEREOF

(WO2006047744) 04.05.2006 A61K 38/40 AGENNIX INCORPORATED
The present invention is directed to a composition consisting of a series of novel biologically active 33-mer peptides.
-- ------------------------------------------------------------------------------

SUSTAINED RELEASE OF ACTIVE MOLECULES FROM POLYMERS TOPICALLY APPLIED TO SKIN OR HAIR

(WO2006047714) 04.05.2006 A61K 47/30 ELC MANAGEMENT LLC
The invention relates to a polymer for topical delivery of biologically active ingredients, the polymer comprising at least on moiety: U-B-A, in which U represents a physiologically acceptable unit of an oligomer or polymer, A represents a biologically active component, and B represents one or more bond(s) linking A to U, which bond is capable of being disrupted by a biological, physical or chemical process occurring in the skin.
---------------------------------- ----------------------------------------------

AN AYURVEDIC COMPOSITION AND PROCESS FOR PREPARING THE COMPOSITION TO ACT AS ANTI SNAKE- VENOM

(WO2006046257) 04.05.2006 A61K 36/48 PAWAR, Geeta, Pandurang
An anti-venom composition comprising extracts of active components of the plants Erythina Indica., Eugenia Jambolana, Mangifera lndica and Jasminum sambac combined at effective ratios to prepare the composition that is capable of administering orally or intra-venous. An ayurvedic product derived of the said extract of active components is also a method of treating snakebites, using the said composition.
--------------------------------------------------------------------------------

CARDIAC SAFE, RAPID MEDICATION DELIVERY

(WO2006044421) 27.04.2006 A61K 9/00 ALEXZA PHARMACEUTICALS, INC.
The disclosure provides methods and compositions for providing an effective dose of an active agent and/or drug composition to a subject by inhalation. The methods of the disclosure are useful in determining a maximal effective dose that limits cardiovascular damage upon inhalation.
------------------------------------------------------------------ --------------

COSMETIC COMPOSITIONS

(WO2006043033) 27.04.2006 A61Q 19/00 THE BOOTS COMPANY PLC
There is disclosed a skincare composition suitable for topical application to the skin. The composition comprises two or more active ingredients selected from the group consisting of a) dipalmitoyl hydroxyproline, salts and esters thereof; b) carnitine; and c) an extract of Haematococcus pluvialis. Compositions prepared in accordance with the invention are useful for improving the appearance of the skin.
-------------------------- ------------------------------------------------------

BIOCOMPATIBLE PROTEIN PARTICLES, PARTICLE DEVICES AND METHODS THEREOF

(WO2006042310) 20.04.2006 A61K 9/16 GEL-DEL TECHNOLOGIES, INC.
The present invention relates to biocompatible protein particles, particle devices and their methods of preparation and use. More specifically the present invention relates to protein particles and devices derived from such particles comprising one or more biocompatible purified proteins combined with one or more biocompatible solvents. In various embodiments of the present invention the protein particles may also include one or more pharmacologically active agents and/or one or more additives.
------------------------------------------------------------------ --------------

SOLUBILIZING AGENTS FOR ACTIVE OR FUNCTIONAL ORGANIC COMPOUNDS

(WO2006041506) 20.04.2006 A61K 8/39 ISP INVESTMENTS INC.
An active or functional organic compound is solubilized in a diaryl organic compound having a polar or polarizable functional group therein, as a solvent, cosolvent or additive, to form a composition thereof. Representative active or functional organic compounds include those present in personal care products, e.g., sunscreens containing UVA/UVB absorbing compounds, such as avobenzone, benzophenone-3, and 4- methylbenzylidene camphor. Such compositions also show increased SPF, UVA/UVB absorbance ratio, and critical wavelength performance properties.
---------- ----------------------------------------------------------------------

COMPACT POWDER COMPRISING POLYAMIDE PARTICLES CONTAINING AN ACTIVE AGENT

(WO2006037665) 13.04.2006 A61Q 19/00 L'OREAL
The invention relates to an anhydrous cosmetic composition, especially in compact form, comprising: a pulverulent phase comprising polyamide particles; a fatty phase; and at least one moisture-sensitive cosmetic or pharmaceutical active agent, characterized in that the said particles have a mean volume diameter of less than or equal to 10 µm and contain at least a fraction of the active agent, and in that the fatty phase represents from 0.1% to 20% of the weight of the composition. The invention also relates to a cosmetic process for caring for greasy skin or for bleaching the skin, comprising the topical application to the skin of the abovementioned composition. The invention also relates to the use of this composition for the manufa...
------------------------------------------ --------------------------------------

WOUND DRESSING COMPOSITIONS, ESPECIALLY FOR DELIVERY OF PROTEASE INHIBITORS

(WO2006037606) 13.04.2006 A61L 26/00 SWITCH BIOTECH AKTIENGESELLSCHAFT
The present invention relates to dry and Hydrated, i.e. wet wound dressings and delivery systems also suitable for active ingredients, their use for the treatment of wounds and skin diseases, preferably chronic wounds, and methods of preparing them. Wound dressings according to the invention comprise a cellulose ether, preferably hydroxyethyl cellulose, and a gellan gum and optionally a protease inhibitor such as alpha-1- antichymotrypsin.
---------------------------------------------------------- ----------------------

STABILIZATION OF ALUM-ADJUVANTED IMMUNOLOGICALLY ACTIVE AGENTS

(WO2006037070) 06.04.2006 A61K 9/70 ALZA CORPORATION
A composition and method for formulating and delivering an adjuvanted immunological active agent, especially a vaccine, wherein adjuvant coagulation and concomitant loss of vaccine efficacy enhancement is mitigated or avoided. The adjuvanted, immunologically-active agent can be subjected to freezing, drying, freeze-drying, or lyophilization, and when reconstituted, retains a high level of potency. The present invention further provides for a composition and method for formulating and delivering a stable, adjuvanted, immunologically-active agent capable of being deposited on a transdermal delivery device or microprojection or array thereof.
--------------------------------------------------------------------------------

TRANSDERMAL SYSTEMS FOR THE DELIVERY OF ESTROGENS AND PROGESTINS

(WO2006036899) 06.04.2006 A61K 9/70 CORIUM INTERNATIONAL, INC.
Transdermal systems are provided for administering an estrogen and/or a progestin to a mammalian female. The systems are monolithic, having a drug reservoir that serves as the means for ensuring adhesion to the skin during drug administration. The drug reservoir includes the active agent(s), a low molecular weight organic acid as a permeation enhancer, and an additional vehicle, in an adhesive matrix. Methods for using the systems for transdermal delivery of active agents are also provided, including methods for providing hormone replacement therapy and for preventing ovulation.
-------------------------------------------------- ------------------------------

A MULTI-COMPONENT CONTROLLED DELIVERY SYSTEM FOR SOAP BARS

(WO2006036617) 06.04.2006 A61K 8/36 SALVONA LLC
The present invention relates to an improved controlled delivery system that can be incorporated in soap bars to enhance deposition of active ingredients and sensory markers onto skin. The carrier system also provides controlled release or prolonged release of these actives from the skin over an extended period of time. The controlled delivery system of the present invention comprises substantially free- flowing, powder formed of solid hydrophobic, positively charged, nanospheres of encapsulated active ingredients, that are encapsulated in moisture sensitive microspheres. The high cationic charge density of the nanosphere improves deposition of active ingredients onto skin. The high cationic charge density on the nanosphere surface is create...
------------------------------------------ --------------------------------------

HIGH DS CATIONIC POLYGALACTOMANNAN FOR SKINCARE PRODUCTS

(WO2006036510) 06.04.2006 A61K 8/73 HERCULES INCORPORATED
A skin care composition is provided with a) from about 1 to about 90 wt % of a surfactant, b) at least about 0.05 wt % of a cationic polymer wherein the cationic polymer has a mean average molecular weight (Mw) from about 2,000 to about 10,000,000 Dalton, and the cationic polymer has a cationic degree of substitution (DS) greater than 0.25 to about 3.0, and c) at least one skin care active ingredient, wherein the skin care composition provides at least one of the functions of cleansing, protection, moisturizing, firming, conditioning, occlusive barrier, emolliency, depositing, and anti-wrinkling to the skin.
------------------------------------------------------------------ --------------

METHOD OF TREATMENT OF ACUTE EXUDATIVE SKIN LESIONS AND COMPOSITION USEFUL THEREFOR

(WO2006032464) 30.03.2006 A61K 9/107 MEDINOVA AG
The invention refers to the use of zinc oxide as unique pharmacologically active ingredient, in combination with a pharmaceutically acceptable hydrophilic vehicle, for the preparation of a pharmaceutical composition dedicated to the topical treatment of edges of chronic wounds and/or acute exudative skin lesions caused by intertrigo, decubitus, ulcus cruris, wet eczema, skin maceration, skin fissuring or skin photo damaging. The invention also provides a pharmaceutical composition comprising zinc oxide as unique pharmacologically active ingredient, in combination with a pharmaceutically acceptable hydrophilic vehicle.
------------------ --------------------------------------------------------------

CARBOHYDRASE INHIBITORS DERIVED FROM CHESTNUT AND USE THEREOF

(WO2006030929) 23.03.2006 A61K 36/18 TSUJITA, Takahiro
The present invention provides a plant- derived carbohydrase inhibitor, wherein the inhibitor is effective for preventing or alleviating diabetes, or preventing obesity, and foods, drinks, and medicines containing the same. The present invention is accomplished by use of an ?-amylase inhibitor or an ?-glucosidase inhibitor as a carbohydrase inhibitor that is extracted from astringent skins of a chestnut using ethanol or aqueous ethanol solution. The present invention can also be accomplished by adding the carbohydrase inhibitor to a food or medical composition as an active ingredient for delaying saccharide digestion or absorption, suppressing a rise in postprandial blood glucose levels or blood insulin levels, or preventing obesity.
---------- ----------------------------------------------------------------------

CARBOHYDRASE INHIBITORS DERIVED FROM FAGACEOUS PLANTS AND USE THEREOF

(WO2006030567) 23.03.2006 A61K 36/00 TSUJITA, Takahiro
The present invention provides a plant-derived carbohydrase inhibitor, wherein the inhibitor is effective for preventing or alleviating diabetes, or preventing obesity, and foods, drinks, and medicines containing the same. The present invention is accomplished by use of an ?-amylase inhibitor or an ?-glucosidase inhibitor as a carbohydrase inhibitor that is extracted from an entire or a part of fagaceous plants using water, another polar solvent, or a mixture thereof. The present invention can also be accomplished by adding the carbohydrase inhibitor to a food or medical composition as an active ingredient for delaying saccharide digestion or absorption, suppressing a rise in postprandial blood glucose levels, or preventing obesity.
------------------ --------------------------------------------------------------

TOPICAL COMPOSITIONS CONTAINING PHOSPHORYLATED POLYPHENOLS

(WO2006029484) 23.03.2006 A61K 31/66 AJINOMOTO OMNICHEM S.A.
The present invention provides topical compositions containing phosphorylated polyphenols in combination with a topically acceptable carrier. The compositions of the invention provide a means for delayed delivery of the polyphenol to keratinous tissues, such as skin, hair and nails, with enzymes of the keratinous tissue dephosphorylating the polyphenol, and returning it to its native active form. The compositions are particularly useful in the regulation of skin conditions.
------------------------------------------ --------------------------------------

COMBINATION OF ORGANIC COMPOUNDS

(WO2006029349) 16.03.2006 A61P 25/30 NOVARTIS AG
The present invention relates to a pharmaceutical composition, comprising a PPAR agonist, or pharmaceutically acceptable salts thereof, alone or in combination with at least one active ingredient selected from the group consisting of (i) HDL increasing compounds; (ii) anti-diabetics; (iii) an anti-hypertensive agent; (iv) cholesterol absorption modulator; (v) apo-A1 analogs and mimetics; (vi) renin inhibitors; (vii) thrombin inhibitors; (viii) aldosterone inhibitors; (ix) GLP-1 agonists; (x) glucagon receptor antagonists; (xi) cannabinoid receptor 1 antagonists; (xii) anti -obesity agents; and (xiii) inhibitors of platelet aggregation or, in each case, a pharmaceutically acceptable salt thereof; and optionally a pharmaceutically acceptable c...
---------------------------------------------------------- ----------------------

TRANSDERMAL DELIVERY OF HYDROPHOBIC BIOACTIVE AGENTS

(WO2006029192) 16.03.2006 A61K 6/00 DERMATRENDS, INC.
A method and related compositions, including the use of N-acyl derivatives of sarcosine, provide for the delivery of bioactive agents through tissue surfaces such as the skin. The method and composition are particularly well suited for hydrophobic active agents such as serotonin (5HT3) receptor antagonists (e.g., ondansetron), antipsychotic agents (e.g., risperidone), benzodiazepines (e.g., flumazenil), and progestins (e.g., levonorgestrel).
------------------------------------------ --------------------------------------

TRANSDERMAL ANTIEMESIS DELIVERY SYSTEM, METHOD AND COMPOSITION THEREFOR

(WO2006028863) 16.03.2006 A61F 13/00 NEXMED HOLDINGS, INC.
A transdermal antiemesis system, preferably in the form of a drug-in-adhesive matrix patch, is disclosed, the system comprises an effective antiemesis amount of a selective serotonin (5-HT3) receptor antagonist as an antiemetic incorporated in a skin adhesive composition containing at least one permeation enhancer in an amount effective to provide a substantially uniform release of drug from the composition and a water-insoluble pressure-sensitive adhesive. A preferred antiemetic is granisetron base. The transdermal antiemesis system of this invention provides controlled release of the active antiemetic ingredient from the skin-contacting adhesive formulation of a transdermal patch, and maintains a substantially uniform, sustained transderm...
---------- ----------------------------------------------------------------------

LOW VISCOSITY SUNLESS TANNING COMPOSITION AND METHODS FOR USING

(WO2006028613) 16.03.2006 A61K 8/06 SKINVISIBLE PHARMACEUTICALS, INC.
A sunless tanning composition is provided according to the invention. The sunless tanning composition includes a polymer component, a tanning active component, water, and the composition is provided as an emulsion and has a viscosity of less than about 25 cSt. A method for using a sunless tanning composition is provided.
---------- ----------------------------------------------------------------------

PEPTIDE-BASED BODY SURFACE REAGENTS FOR PERSONAL CARE

(WO2006028503) 16.03.2006 A61K 6/00 E.I. DUPONT DE NEMOURS AND COMPANY
Peptides have been identified that bind with high affinity to body surfaces, such as hair, skin, nails, teeth, gums, corneal tissue, and oral cavity surfaces. Peptide-based body surface reagents formed by coupling a body surface binding peptide to a benefit agent are described. The peptide-based body surface reagents include peptide-based hair conditioners, hair colorant, skin conditioners, skin colorants, nail colorants and oral care reagents. The peptide-based hair conditioners and hair colorants are comprised of a hair-binding peptide coupled to a hair conditioning agent or a coloring agent, respectively. The peptide-based skin conditioners and skin colorants are comprised of a skin-binding peptide coupled to a skin conditioning agent or...
------------------------------------------------------------------ --------------

NANO-EMULSION, THE USE THEREOF, AND PREPARATION METHOD THEREOF

(WO2006028339) 16.03.2006 A61K 9/113 KIM, Young Dae
The present invention relates to nanoemulsions, the use thereof and preparation method thereof wherein, nanoemulsions contain polyoxypropylene-polyoxyethylene vitamin E as emulsifiers and polyacrylic acid or polyacrylic acid derivative crosspolymers as emulsion assistants, In the present invention nanoemulsions containing POP-POE vitamin E as emulsifiers and polyacrylic acid or polyacrylic acid derivative crosspolymers as emulsion assistants have a very small mean droplet diameter ranging from 43 to 96 nm and are very stable and safe. By using the nanoemulsions described above the inventors prepared nanoemulsion cosmetic compositions with a much smaller mean droplet diameter than nanoemulsions prepared only with emulsifiers, polyoxypropylen...
------------------------------------------ --------------------------------------

COSMETIC POWDER, ITS PREPARING METHOD AND MAKE-UP COSMETIC COMPOSITION COMPRISING THE SAME

(WO2006028311) 16.03.2006 A61K 8/14 LG HOUSEHOLD &HEALTH CARE LTD.
The present invention relates to cosmetic powder, a method of preparing the same, and a make-up cosmetic composition comprising the same in the present invention. More specifically, the cosmetic powder of the present invention comprises powder and matrix layers coated on its surface wherein the matrix layers comprise nano-sized liposome and emulsion (NLE) and lamella liquid crystal. Therefore, the present invention provides cosmetic powder coated with NLE and lamella liquid crystal not only endowing the same skin treatment effects with make-up cosmetics as with skincare products due to the even emission of active components belonging to NLE, but also contributing to obtaining a make-up cosmetic composition with the high skin compatibility, ...
--------------------------------------------------------------------------------

ANDROGEN RECEPTOR MODULATORS

(WO2006026196) 09.03.2006 A61K 31/4745 MERCK &CO., INC.
Compounds of structural Formula (I) are modulators of the androgen receptor (AR) in a tissue selective manner. These compounds are useful in the enhancement of weakened muscle tone and the treatment of conditions caused by androgen deficiency or which can be ameliorated by androgen administration, including osteoporosis, osteopenia, glucocorticoid-induced osteoporosis, periodontal disease, bone fracture, bone damage following bone reconstructive surgery, sarcopenia, frailty, aging skin, male hypogonadism, postmenopausal symptoms in women, atherosclerosis, hypercholesterolemia, hyperlipidemia, obesity, aplastic anemia and other hematopoietic disorders, inflammatory arthritis and joint repair, HIV-wasting, prostate cancer, benign prostatic hy...
---------------------------------------------------------- ----------------------

IMPROVED TOPICAL SKIN CARE COMPOSITIONS

(WO2006026168) 09.03.2006 A61K 8/893 AVON PRODUCTS, INC.
A novel combination of silicon resin, amorphous silica and low oil absorbing spherical powder is described which when added to topical skin care compositions containing high concentrations of active agents, improves their aesthetic feel and ease of application.
-- ------------------------------------------------------------------------------

COSMETIC COMPOSITIONS COMPRISING SPECIFIC CYCLOHEXANMONO-, -DI- OR -TRIOLS OR CYCLOHEXYL METHAN- OR -ETHAN- OR -PROPOANOLS

(WO2006026006) 09.03.2006 A61K 8/34 MOLECULAR RESEARCH CENTER, INC.
A composition and method for improving skin appearance by reducing skin redness and symptoms associated with skin inflammation, irritation and skin aging by topically treating skin is disclosed. In this composition and method, an active material having the formula given below is applied to the patient at the site of said condition: wherein R1 is selected from -OH and C1-C3 alkyl OH; and R2, R3, R4, R5 and R6 are independently selected from -H, -OH, C1-C6 alkyl, and C3-C6 cycloalkyl. The active material should contain no more than five -OH groups. Preferred active materials include 1,2-cyclohexanediol, 1,3-cyclohexanediol, 1,4-cyclohexanediol, 1,2,3- cyclohexanetol, 1,3,5-cyclohexanetriol, and mixtures of those materials. A method of main...
------------------------------------------------------------------ --------------

MICROEMULSION & SUB-MICRON EMULSION PROCESS & COMPOSITIONS

(WO2006024095) 09.03.2006 B01F 3/08 CONNETICS AUSTRALIA PTY LTD
There is provided a process for the preparation of an oil in water (O/W) microemulsion or sub-micron emulsion composition for dermal delivery of at least one pharmaceutically active ingredient, the method including the steps of a) Admixing a first part including at least one of the group consisting of animal, mineral or vegetable oils, silanes, siloxanes, esters, fatty acids, fats, halogen compounds or alkoxylated alcohols; and one or more lipophilic surfactants, and a second part including water and at least one hydrophilic surfactant to achieve homogeneity, b) heating the mix of step a) to a phase assembly temperature in the range of 40 - 99°C, preferably 45 - 950C, more preferably 65 - 850C with continuous mixing to obtain a microemu...
------------------------------------------ --------------------------------------

EFFERVESCENT COMPOSITION INCLUDING A GRAPE-DERIVED COMPONENT

(WO2006023814) 02.03.2006 A61K 36/87 AMERILAB TECHNOLOGIES, INC.
The invention features an effervescent composition that includes at least one grape-derived component, at least one effervescent agent, and optionally at least one active agent, where the sum of the weight of the grape- derived component and the weight of the active agent constitute at least about 10 % by weight of the composition, with the weight of the grape-derived component being greater than weight of the active agent.
---------------------------------- ----------------------------------------------

MICROPROJECTION APPARATUS AND SYSTEM WITH LOW INFECTION POTENTIAL

(WO2006020842) 23.02.2006 A61M 37/00 ALZA CORPORATION
A transdermal agent delivery apparatus and system having a low infection potential comprising a delivery system having a microprojection member (or system) that includes a plurality of microprojections (or array thereof) that are adapted to pierce through the stratum corneum into the underlying epidermis layer, or epidermis and dermis layers. In one embodiment, the microprojection member includes a biocompatible coating having at least one biologically active agent and at least one antimicrobial agent disposed therein. In another embodiment, the microprojection member includes a hydrogel formulation having at least one biologically active agent and at least one antimicrobial agent. In yet another embodiment, the microprojection member inclu...
---------- ----------------------------------------------------------------------

COMPOSITION AND METHOD FOR THE TREATEMENT OF PSORIASIS

(WO2006019353) 23.02.2006 A61K 31/557 SYNPHORA AB
The use of a prostaglandin A2 derivative, and prodrugs of the compound, for the manufacture of a medicament for the treatment and/or alleviation of psoriasis is presented, as well as a method of treatment, involving the topical application of such prostaglandins. Compositions containing a therapeutically active, and physiologically acceptable amount of the above compound or derivatives thereof, as such or in the form of a prodrug, in a suitable vehicle are also described. Importantly, the derivatives can be applied in therapeutically active amounts without or with only minimal side effects, such as hyperemia, irritation or pain.
---------------------------------------------------------- ----------------------

COSMETIC COMPOSITION COMPRISING AS ANTIPERSPIRANT AGENT A FLOCCULATING WATER-SOLUBLE POLYMER; PROCESS FOR TREATING PERSPIRATION

(WO2006018073) 23.02.2006 A61Q 15/00 L'OREAL
The invention relates to a cosmetic composition comprising at least one aqueous phase and at least one antiperspirant active agent, characterized in that the said antiperspirant active agent consists of at least one flocculating water-soluble polymer comprising amine groups on the main chain and in that it does not contain any aluminium and/or zirconium antiperspirant salts. The present invention also relates to a cosmetic process for treating perspiration, which consists in applying to the surface of the skin an effective amount of such a composition. The present invention also relates to the use of a flocculating water-soluble polymer comprising amine groups on the main chain as an antiperspirant active agent in a cosmetic composition, an...
-------------------------------------------------- ------------------------------

NATURAL SUNLIGHT PHOTOSTABLE COMPOSITION

(WO2006016975) 16.02.2006 A61K 8/00 TANNING RESEARCH LABORATORIES, INC.
The present invention relates to photostable compositions that provide protection from ultraviolet radiation ('UVR'). The invention particularly relates to the sunscreens avobenzone, octocrylene and oxybenzone, forming a triplet sunscreen combination. Compositions of the present invention are generally substantially free of substantial amounts of other sunscreens. The triplet combination surprisingly provides and substantially maintains the initial SPF value of the sunscreen composition throughout the period of UVR exposure. Compositions of the invention are photostable such that each of sunscreen active in the triplet combination does not appreciably photodegrade. The present invention accurately communicates the amount of UVR photoprotect...
-------------------------- ------------------------------------------------------

POLYNUCLEOTIDE ENCODING A TRIM-CYP POLYPEPTIDE, COMPOSITIONS THEREOF, AND METHODS OF USING SAME

(WO2006014422) 09.02.2006 C12Q 1/70 THE TRUSTEES OF COLUMBIA UNIVERSITY IN THE CITY OF NEW YORK
The invention provides an isolated nucleic acid encoding a TRIM - cyclophilin A fusion sequence encoding a TRIMcyp fusion protein which is active as an anti-viral agent, and in particular an anti-HIV-1 agent. The invention provides for a nucleic acid encoding a polypeptide having both TRIM activity and cyclophilin activity. The invention provides for an isolated polynucleotide encoding a TRIM-cyclophilin fusion protein, or variants thereof retaining the TRIM and cyclophilin activities. The invention provides for compositions thereof, antibodies that specifically bind thereto, and vectors and host cells comprising the nucleic acid or polypeptide. In addition, the invention provides for methods for treating or preventing viral infection, or r...
-- ------------------------------------------------------------------------------

IMPROVED DETERGENT COMPOSITION WITH BENEFIT AGENTS

(WO2006013020) 09.02.2006 A61K 8/06 UNILEVER PLC
A rinse off liquid or gel cleansing composition comprising a continuous phase comprising one or more detergent actives and a dispersed phase comprising one or more hydrophobic materials, the dispersed phase comprising a water soluble or dispersible benefit agent which is sensitive to a detergent active and/or high pH, which benefit agent is dispersed in the hydrophobic material.
-------------------------------------------------- ------------------------------

NOVEL BACTERIA AND PHARMACEUTICALLY ACTIVE PRODUCTS OBTAINED THEREFROM

(WO2006011137) 02.02.2006 C12R 1/445 STATE OF ISRAEL, DEPARTMENT OF AGRICULTURE, KIMRON VETERINARY INSTITUTE
A substance obtainable from Staphylococcus Aureus bacteria or from a Staphylococcus Aureus bacteria culture, the substance characterized in having at least one of the following characteristics: (a) stimulates proliferation of bovine T-lymphocytes in vitro; (b) accelerates healing of skin wounds in mice and pigs; (c) prevents AIDS- like disease (ALD) in mice infected with ALD virus (ALD-V) when injected substantially simultaneously with the virus; and (d) reduces the viral load in Rhesus Macaques infected with the hybrid simian/human immunodeficiency virus (SHIV) when injected into chronically infected Macaques, or a derivative or fraction of said substance which retains at least one of the characteristics of the substance. Also disclosed is ...
-------------------------------------------------- ------------------------------

DISSOLVABLE FILM COMPOSITION

(WO2006009987) 26.01.2006 A61K 36/82 E-L MANAGEMENT CORP.
A system, a kit and methods for delivering an effective amount of a labile active to the skin, comprising a composition comprising an effective amount of a labile active agent incorporated into a water-soluble polymeric film and an additive composition capable of dissolving the water-soluble polymeric film.
-------------------------- ------------------------------------------------------

BINARY THERMO-GELLING COMPOSITION

(WO2006007183) 19.01.2006 A61K 47/38 KIMBERLY-CLARK WORLDWIDE, INC.
There is provided a new thermo-gelling composition made with methylcellulose and citric acid. This composition may also have an effective amount of a treating agent, which may be a medicinal agent, cosmetic agent, moisturizer, adjuvant, nutritional agent, other ingredients and combinations thereof. The composition is useful in delivering moisturizers or pharmaceutically active agents to the user in a controlled release manner through the mucosal tissues in a body cavity, or on body surfaces, or as a subcutaneously injected medicament. The composition may also be used as a replacement for the soft tissues of the body as in, for example, the foot cushion and cartilage repair.
-- ------------------------------------------------------------------------------

METHODS AND COMPOSITIONS FOR PREVENTING AND TREATING HYPERPIGMENTATION OF SKIN

(WO2006004787) 12.01.2006 A61K 8/19 PROCYTE CORPORATION
Disclosed are methods for treating hyperpigmentation of skin employing topical application of compositions which comprise at least one peptide manganese complex. Also disclosed are methods wherein the composition further comprises retinol, at least one retinol derivative, or a mixture thereof and methods wherein the composition further comprises active agents selected from active drug substances, emollients, sunscreen agents, skin lightening agents, skin protectants, skin conditioning agents, humectants, and mixtures thereof.
------------------------------------------ --------------------------------------

OLEAGINOUS PHARMACEUTICAL AND COSMETIC FOAM

(WO2006003481) 12.01.2006 A61K 9/00 FOAMIX LTD.
The invention relates to stable oleaginous cosmetic or therapeutic foam compositions containing certain active agents, having unique therapeutic properties and methods of treatment using such compositions. The foamable composition includes at least one solvent selected from the group consisting of: a hydrophobic solvent, a silicone oil, an emollient, a co-solvent, and mixtures thereof, wherein the solvent is present at a concentration of about 70% to about 96.5% by weight of the total composition, at least a non-ionic surface-active agent at a concentration of about 0.1 % to less than about 10% by weight of the total composition; at least one gelling agent at a concentration of about 0.1% to about 5% by weight of the total composition; a th...
-------------------------------------------------- ------------------------------

ACTIVE AGENTS USING LIPOSOME MACRO -BEADS

(WO2006001815) 05.01.2006 A61K 9/127 SUVANPRAKORN, Pichit
A topical application and methods for administration of active agents encapsulated within non-permeable macro-beads to enable a wider range of delivery vehicles, to provide longer product shelf-life, to allow multiple active agents within the composition, to allow the controlled use of the active agents, to provide protected and designable release features and to provide visual inspection for damage and inconsistency.
---------------------------------------------------------- ----------------------

THIENOPYRIDONE CARBOXAMIDES AND THEIR MEDICAL USE

(WO2005123744) 29.12.2005 A61P 37/00 ACTIVE BIOTECH AB
A compound of formula (I) wherein R is methyl, ethyl, n-propyl, iso-propyl, n-butyl or allyl; R´ is hydrogen, C1-C4 alkyl, C1-C3 alkoxy; halogen, trifluoromethyl or OCHxFy, R´´ is hydrogen, fluoro or chloro, that R´´ being fluoro or chloro only when R´ is fluoro or chloro; R3 is hydrogen or C1-C5 alkyl, R4 is hydrogen, CH2OCOC(CH3)3, pharmaceutically acceptable inorganic or organic cations, or COR4´ wherein R4´ is C1-C5 alkyl, phenyl, benzyl or phenethyl; R7 is methyl or ethyl; one of A and B is sulphur and the other is C-R2; when A is S, R2 is selected from hydrogen and methyl, with the proviso that R2 is methyl only when R3 is not hydrogen; and when B is S, R2 is hydrogen; and any tautomer t...
---------------------------------- ----------------------------------------------

COMPOSITION IN THE FORM OF A SPRAY COMPRISING A COMBINATION OF CLOBETASOL PROPIONATE AND CALCITRIOL, AN ALCOHOL PHASE AND AN OILY PHASE

(WO2005123091) 29.12.2005 A61K 31/57 GALDERMA S.A.
The invention relates to an anhydrous composition in the form of a spray comprising a combination of clobetasol propionate and calcitriol as pharmaceutical active ingredient, an alcohol phase and an oily phase in a physiologically acceptable medium, to the process for its preparation and to its use in cosmetics and dermatology.
---------------------------------------------------------- ----------------------

COMPOSITION IN SPRAY FORM COMPRISING A COMBINATION OF A CORTICOID AND A VITAMIN D DERIVATIVE IN AN OILY PHASE

(WO2005123090) 29.12.2005 A61K 31/57 GALDERMA S.A.
The invention relates to an anhydrous composition in spray form, comprising as pharmaceutical active the combination of clobetasol propionate and calcitriol and an oily phase in a physiologically acceptable medium, to the process for preparing it and to its use in dermatology.
---------------------------------------------------------- ----------------------

NOVEL TRANSDERMAL PREPARATION AND ITS PRODUCING METHOD

(WO2005123046) 29.12.2005 A61K 9/70 AMOREPACIFIC CORPORATION
Disclosed herein is a transdermal preparation comprising a hydrophobic polymeric pressure-sensitive adhesive matrix layer. Since the transdermal preparation comprises a polymeric matrix layer in which droplets containing an active ingredient are uniformly dispersed, it shows superior skin absorption. In addition, the transdermal preparation can be produced in a simple manner, and can contain an active ingredient at a high concentration, irrespective of the solubility of the active ingredient. Accordingly, the transdermal preparation can be applied to a variety of drugs. Further disclosed is a method for producing the transdermal preparation.
---------------------------------------------------------- ----------------------

HAIRCARE COMPOSITIONS AND METHODS

(WO2005123032) 29.12.2005 A61K 7/06 THE BOOTS COMPANY PLC
Compositions and methods are disclosed for use in the treatment or prevention of hair loss and/or the promotion of hair growth. The compositions comprise in combination Centella asiatica extract, or one or more active principles thereof, green coffee extract, or one or more active principles thereof, and one or more antioxidants, and a dermatologically acceptable carrier.
---------------------------------------------------------- ----------------------

AQUEOUS COSMETIC COMPOSITIONS

(WO2005123026) 29.12.2005 A61K 7/32 UNILEVER PLC
An aqueous cosmetic composition comprising a C1-C4 monohydric alcohol, other than chlorobutanol, a polyalkyleneoxide polysiloxane surfactant, and a cosmetic active.
-------------------------- ------------------------------------------------------

BAR SOAP WITH FIBROUS ASSEMBLY

(WO2005121299) 22.12.2005 C11D 17/04 UNILEVER PLC
A cleansing article composed of a solid or semi-solid foamable composition and a batting layer with bonded fibers is described that provides the user with a pleasant personal cleansing experience and which in one embodiment combines cleansing, aesthetic and/or skin benefit with active agents and exfoliation. The user also experiences substantial lather during use of the cleansing article. The batting layer is at least partially encompassed by the solid or semi-solid foamable composition.
---------------------------------------------------------- ----------------------

COMPOSITIONS AND METHODS FOR TOPICAL DIAGNOSTIC AND THERAPEUTIC TRANSPORT

(WO2005120546) 22.12.2005 A01N 25/34 ESSENTIA BIOSYSTEMS, INC.
Compositions and methods are provided that are useful for the delivery, including transdermal delivery, of biologically active agents, such as non-protein non-nucleotide therapeutics and protein-based therapeutics excluding insulin, botulinum toxins, antibody fragments, and VEGF. The compositions and methods are particularly useful for topical delivery of antifungal agents and antigenic agents suitable for immunization. Alternately, the compositions can be prepared with components useful for targeting the delivery of the compositions as well as imaging components.
-------------------------- ------------------------------------------------------

N- (2- BENZYL) -2-PHENYLBUTANAMIDES AS ANDROGEN RECEPTOR MODULATORS

(WO2005120477) 22.12.2005 A61P 5/26 MERCK &CO., INC.
Compounds of structural formula I are modulators of the androgen receptor (AR) in a tissue selective manner. These compounds are useful in the enhancement of weakened muscle tone and the treatment of conditions caused by androgen deficiency or which can be ameliorated by androgen administration, including osteoporosis, osteopenia, glucocorticoid-induced osteoporosis, periodontal disease bone fracture, bone damage following bone reconstructive surgery, sarcopenia, frailty, aging skin, male hypogonadism, postmenopausal symptoms in women, atherosclerosis, hypercholesterolemia, hyperlipidemia, obesity, aplastic anemia and other hematopoietic disorders, inflammatory arthritis and joint repair, HIV-wasting, prostate cancer, benign prostatic hyper...
---------- ----------------------------------------------------------------------

SOLUBLE STRIP FOR ORAL OR TOPICAL ADMINISTRATION

(WO2005120455) 22.12.2005 A61K 45/06 PASSION FOR LIFE HEALTHCARE LIMITED
A soluble e composition comprising at least one active ingredient distributed within a soluble base material, wherein the active ingredient has: at least an activity which minimises the effects of snoring and/or sleep apnoea and /or in blocking adhesion of harmful bacteria to host tissues to minimise the effects of conditions of the throat or throat disorders and/or for oral care and the composition is provided as a strip for inter-oral administration of the active ingredient to a site on the mucus membranes of the throat of a human or animal subject; or at least an activity in open skin or wound repair or healing and/or in blocking adhesion of harmful bacteria to host tissues and the composition is provided as a strip for topical administr...
---------------------------------------------------------- ----------------------

USE AS AN ANTIPERSPIRANT AGENT OF A FLOCCULATING WATER-SOLUBLE POLYMER; COSMETIC PROCESS FOR TREATING PERSPIRATION

(WO2005120448) 22.12.2005 A61K 7/32 L'OREAL
The present invention relates to the use of a flocculating water-soluble polymer comprising amine groups borne by a side substituent directly attached to the main chain, as an antiperspirant active agent in a cosmetic composition and particularly in a cosmetic composition not containing any antiperspirant aluminium and/or zirconium salts. The present invention also relates to a cosmetic process for treating perspiration, which consists in applying to the surface of the skin an effective amount of a flocculating water-soluble polymer comprising amine groups borne by a side substituent directly attached to the main chain.
---------------------------------------------------------- ----------------------

PHARMACEUTICAL COMPOSITIONS FOR THE TREATMENT OF PRURITUS

(WO2005117871) 15.12.2005 A61K 31/16 BURBAUM, Jonathan, J.
Composition comprising: a carrier; a first active ingredient comprising capsaicin, a capsaicin analog, another vanilloid receptor agonist or mixtures thereof; and at least one second active ingredient that functions as a topical anesthetic to cause localized numbness to induced skin irritation. Technique for treating the symptoms of pruritus comprising the step of applying a composition comprising a carrier, a first active ingredient comprising capsaicin, a capsaicin analog, another vanilloid receptor agonist or mixtures thereof, and at least one second active ingredient that functions as a topical anesthetic, to cause localized numbness to induced skin irritations.
---------------------------------- ----------------------------------------------

DIARYLALKANES AS POTENT INHIBITORS OF BINUCLEAR ENZYMES

(WO2005117849) 15.12.2005 A61K 31/015 UNIGEN PHARMACEUTICALS, INC.
The present invention implements a strategy that combines an enzyme inhibition assay with a chemical dereplication process to identify active plant extracts and the particular compounds - diarylalkanes and/or diarylalkanols within those extracts that specifically inhibit binuclear enzyme function. Included in the present invention are compositions of matter comprised of one or more of diarylalkanes and/or diarylalkanols, which inhibit the activity of binuclear enzymes, particularly tyrosinase and which prevent melanin overproduction. The present invention also provides a method for inhibiting the activity of a binuclear enzyme, particularly tyrosinase and a method for preventing and treating diseases and conditions related to binuclear enzy...
------------------------------------------------------------------ --------------

LIQUID DEPOT FORMULATIONS

(WO2005117830) 15.12.2005 A61K 9/12 CAMURUS AB
The present invention relates to pre-formulations comprising low viscosity, non-liquid crystalline, mixtures of: a) at least one neutral diacyl lipid and/or at least one tocopherol; b) at least one phospholipid; c) at least one biocompatible, oxygen containing, low viscosity organic solvent; wherein at least one bioactive agent is dissolved or dispersed in the low viscosity mixture and wherein the pre-formulation forms, or is capable of forming, at least one liquid crystalline phase structure upon contact with an aqueous fluid. The preformulations are suitable for generating parenteral, non-parenteral and topical depot compositions for sustained release of active agents. The invention additionally relates to a method of delivery of an activ...
------------------ --------------------------------------------------------------

SPRAYABLE FORMULATIONS FOR THE TREATMENT OF ACUTE INFLAMMATORY SKIN CONDITIONS

(WO2005115336) 08.12.2005 A61K 9/12 COLLEGIUM PHARMACEUTICAL, INC.
A topical spray or foam, methods of making the formulation, and methods of use thereof, has been developed. In one preferred embodiment, the composition includes one or more active agents and exhibits both antibacterial activity and antifungal activity. Excipients such as chemical disinfectants, antipruritic agents to minimize itching, and skin protective compounds may be added. The composition may be formulated to be dispensed as a spray or foam and the spray or foam may be administered either by a hand pump or by an aerosolizing propellant. A second single phase formulation has also been developed. The formulation comprises a first drug which is water soluble or hydrophilic and a second drug which is lipid soluble or hydrophobic, wherein ...
-------------------------------------------------------------------------- ------

COMBINATIONS OF HYALURONIC ACID AND POLYUNSATURATED FATTY ACIDS

(WO2005112910) 01.12.2005 A61K 31/202 BIONOVATE LIMITED
A pharmaceutical or veterinary composition comprises a hyaluronic acid or a salt thereof or an ester of hyaluronic acid with an alcohol of the aliphatic, heterocyclic or cycloaliphatic series, or a sulphated form of hyaluronic acid, together with at least one eicosanoid or tetraenoic polyunsaturated fatty acid or an ester or a salt thereof, preferably in the form of an extract of fatty acids from the New Zealand Green Lipped Mussel Perna canaliculus. The compositions are active against inflammatory conditions including osteoarthritis.
---------- ----------------------------------------------------------------------

METHOD AND FORMULATION FOR TRANSDERMAL DELIVERY OF IMMUNOLOGICALLY ACTIVE AGENTS

(WO2005112463) 24.11.2005 H04N 7/18 ALZA CORPORATION
A method for formulating an immunologically active agent and an apparatus for delivery same, the method comprising the steps of providing a bulk immunologically active agent, subjecting the bulk immunologically active agent to tangential-flow filtration to provide an immunologically active agent solution, adding at least one excipient to the agent solution and spray-drying the agent solution to form an immunologically active agent product; the apparatus comprising a microprojection member that includes a plurality of microprojections having a biocompatible coating disposed thereon that includes a spray-dried immunologically active agent. In a preferred embodiment, the immunologically active agent comprises an influenza vaccine, more prefera...
------------------------------------------------------------------ --------------

SKIN CLEANING COMPOSITION CONTAINING LONG-CHAIN ALKYL POLYAMINE

(WO2005110357) 24.11.2005 A61K 7/50 GREENBRIDGE ENVIRONMENTAL CONTROL LIMITED
The present invention describes a skin cleaning and disinfecting composition comprising an active component, wherein the active component comprises at least one alcohol, at least one halogen. The present invention also describes corresponding anti-bacterial, anti-viral and anti-fungal compositions, as well as a method for manufacturing same.
------------------------------------------ --------------------------------------

PERSONAL CARE COMPOSITIONS AND METHODS FOR REGULATING MAMMALIAN HAIR GROWTH AND SKIN CONDITION

(WO2005110353) 24.11.2005 A61K 7/48 THE PROCTER &GAMBLE COMPANY
Personal care compositions comprising at least one chronic skin care active selected from the group consisting of butylated hydroxytoluene (BHT), butylated hydroxyanisole (BHA), hexamidine, hexyl isobutyrate, menthyl anthranilate, methofuran, 3-butylidenepthalide, cetyl pyridinium chloride, green tea extract, catechins, phytosterols, ursolic acid, and plant extract compounds; at least one acute skin care active selected from the group consisting of particulate materials (including particles, pigments, and cross-linked silicone elastomers), panthenol, pantothenic acid derivatives, and tanning actives; and a dermatologically acceptable carrier. The composition can also comprise the cationic thickener, Polyquaternium 37. The present invention ...
-------------------------------------------------------------------------- ------

PERSONAL CARE COMPOSITIONS AND METHODS REGULATING MAMMALIAN GROWTH

(WO2005110352) 24.11.2005 A61K 7/48 THE PROCTER &GAMBLE COMPANY
Personal care compositions comprising at least one chronic skin care active selected from the group consisting of butylated hydroxytoluene (BHT), butylated hydroxyanisole (BHA), hexyl isobutyrate, menthyl anthranilate, methofuran, 3- butylidenepthalide, cetyl pyridinium chloride, green tea extract, catechins, phytosterols, ursolic acid, and plant extract compounds; at least one acute skin care active selected from the group consisting of particulate materials (including particles, pigments, and cross-linked silicone elastomers), alkane polyols, panthenol and pantothenic acid derivatives, and tanning actives; and a dermatologically acceptable carrier. The composition can also comprise the cationic thickener, Polyquaternium 37. The present inv...
-------------------------- ------------------------------------------------------

ANTI ACNE SKINCARE COMPOSITION AND SKINCARE ARTICLE

(WO2005110349) 24.11.2005 A61K 7/48 RECKITT &COLMAN (OVERSEAS) LIMITED
There is disclosed a cleansing and moisturising composition for topical application to the skin. The composition comprises salicylic acid as active ingredient, and has the form of an emulsion comprising 70-95% by weight of an aqueous phase and 5-30% by weight of an oil phase, the salicylic acid being dissolved in the oil phase, and the composition comprising one or more moisturising agents. The composition may be incorporated into a wipe substrate for ease of application to the skin. The compositions have the combined effects of cleansing and moisturising the skin and may be used in the prophylactic or remedial treatment of acne.
---------------------------------- ----------------------------------------------

FLUORINATED 4- AZASTEROIDS AS ANDROGEN RECEPTOR MODULATORS

(WO2005105091) 10.11.2005 A61K 31/437 MERCK &CO., INC.
Compounds of structural formula I are modulators of the androgen receptor (AR) in a tissue selective manner. These compounds are useful in the enhancement of weakened muscle tone and the treatment of conditions caused by androgen deficiency or which can be ameliorated by androgen administration, including osteoporosis, osteopenia, glucocorticoid-induced osteoporosis, periodontal disease, bone fracture, bone damage following bone reconstructive surgery, sarcopenia, frailty, aging skin, male hypogonadism, postmenopausal symptoms in women, atherosclerosis, hypercholesterolemia, hyperlipidemia, obesity, aplastic anemia and other hematopoietic disorders, inflammatory arthritis and joint repair, HIV-wasting, prostate cancer, benign prostatic hype...
---------------------------------------------------------- ----------------------

PERMEATION ENHANCER COMPRISING GENUS CURCUMA OR GERMACRONE FOR TRANSDERMAL AND TOPICAL ADMINISTRATION OF ACTIVE AGENTS

(WO2005105059) 10.11.2005 A61K 9/70 ANTARES PHARMA IPL AG
A formulation, method and system for the topical, transdermal or transmucosal administration of a therapeutically effective active agent. Particularly, the invention provides a formulation, system and method for enhancing the permeation or penetration of active agents across the dermal or mucosal surfaces of a mammalian subject. The formulation includes a plant extract of the genus Curcuma of the family Zingiberaceae, a germacrone, or a natural or synthetic constituent thereof, which has been found to increase penetration of the active agent across the dermal or mucosal surface. If desired, a secondary permeation enhancer of a polyalcohol, a monoalkyl ether of diethylene glycol, a tetraglycol, or a mixture thereof can be used for certain ac...
-------------------------------------------------- ------------------------------

PERSONAL CARE COMPOSITIONS THAT DEPOSIT HYDROPHILIC BENEFIT AGENTS

(WO2005105033) 10.11.2005 A61K 8/35 THE PROCTER &GAMBLE COMPANY
A personal care composition comprising a hydrophilic liquid, a structurant for said hydrophilic liquid, a surface active, a lipid, and an aqueous phase; wherein said lipid, said hydrophilic liquid, said structurant, and said surface active form a lipid phase; wherein said hydrophilic liquid, said structurant, and said surface active are connected to said lipid in said lipid phase. These compositions provide improved skin and/or hair moisturization, appearance, aesthetics and skin and/or hair conditioning during and/or after application, and are useful in providing improved deposition to the desired area of the skin and/or hair. The present invention is further directed to a method of using the personal care composition.
---------------------------------- ----------------------------------------------

PERSONAL CARE COMPOSITIONS THAT DEPOSIT SOLID HYDROPHILIC BENEFIT AGENTS

(WO2005105032) 10.11.2005 A61K 8/35 THE PROCTER &GAMBLE COMPANY
A personal care composition comprising a hydrophilic solid, a surface active, a lipid, and an aqueous phase; wherein the lipid, hydrophilic solid, and surface active form a lipid phase; wherein the hydrophilic solid and the surface active are on the surface of the lipid, within the domain of the lipid, or both on the surface and within the domain of the lipid in the lipid phase. These compositions provide improved skin moisturization, appearance, aesthetics and skin conditioning during and/or after application, and are useful in providing improved deposition to the desired area of the skin. The present invention is further directed to a method of using the personal care composition.
-------------------------------------------------- ------------------------------

APPARATUS AND METHOD FOR TRANSDERMAL DELIVERY OF FENTANY-BASED AGENTS

(WO2005102334) 03.11.2005 A61K 31/445 ALZA CORPORATION
An apparatus and method for transdermally delivering a biologically active agent comprising a delivery system having a microprojection member (or system) that includes a plurality of microprojections (or array thereof) that are adapted to pierce through the stratum corneum into the underlying epidermis layer, or epidermis and dermis layers. In one embodiment, the fentanyl-based agent is contained in a biocompatible coating that is applied to the microprojection member. In a further embodiment, the delivery system includes a gel pack having a fentanyl-based agent-containing hydrogel formulation that is disposed on the microprojection member after application to the skin of a patient. In an alternative embodiment, the fentanyl-based agent...
-------------------------- ------------------------------------------------------

PERSONAL CARE COMPOSITIONS AND CONCENTRATES FOR MAKING THE SAME

(WO2005102263) 03.11.2005 A61K 8/365 LONZA INC.
The present invention relates to color stable personal care compositions that provide anti-oxidiation, moisturization, and/or prevent biodegradation in personal care formulations. These compositions contain erythorbic acid or a salt thereof, caffeic acid or a salt thereof, S- gluconolactone, or a mixture thereof. The present invention further relates to methods of moisturizing skin with erythorbic acid or a salt thereof, or S- gluconolactone. The present invention also relates to concentrates of active ingredients preloaded with a sufficient amount of an anti-oxidation, moisturizing and/or biodegradation prevention agent so that when it is diluted for use, the final formulation includes an anti-oxidation, moisturizing and/or biodegradation pr...
------------------------------------------------------------------ --------------

PERSONAL CARE COMPOSITIONS THAT DEPOSIT HYDROPHILIC BENEFIT AGENTS

(WO2005102011) 03.11.2005 A61K 8/67 THE PROCTER &GAMBLE COMPANY
A personal care composition comprising a hydrophilic benefit active, a multi-wetting material, and an aqueous phase, wherein the hydrophilic benefit active may be a hydrophilic solid or a hydrophilic liquid with a structurant, wherein the multi- wetting material and the hydrophilic benefit active form a multi-wetting phase. These compositions provide improved skin and/or hair moisturization, appearance, aesthetics and skin and/or hair conditioning during and/or after application, and are useful in providing improved deposition to the desired area of the skin and/or hair. The present invention is further directed to a method of using the personal care composition.
---------------------------------------------------------- ----------------------

PERSONAL CARE COMPOSITIONS THAT DEPOSIT SUNLESS TANNING BENEFIT AGENTS

(WO2005102010) 03.11.2005 A61K 8/35 THE PROCTER &GAMBLE COMPANY
A personal care composition that comprises a sunless tanning active, a surface active, a lipid, and an aqueous phase; wherein the lipid, the sunless tanning active, and the surface active form a lipid phase; wherein the sunless tanning active and the surface active are on the surface of the lipid, within the domain of the lipid, or both on the surface and within the domain of the lipid in the lipid phase. These compositions deposit sunless tanning actives on keratinous surfaces as well as provide improved skin moisturization, appearance, aesthetics and skin feel during and/or after application. The present invention is further directed to a method of using the personal care composition.
-- ------------------------------------------------------------------------------

APPARATUS AND METHOD FOR TRANSDERMAL DELIVERY OF INFLUENZA VACCINE

(WO2005099751) 27.10.2005 A61K 39/02 ALZA CORPORATION
An apparatus and method for transdermally delivering an immunologically active agent comprising a delivery system having a microprojection member (or system) that includes a plurality of micrpojections (or array thereof) that are adapted to pierce through the stratum corneum into the underlying epidermis layer, or epidermis and dermis layers, the micrprojection member having a biocompatible coating disposed thereon that includes the immunologically active agent. Preferably, the biocompatible coating is formed from a vaccine coating formulation.
------------------------------------------ --------------------------------------

17 BETA-ACETAMIDE-4- AZASTEROIDS AS ANDROGEN RECEPTOR MODULATORS

(WO2005099707) 27.10.2005 A61K 31/473 MERCK &CO., INC.
Compounds of structural formula (I) are modulators of the androgen receptor (AR) in a tissue selective manner. These compounds are useful in the enhancement of weakened muscle tone and the treatment of conditions caused by androgen deficiency or which can be ameliorated by androgen administration, including osteoporosis, osteopenia, glucocorticoid-induced osteoporosis, periodontal disease, bone fracture, bone damage following bone reconstructive surgery, sarcopenia, frailty, aging skin, male hypogonadism, postmenopausal symptoms in women, atherosclerosis, hypercholesterolemia, hyperlipidemia, obesity, aplastic anemia and other hematopoietic disorders, inflammatory arthritis and joint repair, HIV-wasting, prostate cancer, benign prostatic hy...
---------------------------------------------------------- ----------------------

METHODS FOR THE DIAGNOSIS OF CANCERS OR OF PRECANCEROUS LESIONS

(WO2005098443) 20.10.2005 G01N 33/574 INSERM (Institut National de la Santé et de la Recherche Médicale)
The present invention relates to the use of a compound enabling the detection of the substantial lack of expression of the TP53INP1 protein in a biological sample, for the manufacture of a drug intended for the prognosis or the diagnosis of cancers and/or of precancerous lesions, or for the screening of drugs active on cancers.
------------------ --------------------------------------------------------------

ACTIVE SUBSTANCE COMBINATION COMPRISING A CARBINOL COMBINED TO AT LEAST AN NSAID

(WO2005097099) 20.10.2005 A61K 45/06 LABORATORIOS DEL DR. ESTEVE, S.A.
The present invention relates to an active substance combination comprising at least one substituted carbinol compound and at least one non- steroidal anti-inflammatory drug (NSAID), a medicament comprising said active substance combination, a pharmaceutical formulation comprising said active substance combination for the manufacture of a medicament.
------------------ --------------------------------------------------------------

METHOD FOR THE PREPARATION OF COSMETIC EMULSIONS

(WO2005097059) 20.10.2005 A61K 7/48 LONZA, INC.
A novel method is disclosed for the preparation of oil-in-water emulsions suitable for cosmetic or topical dermatological products. The method comprises the step of mixing at least one cosmetically active ingredient with an aqueous emulsion of washed vegetable oil bodies (oleosomes) and the temperature of the products does never exceed about 40°C during the steps of the method.
------------------------------------------------------------------ --------------

METHODS OF USING AND COMPOSITIONS COMPRISING IMMUNOMODULATORY COMPOUNDS FOR THE TREATMENT AND MANAGEMENT OF SKIN DISEASES OR DISORDERS

(WO2005091991) 06.10.2005 A61K 31/445 CELGENE CORPORATION
Methods of treating, preventing, correcting and/or managing skin diseases or disorders characterized by overgrowths of the epidermis, keratoses, scleroderma, cutaneous vasculitis, acne or wrinkles are disclosed. Specific embodiments encompass the administration of an immunomodulatory compound, or a pharmaceutically acceptable salt, solvate, hydrate, stereoisomer, clathrate, or prodrug thereof, alone or in combination with a second active agent. Specific second active ingredients are capable of affecting or inhibiting cell growth or proliferation, removing or improving acne scars, or reducing or correcting wrinkle lines. Pharmaceutical compositions, single unit dosage forms, and kits suitable for use in methods of the invention are also disc...
-------------------------------------------------- ------------------------------

SKIN TREATMENT METHOD WITH LACTOBACILLUS EXTRACT

(WO2005091933) 06.10.2005 A61K 35/66 E-L MANAGEMENT CORPORATION
The present invention relates to a method of stimulating beta- defensins in skin cells which comprises applying to the skin cells an effective amount of a Lactobacillus extract or active fraction thereof.
---------- ----------------------------------------------------------------------

ANTI-VAGINITIS COMPOSITIONS COMPRISING A TRIAZOLE

(WO2005087270) 22.09.2005 A61K 31/4166 EDKO TRADING AND REPRESENTATION CO. LTD.
The invention provides pharmaceutical compositions for topical administration in treating vaginal infections, e.g. vaginitis. Such compositions comprise: W at least one triazole compound active against Candida albicans, preferably at least one such compound which is additionally active against one or more non- albicans Candida species, and (ii) at least one additional anti-vaginitis medicament, preferably an anti-fungal, anti-protozoal and/or anti-bacterial agent. Preferred compositions include as active agents is terconazole in combination with tinidazole and/or tioconazole. In a further aspect the compositions in accordance with the invention also include a bioadhesive agent, e.g. a mucoadhesive, to promote adhesion to the vaginal mucosa....
------------------------------------------------------------------ --------------

NOVEL COMPOSITIONS FOR TOPICAL DELIVERY

(WO2005087195) 22.09.2005 A61K 9/00 PANACEA BIOTEC LTD.
Pharmaceutical composition for topical administration comprising of at least one active ingredient, its salts, esters, hydrates or derivatives; a gelator system consisting of a fiend of surfactants, a solvent system comprising at least one oily component; an aqueous phase; optionally containing one or more stabilizing agent; and other pharmaceutically acceptable excipients; and process for preparing such compositions are provided. Also provided is a method for the management/treatment of fungal, bacterial or microbial infections, inflammations, autoimmune conditions, or hormonal disorders which comprises administering a pharmaceutically effective amount of such pharmaceutical composition to a subject in need of such treatment. The compositi...
---------------------------------------------------------- ----------------------

USE OF AN OLIGONUCLEOTIDE OR ITS ACTIVE DERIVATIVE FOR THE PREPARATION OF A PHARMACEUTICAL COMPOSITION FOR INHIBITING THE FORMATION OF METASTASES IN CANCER TREATMENT

(WO2005084712) 15.09.2005 A61K 31/713 ANTISENSE PHARMA GMBH
The present invention is related to pharmaceutical compositions for the inhibition of metastases and treatment of cancer such as bladder carcinoma, colon cancer, endometrial cancer, hepatocellular carcinoma, leukemia, lymphoma, melanoma, non-small cell lung cancer (NSCLC), ovarian cancer, pancreatic cancer, prostate cancer, soft tissue cancer, renal cancer, osteosarcoma, mesothelioma, myeloma multiple, bladder carcinoma and esophagcal cancer as well as the use of these pharmaceutical compositions for the treatment of said metastases and cancers. Another aspect of this invention are new antisense oligonucleotides inhibiting the formation of human interleukin 10 and their synthesis. A further aspect of this invention is the use IL-10 antisens...
------------------------------------------------------------------ --------------

PHARMACEUTICAL COMPOSITION FOR TOPICAL USE IN FORM OF XEROGELS OR FILMS AND METHODS FOR PRODUCTION

(WO2005084650) 15.09.2005 A61K 9/70 SWITCH BIOTECH AG
The present invention relates to dry delivery system comprising a xerogel or film with applied active ingredients for topical active ingredient delivery or other purposes. Said delivery system are obtainable by a method according to the invention. The present invention also provides for methods for achieving defined localization of stable or unstable active substances on dry xerogels or films, which can be reconstituted into hydrogels. From the obtained delivery systems, the active substances are released with advantageous release kinetics.
---------------------------------------------------------- ----------------------

FORMULATIONS DECREASING INFECTIVITY OF PULMONARY DISEASES

(WO2005084638) 15.09.2005 A61K 47/02 PULMATRIX INC.
Formulations have been developed for pulmonary delivery to treat or reduce the infectivity of diseases such as viral infections, especially tuberculosis, SARS, influenza and respiratory synticial virus in humans and hoof and mouth disease in animals, or to reduce the symptoms of allergy or other pulmonary disease. Formulations for pulmonary administration include a material that significantly alters physical properties such as surface tension and surface elasticity of lung mucus lining fluid, which may be isotonic saline and, optionally, a carrier. The formulation may be administered as a liquid solution, suspension, aerosol, or powder where the particles consist basically of an osmotically active solute. Drugs, especially antivirals or ant...
---------------------------------- ----------------------------------------------

COMPOSITION FOR REGULATING THE TROPHISM OF HAIR FOLLICLES AND THE CUTANEOUS PRODUCTION OF SEBUM AND USE THEREOF IN ANDROGENETIC ALOPECIA

(WO2005084621) 15.09.2005 A61K 8/97 GIULIANI S.p.A.
The present invention relates to a composition for regulating the trophism of hair follicles and the cutaneous production of sebum and its use in androgenetic alopecia, comprising the synergic association of an extract from Boehmeria Nippononivea with a compound active at the keratin epithelial structure level, selected from specific sulfur-donor compounds and antioxidants. The composition of the invention is suitable for topical and/or oral administration.
---------------------------------------------------------- ----------------------

MULTI-COMPONENT BIOLOGICAL TRANSPORT SYSTEMS

(WO2005084361) 15.09.2005 A61K 38/00 ESSENTIA BIOSYSTEMS, INC.
Compositions and methods are provided that are useful for the delivery, including transdermal delivery, of biologically active agents, such as non-protein non- nucleotide therapeutics and protein-based therapeutics excluding insulin, botulinum toxins, antibody fragments, and VEGF. The compositions and methods are particularly useful for topical delivery of antifungal agents and antigenic agents suitable for immunization. Alternately, the compositions can be prepared with components useful for targeting the delivery of the compositions as well as imaging components.
--------------------------------------------------------------------------------

COSMETIC AND PHARMACEUTICAL FOAM WITH SOLID MATTER

(WO2005076697) 25.08.2005 A61K 9/00 FOAMIX LTD.
A foamable composition includes about 2 to about 30% by weight solid particles; about 2 to about 75% by weight hydrophobic solvent; about 10 to about 85% by weight water; about 0.1 % to about 5% by weight surface- active agent; about 0.1 % to about 5 wt% by weight stabilizer/gelling agent; and a liquefied or compressed gas propellant in a container, which upon release provides a breakable foam suitable for topical administration.
------------------ --------------------------------------------------------------

COMPOSITIONS CONTAINING INTERNALLY ACTIVATED ANTIOXIDANT

(WO2005074951) 18.08.2005 A61K 35/74 E-L MANAGEMENT CORPORATION
The present invention provides a method of activating a heat-activated component by an internal source of heat. As a result of an exothermic reaction between a combination of a heat-generating component and the heat-activated component, a source of heat is created within the composition without the use of an external heating source such as a hair dryer or exposure to the sun. The heat-generating component provides a heat release that triggers the activity of the heat-activated component. The compositions of the present invention are self-contained systems for generating heat to trigger the heat-activated component, and therefore, do not rely upon an external source of heat to affect the heat-activated component.
-------------------------- ------------------------------------------------------

A COMPOSITION CONTAINING GINSENOSIDE F1 OR COMPOUND K FOR SKIN EXTERNAL APPLICATION

(WO2005070436) 04.08.2005 A61K 31/70 AMOREPACIFIC CORPORATION
The present invention relates to an inhibitor for the biosynthesis of gelatinase comprising ginsenoside F1 (20-O-?-D-glucopyranosyl-20(S)-protopanaxatriol) or compound K (20-0-?-D-glucopyranosyl-20(S)-protopanaxadiol), which is a chief metabolite of ginseng saponin, as an active ingredient; and a cosmetic/medical composition for the prevention of skin-aging comprising the same which is superior in inhibiting the decomposition of epidermal-dermal junction and also in accelerating the generation thereof.
---------------------------------- ----------------------------------------------

DERMAL PATCH FOR IONTOPHORESIS

(WO2005068016) 28.07.2005 A61K 9/70 POWER PAPER LTD
The invention is generally directed to a kit and patch for transdermal or intradermal delivery of at least one substance into the skin. The kit includes a dermal patch (10) having an electrochemical cell (14) with two electrodes (22, 24) and a retainer (30) for retaining a conductive fluid/composition which may further include an active substance. The conductive fluid/composition can be deposited on at least one of the two electrodes. Alternatively, the conductive fluid/composition can be applied topically to the skin.
---------------------------------- ----------------------------------------------

TOPICAL SOLUTIONS COMPRISING HIGH CONCENTRATIONS OF PIPERIDINOPYRIMIDINE DERIVATIVES AND METHODS OF USE THEREOF

(WO2005067873) 28.07.2005 A61K 31/505 REGROWTH, LLC
This invention relates to a method for achieving a novel solution comprising a high percentage of a piperidinopyrimidine derivative, more particularly minoxidil. The method of the current invention results in a highly effective solution for facilitating hair growth comprising a high concentration of Minoxidil, that is not cosmetically unattractive when applied to a treatment area and that does not cause skin irritation in the treatment area. In another aspect of the invention said solution comprising high percentage Minoxidil may further comprise co-active ingredients, such as azelaic acid. The present invention also provides a method for stimulating the growth of hair or for preventing hair loss in humans and lower animals.
------------------------------------------------------------------ --------------

PHARMACEUTICAL METHODS, DOSING REGIMES AND DOSAGE FORMS FOR THE TREATMENT OF ALZHEIMER'S DISEASE

(WO2005065069) 21.07.2005 A61K 9/20 MYRIAD GENETICS, INC.
In general, the invention relates to a pharmaceutical dose having R-flurbiprofen as the active ingredient that upon oral administration of a single dose to a fasting subject provides a Cmax of about 30-95 µg per mL. When the dose is administered to an individual having mild-to-moderate Alzheimer's disease (or desiring protection against Alzheimer's disease) twice daily for at least 4 months according to the described guidelines, an improvement or lessening in decline of cognitive function as characterized by cognition tests is observed in the patient. The composition of the invention is formulated with one or more pharmaceutically acceptable excipients, salts or carriers.
---------- ----------------------------------------------------------------------

COMPOSITION COMPRISING XANTHOCERAS SORBIFOLIA EXTRACTS, COMPOUNDS ISOLATED FROM SAME, METHODS FOR PREPARING SAME AND USES THEREOF

(WO2005063273) 14.07.2005 A61K 31/05 PACIFIC ARROW LIMITED
This invention provides methods and process of identification and producing pure, biologically active compound(s) from Xanthoceras sorbifolia. This invention also provides the composition of the pure compound(s) of interest from Xanthoceras sorbifolia. The purified compounds comprise saponins. The composition can be used for treating cancer, arthritis, rheumatism, poor circulation, arteriosclerosis, Raynaud’s syndrome, angina pectoris, cardiac disorder, coronary heart disease, headache, dizziness, kidney disorder, impotence and premature ejaculation; for preventing cerebral aging; for improving memory, cerebral functions; or for curing enuresis, frequent micturition, urinary incontinence, dementia, weak intelligence and Alzheimer...
---------- ----------------------------------------------------------------------

CHOLESTERYL HEMISUCCINATE INCORPORATED LIPID-BASED NANO-CARRIERS AND SKIN- CARE COMPOSITIONS FOR EXTERNAL APPLICATION CONTAINING THE SAME

(WO2005063212) 14.07.2005 A61K 9/127 AMOREPACIFIC CORPORATION
The present invention relates to cholesteryl hemisuccinate (CHEMS)-incorporated lipid-based nano-scale carriers and to skin-care compositions for external application containing the same. The nano- scale carriers of the present invention can increase the skin penetration of biologically active substances, and have high pH-sensitivity and thereby can release effectively the biologically active substances loaded therein within a cell, so as to enhance the effect as a carrier. Further, the skin-care external compositions of the present invention containing said nano-scale carriers can deliver maximally the efficacies of biologically active substances.
---------- ----------------------------------------------------------------------

COSMETIC COMPOSITION

(WO2005063187) 14.07.2005 A61K 8/28 UNILEVER PLC
A composition comprising an antiperspirant or deodorant active and which is substantially free of alcohol and has a viscosity of less than 100 centipoise and a contact angle less than 90o. A product comprising the composition marketed in a porous dome applicator.
-------------------------------------------------- ------------------------------

NEW SUNSCREEN COMPOUNDS AND COMPOSITIONS CONTAINING SAME AND METHODS FOR USE THEREOF

(WO2005062860) 14.07.2005 A61K 8/40 AVON PRODUCTS, INC.
There is provided a photostable and synergistically enhanced topical sunscreen composition that provides increased substantivity, waterproofness, sweat resistance and rub off resistance. There is further provided methods of enhancing the photostability of a sunscreen active in a topical sunscreen composition, synergistically enhancing the W absorbance of a topical sunscreen composition having a sunscreen active, and enhancing the substantivity, waterproofness, sweat resistance and rub off resistance in a topical sunscreen composition. The preferred compositions and methods have a sunscreen active, a cosmetically acceptable vehicle, and novel 2- substituted-3,3-diaryl-2- propenoic acid derivatives with [A] a C16 to C50 straight or branche...
-- ------------------------------------------------------------------------------

COMBINATION THERAPY ASSOCIATING A TGF-BRETA ANTAGONIST WITH A CHEMIOTHERAPEUTIC AGENT

(WO2005059133) 30.06.2005 A61K 31/04 ANTISENSE PHARMA GMBH
The invention concerns a pharmaceutical composition comprising at least one stimulator of the immune cell functions and at least one substance inhibiting the cell proliferation and/or inducing cell death. In a preferred embodiment the stimulator of the function of the immune system and/ or the immune cells are antagonists of TGF-beta selected from the group of oligonucleotides hybridizing with an area of the messenger RNA and or DNA encoding TGF-beta and the at least one substance inhibiting cell proliferation and/or inducing cell death is selected from the group of temozolomide, nitrosoureas, Vinca alkaloids, antagonists of the purine and pyrimidines bases, cytoststatic active antibiotics, caphthotecine derivatives, anti estrogens, anti-an...
---------------------------------- ----------------------------------------------

BIOLOGICAL ACTIVE BLOOD SERUM OBTAINED BY ELECTROSTIMULATION

(WO2005058889) 30.06.2005 A61K 35/16 OWEN HOLDING LTD.
The present invention relates to a method for preparing a blood serum product, the blood serum product and a pharmaceutical composition comprising said blood serum product as well as uses thereof in the treatment of various diseases and conditions, including epileptic seizures and apoplexy.
------------------------------------------------------------------ --------------

USE OF ONDANSETRON FOR THE TREATMENT OF INFLAMMATION, AND PHARMACEUTICAL COMPOSITIONS THEREOF

(WO2005058312) 30.06.2005 A61K 31/4178 GALDERMA RESEARCH &DEVELOPMENT, S.N.C.
The present invention generally relates to the use of ondansetron, its salts and base, as an active principle in the manufacture of pharmaceutical compositions, more particularly dermatological compositions, intended for a curative and/or prophylactic antiinflammatory treatment, by the topical route. More specifically, the present invention provides the use of Ondansetron, its salt and base to topically treat rosacea, an inflammatory skin disorder.
---------------------------------- ----------------------------------------------

METHOD OF TREATMENT FOR UNDESIRED EFFECT FOLLOWING TRANSDERMAL OR TOPICAL DRUG DELIVERY

(WO2005056103) 23.06.2005 A61F 13/00 ACRUX DDS PTY LTD
This invention relates to a method for inhibiting the percutaneous absorption of a physiologically active agent topically applied to a transdermal administration site of a subject, the method including the step of applying to skin of the subject at the transdermal administration site, a device (1, 7) comprising a membrane (8) for contacting the skin of the subject coated on the skin contacting side thereof (11) with a layer of an adhesive (10).
------------------------------------------------------------------ --------------

THE USE OF UROCANIC ACID BEING ABLE TO ACIDIFY THE CELL CYTOPLASM AND FOR PREVENTING OR HALTING CELLULAR PROLIFERATION IN A PERSON

(WO2005056007) 23.06.2005 A61K 31/415 BIOCIS PHARMA OY
This invention relates to the use of urocanic acid or another pharmaceutically acceptable agent being able to acidify the cell cytoplasm, for the manufacture of a pharmaceutical composition useful for causing inhibition or halting of transformed or non-transformed cell proliferation in a person or an animal, wherein an effective amount of said agent is administered in an essentially non-dissociated form to the person or animal. This invention also concerns the use of said agent as an enhancer for other therapeutically active agents. The invention also concerns a pharmaceutical composition.
---------- ----------------------------------------------------------------------

DELIVERY PEPTIDES, THEIR CONSTRUCTS WITH ACTIVE AGENTS AND USE

(WO2005054279) 16.06.2005 A61K 47/48 ORTHOGEN AG
The present invention refers to delivery proteins, protein-cargo complexes, methods, and means for the enhanced delivery or transport of drugs, biologically active agents or other compounds as cargo or cargo molecules onto, into, or across biological membranes or tissues forming a biological barrier.
---------------------------------------------------------- ----------------------

METHODS AND COMPOSITIONS FOR TREATING INFLAMMATORY AND DERMATOLOGICAL CONDITIONS

(WO2005053718) 16.06.2005 A61P 17/00 NATURALEAF, INC.
The present invention relates to a method for the treatment or prophylaxis of a condition selected from a non-arthritic inflammatory condition (e.g., dermatitis, psoriasis, allergic rhinitis, acne, angina, asthma, emphysema, pelvic inflammatory disease, pharyngitis, raw or sore throat, redness or rubor), an arthritic condition, an aesthetic skin condition (e.g., skin aging, wrinkles, skin texture, skin cracking, skin blemishes, skin colour, acne, photo aging or symptom of sun exposure) and a muscle injury in a subject, said method comprising administering to said subject oil from a Canarium nut or other part of a Canarium plant or horticultural relative thereof or one or more pharmacologically active fractions, extracts or components thereo...
-------------------------- ------------------------------------------------------

SPRAYABLE COMPOSITION FOR THE ADMINISTRATION OF VITAMIN D DERIVATIVES

(WO2005053666) 16.06.2005 A61K 31/09 GALDERMA RESEARCH &DEVELOPMENT, S.N.C.
The invention relates to a composition in the form of a spray comprising a pharmaceutical active agent, which is a derivative of vitamin D, at least one volatile silicone and a nonvolatile oily phase in a physiologically acceptable medium, to the process for preparing it and to its use in cosmetics and in dermatology.
---------------------------------- ----------------------------------------------

INDAZOLE COMPOUNDS AND METHODS OF USE THEREOF AS PROTEIN KINASE INHIBITORS

(WO2005051942) 09.06.2005 C07D 401/14 SIGNAL PHARMACEUTICALS, LLC
This invention is directed to Indazole Compounds or pharmaceutically acceptable salts, solvates and hydrates thereof. The Indazole Compounds have utility in the treatment or prevention of a wide range of diseases and disorders that are responsive to the inhibition, modulation or regulation of kinases, such as inflammatory diseases, abnormal angiogenesis and diseases related thereto, cancer, atherosclerosis, a cardiovascular disease, a renal disease, an autoimmune condition, macular degeneration, disease-related wasting, an asbestos-related condition, pulmonary hypertension, diabetes, obesity, pain and others. Thus, methods of treating or preventing such diseases and disorders are also disclosed, as are pharmaceutical compositions comprising...
-------------------------------------------------- ------------------------------

METHOD AND SYSTEM FOR RAPID TRANSDERMAL ADMINISTRATION

(WO2005051476) 09.06.2005 A61M 37/00 ACRUX DDS PTY LTD
Invention relates to a method for transdermal delivery of a topically applied physiologically active agent comprising: providing a micro-projection apparatus comprising an array of microprojections (3) extending from a substrate; applying the array of micro-projections to an area of skin to form an array of microscopic holes therein; and contacting the area of skin with a transdermal composition comprising a physiologically active agent and at least one penetration enhancer wherein the formation of the microscopic holes and penetration enhancer facilitate transdermal delivery of the physiologically active agent.
-- ------------------------------------------------------------------------------

STABLE PERSONAL WASH SOAP COMPOSITION AND PROCESS TO PREPARE THE SAME

(WO2005051343) 09.06.2005 A61K 8/44 UNILEVER PLC
A storage stable personal wash soap composition comprising 15-85 % detergent active, 0.1-20 % of skin lightening agent selected from niacin, niacinamide, their precursors and derivatives, and 0.02 % to 2 % of diethylene triamine penta acetic acid (DTPA).
------------------ --------------------------------------------------------------

AMNIOTIC-DERIVED PEPTIDE AND USES THEREOF

(WO2005049638) 02.06.2005 A61K 38/00 LAJOR BIOTECH, INC.
The present invention relates to the method(s) of synthesis of and the therapeutic and cosmetic applications of biologically active peptides for improving the appearance of skin, for hastening wound healing and for treating and/or preventing the progression of various conditions, injuries and diseases, including but not limited to viral hepatitis B and C, herpes zoster ganglioneuritis, diabetic peripheral polyneuropathy, nephrotic syndrome, juvenile rheumatoid arthritis, rheumatoid arthritis, psoriatic arthritis, bronchial asthma, respiratory infection, breast cancer, epilepsy, psoriasis, atherosclerosis and other forms of vascular obstructions, myocardial infarction, HIV and SARS infection, brain cell malfunction due to ischemia and trauma...
--------------------------------------------------------------------------------

COMPOSITION AND METHOD FOR TREATMENT OF ACNE

(WO2005049060) 02.06.2005 A61K 31/355 GOODLESS, Dean, R.
The present invention relates to a nutritional product, dietary supplement or pharmaceutical composition for the treatment of acne and related skin disorders. The invention also relates to a composition having a combination of ingredients such that it reduces symptoms associated with acne and related skin disorders. The invention relates to such a composition containing a variety of vitamins, minerals and one or more herbal medicine sources. In one preferred embodiment, the vitamins, minerals and one or more herbal medicine sources are present in an amount such that its mechanism of action is through inhibition of the growth of Propionobacterium acnes (P. acnes) and the inhibition of lipogenesis of sebum production. In another preferred emb...
------------------------------------------------------------------ --------------

NEW FORMULATION FOR RETINOID-CONTAINING SOFT GELATIN CAPSULES

(WO2005048994) 02.06.2005 A61K 9/48 BASILEA PHARMACEUTICA AG
A new pharmaceutical formulation for retinoid-containing soft gelatin capsules is disclosed. The new formulation comprises a soft gelatin capsule filled with a fill mass comprising a retinoid as an active ingredient, a natural vegetable oil, a partially hydrogenated natural vegetable oil and medium chain triglycerides. Optionally, the new formulation also comprises a natural wax. In a particularly preferred embodiment, the soft gelatin capsule comprises pig gelatin in the capsule shell in combination with the above fill mass.
-------------------------- ------------------------------------------------------

ANTIPERSPIRANT COMPOSITION AND APPLICATOR THEREFOR

(WO2005048966) 02.06.2005 A61K 8/04 THE PROCTER &GAMBLE COMPANY
An antiperspirant product comprising an antiperspirant composition and an applicator for storing and discharging the antiperspirant composition. The antiperspirant composition comprises an antiperspirant active. The applicator has a longitudinal axis and comprises a release system structured to facilitate discharge of the antiperspirant composition such that the antiperspirant composition discharges as a portion of a foam comprising a dispersion of gas bubbles in a continuous liquid medium comprising the antiperspirant active that is suspended or dissolved therein, and a skin-contacting surface structured to receive and retain the portion of the foam thereon such that the portion of the foam of 0.2 gram is retained on the skin- contacting su...
---------------------------------------------------------- ----------------------

COATING APPARATUS AND METHOD

(WO2005048768) 02.06.2005 A45D 44/00 HYDROCO (AUSTRALIA) PTY LTD
The present invention provides an apparatus for applying a composition to the skin, the apparatus including a chamber, the chamber including means for washing the skin (10), and means for applying the composition (4). Applicants have recognised that incorporating means for washing the skin into a chamber designed for applying a composition to the skin provides a number of advantages such as removal of foreign matter from the skin, and also removal of a proportion of the stratum corneum immediately prior to the removal of a composition such as an artificial tanning agent. Removal of dead skin cells and other contaminants from the skin immediately before the application of a composition improves the reproducibility of the absorption of the ac...
-------------------------------------------------- ------------------------------

TRANSDERMAL TULOBUTEROL DELIVERY

(WO2005046600) 26.05.2005 A61F 13/02 NEXMED HOLDINGS, INC.
A transdermal tulobuterol delivery system, preferably in the form of a single-layer, drug-in-adhesive matrix patch, is disclosed comprising a relatively low, (less than five weight percent) concentration of tulobuterol base dissolved in a skin adhesive composition containing at least one skin permeation enhancer. The transdermal delivery system of this invention provides controlled release of the active ingredient, includes a relatively low concentration of tulobuterol within the skin -contacting adhesive formulation of a transdermal patch, and provides acceptable sustained transdermal delivery of the dissolved tulobuterol, as well as acceptable tack and. peel adhesive properties for the delivery device.
------------------ --------------------------------------------------------------

21 -HETEROCYCLIC-4-AZASTEROID DERIVATIVES AS ANDROGEN RECEPTOR MODULATORS

(WO2005044988) 19.05.2005 A61K 31/473 MERCK &CO., INC.
Compounds of structural formula (I) are modulators of the androgen receptor (AR) in a tissue selective manner. They are useful as agonists of the androgen receptor in bone and/or muscle tissue while antagonizing the AR in the prostate of a male patient or in the uterus of a female patient. These compounds are therefore useful in the enhancement of weakened muscle tone and the treatment of conditions caused by androgen deficiency or which can be ameliorated by androgen administration, including osteoporosis, osteopenia, glucocorticoid-induced osteoporosis, periodontal disease, bone fracture, bone damage following bone reconstructive surgery, sarcopenia, frailty, aging skin, male hypogonadism, postmenopausal symptoms in women, atherosclerosis...
---------- ----------------------------------------------------------------------

DELIVERY OF POLYMER CONJUGATES OF THERAPEUTIC PEPTIDES AND PROTEINS VIA COATED MICROPORJECTIONS

(WO2005044985) 19.05.2005 A61K 9/70 ALZA CORPORATION
An apparatus for transdermally delivering a biologically active agent to a patient comprising a microprojection member (5) having a plurality of microprojections (10) that are adapted to pierce the stratum corneum of the patient, the microprojection member having a biocompatible coating (16) disposed thereon that includes a biologically active agent selected from the group consisting of peptide and protein conjugates.
------------------------------------------------------------------ --------------

PREPARATIONS FOR TOPICAL APPLICATION AND METHODS OF DELIVERING AN ACTIVE AGENT TO A SUBSTRATE

(WO2005044242) 19.05.2005 A61K 9/107 DOW CORNING CORPORATION
A multi-layer dressing and controlled- release composition for topical application to a substrate include an emulsion and an active agent incorporated into the emulsion. The active agent includes a protein. A method of delivering the active agent to the substrate provides the emulsion and incorporates the active agent into the emulsion for delivery of the active agent to the substrate.
------------------------------------------ --------------------------------------

A CONTROLLED-RELEASE COMPOSITION FOR TOPICAL APPLICATION AND A METHOD OF DELIVERING AN ACTIVE AGENT TO A SUBSTRATE

(WO2005044232) 19.05.2005 A61K 9/107 DOW CORNING CORPORATION
A controlled-release composition for topical application to a substrate includes an oil-in-water emulsion and an active agent incorporated into the oil-in-water emulsion. The oil-in-water emulsion is substantially free of lipophilic solvent and is formed by mechanical inversion of a water-in-oil emulsion. The water-in-oil emulsion includes a silicone component, a surfactant, and water. A method of delivering the active agent to the substrate provides the oil-in-water emulsion and incorporates the active agent into the oil-in-water emulsion for delivery of the active agent to the substrate upon application of the oil-in-water emulsion to the substrate.
------------------------------------------------------------------ --------------

METHOD OF PROVIDING A BLENDED COMPOSITION

(WO2005044218) 19.05.2005 A61K 8/19 THE PROCTER &GAMBLE COMPANY
A method to provide a skin composition comprising at least one salt-form active which is aesthetically pleasing and effective. The method has the steps of providing a first container for a first aqueous phase having at least one salt-sensitive thickener; a second container for a second aqueous phase having at least one salt-form active; and dispensing the first and second phases from their respective containers onto a common surface. The first and second phases are then blended together and applied to the area of the skin in need of treatment.
-------------------------- ------------------------------------------------------

PRETREATMENT METHOD AND SYSTEM FOR ENHANCING TRANSDERMAL DRUG DELIVERY

(WO2005042054) 12.05.2005 A61F 13/00 ALZA CORPORATION
A drug delivery system for delivering a biologically active agent through the skin of a patient comprises (i) a pretreatment patch adapted to be placed on the patient's skin, the pretreatment patch having a backing membrane and a microprojection array, the microprojection array being adhered to the backing membrane, the microprojection array including a plurality of microprojections adapted to pierce the stratum corneum of the patient, the pretreatment patch including a skin template that remains on the patient's skin after the pretreatment patch is applied to and removed from the patient's skin, and (ii) a gel patch having a top and bottom surface, the gel patch including a reservoir containing a hydrogel formulation, the gel patch having ...
-- ------------------------------------------------------------------------------

ANTIMICROBIAL SHAMPOO COMPOSITIONS

(WO2005041907) 12.05.2005 A61K 9/00 STIEFEL LABORATORIES, INC.
Topical pharmaceutical shampoos comprising an antimicrobial active ingredient, at least one surfactant, at least one hair conditioning agent, and at least one chelating agent. In a particular aspect., the antimicrobial active ingredient in the present inventive compositions has a concentration of degradation product(s) less than about 5% of the starting concentration of the active ingredient. These compositions are used for topical medical applications, particularly to treat various skin disorders.
---------- ----------------------------------------------------------------------

APPARATUS AND METHOD FOR ENHANCING TRANSDERMAL DRUG DELIVERY

(WO2005041871) 12.05.2005 A61K 9/70 ALZA CORPORATION
An apparatus for transdermally delivering a biologically active agent comprising (i) a gel pack containing a hydrogel formulation and (ii) a microprojection member having top and bottom surfaces, a plurality of openings that extend through the microprojection member and a plurality of stratum corneum-piercing microprotrusions that project from said bottom surface of the microprojection member, the microprojection member being adapted to receive the gel pack whereby the hydrogel formulation flows through the microprojection member openings. Preferably, the hydrogel formulation comprises a water-based hydrogel.
-------------------------------------------------- ------------------------------

COMPOSITION FOR THE COSMETIC TREATMENT OF AGE-RELATED DERMATOLOGICAL SYMPTOMS

(WO2005041854) 12.05.2005 A61K 35/60 CORTEX TECHNOLOGY APS
A composition comprising an extract of a deep sea fish; and an extract of rooibos aspalathus linearis); and optionally an extract of bearberry (arctostaphylos uva-ursi) as active components thereof; and optionally one or more fillers or ancillary agents conventionally used in the formulation of compositions is provided. Upon administration, the composition has beneficial effect in relation to the cosmetic treatment of age-related dermatological symptoms, such as wrinkled and/or aged skin as well as hair loss.
------------------------------------------------------------------ --------------

DNA DELIVERY WITH GEMINI CATIONIC SURFACTANTS

(WO2005039642) 06.05.2005 A61K 9/107 UNIVERSITY OF SASKATCHEWAN
The invention provides a delivery system for a biologically active agent comprising a gemini surfactant in admixture with the biologically active agent in a topical formulation for treatment of skin disorders or metabolic diseases. The invention also provides pharmaceutical compositions in topical formulations comprising the delivery system as set out above, in admixture with pharmaceutically acceptable carriers, diluents, excipients, or supplements suitable for application to the skin or mucosal membrane. Methods of preparation and use are also described.
---------- ----------------------------------------------------------------------

TRANSDERMAL PHARMACEUTICAL FORMULATION FOR MINIMIZING SKIN RESIDUES

(WO2005039531) 06.05.2005 A61K 9/00 ANTARES PHARMA IPL AG
This invention relates to novel transdermal or transmucosal pharmaceutical formulation which reduces the occurrences of contamination of other individuals and the transference to clothing of the user. The novel formulation includes at least one pharmacologically active ingredient, and a solvent system having a monoalkylether of diethylene gycol and a gycol present in specified ratios, and a mixture of water and alcohol. The invention also relates to a method for inhibiting or delaying crystallization of an active agent in a pharmaceutical formulation.
-------------------------- ------------------------------------------------------

COSMETIC COMPOSITION COMPRISING EXTRACT FROM MALLOTUS JAPONICUS FOR IMPROVING SKIN WRINKLE

(WO2005039524) 06.05.2005 A61K 8/02 COREANA COSMETICS CO. LTD.
The present invention relates to compositions for inhibiting elastase activity, enhancing collagen biosynthesis and improving skin wrinkle, comprising Mallotus japonicus extract as active ingredient. The present compositions exhibit the inhibition effect on elastase activity and promotion effect on collagen biosynthesis at a molecular level, and as a result, excellent efficacy in improvement of skin wrinkles.
------------------------------------------ --------------------------------------

COMPOSITION FOR PROTECTING SKIN

(WO2005030161) 07.04.2005 A61Q 17/04 DOOSAN CORPORATION
Disclosed are a composition for protecting skin and uses thereof. The composition comprises sphingomyelin as an active ingredient and protects the skin by inhibiting skin aging, treating a skin wound and improving a skin barrier.
------------------ --------------------------------------------------------------

PHARMACEUTICALLY ACTIVE 4,6-DISUBSTITUTED AMINOPYRIMIDINE DERIVATIVES AS MODULATORS OF PROTEIN KINASES

(WO2005026129) 24.03.2005 C07D 239/42 GPC BIOTECH AG
The present invention relates to 4,6-disubstituted aminopyrimidine derivatives and/or pharmaceutically acceptable salts thereof, the use of these derivatives as pharmaceutically active agents, especially for the prophylaxis and/or treatment of infectious diseases, including opportunistic diseases, prion diseases, immunological diseases, autoimmune diseases, bipolar and clinical disorders, cardiovascular diseases, cell proliferative diseases, diabetes, inflammation, transplant rejections, erectile dysfunction, neurodegenerative diseases and stroke, and pharmaceutical compositions containing at least one of said 4,6-di substituted aminopyrimidine derivatives and/or pharmaceutically acceptable salts thereof. Furhtermore, the present invention ...
---------------------------------- ----------------------------------------------

COMPOSITIONS COMPRISING A DISPERSANT AND MICROCAPSULES CONTAINING AN ACTIVE MATERIAL AND A STABILIZER

(WO2005025626) 24.03.2005 C11D 3/48 THE PROCTER &GAMBLE COMPANY
Compositions for providing controlled-release of an active material comprise a dispersant and microcapsules containing the active material and a stabilizer. The compositions contain the dispersant and/or microcapsules at relatively low levels to avoid negatively impacting the surfaces treated with the compositions. The active material is preferably a perfume and the composition provides a controlled- release scent, along with controlling malodor when the compositions further comprise optional odor control agent. The stabilizer improves the stability of the microcapsule. Methods of providing a controlled-release of an active material on a surface comprise the step of contacting the surface with a composition comprising a dispersant and microc...
-------------------------------------------------- ------------------------------

17-HETEROCYCLIC-4-AZASTEROID DERIVATIVES AS ANDROGEN RECEPTOR MODULATORS

(WO2005025579) 24.03.2005 A61K 31/473 MERCK &CO., INC.
Compounds of structural formula I are modulators of the androgen receptor (AR) in a tissue selective manner. These compounds are useful in the enhancement of weakened muscle tone and the treatment of conditions caused by androgen deficiency or which can be ameliorated by androgen administration, including osteoporosis, osteopenia, glucocorticoid-induced osteoporosis, periodontal disease, bone fracture, bone damage following bone reconstructive surgery, sarcopenia, frailty, aging skin, male hypogonadism, postmenopausal symptoms in women, atherosclerosis, hypercholesterolemia, hyperlipidemia, obesity, aplastic anemia and other hematopoietic disorders, inflammatory arthritis and joint repair, HIV-wasting, prostate cancer, benign prostatic hype...
---------------------------------------------------------- ----------------------

17-HETEROCYCLIC-4-AZASTEROID DERIVATIVES AS ANDROGEN RECEPTOR MODULATORS

(WO2005025572) 24.03.2005 A61K 31/473 MERCK &CO., INC.
Compounds of structural formula I are modulators of the androgen receptor (AR) in a tissue selective manner. These compounds are useful in the enhancement of weakened muscle tone and the treatment of conditions caused by androgen deficiency or which can be ameliorated by androgen administration, including osteoporosis, osteopenia, glucocorticoid-induced osteoporosis, periodontal disease, bone fracture, bone damage following bone reconstructive surgery, sarcopenia, frailty, aging skin, male hypogonadism, postmenopausal symptoms in women, atherosclerosis, hypercholesterolemia, hyperlipidemia, obesity, aplastic anemia and other hematopoietic disorders, inflammatory arthritis and joint repair, HIV-wasting, prostate cancer, benign prostatic hype...
---------- ----------------------------------------------------------------------

TOPICAL PREPARATIONS COMPRISING A HYDROPHILIC CARRIER AND A SILICONE MATRIX

(WO2005025548) 24.03.2005 A61K 38/48 DOW CORNING CORPORATION
Topical preparations for release of an active agent to remove necrotic tissue and to methods of making and using the topical preparations are provided. The preparations may have an internal phase dispersed within an external phase. The internal phase may be a hydrophilic carrier and an active agent. The external phase may be a silicone matrix.
-------------------------------------------------- ------------------------------

PEPTIDE-BASED CONDITIONERS AND COLORANTS FOR HAIR, SKIN, AND NAILS

(WO2005025505) 24.03.2005 A61K 8/64 E. I. DU PONT DE NEMOURS AND COMPANY
Peptides have been identified that bind with high affinity to hair, skin, and nails. Peptide-based hair conditioners, hair colorants, skin conditioners, skin colorants, and nail colorants based are described. The peptide- based hair conditioners and hair colorants consist of a hair-binding peptide coupled to a hair conditioning agent or a coloring agent, respectively. The peptide-based skin conditioners and skin colorants consist of a skin-binding peptide coupled to a skin conditioning agent or a colorant, respectively. The peptide-based nail colorants consist of a nail-binding peptide coupled to a coloring agent. In all these compositions, the peptide may be directly coupled to the active agent or the coupling may be via a spacer. Personal ...
---------- ----------------------------------------------------------------------

METHOD FOR THE PRODUCTION OF FUSION PROTEINS IN TRANSGENIC MAMMAL MILK

(WO2005024044) 17.03.2005 A01N 43/04 GTC BIOTHERAPEUTICS, INC.
Desirable fusion proteins can be produced in and purified from the milk of transgenic animals. The peptides are made as fusion proteins with a suitable fusion partner such as human alpha- fetoprotein. The fusion partner protein acts to promote and increase the half-life of the overall molecule as well as having therapeutic effects on its own. The fusion protein is typically produced through the use of transgenic animals and can be purified away from the now the milk or other bodily fluid of such an animal by an affinity purification method. A particular advantage of producing peptides via this route, in addition to the obvious advantages of high yield and biocompatibility, is that specific post-translational modifications, such as carboxy te...
---------------------------------------------------------- ----------------------

COMPOSITIONS CONTAINING AS THE ACTIVE INGREDIENT COMPONANTES FROM SALVIA SCLAREA SEED

(WO2005023019) 17.03.2005 A21D 2/36 STATE OF ISRAEL, MINISTRY OF AGRICULTURE &RURAL DEVELOPMENT, AGRICULTURAL RESEARCH ORGANIZATION (A.R.O.), VOLCANI CENTER
The present invention concerns a food supplement comprising Salvia sclarea seeds, or flour, oil or pulp or extracts obtained from the seeds as well as finished food products comprising the food supplement. The present invention further concerns a nutraceutical or cosmetic preparation comprising as an active ingredient Salvia sclarea seeds, or flour, oil or pulp or extracts obtained from the seeds.
------------------ --------------------------------------------------------------

COMPOSITIONS OF FLAVONOIDS AND FLAVONOID-CONTAINING EXTRACTS AND THE TREATMENT OF DISEASES

(WO2005020881) 10.03.2005 A61K 31/353 SHANGHAI COMMAN PHARMACEUTICAL CO.
In this invention we describe a group of flavonoids and flavonoid- containing extracts that have pharmaceutical properties which are useful in the medicinal therapy of fibrotic diseases for the treatment or reparation and prevention of fibrotic lesional tissues. Representative flavonoids and flavonoid- containing extracts have the active compositions of the below formula (I). Those compositions can be extracted and purified from the botanicals, including Scutellaria baicalensis Georgi, Scutellaria scordifolia Fish, Oroxylum indicum (L.) Vent, Plantago major L. The compositions of the invention are novel as an anti- fibrotic drugs, as agents for treating fibrosis.
-------------------------- ------------------------------------------------------

HYDROXAMIC ACID DERIVATIVES AND THE METHOD FOR PREPARING THEREOF

(WO2005019162) 03.03.2005 C07C 259/06 AMOREPACIFIC CORPORATION
The present invention provides hydroxamic acid derivatives represented by the following formula (I), having anti- aging efficacy and a method for preparation thereof: wherein, R1 is or, herein, R5 and R6 each independently represents a hydrogen atom, a C1-C10 alkyl group or a C3 -C6 cyclic alkyl group; R2 is CONH, NHCO, CONR7 or NR7CO, herein, R7 represents a C1-C10 alkyl group; R3 is (CH)n-, herein, n=0 or 1; and R4 is a hydrogen atom or a C1-C10 alkyl group. Further, the present invention provides skin-care external compositions for preventing skin aging, containing said hydroxamic acid derivatives represented by the formula (I) as an active ingredient.
------------------ --------------------------------------------------------------

G- CSF DERIVATIVE FOR INDUCING IMMUNOLOGICAL TOLERANCE

(WO2005018663) 03.03.2005 A61K 38/19 THE COUNCIL OF THE QUEENSLAND INSTITUTE OF MEDICAL RESEARCH
The invention relates to a method, composition and use thereof for inducing immunological tolerance, in particular transplantation tolerance in a recipient and self-tolerance in a patient. Tolerance is preferably induced by administering a G- CSF derivative, or biologically active fragment, homolog or variant thereof, in particular peg-G-CSF, to a transplantation donor. Transplantation tolerance may reduce or prevent graft versus host disease or graft rejection and self-tolerance may prevent, treat or improve a condition in relation to an autoimmune disorder. The invention also relates to expanding and stimulating selected donor cells by administering a G-CSF derivative, preferably peg-G-CSF. The donor cells are preferably granulocyte-monocy...
------------------------------------------ --------------------------------------

COMPOSITIONS CONTAINING TOPICAL ACTIVE AGENTS AND PENTYLENE GLYCOL

(WO2005018582) 03.03.2005 A61K 8/34 L'OREAL
Disclosed are cosmetic and dermatological compositions containing a steroid hormone or anti-inflammatory agent and pentylene glycol.
--------------------------------------------------------------------------------

INSECTICIDAL AND ACARICIDAL COMPOSITIONS WITH UV BLOCKERS AND PHEROMONES

(WO2005016385) 24.02.2005 A01N 25/02 SIRENE CALL PTY LTD
The invention is a composition consisting of at least one pesticidally active compound, at least one pheromone, at least one liquid UV absorber that is only sparingly miscible in water and least one optical brightener that is also only sparingly miscible with water, castor oil and at least two viscosity regulators. The composition remains viscous and sticky after application. The composition is very suitable for controlling undesirable Ecto-Parasites from the order Acarina on livestock, notably cattle and domestic animals as well as members of the order Artiodactyle (deer) without harming the treated animal or adversely impacting on the environment or the ecology, or creating pesticide residues.
---------- ----------------------------------------------------------------------

TOPICAL COMPOSITIONS OF AMMONIUM LACTATE

(WO2005016360) 24.02.2005 A61K 8/365 AGIS INDUSTRIES (1983) LTD.
Pharmaceutical, cosmetic and cosmeceutical compositions for topical application, containing, as an active ingredient, ammonium lactate and/or any other alpha-hydroxy carboxylic acid and/or salts thereof, processes of manufacturing these compositions and uses of these compositions in the treatment of medical and cosmetic conditions such as conditions associated with dry skin or scalp.
------------------------------------------ --------------------------------------

TOPICAL OINTMENT FOR VESICATING CHEMICAL WARFARE AGENTS

(WO2005016353) 24.02.2005 A61K 31/19 U.S. ARMY MEDICAL RESEARCH AND MATERIAL COMMAND DEPARTMENT OF THE ARMY
The regulatory effects of the active form of vitamin D, 1-?, 25-dihydroxyvitamin D3(1-?, 25(OH) 2D3) were assessed on the cytokine and chemokine secretion induced by sulfur mustard (HD) on human skin fibroblasts (HSF) and human epidermal keratinocytes (HEK). Stimulation of HSF with HD (10-4 M for 24 hours at 37° C) resulted in about a 5-fold increase in the secretion of interleukin-6 (IL-6) and over a 10- fold increase for interleukin-8 (IL-8), which was inhibited by 1-?, 25(OH)2D3, at ? 10-9 M. 1-?, 25(OH)2D3 also suppressed IL-8 secretion by five-fold and IL-6 by four-fold on HD-stimulated HEK at concentrations ? 10-9 M. The effect of 1-?, 25(OH)2D3 was dose-dependent for the suppression of IL-6 and IL-8 induc...
---------- ----------------------------------------------------------------------

TOPICAL COMPOSITIONS OF UREA AND AMMONIUM LACTATE

(WO2005016329) 24.02.2005 A61K 8/365 AGIS INDUSTRIES (1983) LTD.
Pharmaceutical, cosmetic and cosmeceutical compositions for topical application, containing, as active ingredients, urea and/or derivatives thereof and alpha-hydroxy acid and/or an ammonium salt thereof, such as ammonium lactate, processes of manufacturing same and use of same in the treatment of medical and cosmetic skin and scalp conditions.
------------------------------------------------------------------ --------------

TOPICAL COMPOSITIONS OF UREA

(WO2005016328) 24.02.2005 A61K 8/365 AGIS INDUSTRIES(1983) LTD.
Pharmaceutical, cosmetic and cosmeceutical foamable compositions for topical application, containing, as an active ingredient, urea and/or a derivative thereof, processes of manufacturing these compositions and uses of these compositions in the treatment of various dermatological conditions such as, for example, conditions associated with dry skin and/or scalp.
---------------------------------------------------------- ----------------------

STEROIDAL COMPOSITIONS CONTAINING HYDROXYCARBOXYLIC ACIDS AND METHODS OF USING THE SAME

(WO2005016307) 24.02.2005 A61K 8/365 STIEFEL LABORATORIES, INC.
Pharmaceutical compositions suitable for topical administration comprising two active ingredients, a hydroxycarboxylic acid and prednicarbate, and a pyrrolidone carboxylate salt moisturizing agent. In a particular aspect, the two active ingredients in the present inventive compositions have a purity of at least 90% and a concentration of degradation product (s) less than about 10% of the starting concentration of the active ingredients. These compositions are used for topical medical applications, particularly to treat steroid responsive dermatoses.
------------------ --------------------------------------------------------------

HYDROPHILIC ADHESIVE COMPOSITIONS FOR DELIVERY OF HERBAL MEDICINES

(WO2005013943) 17.02.2005 A61K 9/70 3M INNOVATIVE PROPERTIES COMPANY
A hydrophilic, pressure-sensitive adhesive composition comprising a swellable adhesive polymer, a swelling agent, herbal medicines, and optionally a modifying polymer in an amount sufficient to form a cohesive, pressure-sensitive adhesive composition. The composition is useful as a delivery device for herbal medicine and other active ingredients to or through skin. A method of preparation of the composition is also disclosed.
---------- ----------------------------------------------------------------------

USE OF SPERMINE AND/OR SPERMIDINE AGAINST SKIN AGETING IN DIETARY, PHARMACEUTICAL OR COSMETIC COMPOSITIONS

(WO2005013932) 17.02.2005 A61K 8/41 GIULIANI S.P.A.
The invention concerns the use of spermine and spermidine as active ingredients in the preparation of a composition for dietary, pharmaceutical or cosmetic use in humans for health and beauty of the skin and skin appendages, and related compositions for pharmaceutical or dietary or cosmetic use for administration to humans.
------------------------------------------ --------------------------------------

REGULATION OF MAMMALIAN KERATINOUS TISSUE USING N-ACYL AMINO ACID COMPOSITONS

(WO2005011627) 10.02.2005 A61K 8/368 THE PROCTER &GAMBLE COMPANY
Skin care compositions containing N-acyl amino acid, particularly N-acyl derivatives of Phenylalanine or Tyrosine, their isomers, or their salts; at least one other skin care active selected from sugar amines, vitamin B3, retinoids, peptides, dialkanoyl hydroxyproline, hexamidine, salicylic acid, and phytosterol; and a dermatologically acceptable carrier for the N-acyl amino acid and the skin care active. The invention further relates to methods for regulating the condition of mammalian keratinous tissue wherein the methods each comprise the step of topically applying to the keratinous tissue of a mammal needing such treatment, a safe and effective amount of the skin care composition of the invention.
------------------------------------------ --------------------------------------

COSMETIC COMPOSITION COMPRISING POROUS PARTICLES INCORPORATING OPTICALLY ACTIVE SUBSTANCES

(WO2005011622) 10.02.2005 A61K 8/04 L'OREAL
An object of the invention is to offer an optical additive capable of adequately activating the effects of incorporated optically active substances, providing the base with such optical effects, having a suitable sensation and level of safety, and having exceptional cosmetic properties. A cosmetic composition comprising in a physiologically acceptable medium (a) silicium based porous particles having an aspect ratio of at least 2 and (b) an optically active substance incorporated into said porous particles is offered. The incorporated optically active substances are selected from among UV screening substances, fluorescent substances and photochromic substances.
---------- ----------------------------------------------------------------------

17-ACETAMIDO-4-AZASTEROID DERIVATIVES AS ANDROGEN RECEPTOR MODULATORS

(WO2005009949) 03.02.2005 A61K 31/473 MERCK &CO., INC.
Compounds of structural formula (I) are modulators of the androgen receptor (AR) in a tissue selective manner. They are useful as agonists of the androgen receptor in bone and/or muscle tissue while antagonizing the AR in the prostate of a male patient or in the uterus of a female patient. These compounds are therefore useful in the enhancement of weakened muscle tone and the treatment of conditions caused by androgen deficiency or which can be ameliorated by androgen administration, including osteoporosis, osteopenia, glucocorticoid-induced osteoporosis, periodontal disease, bone fracture, bone damage following bone reconstructive surgery, sarcopenia, frailty, aging skin, male hypogonadism, postmenopausal symptoms in women, atherosclerosis...
---------- ----------------------------------------------------------------------

MICROCAPSULES LOADED WITH ACTIVE INGREDIENTS AND A METHOD FOR THEIR PREPARATION

(WO2005009604) 03.02.2005 A61K 8/11 SOL-GEL TECHNOLOGIES LTD.
The invention relates to microcapsules having a core material encapsulated within a microcapsular shell, the core material comprises at least one active ingredient, wherein the microcapsular shell comprises at least one inorganic polymer comprising polymerized precursors obtained by in-situ polymerization of the precursors; wherein the concentration of the core material based total weight of the microcapsules is above 95% w/w. The invention further relates to a composition and to a suspension comprising the microcapsules. The invention additionally relates to a process for preparing the microcapsules.
---------------------------------- ----------------------------------------------

PENETRATION ENHANCER COMBINATIONS FOR TRANSDERMAL DELIVERY

(WO2005009510) 03.02.2005 A61K 31/00 THE REGENTS OF THE UNIVERSITY OF CALIFORNIA
A high throughput screening and isolation system identifies rare enhancer mixtures from a candidate pool of penetration enhancer combinations. The combinations are screened for high penetration but low irritation potential using a unique data mining method to find new potent and safe chemical penetration enhancer combinations. The members of a library of chemical penetration enhancer combinations are screened with a high throughput device to identify 'hot spots', particular combinations that show higher chemical penetration enhancement compared to neighboring compositions. The irritation potentials of the hot spot combinations are measured to identify combinations that also show low irritation potential. A active component, such as a drug, ...
------------------------------------------------------------------ --------------

DELIVERY SYSTEM FOR TOPICAL MEDICATIONS

(WO2005009322) 03.02.2005 A01N 25/34 MEDICIS PHARMACEUTICAL CORPORATION
The present invention is a delivery system comprising a pad and a liquid composition, comprising an insoluble dermatologically active ingredient with a viscosity that permits substantially uniform absorption of the composition onto the pad, and the pad is in then packaged in a sealed container.
-------------------------- ------------------------------------------------------

METHODS AND PHARMACEUTICAL COMPOSITIONS FOR HEALING WOUNDS

(WO2005007072) 27.01.2005 A61K 31/74 BAR-ILAN UNIVERSITY
A pharmaceutical composition for inducing or accelerating a healing process of a damaged skin or skin wound, the pharmaceutical composition comprises, as an active ingredient, a therapeutically effective amount of insulin and at least one additional agent acting in synergy with said insulin, and a pharmaceutically acceptable carrier being designed for topical application of the pharmaceutical composition. A method of inducing or accelerating a healing process of a damaged skin or skin wound, the method comprises administering to the damaged skin or skin wound a therapeutically effective amount of insulin and at least one additional agent acting in synergy with said insulin to induce or accelerate the healing process of the damaged skin or t...
------------------------------------------------------------------ --------------

17-ACETAMIDO-4-AZASTEROID DERIVATIVES AS ANDROGEN RECEPTOR MODULATORS

(WO2005005606) 20.01.2005 A61K 31/56 MERCK &CO., INC.
Compounds of structural formula I are modulators of the androgen receptor (AR) in a tissue selective manner. These compounds are useful in the enhancement of weakened muscle tone and the treatment of conditions caused by androgen deficiency or which can be ameliorated by androgen administration, including osteoporosis, osteopenia, glucocorticoid-induced osteoporosis, periodontal disease, bone fracture, bone damage following bone reconstructive surgery, sarcopenia, frailty, aging skin, male hypogonadism, postmenopausal symptoms in women, atherosclerosis, hypercholesterolemia, hyperlipidemia, obesity, aplastic anemia and other hematopoietic disorders, inflammatory arthritis and joint repair, HIV-wasting, prostate cancer, benign prostatic hype...
---------------------------------- ----------------------------------------------

17-ACETAMIDO-4- AZASTEROID DERIVATIVES AS ANDROGEN RECEPTOR MODULATORS

(WO2005005380) 20.01.2005 A61K 31/56 MERCK &CO., INC.
Compounds of structural formula I are modulators of the androgen receptor (AR) in a tissue selective manner. They are useful as agonists of the androgen receptor in bone and/or muscle tissue while antagonizing the AR in the prostate of a male patient or in the uterus of a female patient. These compounds are therefore useful in the enhancement of weakened muscle tone and the treatment of conditions caused by androgen deficiency or which can be ameliorated by androgen administration, including osteoporosis, osteopenia, glucocorticoid-induced osteoporosis, periodontal disease, bone fracture, bone damage following bone reconstructive surgery, sarcopenia, frailty, aging skin, male hypogonadism, postmenopausal symptoms in women, atherosclerosis, ...
-- ------------------------------------------------------------------------------

SONOPHORESIS SKIN CARE DEVICE

(WO2005004972) 20.01.2005 A61K 9/00 THE PROCTER &GAMBLE COMPANY
Disclosed is a device for penetrating a skin active agent to the human body via the skin by the use of an ultrasoundapplying apparatus which applies ultrasound to the human body via the skin, comprising: (1) composition comprising: (a) safe and effective amount of the skin active agent; (b) a viscosifying agent that provides the composition of a viscosity of from about 1,000mPas to about 1,000,000mPas; (c) from about 0.1% to about 30% of a water-soluble humectant; and (d) an aqueous carrier; wherein the composition is substantially free of surfactants; and (2) the ultrasound applying apparatus comprising: (e) an application element for applying to the skin ultrasound at a frequency of from about 3MHz to about 10MHz and intensity of from abo...
------------------------------------------------------------------ --------------

SUSTAINED RELEASE COMPOSITIONS AND CONTROLLED DELIVERY METHOD

(WO2005004832) 20.01.2005 A61K 9/14 LIPO CHEMICALS INC.
A sustained release composition comprising cellulose fibers, an active agent, and an optional release retardant is disclosed. The composition has an improved ability to stabilize and release the active agent over an extended time period.
-- ------------------------------------------------------------------------------

17-ACETAMIDO-4-AZASTEROID DERIVATIVES AS ANDROGEN RECEPTOR MODULATORS

(WO2005004807) 20.01.2005 C07J 73/00 MERCK &CO., INC.
Compounds of structural formula I are modulators of the androgen receptor (AR) in a tissue selective manner. These compounds are useful in the enhancement of weakened muscle tone and the treatment of conditions caused by androgen deficiency or which can be ameliorated by androgen administration, including osteoporosis, osteopenia, glucocorticoid-induced osteoporosis, periodontal disease, bone fracture, bone damage following bone reconstructive surgery, sarcopenia, frailty, aging skin, male hypogonadism, postmenopausal symptoms in women, atherosclerosis, hypercholesterolemia, hyperlipidemia, obesity, aplastic anemia and other hematopoietic disorders, inflammatory arthritis and joint repair, HIV-wasting, prostate cancer, benign prostatic hype...
---------------------------------------------------------- ----------------------

TRANSDERMAL HORMONE DELIVERY SYSTEM: COMPOSITIONS AND METHODS

(WO2005002482) 13.01.2005 A61F 13/00 AGILE THERAPEUTICS, INC.
A transdermal hormone delivery system (THDS) is disclosed. The THDS is useful for control of fertility and as therapy for a variety of diseases and conditions treatable by robust delivery of progestin and estrogen hormones, particularly the progestin, levonorgestrel. The THDS comprises a backing layer, an adjoining adhesive polymer matrix comprising an effective amount of at least a progestin hormone, delivery of which is enhanced by one or more skin permeation enhancing agents present in pre-determined amounts. The THDS is capable of providing effective daily doses of progestin and estrogen hormones from a small surface area in contact with the skin, e.g., less than 20 square centimeters. Methods of fertility control and various types of h...
------------------ --------------------------------------------------------------

COMPOSITIONS AND METHODS FOR TREATMENT OF ROSACEA

(WO2005000337) 06.01.2005 A61K 38/06 PROCYTE CORPORATION
A method for treating rosacea of the skin of a patient employs topically applying to the affected skin a composition comprising at least one peptide copper complex. In other embodiments, the present invention is directed to such a method where the composition used therefor further comprises certain disclosed active agents, including active drug and active cosmetic substances. In a related aspect, further embodiments of the present invention are directed to compositions comprising at least one peptide copper complex and certain active drug and active cosmetic substances that render the compositions particularly effective in treating rosacea.
------------------ --------------------------------------------------------------

LIPOSOMAL FORMULATIONS COMPRISING A COMBINATION OF TWO OR MORE ACTIVE AGENTS

(WO2005000266) 06.01.2005 A61K 9/127 NEOPHARM, INC.
The present invention provides a composition comprising a physiologically acceptable carrier and two or more agents encapsulated in a liposome, wherein the combination of the two or more agents possess the following properties: (1) cytotoxicity to tumor cells, (2) nutritional properties, (3) use in application to nails, hair, skin or lips or (4) activity against parasites and insects. The invention also provides a method of making such a composition. The invention further provides the use of said composition for a manufacture of a medicament for treating cancer when the combination of the two or more agents is cytotoxic to tumor cells.
---------------------------------- ----------------------------------------------

COMPOSITONS AND METHODS FOR TOPICAL ADMINISTRATION

(WO2005000241) 06.01.2005 A61K 9/00 MACROCHEM CORPORATION
Vanishing cream base compositions and vanishing cream compositions suitable for topical application of an active agent to an animal or plant comprising water, at least one alcohol, a polymeric thickening agent, a skin penetration enhancing compound, and an emulsifying agent are provided. Methods for the use and manufacture of such creams are also disclosed.
------------------ --------------------------------------------------------------

MODIFIED SOY PROTEINS IN PERSONAL CARE COMPOSITIONS

(WO2004112745) 29.12.2004 A61K 8/64 E.I. DUPONT DE NEMOURS AND COMPANY
Personal care compositions comprising a modified soy protein as an active ingredient are described. The modified soy proteins of the instant invention include soy proteins modified by treatment with a reducing agent and subsequently reacted with a carboxylic acid anhydride; soy proteins modified by treatment with a reducing agent, reacted with a carboxylic acid anhydride and subsequently oxidized; soy proteins modified by reaction with a hydroxy alkyl acrylate; soy proteins modified with ionic monomers such as epoxide, acrylate, and chlorohydrin; and soy proteins modified by reaction with an alkyl acrylimidoglycolate. The compositions may be in the form of skin care, skin cleansing, or anti--wrinkle products, shampoos, make-up, conditio...
--------------------------------------------------------------------------------

NEW SAPONIN COMPOUND, SAPONIN SOLUTION CONTAINING THE SAME A PREPARATION METHOD THEREOF, AND PHARMACEUTICAL COMPOSITIONS, HEALTH FOODS AND COSMETICS CONTAINING THE SAPONIN AS AN ACTIVE COMPONENT

(WO2004111069) 23.12.2004 A23L 1/30 CHOI, Jang Youn
Disclosed are a novel saponin compound, a saponin composition liquid containing the same, a preparation method thereof, and a pharmaceutical composition, functional food and cosmetic product containing the composition liquid as an active ingredient. The pharmaceutical composition and functional food has various pharmacological effects, including immune enhancement, vitality enhancement, improvement of liver function, withdrawal of hangover, promotion of protein generation, promotion of cerebral activities and improvement of attention, activated recuperation of health after surgical operation, and prevention or treatment of diabetes, impaired blood circulation, depression, dermal inflammatory disease, dermal eczema, dermatophytosis, allergic...
---------- ----------------------------------------------------------------------

A COUMERMYCIN/NOVOBIOCIN-REGULATED GENE EXPRESSION SYSTEM

(WO2004108933) 16.12.2004 C12N 15/67 NATIONAL RESEARCH COUNCIL OF CANADA
A chimeric transactivator comprises a transcription activation domain, a repressor protein DNA binding domain and the bacterial DNA gyrase B subunit. A target gene is operatively linked to operator DNA sequences recognized by the repressor binding domain. The addition of the antibiotic coumermycin results in a coumermycin-switched dimerization of the transactivator, which then binds to operator DNA sequences and activates transcription of the target gene. The addition of novobiocin switches off expression of the target gene by abolishing coumermycin-induced dimerization of the transactivator.
---------------------------------------------------------- ----------------------

ADHESIVE COMPOSITIONS, ARTICLES INCORPORATING SAME AND METHODS OF MANUFACTURE

(WO2004108854) 16.12.2004 A61L 15/58 3M INNOVATIVE PROPERTIES COMPANY
A hydrophilic, pressure-sensitive adhesive composition comprising crosslinked poly(N-vinyl lactam), a swelling agent, and a modifying polymer in an amount sufficient to form a cohesive pressure- sensitive adhesive composition is provided. The composition is useful as a medical secural of percutaneous devices. The composition is also useful as a drug delivery device to deliver antimicrobial agents, pharmaceuticals or other active ingredients to or through skin. A method of preparation of the composition is also disclosed.
------------------------------------------------------------------ --------------

EXTENDED RELEASE OSMO-MICROSEALED FORMULATION COMPRISING VENLAFAXINE

(WO2004108117) 16.12.2004 A61K 9/00 ALEMBIC LIMITED
Extended Release Osmo-microsealed Formulation comprising 1hree controlled release systems associated in series, first an inner solid particulate phase containing Venlafaxine Hydrochloride (Active), and one or more hydrophobic polymers-, one or more diluents required to increase the bulk one or more osmogen (agents which can generate osmotic pressure across the hydrophobic coating) and one or more binder polymers essentially to provide strength/hardness to the particle, second, an outer solid continuous phase including one or more hydrophilic polymers, it is further compressed into tablet and third is an optional functional coat surrounding the tablet, this invention also provides process/method for forming the described osmo -microsealed ext...
---------------------------------------------------------- ----------------------

STABLE COSMETIC COMPOSITIONS COMPRISING A SELF-TANNING AGENT

(WO2004105721) 09.12.2004 A61K 8/35 THE PROCTER &GAMBLE COMPANY
Stable topical compositions having a pH of from 3.5 to 4.5 comprising a self- tanning agent, a polymer and a polyhydric alcohol humectant. The compositions of the present invention are highly stable, and deliver high levels of active self- tanning agent to the skin upon topical application.
-------------------------- ------------------------------------------------------

TOPICAL COMPOSITION FOR THE TREATMENT OF SKIN DISORDERS AND METHODS OF USING THE SAME

(WO2004105689) 09.12.2004 A61K 35/78 HOST PHARMACEUTICALS, LLC
A topical composition for the treatment of skin disorders such as scars containing at least one, preferably two select botanical oils alone or in a combination with at least one other active agent and methods of using the same to treat skin disorders.
---------- ----------------------------------------------------------------------

CONTROLLED RELEASE OF ACTIVE AGENTS UTILIZING REPEAT SEQUENCE PROTEIN POLYMERS

(WO2004104021) 02.12.2004 A61K 8/04 DOW CORNING CORPORATION
Systems are provided for the controlled release delivery of active agents through the use of repeat sequence protein polymers. The systems may exist as matrices, gels, hydrogels, films, emulsions or microparticles and are particularly useful for incorporating active agents into personal care product compositions.
-- ------------------------------------------------------------------------------

REPEAT SEQUENCE PROTEIN POLYMER ACTIVE AGENT CONJUGATES, METHODS AND USES

(WO2004104020) 02.12.2004 A61K 8/64 DOW CORNING CORPORATION
Biomolecular conjugates are provided which comprise the conjugation product of a repeat sequence protein polymer and at least one active agent. Additional aspects provide methods for their manufacture and various industrial and consumer applications.
---------------------------------------------------------- ----------------------

TERNARY AND QUATERNARY EUTECTIC MIXTURES.

(WO2004103260) 02.12.2004 A61K 9/00 CRISTÁLIA PRODUTOS QUÍMICOS FARMACÊUTICOS LTDA.
The present invention describes ternary and quaternary eutectic mixtures composed by active local anesthetic substances. These eutectic mixtures possess melting point inferior to 20°C and consist of homogeneous liquid useful in the preparation o pharmaceutical compositions for topical anesthesia or analgesia of tissues as skin or mucous.
---------------------------------- ----------------------------------------------

SUNSCREEN OR MEDICINAL WIPES HAVING HIGH SUNSCREEN FORMULATION TRANSFER RATE

(WO2004100914) 25.11.2004 A61K 8/02 KIMBERLY-CLARK WORLDWIDE INC.
Sunscreen wipes comprising a thixotropic, quick-breaking sunscreen formulation are disclosed. The sunscreen formulation comprises water, at least one sunscreen active, Pemulen TR-2, a stabilizing emulsifier, and a neutralizing agent. By formulating the sunscreen formulation such that it has specific high shear and low shear viscosities at a pH range of from about 5 to about 6, the transfer rate of the sunscreen formulation to the skin during use is significantly increased as compared to conventional sunscreen wipes. The present invention is further directed to a medicinal wipe comprising a wipe substrate and a medical formulation. The medicinal formulation comprises water, Permulen TR-2, high spreadability emollient, medicinal active (such ...
------------------------------------------------------------------ --------------

ANDROGEN RECEPTOR MODULATORS AND METHODS OF USE THEREOF

(WO2004100874) 25.11.2004 A61K 31/56 MERCK &CO., INC.
Compounds of structural formula (I) as herein defined are disclosed as useful in a method for modulating the androgen receptor in a tissue selective manner in a patient in need of such modulation, as well as in a method of agonizing the androgen receptor in a patient, and in particular the method wherein the androgen receptor is antagonized in the prostate of a male patient or in the uterus of a female patient and agonized in bone and/or muscle tissue. These compounds are useful in the treatment of conditions caused by androgen deficiency or which can be ameliorated by androgen administration, including: osteoporosis, periodontal disease, bone fracture, bone damage following bone reconstructive surgery, sarcopenia, frailty, aging skin, male...
------------------------------------------------------------------ --------------

ABUSE-RESISTANT TRANSDERMAL DOSAGE FORM

(WO2004098576) 18.11.2004 A61K 9/70 3M INNOVATIVE PROPERTIES COMPANY
The invention comprises a transdermal dosage form comprising a active agent component comprising a polymeric matrix and an abusable drug substance, an overlay backing, a porous material, and an antagonist reservoir comprising an antagonist to the abusable drug substance. The porous material adjoins the antagonist reservoir and is in fluid communication with the skin-contacting surface defined by the active agent component. In one embodiment, the device comprises a barrier layer interposed between the active agent component and the antagonist reservoir.
---------- ----------------------------------------------------------------------

COMPOSITIONS AND METHODS FOR TREATMENT OF PSORIASIS

(WO2004096258) 11.11.2004 A61K 33/34 PROCYTE CORPORATION
A method for treating psoriasis of the skin of a patient employs topically applying to the affected skin a composition comprising at least one peptide copper complex. In other embodiments, the present invention is directed to such a method where the composition used therefor further comprises certain disclosed active agents, including active drug and active cosmetic substances. In a related aspect, further embodiments of the present invention are directed to compositions comprising at least one peptide copper complex and certain active drug and active cosmetic substances that render the compositions particularly effective in treating psoriasis.
------------------ --------------------------------------------------------------

DERMATOLOGICAL FORMULATION

(WO2004096169) 11.11.2004 A61K 7/48 PROVINCIA ITALIANA DELLA CONGREGAZIONE DEI FIGLI DELL'IMMACOLATA CONCEZIONE - ISTITUTO DERMOPATICO DELL'IMMACOLATA
A dermatological formulation containing active principles which are of strictly natural origin, said formulation being intended for cutaneous protection and prevention against exogenous and endogenous oxidative damages, both through the re-establishment of sebaceous and epidermal lipids and antioxidants equilibrium which are essential for cutaneous homeostasis and become altered by the oxidative stress, and through the presence of a pool of molecules endowed with specific lenitive and anti-inflammatory activity. The further association of molecule which chelate transition metals and are also capable of reactivating the superficial circulation is also provided.
---------------------------------- ----------------------------------------------

COMPOSITION, METHOD AND PHARMACEUTICAL PREPARATION FOR PHARMACEUTICAL SPRAY SUSPENSIONS

(WO2004091577) 28.10.2004 A61K 9/70 PORTEN PHARMACEUTICAL AB
The present invention provides, according to a first aspect a pharmaceutical composition, constituting a spray suspension comprising at least one liquid excipient and at least one solid excipient which essentially is insoluble in the liquid excipient, and at least one pharmaceutical active ingredient. According to a second aspect of the present invention, there is provided a method of preparing porous suspension particles (including an active ingredient), wherein it comprises the steps of ; a. wet-milling or dry-milling the solid excipient(s) or a mixture of at least one active ingredient and a solid excipient(s) in a milling equipment inducing essentially compression and shear forces, resulting in fine particulate quality, where more than ...
---------- ----------------------------------------------------------------------

ACTIVATED CITRUS PEEL EXTRACT

(WO2004091569) 28.10.2004 A01N 65/00 CITRAMED LTD.
The present invention relates to composition comprising an activated citrus peel extract (ACPE) prepared by an activation method which includes exposure of citrus peels to at least one plant or animal pathogen. The ACPE comprises at least one of the following: oligosaccharides, short peptides, flavonoid glycosides, fatty acids, and triglycerides. Compositions comprising the ACPE have been shown useful as dermatological compositions for the treatment of various skin conditions. They have also been shown to be useful in preserving food, beverages and cosmetics.
-------------------------------------------------- ------------------------------

CATIONIC, OXIDIZED POLYSACCHARIDES IN CONDITIONING APPLICATIONS

(WO2004091557) 28.10.2004 A61K 8/73 HERCULES INCORPORATED
A cationic, oxidized polysaccharide or derivative thereof that has a mean average molecular weight (Mw) having a lower limit of 50,000 and an upper limit of 1,000,000 and an aldehyde functionality content of at least 0.001meq/gram is used in personal care and household care compositions. This cationic, oxidized polysaccharide is prepared in continuous or batch processes using hydrolytic reagents, oxidizing reagents, or combination of hydrolytic reagents and oxidizing reagents. Personal care or household care compositions are prepared by adding the cationic, oxidized polysaccharide to a personal care or household composition containing at least one active ingredient other than the cationic, oxidized polysaccharide of this invention.
------------------ --------------------------------------------------------------

PROCESS FOR MEASURING THE SKIN SURFACE OF AN EXAMINED PERSON

(WO2004091501) 28.10.2004 A61B 5/103 MANZO, Robert, P.
The invention relates to a method and a process of determining individual skin structure and function at a point in time for the purpose of determining and formulating skin care products that remedy the deficiencies observed in the skin. Objective and repeatable dermal biometric instrumentation techniques can be used to measure skin moisture content, sebum content, firmness and elasticity properties, skin thickness, transepidermal water loss, skin pH and to perform a photo analysis of the face with UV and visible light. By customizing the skin care products, the individually added active ingredients can be controlled, the diluents can be modified, dermal penetration rates can be controlled, the surfactant systems can be adjusted, and the st...
--------------------------------------------------------------------------------

TOPICAL ANTIANDROGENIC STEROIDS

(WO2004089971) 21.10.2004 A61K 31/56 ENDORECHERCHE, INC.
Steroidal antiandrogens and pharmaceutical compositions thereof, are used for reduction of the risk of developing, or for treatment of, androgen-dependent skin related diseases. In preferred embodiments, the antiandrogen EM-3180 is used for reduction of the risk of developing, or the treatment, of acne, seborrhea, hirsutism or androgenic alopecia: Methods of treatment utilize the antiandrogen alone, or in combination with other active ingredients such as an inhibitor of a 5a-reductase, an inhibitor of type 5 170- hydroxysteroid dehydrogenase, and/or an inhibitor of prostate short-chain dehydrogenase/reductase.
-------------------------------------------------- ------------------------------

PROSTAGLANDIN COMPOSITIONS AND THEIR USE FOR THE TREATMENT OF VASOSPASM

(WO2004089381) 21.10.2004 A61K 31/5575 NEXMED (HOLDINGS), INC.
Compositions and methods for the treatment of vasospasm are provided comprising applying an amount of a semi-solid vasoactive prostaglandin composition to the affected tissue. Also provided are methods of improving microcirculation in a replanted body part.
---------- ----------------------------------------------------------------------

PEST CONTROL FORMULATION AND DISPENSER

(WO2004089083) 21.10.2004 A01N 25/02 SERGEANT'S PET CARE PRODUCTS
The present invention relates to a pest control system which includes a pest control active ingredient and isodiphenyl phosphate as a carrier for the active ingredient. The system releases the active ingredient efficiently and uniformly. The pest control system is less irritating to the animal's skin as compared to prior art systems. The system is useful for making animal collars, ear tags, pest strips, liquid spot-on treatments, and the like.
--------------------------------------------------------------------------------

PHARMACEUTICAL COMPOSITIONS COMPRISING EPINASTINE FOR THE TREATMENT OF SKIN DISEASES

(WO2004087167) 14.10.2004 A61K 31/19 BOEHRINGER INGELHEIM INTERNATIONAL GMBH
The present invention relates to new pharmaceutical compositions for the treatment of skin disease. The composition comprises an antihistaminic- effective amount of Epinastine or a pharmaceutically acceptable salt thereof as a pharmacologically active compound and at least one compound selected from the group consisting of one or more sulfur containing amino acid(s) or peptide(s) as biologically active donor of a -S- or -SH group, at least one vitamin of the B group, at least one vitamin having antioxidant properties and an antiphlogistic- effective amount of an antiphlogistic compound. The compositions also may comprise pharmaceutically acceptable additives.
---------------------------------- ----------------------------------------------

SYNERGISTIC COMBINATIONS OF MACROLIDE T-CELL MODULATOR OR INMUNOSUPPRESSANT AND A RETINOID

(WO2004087118) 14.10.2004 A61K 31/05 NOVARTIS AG
Additive or synergistic combinations of a macrolide T-cell immunomodulator or immunosuppressant such as 33-epichloro-33- desoxyascomycin and a retinoid, such as etretinate, isotretinoin or tazarotene, optionally with a further pharmaceutically active agent, especially an antibacterial, are provided, which are useful in particular in the treatment of dermatological diseases such as eczema, atopic dermatitis, acne, psoriasis, skin aging, sun damage, post-peel erythema and stretch marks.
------------------ --------------------------------------------------------------

A TOPICAL AGENT CONTAINING NIACIN FOR APPLICATION TO THE SKIN PRIOR TO LUMINOUS TREATMENT

(WO2004087093) 14.10.2004 A61K 8/67 CORTEX TECHNOLOGY APS
There is disclosed a topical agent in the form of a topical vasodilator for the application to the skin prior to luminous treatment, e.g. laser treatment, wherein said topical vasodilator in a suitable vehicle consists of the active substance nicotinic acid (Niacin) in the range of 0.5 - 10.0 % by weight. Preferably, the topical vasodilator is a skin cream containing the active substance, Niacin, in the range of 0.5 % by weight.
---------------------------------------------------------- ----------------------

KERATOLYTIC COMPOSITION WITH ANTI-ALLERGIC ANTI-INFLAMMATORY PROPERTIES

(WO2004084855) 07.10.2004 A61K 8/20 MUNISEKHAR, Medasani
A product with an enhanced medicinal and cosmetic composition with a specific utility of “Psoriasis, Eczema and like skin disorders application” is characterized by the fact that it comprises active agents and ingredients as vanilla extract, ammonium chloride, potassium chloride and quaternary ammonium compound having formulated at a specific pH value with other specially selected adjuvants and fillers.
-------------------------------------------------- ------------------------------

PHOTOSTABILIZED TOPICAL FORMULATIONS OF KETOPROFEN CONTAINING TWO UV FILTERS

(WO2004082580) 30.09.2004 A61K 9/06 BERLIN-CHEMIE AKTIENGESELLSCHAFT
The invention relates to topical pharmaceutical formulations containing ketoprofen or its S(+) isomer dexketoprofen or mixtures of the two isomers, together with two UV filters, preferably octyl methoxy cinnamate and phenyl benzimidazol sulphonic acid, and an antioxidant, preferably butyl hydroxy toluene (BHT). The formulations enable a photostability of the active principle, have no, or very low, irritant effect on the skin, are well tolerated, and present an adequate penetration through the skin.
---------- ----------------------------------------------------------------------

THERAPEUTIC, NUTRACEUTICAL AND COSMETIC APPLICATIONS FOR EGGSHELL MEMBRANE AND PROCESSED EGGSHELL MEMBRANE PREPARATIONS

(WO2004080428) 23.09.2004 A61K 8/98 NEW LIFE RESOURCES, LLC
The present invention relates to therapeutic, cosmetic, and nutraceutical applications for eggshell membrane, processed eggshell membrane preparations and eggshell membrane isolates. The invention is directed to treating a mammal that will benefit from the administration of naturally occurring material found in eggshell membrane, processed eggshell membrane, eggshell membrane isolates and combinations thereof by administering to the mammal a composition containing eggshell membrane, processed eggshell membrane, eggshell membrane isolates and combinations thereof, alone or in combination with other active ingredients.
---------------------------------- ----------------------------------------------

RAPIDLY ABSORBING LIPOPHILIC SKIN COMPOSITIONS AND USES THEREFOR

(WO2004080399) 23.09.2004 A61K 35/78 EPITOME PHARMACEUTICALS LIMITED
Topical compositions, and particularly hydrophobic compositions include an essential oil in an amount effective to achieve substantially complete absorption of the composition in the skin without leaving a greasy residue. Especially preferred topical compositions may also include pharmaceutically active agents (e.g., polyphenol), additional essential oils, stabilizers, etc. In further preferred aspects, contemplated compositions may delay onset, or even prevent viral eruptions on the skin, and where applied as a lipstick, will increase reddening of the lip as well as reduce chapping.
------------------------------------------------------------------ --------------

ANIMAL MODEL FOR THE FAST IDENTIFICATION OF PHARMACEUTICAL ACTIVE COMPOUNDS IN VIVO

(WO2004078985) 16.09.2004 A01K 67/027 JANSSEN PHARMACEUTICA N.V.
In a first aspect the present invention provides a tumor cell line stably transfected with an expression vector containing a reporter gene, preferably a fluorescent protein, operably linked to a promotor that also controls expression of a protein that is associated with tumor regression, stabilisation of tumor growth or inhibition of metastatic growth, characterised in that said cell line is capable to form a tumor when implanted or injected into the non-human animal. Compared to the traditional in vivo models, the present invention differs in that the reporter gene is not constitutively expressed, but only after exposure to a test compound that results in the expression of a protein or enzyme associated with tumor regression, stabilisation...
---------------------------------------------------------- ----------------------

ANIMAL MODEL FOR THE FAST IDENTIFICATION OF PHARMACEUTICAL ACTIVE COMPOUNDS IN VIVO

(WO2004078984) 16.09.2004 A01K 67/027 JANSSEN PHARMACEUTICA N.V.
In a first aspect the present invention provides a tumor cell line stably transfected with an expression vector containing a reporter gene, preferably a fluorescent protein, operably linked to a promotor that also controls expression of a protein that is associated with tumor regression, stabilisation of tumor growth or inhibition of metastatic growth, characterised in that said cell line is capable to form a tumor when implanted or injected into the non-human animal. Compared to the traditional in vivo models, the present invention differs in that the reporter gene is not constitutively expressed, but only after exposure to a test compound that results in the expression of a protein or enzyme associated with tumor regression, stabilisation...
---------------------------------------------------------- ----------------------

REGULATION OF MAMMALIAN KERATINOUS TISSUE USING HEXAMIDINE COMPOSITIONS

(WO2004078158) 16.09.2004 A61K 8/34 THE PROCTER &GAMBLE COMPANY
The present invention relates to methods for regulating the condition of mammalian keratinous tissue wherein the methods each comprise the step of topically applying to the keratinous tissue of a mammal needing such treatment, a safe and effective amount of a skin care composition comprising: a) a safe and effective amount of a hexamidine compound selected from the group consisting of hexamidine, its salts, and derivatives; b) a safe and effective amount of one or more skin care active selected from the group consisting of sugar amine, vitamin B3, retinoid, peptide, phytosterol, butylated hydroxytoluene and butylated hydroxyanisole, their derivatives, and combinations thereof; and c) a dermatologically acceptable carrier for the hexamidine ...
------------------ --------------------------------------------------------------

REGULATION OF MAMMALIAN HAIR GROWTH

(WO2004078157) 16.09.2004 A61K 8/34 THE PROCTER &GAMBLE COMPANY
The present invention relates to a topical skin care composition containing a safe and effective amount of a skin care active comprising agmatine, and its salt; a safe and effective amount of a first additional skin care active selected from the group consisting of BHT or BHA, hexamidine, cetyl pyridinium chloride, green tea catechins, phytosterols, ursolic acid, compounds derived from plant extracts, their salts and derivatives; and a dermatologically acceptable carrier for the agmatine composition. The present invention also relates to methods of using such agmatine compositions to regulate hair growth and the condition of mammalian skin. Said methods generally comprise the step of topically applying the composition to the skin of a mamma...
---------------------------------- ----------------------------------------------

INVISIBLE PATCH FOR ACTIVE AGNET CONTROLLED DELIVERY

(WO2004078122) 16.09.2004 A61F 13/00 SALVONA LLC
The present invention relates to a patch for controlled topical or transdermal delivery of effective levels of cosmetic, dermatological, and pharmaceutical active ingredients onto the skin, hair follicles, and sebaceous glands, with minimal discomfort and ease of use. The patch can be transparent or clear and comprises a rate-controlling matrix layer. The matrix layer comprises water-sensitive, bioadhesive, film forming polymers, a water soluble oligomer, and a surfactant. The cosmetic, dermatological, and pharmaceutical active ingredients are soluble or dispersed in the matrix. The patch becomes tacky when wetted and adheres onto the skin. The adhesive properties of the patch are sufficient to maintain the patch in place on the skin for th...
-------------------------------------------------- ------------------------------

AMBIPHILIC POROUS MATRIX

(WO2004075872) 10.09.2004 A61K 8/04 PHARES PHARMACEUTICAL RESEARCH N.V.
Compositions are described which are capable of forming external reservoirs comprising a polymeric matrix for adsorbing sebum in exchange for beneficial oils and transfer of hydrating components to the skin. The compositions may be lotions, creams, gels, pastes, lip sticks and water in oil systems. There is also described a method of preparing said lotions, creams, etc containing an ambiphilic powder mixture or complex comprising synthetic porous agglomerates, a lipophilic component, hydrophilic attractant/polymer, optionally biologically active compound and excipients.
------------------------------------------------------------------ --------------

WATER-SOLUBLE SILK PROTEINS IN COMPOSITIONS FOR SKIN CARE, HAIR CARE OR HAIR COLORING

(WO2004073644) 02.09.2004 A61K 38/17 E.I. DUPONT DE NEMOURS AND COMPANY
Skin care, hair care and hair coloring compositions comprising a water-soluble silk protein as an active ingredient are described. The water-soluble silk protein deposits onto the skin or the natural hair keratin to provide a smooth and durable film to provide added strength for protection against environmental, chemical, and grooming associated damage. The compositions may be in the form of skin care, skin cleansing, or anti- wrinkle products, shampoos, conditioners, lotions, aerosols, gels, mousses, dyes, or bleaches.
---------------------------------------------------------- ----------------------

FILM FOAMING HYDROALCOHOLIC FOAM

(WO2004071479) 26.08.2004 A61K 8/04 CONNETICS AUSTRALIA PTY LTD
The present invention prodides a foam composition comprising an active agent. In particular, the foam composition produces a water resistant, preferably very water resistant, film upon application
------------------------------------------------------------------ --------------

METHODS OF ADMINISTERING A DERMATOLOGICAL AGENT TO A SUBJECT

(WO2004071469) 26.08.2004 A61F 13/00 TEIKOKU PHARMA USA, INC.
Methods for administering a dermatological agent to a subject are provided. In the subject methods an effective amount of a topical formulation of the dermatological agent is topically applied to a host. The topically applied formulation of dermatological agent is then occluded with a hydrogel patch, where a feature of the hydrogel patch is that it lacks a pharmaceutically active agent. Also provided are methods of treating a subject for a disease condition by administering a dermatological agent to the subject. Also provided are kits for use in practicing the subject methods. The subject methods and compositions find use in a variety of different applications.
-------------------------------------------------- ------------------------------

INVERT EMULSION TYPE COMPOSITION CONTAINING AT LEAST ONE ACTIVE AGENT SENSITIVE TO THE PRESENCE OF WATER, AND ITS USES IN COSMETICS AND IN DERMATOLOGY

(WO2004069134) 19.08.2004 A61K 47/24 GALDERMA RESEARCH &DEVELOPMENT, S.N.C.
The present invention relates to a composition containing at least one active agent sensitive to the presence of water, characterized in that the composition is an invert emulsion containing a glycolic or hydroglycolic dispersed hydrophilic phase, a lipophilic continuous phase and an emulsifier having an HLB of between 2 and 7. This invert emulsion makes it possible to avoid the crystallization of the active agent and/or its chemical degradation, while having good stability and being well tolerated.
--------------------------------------------------------------------------------

SKIN LIGHTENING COMPOSITION

(WO2004066973) 12.08.2004 A61K 8/36 UNILEVER PLC
A skin lightening composition comprising: a) 0.05 to 10 % by weight of one of more of vitamin B3 compounds or its derivatives thereof; b) 0.01 to 10 % by weight of allantoin; and c) a cosmetically acceptable vehicle or 15 % to 85 % by weight detergent active.
-------------------------- ------------------------------------------------------

DETERGENT COMPOSITION

(WO2004066972) 12.08.2004 A61K 8/891 UNILEVER PLC
A cleansing cosmetic composition comprising; i) a cationised silicon delivery system selected from one or more of a) a cationised fatty alkyl silicone copolymer; b) a cationised dimethiconol complex and c) a cationised high viscosity lower alkyl silicone fluid with or without cationised silicone gum blend; and ii) detergent active. Also disclosed is a cationised silicone delivery system comprising: a) 15 - 50 parts of a cationised fatty alkyl silicone copolymer; b) 5 - 50 parts of a cationised dimethiconol complex; and c) 1 - 50 parts of a cationised high viscosity lower alkyl silicone fluid with cationised silicone gum blend.
------------------ --------------------------------------------------------------

CLINDAMYCIN PHOSPHATE FOAM

(WO2004064833) 05.08.2004 A61K 8/04 CONNETICS AUSTRALIA PTY LTD.
The present invention provides various pharmaceutically active topical delivery compositions. In particular, compositions of the present invention are present in a pressurized container comprising a quick-breaking alcoholic foaming agent, such that when the composition is released, i.e., dispensed, from the pressurized container, a quick-breaking temperature sensitive foam is formed. In addition, the present invention provides various aspects related to such compositions, including methods for modulating a foam characteristic, methods for improving the shelf-life of a pharmaceutically active compound, methods for the percutaneous treatment of various diseases, infections, and illnesses, and methods for evaluating foam characteristics.
---------------------------------- ----------------------------------------------

METHODS FOR MAKING AND USING TOPICAL DELIVERY AGENTS

(WO2004064769) 05.08.2004 A61K 35/78 HERRERA, Hector
The invention provides methods for making and using topical delivery agents, wherein the delivery agents comprise an oil, e.g., jojoba oil, and an active agent, and formulations made by the methods of the invention.
------------------ --------------------------------------------------------------

COMPOSITION COMPRISING A DESFERRIOXAMINE-METAL COMPLEX AND ITS USE FOR TREATING TISSUE DAMAGE FOLLOWING EXPOSURE TO WARFARE AGENT

(WO2004060490) 22.07.2004 A61K 31/28 YISSUM RESEARCH DEVELOPMENT COMPANY OF THE HEBREW UNIVERSITY OF JERUSALEM
Mustard agents are among the most powerful tactical chemical weapons that exist today, and no specific antidote or highly effective treatment against mustard toxicity is currently available. The present invention intends to provide such antidote, in the form of a desferrioxamine (DFO)-metal complex for use in the topical treatment and/or prevention of damage to a tissue exposed to such chemical weapons. More specifically, this DFO-metal complex contains zinc or gallium, and it is most effectively active following injury by nitrogen or sulfur mustard, The invention also provides pharmaceutical compositions for the topical treatment and/or prevention of tissue damage upon chemical weapon injury, comprising as active agent said DFO-metal compl...
-------------------------- ------------------------------------------------------

TOPICAL COMPOSITIONS HAVING A NATURAL INGREDIENT AND METHOD OF USE

(WO2004060288) 22.07.2004 A61K 8/97 AVON PRODUCTS, INC.
There are disclosed topical compositions for alleviation of skin irritation symptoms or conditions having at least one plant extract effective to inhibit COX-2 enzyme, NGF protein, and/or TNF-alpha protein activity. Preferably, the compositions have a cosmetically, dermatologically, or pharmaceutically acceptable vehicle. In addition to the enzyme inhibitory plant material and acceptable vehicle, compositions may also have at least one active ingredient known to produce skin irritation. There is also a method for treatment of skin irritation symptoms or conditions involving topically applying compositions of the invention. Also disclosed are compositions and methods for topical administration of compositions to the skin that improve the aes...
---------- ----------------------------------------------------------------------

USE OF ACTIVE EXTRACTS TO IMPROVE THE APPEARANCE OF SKIN, LIPS, HAIR AND/OR NAILS

(WO2004060285) 22.07.2004 A61Q 19/02 AVON PRODUCTS, INC.
There is provided a composition having at least one of the following active extracts Butea frondosa, Naringi crenulata, Stenoloma chusana, or any combinations thereof. There is also provided a composition having at least one of the following additional extracts Azadirachta indica, Glycyrrhiza glabra linn., Morinda citrifolia, tomato glycolipid or any combinations thereof in combination with one or more of the active extracts. The compositions and methods of the invention are effective to improve the aesthetic appearance of skin, lips, hair and/or nails, especially by lightening the skin, lips, hair and/or nails.
-------------------------- ------------------------------------------------------

A METHOD AND ARTICLE TO CONTROL CELLULITE

(WO2004060268) 22.07.2004 A61K 9/70 ASAHI KASEI CORPORATION
A multilayer, flexible patch configured for the transdermal treatment of the skin of a human subject with an active ingredient, which ingredient is adapted for reducing the incidence of human cellulite and other fatty tissues comprising a pressure sensitive, skin adherable first layer selected from one of the polymeric materials comprising acrylate copolymer, vinyl ether copolymer, and a silicone adhesive polymer. It contains, by dispersal therethrough, an active ingredient selected from the group consisting of xanthine, hypoxanthine, theophylline, 7-theophylline acetic acid, caffeine, and theobromine. There is an outer backing, second layer comprising a water-soluble, skin conformable fabric adapted to provide moisture vapor permeability s...
-------------------------- ------------------------------------------------------

METASTABLE INSECT REPELLENT EMULSION COMPOSITION AND METHOD OF USE

(WO2004060063) 22.07.2004 A01N 25/02 AVON PRODUCTS, INC.
There is provided an improved insect repellent emulsion composition. The composition has an inner discontinuous phase and an outer continuous phase. The inner discontinuous phase and/or outer continuous phase has an insect repellent active therein. The inner discontinuous phase is generally dispersed in the outer continuous phase and is in the form of discrete droplets having a multimodal droplet size distribution. There is also provided a method of protecting skin from being bitten by insects in which the above composition is applied topically to the skin. There is also provided a method of enhancing the performance of a insect repellent emulsion by forming the inner discontinuous phase as a multiplicity of droplets having a multimodal dro...
--------------------------------------------------------------------------------

SPHINGOLIPID DERIVATIVES MODIFIED BY POLYETHYLENE GLYCOL AND COMPOSITION CONTAINING THE SAME

(WO2004054963) 01.07.2004 A61K 31/133 DOOSAN CORPORATION
The present invention relates to sphingolipid derivatives modified by polyethylene glycol which have superior stability and solubility to conventional sphingolipid derivatives and remarkably reduced toxicity, wherein the sphingolipid is selected from the group consisting of phytosphingosine, sphiganine and sphingadiene. The sphingolipid derivatives are effective in stabilizing other active ingredients in the form of liposome compositions, etc.
---------- ----------------------------------------------------------------------

ACTIVE TOPICAL SKIN PROTECTANTS CONTAINING AMINES,POLYALKENIMINES AND/OR DERIVATIVES

(WO2004054521) 01.07.2004 A61K 8/81 BRAUE, Ernest, H.
A topical skin protectant formulation containing a barrier cream and an active moiety for protecting warfighters and civilians against all types of harmful chemicals, specifically chemical warfare agents (CWA). The active moiety is an amine, polyalkenimines and/or derivatives. The topical skin protectant offers a barrier property and an active moiety that serves to neutralize chemical warfare agents into less toxic agents.
-------------------------------------------------- ------------------------------

METHODS OF PRODUCING LIGNIN PEROXIDASE AND ITS USE IN SKIN AND HAIR LIGHTENING

(WO2004052275) 24.06.2004 C09B 29/00 R.B.T. (Rakuto Bio Technologies) Ltd.
Methods of producing lignin peroxidase are provided. Also provided are methods and cosmetic compositions suitable for skin and hair lightening as well as kits and an article-of manufacturing including active ingredients for skin and hair lightening.
-- ------------------------------------------------------------------------------

SELECTIVE CYCLOOXYGENASE-2 INHIBITOR PATCH

(WO2004047816) 10.06.2004 A61K 9/70 PHARMACIA CORPORATION
A pharmaceutical composition for application to an area of skin of a subject for local and/or systemic treatment of a COX-2 mediated disorder comprises a backing sheet that is flexibly conformable to the area of skin, the backing sheet having opposing surfaces that are respectively distal and proximal to the skin when applied; and a coating on the proximal surface of the backing sheet that comprises (a) an adhesive, (b) an active agent comprising a selective COX-2 inhibitory sulfonamide drug of low water solubility, and (c) a solvent system for the active agent, wherein the active agent is in a therapeutically effective total amount and the solvent system is selected with regard to composition and amount thereof to be effective to maintain ...
-- ------------------------------------------------------------------------------

DERMAL DELIVERY OF A WATER-SOLUBLE SELECTIVE CYCLOOXYGENASE-2 INHIBITOR, E.G. PARECOXIB AND VALDECOXIB

(WO2004047815) 10.06.2004 A61K 9/70 PHARMACIA CORPORATION
A pharmaceutical composition for application to an area of skin of a subject for local and/or systemic treatment of a COX-2 mediated disorder comprises a backing sheet that is flexibly conformable to the area of skin, the backing sheet having opposing surfaces that are respectively distal and proximal to the skin when applied; and a coating on the proximal surface of the backing sheet that comprises (a) an adhesive and (b) an active agent comprising valdecoxib or a prodrug thereof or a salt thereof, the active agent being in a therapeutically effective total amount and dispersed in a matrix that comprises zero to less than an active agent solubilizing effective amount in total of one or more solvents other than the adhesive. A method of loc...
---------------------------------- ----------------------------------------------

DERMAL DELIVERY OF A WATER-SOLUBLE SELECTIVE CYCLOOXYGENASE-2 INHIBITOR, E.G. PARECOXIB, VALDECOXIB AND BENZOPYRAN DERIVATIVES

(WO2004047814) 10.06.2004 A61K 9/70 PHARMACIA CORPORATION
A pharmaceutical composition for application to an area of skin of a subject for local and/or systemic treatment of a COX-2 mediated disorder comprises a backing sheet that is flexibly conformable to the area of skin, the backing sheet having opposing surfaces that are respectively distal and proximal to the skin when applied; and a coating on the proximal surface of the backing sheet that comprises (a) an adhesive and (b) a water-soluble active agent selected from selective COX-2 inhibitory drugs, prodrugs and salts thereof, the active agent being in a therapeutically effective total amount and dispersed in a matrix that comprises zero to less than an active agent solubilizing effective amount in total of one or more solvents other than th...
---------------------------------- ----------------------------------------------

MEDICAL DEVICES EMPLOYING NOVEL POLYMERS

(WO2004045549) 03.06.2004 A61K 9/14 POLYMERIX CORPORATION
Medical devices with at least one surface comprising a polymer or polymers on the surface are provided. The polymer or polymers are capable of breaking down (e.g., including, but not limited to, hydrolyzing) in the physiologic milieu to form an active agent or agents under physiologic conditions, and can contain other active agents dispersed within or appended to the polymer matrix. Methods of delivering an active agent to an interior surface of a vein or artery are also provided.
---------------------------------------------------------- ----------------------

MULTI-PORTION ANTIPERSPIRANT COMPOSITION

(WO2004045514) 03.06.2004 A61K 8/28 THE GILLETTE COMPANY
Disclosed is a non-flowable anhydrous topical antiperspirant composition comprising a first portion and a second portion contiguous with the first portion. The first portion is semi-opaque to opaque and comprises a first hydrophobic carrier vehicle and a first gellant and has a particulate antiperspirant active suspended therein. The second portion is translucent to transparent and comprises a second hydrophobic carrier vehicle and a second gellant. Preferably, the second hydrophobic carrier vehicle has an average refractive index that approximately matches the refractive index of the second gellant. Ideally, for greater translucency the second portion will be substantially free of antiperspirant salt and/or other opacifying materials. Pref...
---------------------------------------------------------- ----------------------

IMPROVED COSMETIC COMPOSITION

(WO2004043422) 27.05.2004 A61K 7/48 UNILEVER PLC
A skin care cosmetic composition comprising: a. 0.05 % to 5 % by weight vitamin B12 or a derivative thereof; b. 0.1 % to 10 % by weight of a skin lightening vitamin chosen from niacinamide, pyridoxine or precursors thereof; c. up to 10 % by weight sunscreen; and d. 10 % to 99 % by weight of a cosmetically acceptable vehicle or 15 % to 85 % by weight detergent active.
---------------------------------------------------------- ----------------------

A MULTI COMPONENT CONTROLLED DELIVERY SYSTEM FOR SOAP BARS

(WO2004041991) 21.05.2004 C11D 9/00 SALVONA LLC
The present invention relates to an improved controlled delivery system that can be incorporated in soap bars to enhance deposition of active ingredients and sensory markers onto skin. The carrier system also provides controlled release or prolonged release of these actives from the skin over an extended period of time. The controlled delivery system of the present invention comprises substantially free- flowing, powder formed of solid hydrophobic, positively charged, nanospheres of encapsulated active ingredients, that are encapsulated in moisture sensitive microspheres. The high cationic charge density of the nanosphere improves deposition of active ingredients onto skin. The high cationic charge density on the nanosphere surface is create...
------------------------------------------ --------------------------------------

CARBONYLAMINO-BENZIMIDAZOLE DERIVATIVES AS ANDROGEN RECEPTOR MODULATORS

(WO2004041277) 21.05.2004 C07D 417/04 MERCK &CO., INC.
Compounds of structural formula (I) are modulators of the androgen receptor (AR) in a tissue selective manner. They are useful as agonists of the androgen receptor in bone and/or muscle tissue while antagonizing the AR in the prostate of a male patient or in the uterus of a female patient. These compounds are therefore useful in the enhancement of weakened muscle tone and the treatment of conditions caused by androgen deficiency or which can be ameliorated by androgen administration, including osteoporosis, osteopenia, glucocorticoid-induced osteoporosis, periodontal disease, bone fracture, bone damage following bone reconstructive surgery, sarcopenia, frailty, aging skin, male hypogonadism, postmenopausal symptoms in women, atherosclerosis...
---------- ----------------------------------------------------------------------

OINTMENT COMPOSITION FOR TREATING DECUBITUS ULCERS AND METHODS FOR ITS MAKING AND ITS USE

(WO2004039390) 13.05.2004 A61K 33/22 GOULBOURNE, Mary, J.
An ointment composition for treating decubitus ulcers and methods for its making and its use. The composition includes a skin protestant ointment, a rash cream, an antibiotic ointment, virgin olive oil, and boric acid powder. The skin protestant ointment includes active ingredients petroleum 53.4%, lanolin 15.5%, and inactive ingredients cod liver oil containing vitamin A & vitamin D, a fragrance, light mineral oil, microcrystalline wax, and paraffin. The rash cream includes active ingredients dimethicone 1% and zinc oxide 10%, and inactive ingredients aloe barbadensis extract, benzyl alcohol, coconut oil, cod liver oil containing vitamin A ...
------------------------------------------------------------------ --------------

NASAL STICK FOR THE APPLOCATION OF MEDICAMENTS AND SKIN CARE SUBSTANCES

(WO2004039350) 13.05.2004 A61K 9/00 CELL CENTER COLOGNE GMBH
A stick for the topical or transmucosal application of a skin care or active agent onto and via the nasal mucosa, respectively, is provided, wherein the stick material contains a composition of at least one carrier substance and at least one skin care or active agent, which is capable of acting on the nasal mucosa and/or being resorbed by it or which contains at least one volatile substance that acts on the deeper respiratory tract and/or is being resorbed by the deeper respiratory tract. Furthermore, the use of a medical skin care or cosmetical stick or of a stick material or of a refill cartridge containing said material for the topical or transmucosal application is described.
-------------------------- ------------------------------------------------------

PURINE NUCLEOSIDES

(WO2004038006) 06.05.2004 C07D 473/32 THE GOVERNMENT OF THE UNITED STATES OF AMERICA, represented by THE SECRETARY, DEPARTMENT OF HEALTH AND HUMAN SERVICES
Disclosed are purine nucleoside compounds that are selective to A3 adenosine receptors and are useful for the treatment of cancer and inflammatory diseases. The compounds are shown by the following general formula (I), including isomers thereof: wherein X is sulfur or oxygen; Rl is hydrogen, alkyl, benzyl, halobenzyl, or phenylalkyl; R2 is hydrogen, halogen, alkoxy, alkenyl, alkynyl, alkylthio, or thio; R3 and R3' are hydrogen, hydroxyalkyl, alkoxycarbonyl, or alkylaminocabonyl, whereas R3 and R3' do not have identical substituents simultaneously; and R4 is hydrogen or alkyl. Also disclosed are a pharmaceutical composition comprising a compound of formula (I), an isomer, or its pharmacologically acceptable salt as an active ingredient and a...
---------- ----------------------------------------------------------------------

APPARATUS FOR THE TREATMENT OF MAXILLARY AND FRONTAL SINUSITIS AND NEURITIS AND NEURALGIA OF THE TRIGEMINAL NERVE

(WO2004037244) 06.05.2004 A61M 35/00 MARINELLO, Andrea
The invention relates to a device comprising a facial mask, an inflatable elastic pad affixed to the mask and a compress containing a revulsive having an active ingredient.
---------- ----------------------------------------------------------------------

CATIONIC CARDIOLIPIN ANALOGS AND USE THEREOF

(WO2004035523) 29.04.2004 A61K 9/127 NEOPHARM, INC.
The invention provides cationic cardiolipin compounds, and methods for synthesizing and using them in liposomal formulation, gene transfection, etc. In particular, the invention provides liposomes comprising cationic cardiolipin analog, pharmaceutical compositions comprising cationic cardiolipin analogs, and methods of using such liposomes and compositions, in delivering active pharmaceutical agents to treat human and animal diseases and/or in diagnostic assays.
-------------------------------------------------- ------------------------------

EXTRACT WITH ANTI-TUMOR AND ANTI- POISONOUS ACTIVITY

(WO2004032948) 22.04.2004 A61P 35/00 UNIBIOSCREEN S.A.
The present invention relates to extracts of the plant Calotropis procera, having a pharmacological activity, in particular an anti-poisonous activity, and active compounds isolated thereof. Furthermore, the invention relates to methods for the extraction of said extracts. Also, the invention concerns a pharmaceutical composition or product for the treatment of cancer comprising an effective amount of said extracts or an active compound thereof, a therapeutic compound and optionally a pharmaceutical acceptable carrier.
-------------------------- ------------------------------------------------------

PROCESS FOR MAKING HOLLOW FIBER MIXED MATRIX MEMBRANES

(WO2004026449) 01.04.2004 B01D 53/22 L'AIR LIQUIDE
Isopycnic or asymmetric mixed matrix hollow fiber membranes for gas separation can be made by a continuous spinning process. Mixed matrix membranes are characterized by a continuous phase of selectively gas permeable polymer in which are uniformly dispersed discrete absorbent particles such as molecular sieves that also have selectivity enhancing properties. The fibers can be monolithic in which the fiber wall is entirely mixed matrix, or composite in which an active mixed matrix layer is positioned adjacent to a supporting substrate layer. The novel mixed matrix hollow fiber membranes provide higher selectivity than dense film membranes of the continuous phase polymer. A monofunctional organosilicon compounds can be used to treat the zeoli...
-- ------------------------------------------------------------------------------

ORALLY ADMINISTRABLE COMPOSITION FOR IMPROVING SKIN QUALITY

(WO2004026287) 01.04.2004 A23K 1/16 NESTEC S.A.
The present invention relates to an orally administrable composition for improving skin quality and prevent or restore age- related alterations of skin in humans or animals, which comprises as an active ingredient an effective amount of a molecule that stimulates energy metabolism of the cell or an antioxidant or combinatory admixtures thereof, in an orally acceptable carrier.
---------------------------------------------------------- ----------------------

NOVEL PHOTOSTABILIZERS, UV ABSORBERS, AND METHODS OF PHOTOSTABILIZING A SUNSCREEN COMPOSITION

(WO2004026197) 01.04.2004 A61K 8/35 CPH INNOVATIONS CORPORATION
Polymers and compounds including a diphenylmethylene or a 9H-fluorene moiety; and sunscreen compositions including a mixture of a photoactive compound and any one of the foregoing derivatives are disclosed herein. Also disclosed are methods for stabilizing a sunscreen composition by the addition of one or more of the foregoing derivatives, methods of filtering out ultra-violet light from a substrate by the use of one or more such derivatives, and methods for terminating a polymerization reaction by the addition of derivatives of diphenylmethylene and/or 9H-fluorene. Synergistic combinations of the polymer with (1) diesters or polyesters of a naphthalene dicarboxylic acid, or (2) oxybenzone enhance the photostability of sunscreen composition...
-- ------------------------------------------------------------------------------

OPTICALLY ACTIVATED PARTICLES FOR USE IN COSMETIC COMPOSITIONS

(WO2004024103) 25.03.2004 A61K 8/11 LIPO CHEMICALS, INC.
Optically activated particles for use in cosmetic and pharmaceutical compositions are disclosed. The optically activated particles include a solid substrate having a fluorescent compound fixed thereto, and coated or encapsulated with a transparent or translucent coating of crosslinked polyvinyl alcohol. The optically activated particles absorb light at a UV wavelength and emit visible light at longer wavelengths, and are able to both absorb and scatter light in a diffuse manner in order to reduce the visual perception of skin imperfections, including cellulite, wrinkles, shadows, skin discolorations, blotchiness, mild scars.
---------------------------------- ----------------------------------------------

COMPOSITION BASED ON TRIETHYL CITRATE FOR THE TREATMENT OF BACTERIAL INFECTIONS OF THE SKIN

(WO2004019929) 11.03.2004 A61K 31/215 DE PAOLI AMBROSI, Gianfranco
This invention concerns a composition for topical use containing as an active ingredient triethyl citrate either pure or in combination with synergists, and the pharmaceutical or cosmetic use of the composition, on its own or in association with an antibiotic, at least in the treatment of cutaneous pathologies directly or indirectly affected by bacterial infections.
-------------------------------------------------- ------------------------------

COMPOSITION COMPRISING THE EXTRACT OF ACTINIDIA ARGUTA AND RELATED SPECIES FOR THE PREVENTION AND TREATMENT OF ALLERGIC DISEASE AND NON-ALLERGIC INFLAMMATORY DISEASE

(WO2004017982) 04.03.2004 A23L 1/30 PANGENOMICS CO., LTD
The present invention provides a pharmaceutical composition comprising the extract of hardy kiwifruit as an active ingredient in an effective amount to treat and prevent allergic disease and non- allergic inflammatory disease by reducing inflammation action, by inhibiting histamine release from mast cell, and by increasing the level of Th1 cytokines, IgG2a in serum and reducing the level of Th2 cytokines and IgE in serum. The present invention also provides a use of above extract for the preparation of pharmaceutical composition. The present invention also provides a health food or food additives, a cosmetic composition, a feed or feed additives comprising above extract for prevention or alleviation of allergic disease and non-allergic infla...
------------------------------------------------------------------ --------------

PERCUTANEOUS AND PERUNGUAL DELIVERY SYSTEM

(WO2004010988) 05.02.2004 A61K 8/67 CONNETICS AUSTRALLIA PTY LTD
The invention relates to a substantially homogeneous liquid composition capable of percutaneous delivery of one or more physiologically active agents, the composition including at least one physiologically active agent, a volatile solvent, and a rate modulating carrier comprising a hydrophilic polymer and a hydrophobic polymer the combination of the hydrophilic and hydrophobic polymers being elected to enable modulation of the rate of physiologically active agent. The invention also relates to method of delivering an effective amount of an active agent and method of treatment of a patient using the composition of the invention.
------------------------------------------ --------------------------------------

USE OF LIGNANS FOR PREVENING OR TREATING THE SINGS OF AGEING OF THE SKIN

(WO2004010965) 05.02.2004 A61K 8/34 L'OREAL
The invention relates to the cosmetic use of at least one lignan of given formula, or of a plant extract containing it (such as an extract of flax seeds), in a composition suitable for topical application to the skin, containing a cosmetically acceptable medium, for preventing or treating the signs of ageing of the skin, in particular the loss of firmness, elasticity and/or tonicity of the skin and/or the formation of wrinkles and fine lines. The invention also relates to a topical cosmetic composition containing these lignans in combination with other anti-ageing active agents. Lastly, the invention relates to a cosmetic process for treating dry skin, comprising the topical application to the said skin of a composition containing at least ...
-------------------------- ------------------------------------------------------

RAPID, EFFICIENT PURIFICATION OF HSV-SPECIFIC T-LYMPHOCYTES AND HSV ANTIGENS IDENTIFIED VIA SAME

(WO2004009021) 29.01.2004 A61K 38/08 UNIVERSITY OF WASHINGTON
Described is a method of identifying an immunologically active antigen of a virus that attacks skin, as well as a method of enriching a population of lymphocytes for T lymphocytes that are specific to a virus that attacks skin. Also provided are HSV antigens and epitopes that are useful for the prevention and treatment of HSV infection that have been identified via the methods of the invention. T-cells having specificity for antigens of the invention have demonstrated cytotoxic activity against cells loaded with virally-encoded peptide epitopes, and in many cases, against cells infected with HSV. The identification of immunogenic antigens responsible for T-cell specificity provides improved anti-viral therapeutic and prophylactic strategies...
-------------------------------------------------- ------------------------------

COMPOSITION FOR CYTOCOMPATIBLE, INJECTABLE, SELF-GELLING CHITOSAN SOLUTIONS FOR ENCAPSULATING AND DELIVERING LIVE CELLS OR BIOLOGICALLY ACTIVE FACTORS

(WO2004006961) 22.01.2004 A61K 9/00 BIO SYNTECH CANADA INC.
The present invention provides compositions and methods for tissue repair using a cytocompatible self-gelling cross-linked hydrogel. The composition comprises a biocompatible mixture of chitosan, bifunctional dialdehyde, and hydroxylated polymer, which can be used to immobilize or encapsulate viable cells, or bioactive substances. The method includes the process of mixing bioactive substances, live cells, and/or extracellular matrix components with a cross-linking solution comprising a bifunctional aldehyde-treated hydroxylated polymer such as hydroxyethyl cellulose. The cross-linking solution is then mixed homogenously with a neutral isotonic chitosan solution. The chitosan becomes cross-linked by the bifunctional aldehyde, while the cells...
-- ------------------------------------------------------------------------------

THERAPEUTIC TUBERCULOSIS VACCINES

(WO2004006952) 22.01.2004 A61K 39/02 STATENS SERUM INSTITUT
The present invention is based on a number of M.tuberculosis derived proteins and protein fragments which are induced during the latent stage of infection characterized by low oxygen tension in the microenvironment of the infecting TB-bacteria. The invention is directed to the use of these polypeptides, immunologically active fragments thereof and the genes encoding them for immunological compositions such as therapeutic vaccines and diagnostic reagents.
-------------------------------------------------- ------------------------------

COMPOSITIONS HAVING ENHANCED DEPOSITION OF A TOPICALLY ACTIVE ON A SURFACE

(WO2004004677) 15.01.2004 A01N 25/24 THE DIAL CORPORATION
Topically active compositions having enhanced effectiveness are disclosed. The compositions contain a topically active compound, an an-ionic surfactant, a hydric solvent, a hydrotrope, an optional cosurfactant, and water, wherein a percent saturation of the topical active compound of the composition is at least 25 %. The compositions exhibit a rapid and effective topical effect, and effectively deposit the topically active compound for an effective residual effect.
------------------------------------------ --------------------------------------


MODIFIED SOY PROTEINS IN PERSONAL CARE COMPOSITIONS

(WO2004112745) 29.12.2004 A61K 8/64 E.I. DUPONT DE NEMOURS AND COMPANY
Personal care compositions comprising a modified soy protein as an active ingredient are described. The modified soy proteins of the instant invention include soy proteins modified by treatment with a reducing agent and subsequently reacted with a carboxylic acid anhydride; soy proteins modified by treatment with a reducing agent, reacted with a carboxylic acid anhydride and subsequently oxidized; soy proteins modified by reaction with a hydroxy alkyl acrylate; soy proteins modified with ionic monomers such as epoxide, acrylate, and chlorohydrin; and soy proteins modified by reaction with an alkyl acrylimidoglycolate. The compositions may be in the form of skin care, skin cleansing, or anti--wrinkle products, shampoos, make-up, conditio...
--------------------------------------------------------------------------------

NEW SAPONIN COMPOUND, SAPONIN SOLUTION CONTAINING THE SAME A PREPARATION METHOD THEREOF, AND PHARMACEUTICAL COMPOSITIONS, HEALTH FOODS AND COSMETICS CONTAINING THE SAPONIN AS AN ACTIVE COMPONENT

(WO2004111069) 23.12.2004 A23L 1/30 CHOI, Jang Youn
Disclosed are a novel saponin compound, a saponin composition liquid containing the same, a preparation method thereof, and a pharmaceutical composition, functional food and cosmetic product containing the composition liquid as an active ingredient. The pharmaceutical composition and functional food has various pharmacological effects, including immune enhancement, vitality enhancement, improvement of liver function, withdrawal of hangover, promotion of protein generation, promotion of cerebral activities and improvement of attention, activated recuperation of health after surgical operation, and prevention or treatment of diabetes, impaired blood circulation, depression, dermal inflammatory disease, dermal eczema, dermatophytosis, allergic...
---------- ----------------------------------------------------------------------

A COUMERMYCIN/NOVOBIOCIN-REGULATED GENE EXPRESSION SYSTEM

(WO2004108933) 16.12.2004 C12N 15/67 NATIONAL RESEARCH COUNCIL OF CANADA
A chimeric transactivator comprises a transcription activation domain, a repressor protein DNA binding domain and the bacterial DNA gyrase B subunit. A target gene is operatively linked to operator DNA sequences recognized by the repressor binding domain. The addition of the antibiotic coumermycin results in a coumermycin-switched dimerization of the transactivator, which then binds to operator DNA sequences and activates transcription of the target gene. The addition of novobiocin switches off expression of the target gene by abolishing coumermycin-induced dimerization of the transactivator.
---------------------------------------------------------- ----------------------

ADHESIVE COMPOSITIONS, ARTICLES INCORPORATING SAME AND METHODS OF MANUFACTURE

(WO2004108854) 16.12.2004 A61L 15/58 3M INNOVATIVE PROPERTIES COMPANY
A hydrophilic, pressure-sensitive adhesive composition comprising crosslinked poly(N-vinyl lactam), a swelling agent, and a modifying polymer in an amount sufficient to form a cohesive pressure- sensitive adhesive composition is provided. The composition is useful as a medical secural of percutaneous devices. The composition is also useful as a drug delivery device to deliver antimicrobial agents, pharmaceuticals or other active ingredients to or through skin. A method of preparation of the composition is also disclosed.
------------------------------------------------------------------ --------------

EXTENDED RELEASE OSMO-MICROSEALED FORMULATION COMPRISING VENLAFAXINE

(WO2004108117) 16.12.2004 A61K 9/00 ALEMBIC LIMITED
Extended Release Osmo-microsealed Formulation comprising 1hree controlled release systems associated in series, first an inner solid particulate phase containing Venlafaxine Hydrochloride (Active), and one or more hydrophobic polymers-, one or more diluents required to increase the bulk one or more osmogen (agents which can generate osmotic pressure across the hydrophobic coating) and one or more binder polymers essentially to provide strength/hardness to the particle, second, an outer solid continuous phase including one or more hydrophilic polymers, it is further compressed into tablet and third is an optional functional coat surrounding the tablet, this invention also provides process/method for forming the described osmo -microsealed ext...
---------------------------------------------------------- ----------------------

STABLE COSMETIC COMPOSITIONS COMPRISING A SELF-TANNING AGENT

(WO2004105721) 09.12.2004 A61K 8/35 THE PROCTER &GAMBLE COMPANY
Stable topical compositions having a pH of from 3.5 to 4.5 comprising a self- tanning agent, a polymer and a polyhydric alcohol humectant. The compositions of the present invention are highly stable, and deliver high levels of active self- tanning agent to the skin upon topical application.
-------------------------- ------------------------------------------------------

TOPICAL COMPOSITION FOR THE TREATMENT OF SKIN DISORDERS AND METHODS OF USING THE SAME

(WO2004105689) 09.12.2004 A61K 35/78 HOST PHARMACEUTICALS, LLC
A topical composition for the treatment of skin disorders such as scars containing at least one, preferably two select botanical oils alone or in a combination with at least one other active agent and methods of using the same to treat skin disorders.
---------- ----------------------------------------------------------------------

CONTROLLED RELEASE OF ACTIVE AGENTS UTILIZING REPEAT SEQUENCE PROTEIN POLYMERS

(WO2004104021) 02.12.2004 A61K 8/04 DOW CORNING CORPORATION
Systems are provided for the controlled release delivery of active agents through the use of repeat sequence protein polymers. The systems may exist as matrices, gels, hydrogels, films, emulsions or microparticles and are particularly useful for incorporating active agents into personal care product compositions.
-- ------------------------------------------------------------------------------

REPEAT SEQUENCE PROTEIN POLYMER ACTIVE AGENT CONJUGATES, METHODS AND USES

(WO2004104020) 02.12.2004 A61K 8/64 DOW CORNING CORPORATION
Biomolecular conjugates are provided which comprise the conjugation product of a repeat sequence protein polymer and at least one active agent. Additional aspects provide methods for their manufacture and various industrial and consumer applications.
---------------------------------------------------------- ----------------------

TERNARY AND QUATERNARY EUTECTIC MIXTURES.

(WO2004103260) 02.12.2004 A61K 9/00 CRISTÁLIA PRODUTOS QUÍMICOS FARMACÊUTICOS LTDA.
The present invention describes ternary and quaternary eutectic mixtures composed by active local anesthetic substances. These eutectic mixtures possess melting point inferior to 20°C and consist of homogeneous liquid useful in the preparation o pharmaceutical compositions for topical anesthesia or analgesia of tissues as skin or mucous.
---------------------------------- ----------------------------------------------

SUNSCREEN OR MEDICINAL WIPES HAVING HIGH SUNSCREEN FORMULATION TRANSFER RATE

(WO2004100914) 25.11.2004 A61K 8/02 KIMBERLY-CLARK WORLDWIDE INC.
Sunscreen wipes comprising a thixotropic, quick-breaking sunscreen formulation are disclosed. The sunscreen formulation comprises water, at least one sunscreen active, Pemulen TR-2, a stabilizing emulsifier, and a neutralizing agent. By formulating the sunscreen formulation such that it has specific high shear and low shear viscosities at a pH range of from about 5 to about 6, the transfer rate of the sunscreen formulation to the skin during use is significantly increased as compared to conventional sunscreen wipes. The present invention is further directed to a medicinal wipe comprising a wipe substrate and a medical formulation. The medicinal formulation comprises water, Permulen TR-2, high spreadability emollient, medicinal active (such ...
------------------------------------------------------------------ --------------

ANDROGEN RECEPTOR MODULATORS AND METHODS OF USE THEREOF

(WO2004100874) 25.11.2004 A61K 31/56 MERCK &CO., INC.
Compounds of structural formula (I) as herein defined are disclosed as useful in a method for modulating the androgen receptor in a tissue selective manner in a patient in need of such modulation, as well as in a method of agonizing the androgen receptor in a patient, and in particular the method wherein the androgen receptor is antagonized in the prostate of a male patient or in the uterus of a female patient and agonized in bone and/or muscle tissue. These compounds are useful in the treatment of conditions caused by androgen deficiency or which can be ameliorated by androgen administration, including: osteoporosis, periodontal disease, bone fracture, bone damage following bone reconstructive surgery, sarcopenia, frailty, aging skin, male...
------------------------------------------------------------------ --------------

ABUSE-RESISTANT TRANSDERMAL DOSAGE FORM

(WO2004098576) 18.11.2004 A61K 9/70 3M INNOVATIVE PROPERTIES COMPANY
The invention comprises a transdermal dosage form comprising a active agent component comprising a polymeric matrix and an abusable drug substance, an overlay backing, a porous material, and an antagonist reservoir comprising an antagonist to the abusable drug substance. The porous material adjoins the antagonist reservoir and is in fluid communication with the skin-contacting surface defined by the active agent component. In one embodiment, the device comprises a barrier layer interposed between the active agent component and the antagonist reservoir.
---------- ----------------------------------------------------------------------

COMPOSITIONS AND METHODS FOR TREATMENT OF PSORIASIS

(WO2004096258) 11.11.2004 A61K 33/34 PROCYTE CORPORATION
A method for treating psoriasis of the skin of a patient employs topically applying to the affected skin a composition comprising at least one peptide copper complex. In other embodiments, the present invention is directed to such a method where the composition used therefor further comprises certain disclosed active agents, including active drug and active cosmetic substances. In a related aspect, further embodiments of the present invention are directed to compositions comprising at least one peptide copper complex and certain active drug and active cosmetic substances that render the compositions particularly effective in treating psoriasis.
------------------ --------------------------------------------------------------

DERMATOLOGICAL FORMULATION

(WO2004096169) 11.11.2004 A61K 7/48 PROVINCIA ITALIANA DELLA CONGREGAZIONE DEI FIGLI DELL'IMMACOLATA CONCEZIONE - ISTITUTO DERMOPATICO DELL'IMMACOLATA
A dermatological formulation containing active principles which are of strictly natural origin, said formulation being intended for cutaneous protection and prevention against exogenous and endogenous oxidative damages, both through the re-establishment of sebaceous and epidermal lipids and antioxidants equilibrium which are essential for cutaneous homeostasis and become altered by the oxidative stress, and through the presence of a pool of molecules endowed with specific lenitive and anti-inflammatory activity. The further association of molecule which chelate transition metals and are also capable of reactivating the superficial circulation is also provided.
---------------------------------- ----------------------------------------------

COMPOSITION, METHOD AND PHARMACEUTICAL PREPARATION FOR PHARMACEUTICAL SPRAY SUSPENSIONS

(WO2004091577) 28.10.2004 A61K 9/70 PORTEN PHARMACEUTICAL AB
The present invention provides, according to a first aspect a pharmaceutical composition, constituting a spray suspension comprising at least one liquid excipient and at least one solid excipient which essentially is insoluble in the liquid excipient, and at least one pharmaceutical active ingredient. According to a second aspect of the present invention, there is provided a method of preparing porous suspension particles (including an active ingredient), wherein it comprises the steps of ; a. wet-milling or dry-milling the solid excipient(s) or a mixture of at least one active ingredient and a solid excipient(s) in a milling equipment inducing essentially compression and shear forces, resulting in fine particulate quality, where more than ...
---------- ----------------------------------------------------------------------

ACTIVATED CITRUS PEEL EXTRACT

(WO2004091569) 28.10.2004 A01N 65/00 CITRAMED LTD.
The present invention relates to composition comprising an activated citrus peel extract (ACPE) prepared by an activation method which includes exposure of citrus peels to at least one plant or animal pathogen. The ACPE comprises at least one of the following: oligosaccharides, short peptides, flavonoid glycosides, fatty acids, and triglycerides. Compositions comprising the ACPE have been shown useful as dermatological compositions for the treatment of various skin conditions. They have also been shown to be useful in preserving food, beverages and cosmetics.
-------------------------------------------------- ------------------------------

CATIONIC, OXIDIZED POLYSACCHARIDES IN CONDITIONING APPLICATIONS

(WO2004091557) 28.10.2004 A61K 8/73 HERCULES INCORPORATED
A cationic, oxidized polysaccharide or derivative thereof that has a mean average molecular weight (Mw) having a lower limit of 50,000 and an upper limit of 1,000,000 and an aldehyde functionality content of at least 0.001meq/gram is used in personal care and household care compositions. This cationic, oxidized polysaccharide is prepared in continuous or batch processes using hydrolytic reagents, oxidizing reagents, or combination of hydrolytic reagents and oxidizing reagents. Personal care or household care compositions are prepared by adding the cationic, oxidized polysaccharide to a personal care or household composition containing at least one active ingredient other than the cationic, oxidized polysaccharide of this invention.
------------------ --------------------------------------------------------------

PROCESS FOR MEASURING THE SKIN SURFACE OF AN EXAMINED PERSON

(WO2004091501) 28.10.2004 A61B 5/103 MANZO, Robert, P.
The invention relates to a method and a process of determining individual skin structure and function at a point in time for the purpose of determining and formulating skin care products that remedy the deficiencies observed in the skin. Objective and repeatable dermal biometric instrumentation techniques can be used to measure skin moisture content, sebum content, firmness and elasticity properties, skin thickness, transepidermal water loss, skin pH and to perform a photo analysis of the face with UV and visible light. By customizing the skin care products, the individually added active ingredients can be controlled, the diluents can be modified, dermal penetration rates can be controlled, the surfactant systems can be adjusted, and the st...
--------------------------------------------------------------------------------

TOPICAL ANTIANDROGENIC STEROIDS

(WO2004089971) 21.10.2004 A61K 31/56 ENDORECHERCHE, INC.
Steroidal antiandrogens and pharmaceutical compositions thereof, are used for reduction of the risk of developing, or for treatment of, androgen-dependent skin related diseases. In preferred embodiments, the antiandrogen EM-3180 is used for reduction of the risk of developing, or the treatment, of acne, seborrhea, hirsutism or androgenic alopecia: Methods of treatment utilize the antiandrogen alone, or in combination with other active ingredients such as an inhibitor of a 5a-reductase, an inhibitor of type 5 170- hydroxysteroid dehydrogenase, and/or an inhibitor of prostate short-chain dehydrogenase/reductase.
-------------------------------------------------- ------------------------------

PROSTAGLANDIN COMPOSITIONS AND THEIR USE FOR THE TREATMENT OF VASOSPASM

(WO2004089381) 21.10.2004 A61K 31/5575 NEXMED (HOLDINGS), INC.
Compositions and methods for the treatment of vasospasm are provided comprising applying an amount of a semi-solid vasoactive prostaglandin composition to the affected tissue. Also provided are methods of improving microcirculation in a replanted body part.
---------- ----------------------------------------------------------------------

PEST CONTROL FORMULATION AND DISPENSER

(WO2004089083) 21.10.2004 A01N 25/02 SERGEANT'S PET CARE PRODUCTS
The present invention relates to a pest control system which includes a pest control active ingredient and isodiphenyl phosphate as a carrier for the active ingredient. The system releases the active ingredient efficiently and uniformly. The pest control system is less irritating to the animal's skin as compared to prior art systems. The system is useful for making animal collars, ear tags, pest strips, liquid spot-on treatments, and the like.
--------------------------------------------------------------------------------

PHARMACEUTICAL COMPOSITIONS COMPRISING EPINASTINE FOR THE TREATMENT OF SKIN DISEASES

(WO2004087167) 14.10.2004 A61K 31/19 BOEHRINGER INGELHEIM INTERNATIONAL GMBH
The present invention relates to new pharmaceutical compositions for the treatment of skin disease. The composition comprises an antihistaminic- effective amount of Epinastine or a pharmaceutically acceptable salt thereof as a pharmacologically active compound and at least one compound selected from the group consisting of one or more sulfur containing amino acid(s) or peptide(s) as biologically active donor of a -S- or -SH group, at least one vitamin of the B group, at least one vitamin having antioxidant properties and an antiphlogistic- effective amount of an antiphlogistic compound. The compositions also may comprise pharmaceutically acceptable additives.
---------------------------------- ----------------------------------------------

SYNERGISTIC COMBINATIONS OF MACROLIDE T-CELL MODULATOR OR INMUNOSUPPRESSANT AND A RETINOID

(WO2004087118) 14.10.2004 A61K 31/05 NOVARTIS AG
Additive or synergistic combinations of a macrolide T-cell immunomodulator or immunosuppressant such as 33-epichloro-33- desoxyascomycin and a retinoid, such as etretinate, isotretinoin or tazarotene, optionally with a further pharmaceutically active agent, especially an antibacterial, are provided, which are useful in particular in the treatment of dermatological diseases such as eczema, atopic dermatitis, acne, psoriasis, skin aging, sun damage, post-peel erythema and stretch marks.
------------------ --------------------------------------------------------------

A TOPICAL AGENT CONTAINING NIACIN FOR APPLICATION TO THE SKIN PRIOR TO LUMINOUS TREATMENT

(WO2004087093) 14.10.2004 A61K 8/67 CORTEX TECHNOLOGY APS
There is disclosed a topical agent in the form of a topical vasodilator for the application to the skin prior to luminous treatment, e.g. laser treatment, wherein said topical vasodilator in a suitable vehicle consists of the active substance nicotinic acid (Niacin) in the range of 0.5 - 10.0 % by weight. Preferably, the topical vasodilator is a skin cream containing the active substance, Niacin, in the range of 0.5 % by weight.
---------------------------------------------------------- ----------------------

KERATOLYTIC COMPOSITION WITH ANTI-ALLERGIC ANTI-INFLAMMATORY PROPERTIES

(WO2004084855) 07.10.2004 A61K 8/20 MUNISEKHAR, Medasani
A product with an enhanced medicinal and cosmetic composition with a specific utility of “Psoriasis, Eczema and like skin disorders application” is characterized by the fact that it comprises active agents and ingredients as vanilla extract, ammonium chloride, potassium chloride and quaternary ammonium compound having formulated at a specific pH value with other specially selected adjuvants and fillers.
-------------------------------------------------- ------------------------------

PHOTOSTABILIZED TOPICAL FORMULATIONS OF KETOPROFEN CONTAINING TWO UV FILTERS

(WO2004082580) 30.09.2004 A61K 9/06 BERLIN-CHEMIE AKTIENGESELLSCHAFT
The invention relates to topical pharmaceutical formulations containing ketoprofen or its S(+) isomer dexketoprofen or mixtures of the two isomers, together with two UV filters, preferably octyl methoxy cinnamate and phenyl benzimidazol sulphonic acid, and an antioxidant, preferably butyl hydroxy toluene (BHT). The formulations enable a photostability of the active principle, have no, or very low, irritant effect on the skin, are well tolerated, and present an adequate penetration through the skin.
---------- ----------------------------------------------------------------------

THERAPEUTIC, NUTRACEUTICAL AND COSMETIC APPLICATIONS FOR EGGSHELL MEMBRANE AND PROCESSED EGGSHELL MEMBRANE PREPARATIONS

(WO2004080428) 23.09.2004 A61K 8/98 NEW LIFE RESOURCES, LLC
The present invention relates to therapeutic, cosmetic, and nutraceutical applications for eggshell membrane, processed eggshell membrane preparations and eggshell membrane isolates. The invention is directed to treating a mammal that will benefit from the administration of naturally occurring material found in eggshell membrane, processed eggshell membrane, eggshell membrane isolates and combinations thereof by administering to the mammal a composition containing eggshell membrane, processed eggshell membrane, eggshell membrane isolates and combinations thereof, alone or in combination with other active ingredients.
---------------------------------- ----------------------------------------------

RAPIDLY ABSORBING LIPOPHILIC SKIN COMPOSITIONS AND USES THEREFOR

(WO2004080399) 23.09.2004 A61K 35/78 EPITOME PHARMACEUTICALS LIMITED
Topical compositions, and particularly hydrophobic compositions include an essential oil in an amount effective to achieve substantially complete absorption of the composition in the skin without leaving a greasy residue. Especially preferred topical compositions may also include pharmaceutically active agents (e.g., polyphenol), additional essential oils, stabilizers, etc. In further preferred aspects, contemplated compositions may delay onset, or even prevent viral eruptions on the skin, and where applied as a lipstick, will increase reddening of the lip as well as reduce chapping.
------------------------------------------------------------------ --------------

ANIMAL MODEL FOR THE FAST IDENTIFICATION OF PHARMACEUTICAL ACTIVE COMPOUNDS IN VIVO

(WO2004078985) 16.09.2004 A01K 67/027 JANSSEN PHARMACEUTICA N.V.
In a first aspect the present invention provides a tumor cell line stably transfected with an expression vector containing a reporter gene, preferably a fluorescent protein, operably linked to a promotor that also controls expression of a protein that is associated with tumor regression, stabilisation of tumor growth or inhibition of metastatic growth, characterised in that said cell line is capable to form a tumor when implanted or injected into the non-human animal. Compared to the traditional in vivo models, the present invention differs in that the reporter gene is not constitutively expressed, but only after exposure to a test compound that results in the expression of a protein or enzyme associated with tumor regression, stabilisation...
---------------------------------------------------------- ----------------------

ANIMAL MODEL FOR THE FAST IDENTIFICATION OF PHARMACEUTICAL ACTIVE COMPOUNDS IN VIVO

(WO2004078984) 16.09.2004 A01K 67/027 JANSSEN PHARMACEUTICA N.V.
In a first aspect the present invention provides a tumor cell line stably transfected with an expression vector containing a reporter gene, preferably a fluorescent protein, operably linked to a promotor that also controls expression of a protein that is associated with tumor regression, stabilisation of tumor growth or inhibition of metastatic growth, characterised in that said cell line is capable to form a tumor when implanted or injected into the non-human animal. Compared to the traditional in vivo models, the present invention differs in that the reporter gene is not constitutively expressed, but only after exposure to a test compound that results in the expression of a protein or enzyme associated with tumor regression, stabilisation...
---------------------------------------------------------- ----------------------

REGULATION OF MAMMALIAN KERATINOUS TISSUE USING HEXAMIDINE COMPOSITIONS

(WO2004078158) 16.09.2004 A61K 8/34 THE PROCTER &GAMBLE COMPANY
The present invention relates to methods for regulating the condition of mammalian keratinous tissue wherein the methods each comprise the step of topically applying to the keratinous tissue of a mammal needing such treatment, a safe and effective amount of a skin care composition comprising: a) a safe and effective amount of a hexamidine compound selected from the group consisting of hexamidine, its salts, and derivatives; b) a safe and effective amount of one or more skin care active selected from the group consisting of sugar amine, vitamin B3, retinoid, peptide, phytosterol, butylated hydroxytoluene and butylated hydroxyanisole, their derivatives, and combinations thereof; and c) a dermatologically acceptable carrier for the hexamidine ...
------------------ --------------------------------------------------------------

REGULATION OF MAMMALIAN HAIR GROWTH

(WO2004078157) 16.09.2004 A61K 8/34 THE PROCTER &GAMBLE COMPANY
The present invention relates to a topical skin care composition containing a safe and effective amount of a skin care active comprising agmatine, and its salt; a safe and effective amount of a first additional skin care active selected from the group consisting of BHT or BHA, hexamidine, cetyl pyridinium chloride, green tea catechins, phytosterols, ursolic acid, compounds derived from plant extracts, their salts and derivatives; and a dermatologically acceptable carrier for the agmatine composition. The present invention also relates to methods of using such agmatine compositions to regulate hair growth and the condition of mammalian skin. Said methods generally comprise the step of topically applying the composition to the skin of a mamma...
---------------------------------- ----------------------------------------------

INVISIBLE PATCH FOR ACTIVE AGNET CONTROLLED DELIVERY

(WO2004078122) 16.09.2004 A61F 13/00 SALVONA LLC
The present invention relates to a patch for controlled topical or transdermal delivery of effective levels of cosmetic, dermatological, and pharmaceutical active ingredients onto the skin, hair follicles, and sebaceous glands, with minimal discomfort and ease of use. The patch can be transparent or clear and comprises a rate-controlling matrix layer. The matrix layer comprises water-sensitive, bioadhesive, film forming polymers, a water soluble oligomer, and a surfactant. The cosmetic, dermatological, and pharmaceutical active ingredients are soluble or dispersed in the matrix. The patch becomes tacky when wetted and adheres onto the skin. The adhesive properties of the patch are sufficient to maintain the patch in place on the skin for th...
-------------------------------------------------- ------------------------------

AMBIPHILIC POROUS MATRIX

(WO2004075872) 10.09.2004 A61K 8/04 PHARES PHARMACEUTICAL RESEARCH N.V.
Compositions are described which are capable of forming external reservoirs comprising a polymeric matrix for adsorbing sebum in exchange for beneficial oils and transfer of hydrating components to the skin. The compositions may be lotions, creams, gels, pastes, lip sticks and water in oil systems. There is also described a method of preparing said lotions, creams, etc containing an ambiphilic powder mixture or complex comprising synthetic porous agglomerates, a lipophilic component, hydrophilic attractant/polymer, optionally biologically active compound and excipients.
------------------------------------------------------------------ --------------

WATER-SOLUBLE SILK PROTEINS IN COMPOSITIONS FOR SKIN CARE, HAIR CARE OR HAIR COLORING

(WO2004073644) 02.09.2004 A61K 38/17 E.I. DUPONT DE NEMOURS AND COMPANY
Skin care, hair care and hair coloring compositions comprising a water-soluble silk protein as an active ingredient are described. The water-soluble silk protein deposits onto the skin or the natural hair keratin to provide a smooth and durable film to provide added strength for protection against environmental, chemical, and grooming associated damage. The compositions may be in the form of skin care, skin cleansing, or anti- wrinkle products, shampoos, conditioners, lotions, aerosols, gels, mousses, dyes, or bleaches.
---------------------------------------------------------- ----------------------

FILM FOAMING HYDROALCOHOLIC FOAM

(WO2004071479) 26.08.2004 A61K 8/04 CONNETICS AUSTRALIA PTY LTD
The present invention prodides a foam composition comprising an active agent. In particular, the foam composition produces a water resistant, preferably very water resistant, film upon application
------------------------------------------------------------------ --------------

METHODS OF ADMINISTERING A DERMATOLOGICAL AGENT TO A SUBJECT

(WO2004071469) 26.08.2004 A61F 13/00 TEIKOKU PHARMA USA, INC.
Methods for administering a dermatological agent to a subject are provided. In the subject methods an effective amount of a topical formulation of the dermatological agent is topically applied to a host. The topically applied formulation of dermatological agent is then occluded with a hydrogel patch, where a feature of the hydrogel patch is that it lacks a pharmaceutically active agent. Also provided are methods of treating a subject for a disease condition by administering a dermatological agent to the subject. Also provided are kits for use in practicing the subject methods. The subject methods and compositions find use in a variety of different applications.
-------------------------------------------------- ------------------------------

INVERT EMULSION TYPE COMPOSITION CONTAINING AT LEAST ONE ACTIVE AGENT SENSITIVE TO THE PRESENCE OF WATER, AND ITS USES IN COSMETICS AND IN DERMATOLOGY

(WO2004069134) 19.08.2004 A61K 47/24 GALDERMA RESEARCH &DEVELOPMENT, S.N.C.
The present invention relates to a composition containing at least one active agent sensitive to the presence of water, characterized in that the composition is an invert emulsion containing a glycolic or hydroglycolic dispersed hydrophilic phase, a lipophilic continuous phase and an emulsifier having an HLB of between 2 and 7. This invert emulsion makes it possible to avoid the crystallization of the active agent and/or its chemical degradation, while having good stability and being well tolerated.
--------------------------------------------------------------------------------

SKIN LIGHTENING COMPOSITION

(WO2004066973) 12.08.2004 A61K 8/36 UNILEVER PLC
A skin lightening composition comprising: a) 0.05 to 10 % by weight of one of more of vitamin B3 compounds or its derivatives thereof; b) 0.01 to 10 % by weight of allantoin; and c) a cosmetically acceptable vehicle or 15 % to 85 % by weight detergent active.
-------------------------- ------------------------------------------------------

DETERGENT COMPOSITION

(WO2004066972) 12.08.2004 A61K 8/891 UNILEVER PLC
A cleansing cosmetic composition comprising; i) a cationised silicon delivery system selected from one or more of a) a cationised fatty alkyl silicone copolymer; b) a cationised dimethiconol complex and c) a cationised high viscosity lower alkyl silicone fluid with or without cationised silicone gum blend; and ii) detergent active. Also disclosed is a cationised silicone delivery system comprising: a) 15 - 50 parts of a cationised fatty alkyl silicone copolymer; b) 5 - 50 parts of a cationised dimethiconol complex; and c) 1 - 50 parts of a cationised high viscosity lower alkyl silicone fluid with cationised silicone gum blend.
------------------ --------------------------------------------------------------

CLINDAMYCIN PHOSPHATE FOAM

(WO2004064833) 05.08.2004 A61K 8/04 CONNETICS AUSTRALIA PTY LTD.
The present invention provides various pharmaceutically active topical delivery compositions. In particular, compositions of the present invention are present in a pressurized container comprising a quick-breaking alcoholic foaming agent, such that when the composition is released, i.e., dispensed, from the pressurized container, a quick-breaking temperature sensitive foam is formed. In addition, the present invention provides various aspects related to such compositions, including methods for modulating a foam characteristic, methods for improving the shelf-life of a pharmaceutically active compound, methods for the percutaneous treatment of various diseases, infections, and illnesses, and methods for evaluating foam characteristics.
---------------------------------- ----------------------------------------------

METHODS FOR MAKING AND USING TOPICAL DELIVERY AGENTS

(WO2004064769) 05.08.2004 A61K 35/78 HERRERA, Hector
The invention provides methods for making and using topical delivery agents, wherein the delivery agents comprise an oil, e.g., jojoba oil, and an active agent, and formulations made by the methods of the invention.
------------------ --------------------------------------------------------------

COMPOSITION COMPRISING A DESFERRIOXAMINE-METAL COMPLEX AND ITS USE FOR TREATING TISSUE DAMAGE FOLLOWING EXPOSURE TO WARFARE AGENT

(WO2004060490) 22.07.2004 A61K 31/28 YISSUM RESEARCH DEVELOPMENT COMPANY OF THE HEBREW UNIVERSITY OF JERUSALEM
Mustard agents are among the most powerful tactical chemical weapons that exist today, and no specific antidote or highly effective treatment against mustard toxicity is currently available. The present invention intends to provide such antidote, in the form of a desferrioxamine (DFO)-metal complex for use in the topical treatment and/or prevention of damage to a tissue exposed to such chemical weapons. More specifically, this DFO-metal complex contains zinc or gallium, and it is most effectively active following injury by nitrogen or sulfur mustard, The invention also provides pharmaceutical compositions for the topical treatment and/or prevention of tissue damage upon chemical weapon injury, comprising as active agent said DFO-metal compl...
-------------------------- ------------------------------------------------------

TOPICAL COMPOSITIONS HAVING A NATURAL INGREDIENT AND METHOD OF USE

(WO2004060288) 22.07.2004 A61K 8/97 AVON PRODUCTS, INC.
There are disclosed topical compositions for alleviation of skin irritation symptoms or conditions having at least one plant extract effective to inhibit COX-2 enzyme, NGF protein, and/or TNF-alpha protein activity. Preferably, the compositions have a cosmetically, dermatologically, or pharmaceutically acceptable vehicle. In addition to the enzyme inhibitory plant material and acceptable vehicle, compositions may also have at least one active ingredient known to produce skin irritation. There is also a method for treatment of skin irritation symptoms or conditions involving topically applying compositions of the invention. Also disclosed are compositions and methods for topical administration of compositions to the skin that improve the aes...
---------- ----------------------------------------------------------------------

USE OF ACTIVE EXTRACTS TO IMPROVE THE APPEARANCE OF SKIN, LIPS, HAIR AND/OR NAILS

(WO2004060285) 22.07.2004 A61Q 19/02 AVON PRODUCTS, INC.
There is provided a composition having at least one of the following active extracts Butea frondosa, Naringi crenulata, Stenoloma chusana, or any combinations thereof. There is also provided a composition having at least one of the following additional extracts Azadirachta indica, Glycyrrhiza glabra linn., Morinda citrifolia, tomato glycolipid or any combinations thereof in combination with one or more of the active extracts. The compositions and methods of the invention are effective to improve the aesthetic appearance of skin, lips, hair and/or nails, especially by lightening the skin, lips, hair and/or nails.
-------------------------- ------------------------------------------------------

A METHOD AND ARTICLE TO CONTROL CELLULITE

(WO2004060268) 22.07.2004 A61K 9/70 ASAHI KASEI CORPORATION
A multilayer, flexible patch configured for the transdermal treatment of the skin of a human subject with an active ingredient, which ingredient is adapted for reducing the incidence of human cellulite and other fatty tissues comprising a pressure sensitive, skin adherable first layer selected from one of the polymeric materials comprising acrylate copolymer, vinyl ether copolymer, and a silicone adhesive polymer. It contains, by dispersal therethrough, an active ingredient selected from the group consisting of xanthine, hypoxanthine, theophylline, 7-theophylline acetic acid, caffeine, and theobromine. There is an outer backing, second layer comprising a water-soluble, skin conformable fabric adapted to provide moisture vapor permeability s...
-------------------------- ------------------------------------------------------

METASTABLE INSECT REPELLENT EMULSION COMPOSITION AND METHOD OF USE

(WO2004060063) 22.07.2004 A01N 25/02 AVON PRODUCTS, INC.
There is provided an improved insect repellent emulsion composition. The composition has an inner discontinuous phase and an outer continuous phase. The inner discontinuous phase and/or outer continuous phase has an insect repellent active therein. The inner discontinuous phase is generally dispersed in the outer continuous phase and is in the form of discrete droplets having a multimodal droplet size distribution. There is also provided a method of protecting skin from being bitten by insects in which the above composition is applied topically to the skin. There is also provided a method of enhancing the performance of a insect repellent emulsion by forming the inner discontinuous phase as a multiplicity of droplets having a multimodal dro...
--------------------------------------------------------------------------------

SPHINGOLIPID DERIVATIVES MODIFIED BY POLYETHYLENE GLYCOL AND COMPOSITION CONTAINING THE SAME

(WO2004054963) 01.07.2004 A61K 31/133 DOOSAN CORPORATION
The present invention relates to sphingolipid derivatives modified by polyethylene glycol which have superior stability and solubility to conventional sphingolipid derivatives and remarkably reduced toxicity, wherein the sphingolipid is selected from the group consisting of phytosphingosine, sphiganine and sphingadiene. The sphingolipid derivatives are effective in stabilizing other active ingredients in the form of liposome compositions, etc.
---------- ----------------------------------------------------------------------

ACTIVE TOPICAL SKIN PROTECTANTS CONTAINING AMINES,POLYALKENIMINES AND/OR DERIVATIVES

(WO2004054521) 01.07.2004 A61K 8/81 BRAUE, Ernest, H.
A topical skin protectant formulation containing a barrier cream and an active moiety for protecting warfighters and civilians against all types of harmful chemicals, specifically chemical warfare agents (CWA). The active moiety is an amine, polyalkenimines and/or derivatives. The topical skin protectant offers a barrier property and an active moiety that serves to neutralize chemical warfare agents into less toxic agents.
-------------------------------------------------- ------------------------------

METHODS OF PRODUCING LIGNIN PEROXIDASE AND ITS USE IN SKIN AND HAIR LIGHTENING

(WO2004052275) 24.06.2004 C09B 29/00 R.B.T. (Rakuto Bio Technologies) Ltd.
Methods of producing lignin peroxidase are provided. Also provided are methods and cosmetic compositions suitable for skin and hair lightening as well as kits and an article-of manufacturing including active ingredients for skin and hair lightening.
-- ------------------------------------------------------------------------------

SELECTIVE CYCLOOXYGENASE-2 INHIBITOR PATCH

(WO2004047816) 10.06.2004 A61K 9/70 PHARMACIA CORPORATION
A pharmaceutical composition for application to an area of skin of a subject for local and/or systemic treatment of a COX-2 mediated disorder comprises a backing sheet that is flexibly conformable to the area of skin, the backing sheet having opposing surfaces that are respectively distal and proximal to the skin when applied; and a coating on the proximal surface of the backing sheet that comprises (a) an adhesive, (b) an active agent comprising a selective COX-2 inhibitory sulfonamide drug of low water solubility, and (c) a solvent system for the active agent, wherein the active agent is in a therapeutically effective total amount and the solvent system is selected with regard to composition and amount thereof to be effective to maintain ...
-- ------------------------------------------------------------------------------

DERMAL DELIVERY OF A WATER-SOLUBLE SELECTIVE CYCLOOXYGENASE-2 INHIBITOR, E.G. PARECOXIB AND VALDECOXIB

(WO2004047815) 10.06.2004 A61K 9/70 PHARMACIA CORPORATION
A pharmaceutical composition for application to an area of skin of a subject for local and/or systemic treatment of a COX-2 mediated disorder comprises a backing sheet that is flexibly conformable to the area of skin, the backing sheet having opposing surfaces that are respectively distal and proximal to the skin when applied; and a coating on the proximal surface of the backing sheet that comprises (a) an adhesive and (b) an active agent comprising valdecoxib or a prodrug thereof or a salt thereof, the active agent being in a therapeutically effective total amount and dispersed in a matrix that comprises zero to less than an active agent solubilizing effective amount in total of one or more solvents other than the adhesive. A method of loc...
---------------------------------- ----------------------------------------------

DERMAL DELIVERY OF A WATER-SOLUBLE SELECTIVE CYCLOOXYGENASE-2 INHIBITOR, E.G. PARECOXIB, VALDECOXIB AND BENZOPYRAN DERIVATIVES

(WO2004047814) 10.06.2004 A61K 9/70 PHARMACIA CORPORATION
A pharmaceutical composition for application to an area of skin of a subject for local and/or systemic treatment of a COX-2 mediated disorder comprises a backing sheet that is flexibly conformable to the area of skin, the backing sheet having opposing surfaces that are respectively distal and proximal to the skin when applied; and a coating on the proximal surface of the backing sheet that comprises (a) an adhesive and (b) a water-soluble active agent selected from selective COX-2 inhibitory drugs, prodrugs and salts thereof, the active agent being in a therapeutically effective total amount and dispersed in a matrix that comprises zero to less than an active agent solubilizing effective amount in total of one or more solvents other than th...
---------------------------------- ----------------------------------------------

MEDICAL DEVICES EMPLOYING NOVEL POLYMERS

(WO2004045549) 03.06.2004 A61K 9/14 POLYMERIX CORPORATION
Medical devices with at least one surface comprising a polymer or polymers on the surface are provided. The polymer or polymers are capable of breaking down (e.g., including, but not limited to, hydrolyzing) in the physiologic milieu to form an active agent or agents under physiologic conditions, and can contain other active agents dispersed within or appended to the polymer matrix. Methods of delivering an active agent to an interior surface of a vein or artery are also provided.
---------------------------------------------------------- ----------------------

MULTI-PORTION ANTIPERSPIRANT COMPOSITION

(WO2004045514) 03.06.2004 A61K 8/28 THE GILLETTE COMPANY
Disclosed is a non-flowable anhydrous topical antiperspirant composition comprising a first portion and a second portion contiguous with the first portion. The first portion is semi-opaque to opaque and comprises a first hydrophobic carrier vehicle and a first gellant and has a particulate antiperspirant active suspended therein. The second portion is translucent to transparent and comprises a second hydrophobic carrier vehicle and a second gellant. Preferably, the second hydrophobic carrier vehicle has an average refractive index that approximately matches the refractive index of the second gellant. Ideally, for greater translucency the second portion will be substantially free of antiperspirant salt and/or other opacifying materials. Pref...
---------------------------------------------------------- ----------------------

IMPROVED COSMETIC COMPOSITION

(WO2004043422) 27.05.2004 A61K 7/48 UNILEVER PLC
A skin care cosmetic composition comprising: a. 0.05 % to 5 % by weight vitamin B12 or a derivative thereof; b. 0.1 % to 10 % by weight of a skin lightening vitamin chosen from niacinamide, pyridoxine or precursors thereof; c. up to 10 % by weight sunscreen; and d. 10 % to 99 % by weight of a cosmetically acceptable vehicle or 15 % to 85 % by weight detergent active.
---------------------------------------------------------- ----------------------

A MULTI COMPONENT CONTROLLED DELIVERY SYSTEM FOR SOAP BARS

(WO2004041991) 21.05.2004 C11D 9/00 SALVONA LLC
The present invention relates to an improved controlled delivery system that can be incorporated in soap bars to enhance deposition of active ingredients and sensory markers onto skin. The carrier system also provides controlled release or prolonged release of these actives from the skin over an extended period of time. The controlled delivery system of the present invention comprises substantially free- flowing, powder formed of solid hydrophobic, positively charged, nanospheres of encapsulated active ingredients, that are encapsulated in moisture sensitive microspheres. The high cationic charge density of the nanosphere improves deposition of active ingredients onto skin. The high cationic charge density on the nanosphere surface is create...
------------------------------------------ --------------------------------------

CARBONYLAMINO-BENZIMIDAZOLE DERIVATIVES AS ANDROGEN RECEPTOR MODULATORS

(WO2004041277) 21.05.2004 C07D 417/04 MERCK &CO., INC.
Compounds of structural formula (I) are modulators of the androgen receptor (AR) in a tissue selective manner. They are useful as agonists of the androgen receptor in bone and/or muscle tissue while antagonizing the AR in the prostate of a male patient or in the uterus of a female patient. These compounds are therefore useful in the enhancement of weakened muscle tone and the treatment of conditions caused by androgen deficiency or which can be ameliorated by androgen administration, including osteoporosis, osteopenia, glucocorticoid-induced osteoporosis, periodontal disease, bone fracture, bone damage following bone reconstructive surgery, sarcopenia, frailty, aging skin, male hypogonadism, postmenopausal symptoms in women, atherosclerosis...
---------- ----------------------------------------------------------------------

OINTMENT COMPOSITION FOR TREATING DECUBITUS ULCERS AND METHODS FOR ITS MAKING AND ITS USE

(WO2004039390) 13.05.2004 A61K 33/22 GOULBOURNE, Mary, J.
An ointment composition for treating decubitus ulcers and methods for its making and its use. The composition includes a skin protestant ointment, a rash cream, an antibiotic ointment, virgin olive oil, and boric acid powder. The skin protestant ointment includes active ingredients petroleum 53.4%, lanolin 15.5%, and inactive ingredients cod liver oil containing vitamin A & vitamin D, a fragrance, light mineral oil, microcrystalline wax, and paraffin. The rash cream includes active ingredients dimethicone 1% and zinc oxide 10%, and inactive ingredients aloe barbadensis extract, benzyl alcohol, coconut oil, cod liver oil containing vitamin A ...
------------------------------------------------------------------ --------------

NASAL STICK FOR THE APPLOCATION OF MEDICAMENTS AND SKIN CARE SUBSTANCES

(WO2004039350) 13.05.2004 A61K 9/00 CELL CENTER COLOGNE GMBH
A stick for the topical or transmucosal application of a skin care or active agent onto and via the nasal mucosa, respectively, is provided, wherein the stick material contains a composition of at least one carrier substance and at least one skin care or active agent, which is capable of acting on the nasal mucosa and/or being resorbed by it or which contains at least one volatile substance that acts on the deeper respiratory tract and/or is being resorbed by the deeper respiratory tract. Furthermore, the use of a medical skin care or cosmetical stick or of a stick material or of a refill cartridge containing said material for the topical or transmucosal application is described.
-------------------------- ------------------------------------------------------

PURINE NUCLEOSIDES

(WO2004038006) 06.05.2004 C07D 473/32 THE GOVERNMENT OF THE UNITED STATES OF AMERICA, represented by THE SECRETARY, DEPARTMENT OF HEALTH AND HUMAN SERVICES
Disclosed are purine nucleoside compounds that are selective to A3 adenosine receptors and are useful for the treatment of cancer and inflammatory diseases. The compounds are shown by the following general formula (I), including isomers thereof: wherein X is sulfur or oxygen; Rl is hydrogen, alkyl, benzyl, halobenzyl, or phenylalkyl; R2 is hydrogen, halogen, alkoxy, alkenyl, alkynyl, alkylthio, or thio; R3 and R3' are hydrogen, hydroxyalkyl, alkoxycarbonyl, or alkylaminocabonyl, whereas R3 and R3' do not have identical substituents simultaneously; and R4 is hydrogen or alkyl. Also disclosed are a pharmaceutical composition comprising a compound of formula (I), an isomer, or its pharmacologically acceptable salt as an active ingredient and a...
---------- ----------------------------------------------------------------------

APPARATUS FOR THE TREATMENT OF MAXILLARY AND FRONTAL SINUSITIS AND NEURITIS AND NEURALGIA OF THE TRIGEMINAL NERVE

(WO2004037244) 06.05.2004 A61M 35/00 MARINELLO, Andrea
The invention relates to a device comprising a facial mask, an inflatable elastic pad affixed to the mask and a compress containing a revulsive having an active ingredient.
---------- ----------------------------------------------------------------------

CATIONIC CARDIOLIPIN ANALOGS AND USE THEREOF

(WO2004035523) 29.04.2004 A61K 9/127 NEOPHARM, INC.
The invention provides cationic cardiolipin compounds, and methods for synthesizing and using them in liposomal formulation, gene transfection, etc. In particular, the invention provides liposomes comprising cationic cardiolipin analog, pharmaceutical compositions comprising cationic cardiolipin analogs, and methods of using such liposomes and compositions, in delivering active pharmaceutical agents to treat human and animal diseases and/or in diagnostic assays.
-------------------------------------------------- ------------------------------

EXTRACT WITH ANTI-TUMOR AND ANTI- POISONOUS ACTIVITY

(WO2004032948) 22.04.2004 A61P 35/00 UNIBIOSCREEN S.A.
The present invention relates to extracts of the plant Calotropis procera, having a pharmacological activity, in particular an anti-poisonous activity, and active compounds isolated thereof. Furthermore, the invention relates to methods for the extraction of said extracts. Also, the invention concerns a pharmaceutical composition or product for the treatment of cancer comprising an effective amount of said extracts or an active compound thereof, a therapeutic compound and optionally a pharmaceutical acceptable carrier.
-------------------------- ------------------------------------------------------

PROCESS FOR MAKING HOLLOW FIBER MIXED MATRIX MEMBRANES

(WO2004026449) 01.04.2004 B01D 53/22 L'AIR LIQUIDE
Isopycnic or asymmetric mixed matrix hollow fiber membranes for gas separation can be made by a continuous spinning process. Mixed matrix membranes are characterized by a continuous phase of selectively gas permeable polymer in which are uniformly dispersed discrete absorbent particles such as molecular sieves that also have selectivity enhancing properties. The fibers can be monolithic in which the fiber wall is entirely mixed matrix, or composite in which an active mixed matrix layer is positioned adjacent to a supporting substrate layer. The novel mixed matrix hollow fiber membranes provide higher selectivity than dense film membranes of the continuous phase polymer. A monofunctional organosilicon compounds can be used to treat the zeoli...
-- ------------------------------------------------------------------------------

ORALLY ADMINISTRABLE COMPOSITION FOR IMPROVING SKIN QUALITY

(WO2004026287) 01.04.2004 A23K 1/16 NESTEC S.A.
The present invention relates to an orally administrable composition for improving skin quality and prevent or restore age- related alterations of skin in humans or animals, which comprises as an active ingredient an effective amount of a molecule that stimulates energy metabolism of the cell or an antioxidant or combinatory admixtures thereof, in an orally acceptable carrier.
---------------------------------------------------------- ----------------------

NOVEL PHOTOSTABILIZERS, UV ABSORBERS, AND METHODS OF PHOTOSTABILIZING A SUNSCREEN COMPOSITION

(WO2004026197) 01.04.2004 A61K 8/35 CPH INNOVATIONS CORPORATION
Polymers and compounds including a diphenylmethylene or a 9H-fluorene moiety; and sunscreen compositions including a mixture of a photoactive compound and any one of the foregoing derivatives are disclosed herein. Also disclosed are methods for stabilizing a sunscreen composition by the addition of one or more of the foregoing derivatives, methods of filtering out ultra-violet light from a substrate by the use of one or more such derivatives, and methods for terminating a polymerization reaction by the addition of derivatives of diphenylmethylene and/or 9H-fluorene. Synergistic combinations of the polymer with (1) diesters or polyesters of a naphthalene dicarboxylic acid, or (2) oxybenzone enhance the photostability of sunscreen composition...
-- ------------------------------------------------------------------------------

OPTICALLY ACTIVATED PARTICLES FOR USE IN COSMETIC COMPOSITIONS

(WO2004024103) 25.03.2004 A61K 8/11 LIPO CHEMICALS, INC.
Optically activated particles for use in cosmetic and pharmaceutical compositions are disclosed. The optically activated particles include a solid substrate having a fluorescent compound fixed thereto, and coated or encapsulated with a transparent or translucent coating of crosslinked polyvinyl alcohol. The optically activated particles absorb light at a UV wavelength and emit visible light at longer wavelengths, and are able to both absorb and scatter light in a diffuse manner in order to reduce the visual perception of skin imperfections, including cellulite, wrinkles, shadows, skin discolorations, blotchiness, mild scars.
---------------------------------- ----------------------------------------------

COMPOSITION BASED ON TRIETHYL CITRATE FOR THE TREATMENT OF BACTERIAL INFECTIONS OF THE SKIN

(WO2004019929) 11.03.2004 A61K 31/215 DE PAOLI AMBROSI, Gianfranco
This invention concerns a composition for topical use containing as an active ingredient triethyl citrate either pure or in combination with synergists, and the pharmaceutical or cosmetic use of the composition, on its own or in association with an antibiotic, at least in the treatment of cutaneous pathologies directly or indirectly affected by bacterial infections.
-------------------------------------------------- ------------------------------

COMPOSITION COMPRISING THE EXTRACT OF ACTINIDIA ARGUTA AND RELATED SPECIES FOR THE PREVENTION AND TREATMENT OF ALLERGIC DISEASE AND NON-ALLERGIC INFLAMMATORY DISEASE

(WO2004017982) 04.03.2004 A23L 1/30 PANGENOMICS CO., LTD
The present invention provides a pharmaceutical composition comprising the extract of hardy kiwifruit as an active ingredient in an effective amount to treat and prevent allergic disease and non- allergic inflammatory disease by reducing inflammation action, by inhibiting histamine release from mast cell, and by increasing the level of Th1 cytokines, IgG2a in serum and reducing the level of Th2 cytokines and IgE in serum. The present invention also provides a use of above extract for the preparation of pharmaceutical composition. The present invention also provides a health food or food additives, a cosmetic composition, a feed or feed additives comprising above extract for prevention or alleviation of allergic disease and non-allergic infla...
------------------------------------------------------------------ --------------

PERCUTANEOUS AND PERUNGUAL DELIVERY SYSTEM

(WO2004010988) 05.02.2004 A61K 8/67 CONNETICS AUSTRALLIA PTY LTD
The invention relates to a substantially homogeneous liquid composition capable of percutaneous delivery of one or more physiologically active agents, the composition including at least one physiologically active agent, a volatile solvent, and a rate modulating carrier comprising a hydrophilic polymer and a hydrophobic polymer the combination of the hydrophilic and hydrophobic polymers being elected to enable modulation of the rate of physiologically active agent. The invention also relates to method of delivering an effective amount of an active agent and method of treatment of a patient using the composition of the invention.
------------------------------------------ --------------------------------------

USE OF LIGNANS FOR PREVENING OR TREATING THE SINGS OF AGEING OF THE SKIN

(WO2004010965) 05.02.2004 A61K 8/34 L'OREAL
The invention relates to the cosmetic use of at least one lignan of given formula, or of a plant extract containing it (such as an extract of flax seeds), in a composition suitable for topical application to the skin, containing a cosmetically acceptable medium, for preventing or treating the signs of ageing of the skin, in particular the loss of firmness, elasticity and/or tonicity of the skin and/or the formation of wrinkles and fine lines. The invention also relates to a topical cosmetic composition containing these lignans in combination with other anti-ageing active agents. Lastly, the invention relates to a cosmetic process for treating dry skin, comprising the topical application to the said skin of a composition containing at least ...
-------------------------- ------------------------------------------------------

RAPID, EFFICIENT PURIFICATION OF HSV-SPECIFIC T-LYMPHOCYTES AND HSV ANTIGENS IDENTIFIED VIA SAME

(WO2004009021) 29.01.2004 A61K 38/08 UNIVERSITY OF WASHINGTON
Described is a method of identifying an immunologically active antigen of a virus that attacks skin, as well as a method of enriching a population of lymphocytes for T lymphocytes that are specific to a virus that attacks skin. Also provided are HSV antigens and epitopes that are useful for the prevention and treatment of HSV infection that have been identified via the methods of the invention. T-cells having specificity for antigens of the invention have demonstrated cytotoxic activity against cells loaded with virally-encoded peptide epitopes, and in many cases, against cells infected with HSV. The identification of immunogenic antigens responsible for T-cell specificity provides improved anti-viral therapeutic and prophylactic strategies...
-------------------------------------------------- ------------------------------

COMPOSITION FOR CYTOCOMPATIBLE, INJECTABLE, SELF-GELLING CHITOSAN SOLUTIONS FOR ENCAPSULATING AND DELIVERING LIVE CELLS OR BIOLOGICALLY ACTIVE FACTORS

(WO2004006961) 22.01.2004 A61K 9/00 BIO SYNTECH CANADA INC.
The present invention provides compositions and methods for tissue repair using a cytocompatible self-gelling cross-linked hydrogel. The composition comprises a biocompatible mixture of chitosan, bifunctional dialdehyde, and hydroxylated polymer, which can be used to immobilize or encapsulate viable cells, or bioactive substances. The method includes the process of mixing bioactive substances, live cells, and/or extracellular matrix components with a cross-linking solution comprising a bifunctional aldehyde-treated hydroxylated polymer such as hydroxyethyl cellulose. The cross-linking solution is then mixed homogenously with a neutral isotonic chitosan solution. The chitosan becomes cross-linked by the bifunctional aldehyde, while the cells...
-- ------------------------------------------------------------------------------

THERAPEUTIC TUBERCULOSIS VACCINES

(WO2004006952) 22.01.2004 A61K 39/02 STATENS SERUM INSTITUT
The present invention is based on a number of M.tuberculosis derived proteins and protein fragments which are induced during the latent stage of infection characterized by low oxygen tension in the microenvironment of the infecting TB-bacteria. The invention is directed to the use of these polypeptides, immunologically active fragments thereof and the genes encoding them for immunological compositions such as therapeutic vaccines and diagnostic reagents.
-------------------------------------------------- ------------------------------

COMPOSITIONS HAVING ENHANCED DEPOSITION OF A TOPICALLY ACTIVE ON A SURFACE

(WO2004004677) 15.01.2004 A01N 25/24 THE DIAL CORPORATION
Topically active compositions having enhanced effectiveness are disclosed. The compositions contain a topically active compound, an an-ionic surfactant, a hydric solvent, a hydrotrope, an optional cosurfactant, and water, wherein a percent saturation of the topical active compound of the composition is at least 25 %. The compositions exhibit a rapid and effective topical effect, and effectively deposit the topically active compound for an effective residual effect.
------------------------------------------ --------------------------------------

POLYMER RESIN FORMULATION HAVING ANTI-MICROBIAL OR ANTI-COGULABILITY AND PREPARATION METHOD THEREOF

(WO2003000924) 31.12.2003 A61F 2/06 MICRO SCIENCE TECH CO., LTD.
The present invention relates to an anti-microbial or anti-coagulating polymer resin and a method for preparing the same, and a medical appliance or instrument using the same, and more particularly to a method for preparing an anti-microbial or anti-coagulating medical polymer resin comprising the steps of simply mixing a polymer resin with at least one kind of pharmaceutically active material without using a solvent. The pharmaceutically active material is preferably an anti-microbial or anti-coagulant. According to the present invention, an anti-microbial or anti-coagulating material that is safe to a human body is mixed with a polymer resin by simple addition in an environmentally favorable non-solvent method, thereby maintaining superio...
--------------------------------------------------------------------------------

METASTABLE PHARMACEUTICAL COMPOSITIONS

(WO2003000361) 31.12.2003 A61K 9/70 ACRUX DDS PTY LTD
The present invention provides a pharmaceutical composition for transdermal delivery comprising; one or more physiologically active agents; and a volatile pharmaceutically acceptable solvent; and wherein the physiological active agent forms a metastable deposit upon evaporation of the volatile solvent.
---------------------------------------------------------- ----------------------

USE OF TOPICAL PHARMACEUTICAL COMPOSITIONS COMPRISING AN ACTIVE AGENT AND PERMEATION-ENHANCING BASE FOR THE MANUFACTURE OF A MEDICAMENT TO TREAT VARIOUS FORMS OF INFLAMMATORY DERMATOSIS

(WO2003000360) 31.12.2003 A61K 9/06 DERMATRENDS, INC.
Provided is a topical pharmaceutical composition for the treatment of inflammatory dermatoses, including acne vulgaris, together with methods for its use. The composition and methods involve the topical use of an active agent effective in the treatment of inflammatory dermatoses plus a permeation-enhancing base that, in one embodiment, gives the composition a pH of about 8.0 to about 13.0, preferably about 8.0 to 11.5, and most preferably about 8.5 to 10.5.
---------------------------------------------------------- ----------------------

TOPICAL PHARMACEUTICAL COMPOSITION COMPRISING SKIN PENETRATION ENHANCERS FOR THE TREATMENT OF WARTS

(WO2003000359) 31.12.2003 A61K 9/06 DERMATRENDS, INC.
Provided is a topical pharmaceutical composition for the treatment of warts, together with methods for its use. The composition and methods involve the topical use of an active agent effective in the treatment of warts plus a permeation-enhancing base that, in one embodiment, gives the composition a pH of about 8.0 to about 13.0, preferably about 8.0 to 11.5, and most preferably about 8.5 to 10.5. This composition can be used to treat human papilloma virus infections, particularly cutaneous warts.
-------------------------- ------------------------------------------------------

TOPICAL ADMINISTRATION OF BASIC ANTIFUNGAL COMPOSITIONS TO TREAT FUNGAL INFECTIONS OF THE NAILS

(WO2003000291) 31.12.2003 A61K 9/70 DERMATRENDS, INC.
Methods and topical pharmaceutical formulations are provided for the treatment of nail fungus (onychomycosis). The invention involves a pharmacologically active antifungal agent, plus a pharmaceutically acceptable base in a formulation having a pH of 7.5 to about 13.0, preferably about 8.0 to 11.5, and most preferably about 8.5 to 10.5. These basic formulations permeate the nail and are effective in treating fungal infections of the nail and surrounding tissues.
-------------------------- ------------------------------------------------------

TRANSDERMAL AEROSOL COMPOSITIONS

(WO2003000275) 31.12.2003 A61K 9/70 ACRUX DDS PTY LTD
The present invention provides a pharmaceutical composition for transdermal delivery comprising: one or more physiologically active agents; one or more dermal penetration enhancers; a pharmaceutically acceptable carrier comprising a volatile solvent; and a hydrofluorocarbon propellent; wherein the carrier and penetration enhancers combine to provide a single-phase solution of the one or more physiologically active agents.
------------------------------------------ --------------------------------------

USE OF BASES FOR THE MANUFACTURE OF A MEDICAMENT IN THE TREATMENT OF DIFFERENT FORMS OF INFLAMMATORY DERMATOSIS

(WO2003000271) 31.12.2003 A61K 8/19 DERMATRENDS, INC.
Provided are methods and topical pharmaceutical formulations for the treatment of inflammatory dermatoses. The invention involves the topical administration of a pharmacologically active base in a formulation having a pH of about 7.5 to about 13.0, preferably about 8.0 to 11.5, and most preferably about 8.5 to 10.5. These basic formulations are particularly suited to the treatment of acne vulgaris.
--------------------------------------------------------------------------------

TOPICAL ADMINISTRATION OF PHARMACOLOGICALLY ACTIVE BASES IN THE TREATMENT OF WARTS

(WO2003000268) 31.12.2003 A61K 9/70 DERMATRENDS, INC.
Provided are methods and topical pharmaceutical formulations for use in the treatment of warts. The invention involves the topical administration of a pharmacologically active base in a formulation having a pH of about 7.5 to about 13.0, preferably about 8.0 to 11.5, and most preferably about 8.5 to 10.5. These basic formulations can be used to treat human papilloma virus infections, particularly cutaneous warts.
------------------------------------------------------------------ --------------

TRANSDERMAL DELIVERY RATE CONTROL USING AMORPHOUS PHARMACEUTICAL COMPOSITIONS

(WO2003000263) 31.12.2003 A61K 9/70 ACRUX DDS PTY LTD
A pharmaceutical composition for transdermal delivery comprising one or more physiologically active agents; one or more dermal penetration enhancers; and a volatile pharmaceutically acceptable carrier comprising a volatile solvent; and wherein the physiologically active agent and dermal penetration enhancer form an amorphous deposit upon evaporation of the volatile carrier, said amorphous deposit forming a reservoir within the stratum corneum; and (A) wherein the composition has a release rate profile of physiologically active agent so as to provide a ratio of the maximum concentration (Cmax) to the average concentration (Cavg) for the physiologically active agent over the dosage interval within the range of 1 to 10.
-------------------------------------------------------------------------- ------

TOPICAL ADMINISTRATION OF PHARMACOLOGICALLY ACTIVE BASES FOR SKIN LIGHTENING

(WO2003000259) 31.12.2003 A61K 8/02 DERMATRENDS, INC.
Provided are methods and topical pharmaceutical formulations for skin lightening. The invention involves the topical administration of a pharmacologically active base in a formulation having a pH of about 8.0 to about 13.0, preferably about 8.0 to 11.5, more preferably about 8.5 to 11.5, and most preferably about 8.5 to 10.5. these basic formulations can be used to treat regions of hyperpigmented skin, comprising, as examples, age spots, freckles, disease-related hyperpigmented skin, melasma related to pregnancy or the use of oral contraceptives, and hyperpigmented skin due to chemical exposure or ingestion.
------------------------------------------ --------------------------------------

TOPICAL PHARMACEUTICAL COMPOSITION TO TREAT HYPERPIGMENTATION OF THE SKIN

(WO2003000249) 31.12.2003 A61K 8/02 DERMATRENDS, INC.
Provided is a topical pharmaceutical composition for skin lightening, which is particularly useful in treating skin hyperpigmentation, together with methods for its use. The composition and methods involve the topical use of an active agent effective in the treatment of skin hyperpigmentation plus a permeation-enhancing base that, in one embodiment, gives the composition a pH of about 8.0 to about 13.0, preferably about 8.0 to 11.5, and most preferably about 8.5 to 10.5.
------------------------------------------ --------------------------------------

METHOD OF CELL GROWTH INHIBITION WITH AGNOPROTEIN

(WO2003106626) 24.12.2003 A61K 38/16 TEMPLE UNIVERSITY OF THE COMMONWEALTH SYSTEM OF HIGHER EDUCATION
The growth of normal and abnormally proliferating cells can be inhibited by the introduction of agnoprotein, or biologically active fragments or derivatives of agnoprotein, into the cell in the absence of any other polyoma virus protein or viral replication.
---------- ----------------------------------------------------------------------

METHOD OF TREATING ROSACEA BY TOPICAL APPLICATION OF A CYCLOHEXANE DERIVATIVE

(WO2003105816) 24.12.2003 A61K 31/045 CHOMCZYNSKI, Piotr
A method for topically treating rosacea is disclosed. In this method, an active material having the formula given below is applied to the patient at the site of said rosacea: wherein R1 is selected from -OH and C1-C3 alkyl OH; and R2, R3, R4, R5 and R6 are independently selected from -H, -OH, C1-C6 alkyl, and C3-C6 cycloalkyl. Preferred active materials include 1,2-cyclohexanediol, 1,3-cyclohexanediol, 1,4- cyclohexanediol, and mixtures of those materials. Methods for treating acne vulgaris, as well as colds, flu, sinusitis, and ear infections, using these actives are also disclosed.
---------------------------------------------------------- ----------------------

COMPOSITIONS AND METHODS FOR THE PROPHYLAXIS AND TREATMENT OF APHTHOUS ULCERS AND HERPES SIMPLEX LESIONS

(WO2003103691) 18.12.2003 A61K 9/00 CHIOU CONSULTING, INC.
Disclosed is a topical method for providing adequate analgesic, anti-inflammatory, antimicrobial and tissue- regenerating activities for the hitherto most effective prophylaxis and treatment of aphtous ulcers and herpes simplex lesions and for the effective treatment of burns and other oral mucosal ulcers comprising topically administering to the affected tissue an effective amount of a composition comprised of one or more safe and efficacious polyvalent metal compounds such as magnesium sulfate, preferably with one or more safe and efficacious anti-inflammatory compounds, such as a novel ultra-low-strength hydrocortisone (acetate), that potentiate the activities of polyvalent metal compounds. Both the ionic and neutral moieties of the polyv...
--------------------------------------------------------------------------------

METHOD AND COMPOSITION FOR IMPROVING SENSORY CHARACTERISTICS OF SEMISOLID PREDOMINANTLY ANHYDROUS

(WO2003103624) 18.12.2003 A61K 8/34 SUESS, Hans, R.
A composition comprises amphiphobic halo carbon particles, and amphiphilic lipids having at least 2 hydroxyl groups. This composition may be used in methods of decreasing oiliness, greasiness, stickiness and tackiness of anhydrous semisolid lipids, methods of delivering pharmaceutical active ingredients, methods of preventing or treating sunburn or ultraviolet radiation, methods or preventing or treating skin disorders and methods of delivering cosmetics.
---------- ----------------------------------------------------------------------

COMPOSITIONS COMPRISINS VITAMIN K

(WO2003101415) 11.12.2003 A61K 8/67 THE BOOTS COMPANY PLC
In a composition comprising, as active ingredient, vitamin K, the vitamin K is present as a complex with a cyclodextrin. The cyclodextrin is most preferably ?-cyclodextrin and the vitamin K is most preferably vitamin K1. The composition may have a generally beneficial effect on the skin, either in a therapeutic or merely cosmetic sense, e.g. in the improving the appearance of the skin or the treatment of bruising and other skin conditions associated with deposition of discolouring material beneath the skin. One particular use of the composition is for improving the appearance of the skin around the eyes, in particular a method for the cosmetic treatment of dark areas ('shadows') in the vicinity of the eyes.
---------------------------------- ----------------------------------------------

COMPOSITIONS CONTAINING DOLICHOL FOR DERMATOLOGICAL AND COSMETIC USE

(WO2003101413) 11.12.2003 A61K 8/34 ABIOGEN PHARMA S.P.A.
Disclosed are cosmetic and dermatological compositions containing dolichol which are active against the harmful action of light and free radicals, and against skin aging.
-------------------------- ------------------------------------------------------

PREPARATIONS FOR TOPICAL SKIN USE AND TREATMENT

(WO2003101404) 11.12.2003 A61K 9/70 DOW CORNING CORPORATION
The present invention is related to topical preparations for release of an active agent and to methods of making and using the topical preparations. The preparations may have an internal phase dispersed within an external phase. The internal phase may be a hydrophilic carrier and an active agent. The external phase may be a silicone matrix. It is emphasized that this abstract is provided to comply with the rules requiring an abstract that will allow a searcher or other reader to quickly ascertain the subject matter of the technical disclosure. It is submitted with the understanding that is will not be used to interpret or limit the scope or meaning of the claims.
------------------ --------------------------------------------------------------

DUAL DISPENSER FOR AESTHETICALLY ACCEPTABLE DELIVERY OF ANHYDROUS SKIN TREATMENT COMPOSITIONS

(WO2003099295) 04.12.2003 A61K 8/02 IMAGINATIVE RESEARCH ASSOCIATES, INC.
Two separate compositions, one containing multiple doses of an anhydrous first composition that includes a first active ingredient that is hydrolytically unstable and which provides a benefit to the skin of a user; and a second aqueous composition which may or may not contain a second active ingredient are packaged within and dispensed from a common dispenser. By packaging these two compositions in this manner, long shelflife, good aesthetics and convenient dispensing and application are provided.
---------------------------------- ----------------------------------------------

COSMETIC COMPOSITIONS CONTAINING SALTS OF MALONIC ACID

(WO2003099254) 04.12.2003 A61K 8/02 UNILEVER PLC
A cosmetic composition is provided which includes as an active material a salt of malonic acid in a cosmetically acceptable carrier, wherein the composition exhibits a Flexibility Value greater than 1 according to the Porcine Skin Test.
-------------------------------------------------- ------------------------------

COSMETIC COMPOSITIONS WITH AMMONIUM MALONATES

(WO2003099251) 04.12.2003 A61K 8/02 UNILEVER PLC
A cosmetic composition is provided which includes as an active material a salt formed from neutralization of malonic acid with ammonia or a C1-C10 hydrocarbyl amine, the composition having a pH from 1.8 to 6.5. Particularly preferred is ammonium malonate.
------------------------------------------------------------------ --------------

SUNSCREEN COMPOSITIONS AND CONTAINING AZOLIUM COMPOUNDS

(WO2003099249) 04.12.2003 A61K 8/49 ALTEON, INC.
Disclosed herein are novel methods for reducing or preventing the harmful effects of solar radiation on skin. Also disclosed are novel sunscreen compositions comprising thaizolium, thiadiazolium or triazolium compounds or derivatives and analogs thereof for reducing or preventing the harmful effects of solar radiation on skin. Sunscreen active agents that provide UV-A and UV-B filters are also included. The invention further discloses additional sunscreen active agents, emollients, humectants, dry- feel modifiers, waterproofing agents, insect repellants, antimicrobial preservatives, antioxidants, chelating agents, fragrances and moisturizers, suitable carriers for topical application and emulsions.
------------------ --------------------------------------------------------------

SUNSCREEN COMPOSITIONS AND METHODS OF USE THEREOF

(WO2003099241) 04.12.2003 A61K 8/49 MANISCALCO, Tony
Disclosed herein are novel methods for reducing or preventing the harmful effects of solar radiation on skin. Also disclosed are novel sunscreen compositions comprising 3-[2-(4diethylaminophenyl)-2-oxoethyl]thiazolium salt for reducing or preventing the harmful effects of solar radiation on skin. Agents that provide UV-A and UV-B filters are also included. The invention further discloses additional sunscreen active agents, emollients, humectants, dry-feel modifiers, waterproofing agents, insect repellants, antimicrobial preservatives, antioxidants, chelating agents, fragrances and moisturizers, suitable carriers for topical application and emulsions.
------------------------------------------ --------------------------------------

VEHICLES FOR DELIVERY OF BIOLOGICALLY ACTIVE SUBSTANCES

(WO2003099163) 04.12.2003 A61K 9/00 UNIVERSITY OF TENNESSEE RESEARCH FOUNDATION
A formulation containing one or more biologically active substances dissolved, dispersed, emulsified, or suspended within a vehicle of one or more citric acid esters and/or citric acid ethers. Methods for making and using are disclosed, as are kits for administration of the pharmaceutical formulation.
-------------------------------------------------- ------------------------------

PERSONAL CARE COMPOSITIONS COMPRISING A DICARBOXY FUNCTIONALIZED POLYORGANOSILOXANE

(WO2003094871) 20.11.2003 A61K 8/896 THE PROCTER &GAMBLE COMPANY
Disclosed are personal care or cosmetic compositions comprising a dicarboxy functionalized polyorganosiloxane and methods for the cleaning or the treatment of hair or skin and for enhancing delivery of active agents to hair or skin with the compositions. Said personal care or cosmetic compositions can be formulated in a wide variety of types of products for the skin and/or hair (or, more generally, keratin) such as mousses, gels (in particular hair dressing gels), conditioners, hair dressing formulations or to aid comb-through of hair, rinsing formulae, hand and body lotions, skin moisturising products, skin cleansing or disinfecting compositions, shower gels, toilet milks, cream foundations, make-up removal compositions, sun and ultraviole...
-- ------------------------------------------------------------------------------

THERAPEUTIC 1,2,3,6-TETRAHYDROPYRIMIDINE-2-ONE COMPOSITIONS AND METHODS THEREWITH

(WO2003092697) 13.11.2003 A61K 31/513 CRAGMONT PHARMACEUTICALS, LLC
A therapeutic composition is provided that comprises a 1-R1-phenyl, 4-R2-phenyl substituted 1,2,3,6-tetrahydropyrimidine-2-one cold receptor agonist in a therapeutically effective amount. The composition preferably further comprises one or more pharmaceutically active drugs such as an anti-inflammatory glucocorticosteroid, a sympathomimetic amine decongestant, an antihistamine, a local anesthetic, menthol or a menthol analog, an immunosuppressant, and mixtures thereof. The cold receptor agonist may be represented by the general formula (1)- [R1-phenyl]-4-[R2-phenyl]-1,2,3,6-tetrahydropyrimidine-2-one wherein: R1 is - hydroxy, -chloro, - fluoro, -alkyl, -acetoxy, -trifluoromethyl ; and R2 is -nitro, -chloro, -fluoro, -alkyl, -trifluoromethyl. ...
-------------------------- ------------------------------------------------------

PERSONAL CARE COMPOSITION WITH COLOR CHANGE INDICATOR

(WO2003092636) 13.11.2003 A61K 8/29 UNILEVER PLC
A substantially dry composition, especially for personal care products is provided which includes a colorant activatable in water to release a visual color, and an oil-soluble carrier. The colorant is insoluble in the carrier and the visual color is not imparted to the composition in its substantially dry state. Addition of water to the composition activates a color change which renders the visual color perceivable by a consumer. Color changes can be associated as a signal of performance by a consumer.
------------------ --------------------------------------------------------------

4- AZASTEROID DERIVATIVES AS ANDROGEN RECEPTOR MODULATORS

(WO2003092588) 13.11.2003 C07J 73/00 MERCK &CO., INC.
Compounds of structural formula I are modulators of the androgen receptor (AR) in a tissue selective manner. They are useful as agonists of the androgen receptor in bone and/or muscle tissue while antagonizing the AR in the prostate of a male patient or in the uterus of a female patient. These compounds are therefore useful in the treatment of conditions caused by androgen deficiency or which can be ameliorated by androgen administration, including osteoporosis, osteopenia, glucocorticoid-induced osteoporosis, periodontal disease, bone fracture, bone damage following bone reconstructive surgery, sarcopenia, frailty, aging skin, male hypogonadism, postmenopausal symptoms in women, atherosclerosis, hypercholesterolemia, hyperlipidemia, obesit...
------------------------------------------------------------------ --------------

EMOLLIENT PARTICLES, SUNSCREEN COMPOSITIONS AND METHODS OF MANUFACTURE THEREOF

(WO2003090698) 06.11.2003 A61K 8/04 INTERNATIONAL FLORA TECHNOLOGIES LTD.
Compositions consisting of emollient particles that carry at least one of active sunscreen material, self-tanning material and visual effects material, and transparent and translucent topical sunscreen preparations having disposed therein such emollient particles.
---------------------------------- ----------------------------------------------

COMPOSITIONS COMPRISING A DISPERSANT AND MICROCAPSULES CONTAINING AN ACTIVE MATERIAL

(WO2003089561) 30.10.2003 A01N 25/28 THE PROCTER &GAMBLE COMPANY
Compositions for providing controlled-release of an active material comprise a dispersant and microcapsules containing the active material. The compositions contain the dispersant and/or microcapsules at relatively low levels to avoid negatively impacting the surfaces treated with the compositions. The active material is preferably a perfume and the composition provides a controlled-release scent, along with controlling malodor when the compositions further comprise optional odor control agent. Methods of providing a controlled-release of an active material on a surface comprise the step of contacting the surface with a composition comprising a dispersant and microcapsules containing an active material.
-------------------------- ------------------------------------------------------

MALODOR- CONTROLLING COMPOSITIONS COMPRISING ODOR CONTROL AGENTS AND MICROCAPSULES CONTAINING AN ACTIVE MATERIAL

(WO2003089019) 30.10.2003 A61L 9/01 THE PROCTER &GAMBLE COMPANY
Malodor-controlling compositions comprise microcapsules containing an active material and/or an optional odor control agent, an odor control agent outside of the microcapsules, and an aqueous carrier. The active material is preferably a perfume and the composition provides a controlled-release scent, along with controlling malodor. Methods of reducing or removing malodor from a surface having malodor comprise the step of contacting the surface with a malodor- controlling composition comprising microcapsules containing an active material and an odor control agent.
-------------------------------------------------- ------------------------------

METHODS FOR LIGHTENING SKIN AND HAIR

(WO2003086313) 23.10.2003 A61K 6/00 TRUSTEES OF BOSTON UNIVERSITY
Methods are described wherein the skin of a vertebrate, or the skin or hair of a mammal can be lightened by administration of a substance, e.g., protein, peptide, active fusion protein, active fragment, or molecular mimic, that binds to BMP-4 transmembrane receptors on melanocytes and decreases the level of melanin synthesis. Also described are methods to identify molecules that mimic the function of BMP-14 in causing a decrease in melanin in melanocytes.
------------------ --------------------------------------------------------------

TOPICAL PHARMACEUTICAL COMPOSITIONS COMPRISING PROANTHOCYANIDINS FOR THE TREATMENT OF DERMATITIS

(WO2003084553) 16.10.2003 A61K 31/425 SINCLAIR PHARMACEUTICALS LIMITED
Pharmaceutical compositions for the topical administration, comprising as active ingredients proanthocyanidins alone or combined with glycyrrhetinic acid, telmesteine, alpha-bisabolol or other components having complementary activity, in admixture with a suitable carrier, useful for the treatment of avariety of pathologies such as atopic dermatitis, allergic contact dermatitis, seborrheic dermatitis, radiation dermatitis, psoriasis, xerosis and atopia as well as for the treatment of mucosae inflammatory conditions.
-- ------------------------------------------------------------------------------

POLYMERIC FIBER COMPOSITION AND METHOD

(WO2003083189) 09.10.2003 D01F 1/10 SCHNURER, John, H.
The present invention generally relates to specific combinations of active particles, forming a powder, that may be combined with carrier materials such as resins to produce fibers for textiles, films, coatings, and/or protective or insulating materials. The specific mixture of particles and materials may be carefully engineered to impart unique and valuable properties to end products including integration with optical energies, heat, and other electromagnetic energies. Resultant compositions may interact with light in the visible spectrum and optical and electromagnetic energy beyond the visible spectrum.
------------------------------------------------------------------ --------------

TOPICAL USE OF VITAMIN B6 COMPOSITIONS

(WO2003082230) 09.10.2003 A61K 8/64 THE PROCTER &GAMBLE COMPANY
The present invention relates to methods for regulating the condition of mammalian keratinous tissue wherein the methods each comprise the step of topically applying to the keratinous tissue of a mammal needing such treatment, a safe and effective amount of a skin care composition comprising: a) a safe and effective amount of a vitamin B6 compound selected from the group consisting of pyridoxine, esters of pyridoxine, amines of pyridoxine, salts of pyridoxine and derivatives thereof, including pyridoxamine, pyridoxal, pyridoxal phosphate, and pyridoxic acid; b) a safe and effective amount of a skin care active selected from the group consisting of peptides, phytosterol, sugar amines, their derivatives, and combinations thereof; and c) a der...
---------------------------------------------------------- ----------------------

FLUORINATED 4-AZASTEROID DERIVATIVES AS ANDROGEN RECEPTOR MODULATORS

(WO2003077919) 25.09.2003 A61K 31/473 MERCK &CO., INC.
Compounds of structural formula I are modulators of the androgen receptor (AR) in a tissue selective manner. They are useful as agonists of the androgen receptor in bone and/or muscle tissue while antagonizing the AR in the prostate of a male patient or in the uterus of a female patient. These compounds are therefore useful in the treatment of conditions caused by androgen deficiency or which can be ameliorated by androgen administration, including osteoporosis, osteopenia, glucocorticoid-induced osteoporosis, periodontal disease, bone fracture, bone damage following bone reconstructive surgery, sarcopenia, frailty, aging skin, male hypogonadism, postmenopausal symptoms in women, atherosclerosis, hypercholesterolemia, hyperlipidemia, obesit...
-------------------------- ------------------------------------------------------

PHARMACEUTICALLY ACTIVE COMPOUNDS CONTAINING PHOSPHOROUS DEFFICIENT OIL

(WO2003077811) 25.09.2003 A61K 47/44 McCLUNG, Jackie, H.
The present disclosure provides a therapeutic composition that is useful for the alleviation of a human ailment. The composition preferably includes a transdermal delivery component and a pharmaceutically active component. In the presently preferred embodiment, the transdermal delivery component includes a phosphorous deficient oil. In a particularly preferred embodiment, the transdermal delivery component is emu oil. A method for treating an infirm person with the therapeutic composition is also disclosed.
------------------------------------------------------------------ --------------

CONTROLLED DELIVERY PATCH OF ACTIVE INGREDIENT

(WO2003075812) 18.09.2003 A61K 8/02 SALVONA L.L.C.
The present invention relates to a patch for controlled topical or transdermal delivery of effective levels of cosmetic, dermatological, and pharmaceutical active ingredients onto the skin, hair follicles, and sebaceous glands, with minimal discomfort and ease of use. The patch can be transparent or clear and comprises a rate-controlling polymeric matrix layer. The polymeric matrix layer comprises water-soluble, bioadhesive, film forming polymers. The cosmetic, dermatological, and pharmaceutical active ingredients are soluble or dispersed in the polymeric matrix. The patch becomes tacky when wetted and adheres onto the skin. The adhesive properties of the patch are sufficient to maintain the patch in place on the skin for the recommended tr...
------------------------------------------------------------------ --------------

COMPOSITIONS COMPRISING Nm23 PROTEIN FOR THE USE OF MATRIX METALLOPROTEINASE INHIBITOR AND ANGIOGENESIS INHIBITOR

(WO2003074074) 12.09.2003 A61K 38/45 ANGIOLAB, INC.
The present invention relates to a pharmaceutical compositions comprising Nm23 as an active ingredient for inhibiting MMP activity and angiogenesis. The pharmaceutical formulations comprising Nm23 can be used as a drug for prevention and treatment of wide-ranging diseases mediated by overactivity of MMP and/or abnormal angiogenesis.
---------------------------------- ----------------------------------------------

WHITENING COSMETIC COMPOSITION

(WO2003074019) 12.09.2003 A61K 8/67 SHOWA DENKO K.K.
A preparation for external use on skin which comprises an active ingredient exhibiting superior effects of preventing pigmentation or eliminating pigments formed in the skin, and has a high level of safety, and in particular, a cosmetic composition exhibiting superior so-called whitening effects, are provided. The whitening cosmetic composition comprises a tocopherol alkylglycine ester and/or a salt thereof.
---------------------------------------------------------- ----------------------

THERAPEUTIC METHODS EMPLOYING PAI-1 INHIBITORS AND TRANSGENIC NON-HUMAN ANIMAL FOR SCREENING CANDIDATE PAI-1 INHIBITORS

(WO2003071267) 28.08.2003 A01K 67/027 VANDERBILT UNIVERSITY
A method of treating a warm-blooded vertebrate animal having a medical condition in need of treatment with a composition that exhibits PAI-1 inhibition activity is disclosed. The method includes the steps of administering a treatment effective amount of the composition to a warmblooded vertebrate animal having a medical condition selected from the group consisting of alopecia, undesired weight loss, Alzheimer's Disease, systemic amyloidosis, myelofibrosis, male pattern baldness, glomerulosclerosis, and combinations thereof; and observing an improvement in the medical condition in the warm-blooded vertebrate animal having the medical condition. A method of testing a candidate composition for PAI-1 inhibition activity is also disclosed. The m...
---------------------------------- ----------------------------------------------

CARBOHYDRATE-BASED ANTI-WRINKLE AND TISSUE REMODELLING COMPOUNDS

(WO2003068243) 21.08.2003 A61K 8/02 CLEARCOLL PTY LTD
A process and cosmetic preparation for skin augmentation of a subject comprising an active component comprising a 1,4 linked D -glucose oligosaccharide or polysaccharide wherein after delivery, the oligosaccaharide or polysaccharide causes an accumulation of fibroblasts in the skin at or near to the site of delivery and induces production of collagen in the skin.
------------------------------------------------------------------ --------------

COMPOSITIONS COMPRISING LYCOPENE FOR THE TREATMENT AND PREVENTION OF ANGIOGENESIS ASSOCIATED PATHOLOGIES

(WO2003068202) 21.08.2003 A23L 1/30 DSM IP ASSETS B.V.
The invention is concerned with the use of lycopene, optionally in combination with vitamin E and/or C or other biologically active ingredients as disclosed in the specification, in the manufacture of a composition for the primary and secondary prevention of angiogenesis-associated pathologies and coadjuvant treatment thereof, as well as with particular novel formulations comprising lycopene.
------------------------------------------ --------------------------------------

DRUG NANOPARTICLES WITH LYSOZYME SURFACE STABILISER

(WO2003066021) 14.08.2003 A61K 9/14 ELAN PHARMA INTERNATIONAL, LTD.
The present invention is directed to nanoparticulate active agent compositions comprising lysozyme as a surface stabilizer. Also encompassed by the invention are pharmaceutical compositions comprising a nanoparticulate active agent composition of the invention and methods of making and using such nanoparticulate and pharmaceutical compositions.
-------------------------- ------------------------------------------------------

RINSE-OFF SKIN CONDITIONING COMPOSITIONS

(WO2003066016) 14.08.2003 A61K 8/04 THE PROCTER &GAMBLE COMPANY
Skin conditioning compositions, and corresponding methods of application, wherein the compositions comprise a lipophilic carrier, solid particulates and preferably a skin benefit agent; and wherein the compositions have a Deposition Efficiency of at least about 30%, provide skin conditioning benefits. Preferred embodiments are further defined by selected lipophilic carrier rheologies, defined solid particulates for improved skin feel, and selected skin benefit agents for use in the composition. These compositions and corresponding methods provide improved cosmetics, skin feel, and/or skin active efficacy.
-- ------------------------------------------------------------------------------

COMPOSITION FOR SKIN WHITENING CONTAINING LYSOPHOSPHATIDYLETHANOLAMINE AS AN ACTIVE INGREDIENT

(WO2003066015) 14.08.2003 A61K 8/55 DOOSAN CORPORATION
Lysophosphatidylethanolamine has skin whitening ability and thus a composition containing lysophosphatidylethanolamine as an active ingredient can be used to relieve hyperpigmentation or discoloration. The composition containing lysophosphatidylethanolamine can also induce moisturizing effect on skin, is very safe, and very stable.
-------------------------------------------------- ------------------------------

BIOACTIVE KERATIN PEPTIDES

(WO2003064449) 07.08.2003 A61K 38/00 KERAPLAST TECHNOLOGIES, LTD.
Compositions containing biologically active peptides are disclosed. Active peptides are isolated fragments derived from human hair or sheep wool keratin proteins. Compositions may be prepared for pharmaceutical or topical administration or for use in cosmetic preparations.
---------------------------------------------------------- ----------------------

COMPOSITION BASED ON ETYLLINOLEATE AND TRIETHYLCITRATE FOR THE TREATMENT OF SEBORRHEA AND ACNE

(WO2003061766) 31.07.2003 A61K 8/37 GENERAL TOPICS S.R.L.
The present invention relates to a composition for topical use for treating and improving the aesthetic conditions of the skin, which comprises, as an active ingredient, a mixture of ethyllinoleate and triethylcitrate. This composition is active in the treatment of seborrhea and acne.
------------------------------------------------------------------ --------------

COMPOSITION CONTAINING MOUTAN ROOT BARK EXTRACT AS ACTIVE INGREDIENT

(WO2003061554) 31.07.2003 A61K 31/496 MICRO SCIENCE TECH CO., LTD
The present invention relates to a composition comprising a Moutan root bark extract as an active ingredient, and particularly to a composition for the prevention and treatment of athlete's foot, osmidrosis, or acne; a composition for oral cleansing; a bactericidal/disinfectant composition; a composition for eliminating dandruff- causing pathogens and controlling odor; and a functional kitchen detergent composition. The compositions comprising the Moutan root bark extract as an active ingredient of the present invention have superior bactericidal effects against bacteria including athlete's foot-causing pathogens, skin eczema-causing pathogens and skin flora, and fungi, and they can be easily and simply applied to medicines, cosmetics, or cl...
---------------------------------------------------------- ----------------------

ANTIPERSPIRANT COMPOSITIONS

(WO2003059308) 24.07.2003 A61K 8/26 UNILEVER PLC
Clear solid suspension antiperspirant compositions comprise 0.5 to 50% by weight of a particulate antiperspirant active material of which less than 50% by weight of its particles are below 10mm diameter and a refractive index of from 1.49 to 1.57 at 22oC is suspended in a water-immiscible carrier liquid of which at least 50% by weight is selected from liquid non-volatile silicone oils and liquid alkyl-aryl esters and not more than 25% by weight of the carrier liquid comprises a volatile silicone oil. The carrier liquid and the antiperspirant have refractive indexes which differ by no more than 0.02 at 22oC and the structurant which solidifies the carrier liquid comprises a fibre-forming non-polymeric structurant, and preferably an N-acyl am...
------------------ --------------------------------------------------------------

COSMETIC COMPOSITIONS COMPRISING A CYCLODIPEPTIDE COMPOUND

(WO2003059306) 24.07.2003 A61K 8/26 UNILEVER PLC
An improved process for the preparation of cosmetic formulations containing a cosmetic active and a continuous phase comprising a water-immiscible liquid carrier, that are structured by a cyclo dipeptide (CDP) having the general formula in which R1 and/or R2, which may be the same or preferably different, each represents a hydrocarbon or alkylene ester group and the other may alternatively represent hydrogen,which employs a monohydric alcohol having a melting point of below 30oC and a boiling point of greater than 100oC and a cosmetic active material optionally together with at least one water-immiscible liquid carrier oil to assist in the dissolution of the structurant and modify the gelling temperature of the resultant mixture. Preferably...
------------------ --------------------------------------------------------------

17 -HYDROXY-4-AZA-ANDROSTAN-3-ONES AS ANDROGEN RECEPTOR MODULATORS

(WO2003059293) 24.07.2003 A61K 31/473 MERCK &CO., INC.
Compounds of structural formula I as herein defined are disclosed as useful in a method for modulating the androgen receptor in a tissue selective manner in a patient in need of such modulation, as well as in a method of activating the function of the androgen receptor in a patient, and in particular the method wherein the function of the androgen receptor is blocked in the prostate of a male patient or in the uterus of a female patient and activated in bone and/or muscle tissue. These compounds are useful in the treatment of conditions caused by androgen deficiency or which can be ameliorated by androgen administration, including osteoporosis, periodontal disease, bone fracture, bone damage following bone reconstructive surgery, sarcopenia...
------------------ --------------------------------------------------------------

TOPICAL COSMETIC COMPOSITION HAVING A NATURAL PLANT ACTIVE INGREDIENT AND METHOD OF USING SAME

(WO2003057234) 17.07.2003 A61K 8/97 AVON PRODUCTS, INC.
There are disclosed topical cosmetic compositions having at least one natural active ingredient and a pharmaceutically or cosmetically acceptable vehicle. There is also a method for improving the aesthetic appearance of skin, hair and/or nails that includes topically applying the compositions of the present invention.
-- ------------------------------------------------------------------------------

TOPICAL APPLICATION OF ALPHA-DFMO AND ANTI-INFLAMMATORY DRUG FOR TREATMENT OF ACTINIC KERATOSES

(WO2003057172) 17.07.2003 A61K 31/198 TOPICAL TECHNOLOGIES, INC.
Topical alpha-DFMO is mixed with a hydrophillic ointment base, along with at least one additional active drug, for treating actinic keratoses by topical application to human skin tissues. In one case, the topical steroid triamcinolone is combined with the alpha-DFMO. In a second case, the topical non-steroid anti-inflammatory diclofenac is combined with the alpha-DFMO. In a third instance, both triamcinolone and diclofenac are combined with the alpha -DFMO. In all such instances, topical application of such combinations was found to inhibit squamous cell cancer, and the combined effect of such components, when selected in appropriate proportions, in inhibiting squamous cell cancer cells is significantly greater than the effectiveness of each...
------------------ --------------------------------------------------------------

STABLE SURFACTANT COMPOSITIONS FOR SUSPENDING COMPONENTS

(WO2003055456) 10.07.2003 A61K 8/04 RHODIA INC.
A free-flowing surfactant composition comprising at least one anionic surface-active agent, an alkanolamide, an electrolyte, and water is described. In particular, the composition is a surfactant composition that has free-flowing non-Newtonian shear thinning properties and the ability to suspend components and is stable under at least one freeze/thaw cycle.
---------- ----------------------------------------------------------------------

NEW COMPOSITION

(WO2003055454) 10.07.2003 A61K 8/06 PONSUS PHARMA AB
The invention relates to a pharmaceutical and/or cosmetical composition, character -ised in that it comprises one or more substances active in preventing hair loss and/or stimulating hair growth and a preparation comprising lipophilic and hydrophilic components for application on the skin, which preparation exists as a two-phase system and thereby is capable of creating a semi-permeable membrane in the skin.The invention also relates to a process for the manufacture of the skin preparation as defined above, which is characterised in that the lipophilic components are dis-solved in water in a separate container to be combined with hydrophilic compo-nents, which have been blended and brought to react in another vessel.Finally, the present inve...
------------------------------------------ --------------------------------------

INSECT REPELLENT COMPOSITION COMPRISING AN EXTRACT OF TARCHONANTHUS CAMPHORATUS AND REPELLENCY ENHANCER

(WO2003055316) 10.07.2003 A01N 65/00 DRAGOCO GERBERDING &Co. AG
Insect repellent compositions more efficient than those comprising Tarchonanthus camphoratus (or fractions of such extracts) alone, the insect repellant compositions of the invention comprising an extract of Tarchonanthus camphoratus (or fractions of such extracts), and a natural or synthetic triglyceride, wherein the total amount of said extract and said triglyceride is an insect repellent active amount. Also disclosed is a method for synergistically enhancing the insect repellent activity of an extract of Tarchonanthus camphorates, and a method for repelling insects.
---------------------------------------------------------- ----------------------

COMPOSITIONS AND METHODS FOR HIGH SORPTION OF SKIN MATERIALS AND DELIVERY OF SULFUR

(WO2003051979) 26.06.2003 A61K 8/23 MEDICIS PHARMACEUTICALS
A composition and method for delivering sulfur to skin and absorbing irritants in the skin. A high sorption base is employed which comprises non-swelling clay, gum, swelling clay, silicon and combinations thereof. The absorption of the irritants does not hinder the delivery of the active ingredient to the skin.
---------------------------------- ----------------------------------------------

TOPICAL COMPOSITIONS AND METHODS OF APPLICATION

(WO2003051279) 26.06.2003 A61K 8/37 AVON PRODUCTS, INC.
There are topical emulsion compositions having a cosmetic drug or medicinal active, a novel compound of the present invention, and a vehicle. The novel compound is represented by a formula selected from the group consisting of L-A-H and A-L-H, wherein L is a lipophilic moiety, A is an aromatic moiety, and H is a hydrophilic moiety. Also provided are methods of emulsifying a composition; improving the photostability of a composition; and enhancing the effectiveness of a sunscreen composition.
------------------ --------------------------------------------------------------

USE OF PROTEASE-ACTIVATED RECEPTOR-2 INHIBITOR IN THE MANIFACTURE OF A MEDICAMENT FOR TREATING DELAYED HYPERSENSITIVITY

(WO2003049723) 19.06.2003 A61K 31/00 KOWA COMPANY LTD
The present invention provides a pharmaceutical composition by a novel action mechanism without serious side effects for delayed hypersensitivity and a screening method of the same. The invention also provides a novel assay method of inhibitors/suppressive agents of PAR-2. The invention relates to a pharmaceutical composition for delayed hypersensitivity containing one or two or more active ingredients selected from the group consisting of inhibitors of PAR-2 and suppressive agents of PAR-2 gene expression and a pharmaceutically acceptable carrier, and to a method for screening active ingredients for pharmaceutical composition for delayed hypersensitivity by contacting a subject substance with cells expressing PAR-2 and by determining expre...
-------------------------- ------------------------------------------------------

AGGLOMERATED PARTICLES INCLUDING AN ACTIVE AGENT COPROCESSED WITH SILICIFIED MICROCRYSTALLINE CELLULOSE

(WO2003047551) 12.06.2003 A61K 9/16 PENWEST PHARMACEUTICAL COMPANY
A solid dosage form is provided which includes an active agent and silicified microcrystalline cellulose, the dosage form formed by: a) combining a wetted active agent with dry silicified microcrystalline cellulose in a dryer to form agglomerated particles; and b) incorporating the agglomerated particles into the solid dosage form. In certain preferred embodiments, step b comprises combining said silicified microcrystalline cellulose, said active agent, and colloidal silicon dioxide in a dryer. Preferably, the dryer is spray dryer, and, in certain embodiments, the active agent may be an herbal extract.
-- ------------------------------------------------------------------------------

METHODS FOR THE TREATMENT OF HYPERPIGMENTATION OF SKIN

(WO2003047543) 12.06.2003 A61K 8/19 PROCYTE CORPORATION
Methods for treating hyperpigmentation of skin employ topical application of compositions to skin in need thereof, where the compositions comprise at least one peptide copper complex, or at least one peptide copper complex in combination with retinol, at least one retinol derivative, or a mixture thereof. Also disclosed are methods that use such compositions further comprising active agents selected from active drug substances, emollients, sunscreen agents, skin-lightening agents, skin protectants, skin conditioning agents, and humectants.
-------------------------------------------------- ------------------------------

MINT EXTRACT AND RELATED PHARMACEUTICAL COMPOSITIONS

(WO2003045412) 05.06.2003 A61K 39/00 ANTON, Susan, Evelyn
A pharmaceutical composition comprises extract (or synthetic or other equivalent thereof) of one or more members of the mint (mentha) family, e.g. peppermint, pennyroyal, spearmint (mint), e.g. menthol or peppermint oil, for use as an active substance for topical application to the external skin area in the vicinity of the vulva or anus, and is applied for alleviating burning pain sensations in such vicinity, or alleviating pain sensations in the uretha or rectum, such pain sensations being of a kind usually occurring upon passing acid urine or faeces and usually associated with what is popularly called cystitis or irritable bowel syndrome; or again comprises an emollient, e.g. comprising liquid paraffin and/or white soft paraffin, and extr...
-------------------------- ------------------------------------------------------

METHOD FOR IDENTIFICATION OF TUMOR TARGETING ENZYMES

(WO2003043631) 30.05.2003 A61K 31/337 CHUGAI SEIYAKU KABUSHIKI KAISHA
The present invention relates to a method for identification of enzymes that are preferentially expressed in certain tumor tissue as compared with rapidly growing normal cells or tissue, use of said enzymes for the compound design to generate an active anticancer substance selectively in tumor tissue, compounds designed based on said enzymes, their pharmaceutically acceptable salts as well as pharmaceutical composition thereof.
------------------------------------------------------------------ --------------

TOPICAL COMPOSITIONS CONTAINING ENZYMES STABILIZED WITH INHIBITORS

(WO2003041680) 22.05.2003 A61K 8/02 THE PROCTER &GAMBLE COMPANY
Leave-on personal care compositions comprising a stabilized enzyme, at least 30 % water, less than 5 % of an earth alkali metal salt, and an enzyme inhibitor having an inhibition constant (Ki) from 10 nanomolar (nM) to 25,000 nM. Also, a method of providing a skin care benefits, e.g. skin feel and/or skin appearance, preferably skin moisturization, skin softness, and/or skin smoothness, comprising topically applying a safe and effective amount of the inventive compositions described herein to skin in need of such a skin care benefit. Further, a method of providing a consumer with a leave-on enzyme-containing personal care product, wherein the enzyme is inhibited and inactive on shelf, but is active on skin without the need for a separate re...
-------------------------------------------------- ------------------------------

SELF DOSING SKIN PREPARATION

(WO2003041666) 22.05.2003 A61K 8/02 INVENT RESOURCES, INC.
A self dosing skin composition and method releases sun blocking agent or other active ingredient onto the skin of a user as a function of exposure to at least one environmental condition over time. The environmental condition is preferably exposure to sun light, in particular, harmful UV radiation. The composition includes medium adapted to be spread onto the skin of a user and a reservoir defining at least one wall for containing at least one sun blocking or other agent. The reservoir is dispersed in the medium and the wall is designed and/or selected to deteriorate over time with exposure to the environmental condition or conditions, for releasing the agent into the medium and onto the skin. At least one agent is provided in the reservoir...
---------- ----------------------------------------------------------------------

PHARMACEUTICAL COMBINATONS COMPRISING A FUNGICIDE, A BACTERIOSTATIC SULPHONAMIDE AND AN ANTIBACTERIAL COMPOUND FOR TOPICAL APPLICATION

(WO2003039559) 15.05.2003 A61K 31/137 HUMAN RT.
Medical combination and its method of topical use comprising active ingredients which are sparingly soluble in water, preferably in one single composition against microbes which are pathogenic in humans and animals and which usually appear together. It comprises at least one active ingredient which is effective against several of the opportunally pathogenic strains of the group consisting of fungi Candida, Aspergillus, and/or Fusarium, and aerobic bacteria: Gram-negative bacilli such as Proteus, Pseudomonas, enterobacter species, Escherichia coli, Klebsiella, Serratia marcescens, Citrobacter, Aeromonas; Gram- negative cocci such as Neisseria, Acinetobacter species; Gram-positive bacilli such as Corynebacterium species, Bacillus sphaericus, G...
------------------ --------------------------------------------------------------

METHOD AND APPARATUS FOR THE STIMULATION OF HAIR GROWTH

(WO2003039478) 15.05.2003 A61N 5/06 LIGHT BIOSCIENCE, INC.
A system for producing hair growth stimulation using light energy, topical compositions, and combinations thereof. By using photomodulation resulting from cellular responses to exposure to specific wavelengths of light, optionally in conjunction with topical compositions and procedures for enhancing the penetration of such compositions, hair follicles are activated to produce hair growth.
------------------------------------------ --------------------------------------

SMALL MOLECULE INHIBITORS TARGETED AT BCL-2

(WO2003038060) 08.05.2003 A61K 31/00 THE REGENTS OF THE UNIVERSITY OF MICHIGAN
The present invention relates to small molecule antagonists of Bcl -2 family proteins such as Bcl-2 and/or Bcl-XL. In particular, the present invention provides non-peptide cell permeable small molecules (e.g., tricyclo- dibenzo-diazocine-dioxides) that bind to a pocket in Bcl-2/BcI-XL that block the anti-apoptotic function of these proteins in cancer cells and tumor tissues exhibiting Bcl-2 protein overexpression. In preferred embodiments, the small molecules of the present invention are active at the BH3 binding pocket of Bcl-2 family proteins (e.g., Bcl-2, Bcl-XL, and Mcl-1). The compositions and methods of the present invention are useful the...
---------------------------------- ----------------------------------------------

TRANSDERMAL TRANSPORT DEVICE WITH SUCTION

(WO2003037407) 08.05.2003 A61M 5/142 MASSACHUSETTS INSTITUTE OF TECHNOLOGY
A transdermal transport device includes a reservoir for holding a formulation of an active principle, and one or more needles (14). Each needle has a bore through which the formulation is transported between the reservoir and a biological body, and has an end portion that is substantially algined in a plane parallel to a surfaceof the biological body when the device is placed on the surface. The device also includes a vaccum generator (28) which creates a suction to draw a portion of the surface beyond the plane of the end portions to enable the end portions to penetrate the portion of the surface as the needles are translated along an axis that is substantially parallel to the plane.
------------------------------------------------------------------ --------------

IMPEDANCE SENSOR

(WO2003037405) 08.05.2003 A61M 5/142 MASSACHUSETTS INSTITUTE OF TECHNOLOGY
A transdermal transport device includes a reservoir for holding a formulation of an active principle, a needle (14) with a bore through which the formulation is transported between the reservoir and a target area of a biological body, and an impedance sensor(32). The impedance sensor has an electrode positioned to measure the impedance of a portion of the target area between the needle and the electrode to indicate the depth of penetration of the needle into the target area.
-------------------------- ------------------------------------------------------

MICRONEEDLE TRANSDERMAL TRANSPORT DEVICE

(WO2003037404) 08.05.2003 A61M 5/142 MASSACHUSETTS INSTITUTE OF TECHNOLOGY
A transdermal transport device includes a reservoir for holding a formulation of an active principle, and a needle (14) with a bore extending along the length of the needle from a first end of the needle to a second end of the needle. The second end is substantially aligned to a plane parallel to a body surface of a biological body when the device is placed on the body surface. The device also includes an actuator which pumps the formulation through the bore of the needle between a target area of the body and the reservoir.
---------- ----------------------------------------------------------------------

PERSONAL CARE COMPOSITIONS CONTAINING A WATER-DISINTEGRATABLE POLYMERIC FOAM

(WO2003037294) 08.05.2003 A61K 8/02 THE PROCTER &GAMBLE COMPANY
Disclosed are personal care compositions for topical application to the hair or skin, and corresponding methods of application, said compositions and methods comprising or are directed to a solid polymeric foam containing (A) a solid polymer-containing structurant having a defined water solubility and/or dissolution profile; and (B) an active ingredient comprising a surfactant in a weight ration of the surfactant to the solid polymer structurant of from about 1:8 to about 10:1, preferably 1:1.6:1 to about 10:1; wherein the solid polymeric foam disintegrates in water in accordance with a Substrate Disintegration Test such that no individual foam pieces remain after disintegration that have a topographical area of more than about 10% of the t...
-------------------------------------------------- ------------------------------

CREAM FOR TREATMENT OF SKIN INJURED BY THE SUN

(WO2003037291) 08.05.2003 A61K 8/35 MACRONOVA AB
This invention relates to a cream of the kind described in the preamble of claim 1 for topical treatment of visibly photodamaged skin caused by processes involving the influence of free radicals and where the cream also affects the energy production of the cells, wherein the active ingredients of the cream is carried in stabilizing cream base. The cream is characterised in 0.5% and 7% by weight d, 1-?-lipoic acid, between 0.05 and 0.5 % by weight coenzyme Q-10, between 0.001 and 3% by weight acetyl-1-carnitine hydrochloride, which constitute the active ingredients, whereby having a compound synergy effect.
------------------------------------------ --------------------------------------

METHOD OF USING PERSONAL CARE COMPOSITIONS CONTAINING A HIGH DENSITY, WATER DISINTEGRATABLE, POLYMERIC FOAM

(WO2003037282) 08.05.2003 A61K 8/02 THE PROCTER &GAMBLE COMPANY
Disclosed is a method of topically applying active ingredients to the hair or skin, said method comprising the steps of: (A) applying to the hair or skin a combination of water and a personal care composition, said composition comprising a high- density solid polymeric foam having an Foam Density of from about 0.23 grams/cm?3¿ to about 1.20 grams/ cm?3¿, said polymeric foam comprising: (i) a solid polymer structurant; and (ii) an active ingredient comprising a surfactant in a weight ratio of the surfactant to the solid polymer structurant of from about 1:8 to about 10:1; and (B) rinsing the hair or skin with water to disintegrate and rinse-away the high-density polymeric foam such that the disintegrated polymeric foam contains no individua...
---------------------------------------------------------- ----------------------

BENZIMIDAZOLES AND ANALOGUES AND THEIR USE AS PROTEIN KINASES INHIBITORS

(WO2003035065) 01.05.2003 C07D 401/14 AVENTIS PHARMACEUTICALS INC
The invention is directed to physiologically active compounds of the general formula (Ix) and compositions containing such compounds, and their prodrugs, and pharmaceutically acceptable salts and solvates of such compounds and their prodrugs, as well as to novel compounds within the scope of formula (Ix), and to processes for their preparation. Such compounds and compositions have valuable pharmaceutical properties, in particular the ability to inhibit kinases.
---------------------------------------------------------- ----------------------

POTENTIATED TOPICAL COMPOSITION

(WO2003035021) 01.05.2003 A61K 8/02 FAERGEMANN, Jan
A topical composition for skin care or administration of a pharmacologically active agent in form of a lotion, cream or similar comprises from 5 % to 70 % by weight of pentane-1,5-diol and a cosmetically or pharmaceutically acceptable carrier, with the proviso that the composition does not comprise polysiloxane, volatile siloxane, phosphatidylcholine, creatine, carnitine, panthenol, pyruvic acid, monoglyceride of lauric acid, monoglyceride of myristic acid. Also disclosed are corresponding methods of administration, a patch for holding said composition against the skin, and methods for preventing or treating a dry skin condition and of keeping skin in a humid state.
---------- ----------------------------------------------------------------------

ANDROGEN RECEPTOR MODULATORS AND METHODS OF USE THEREOF

(WO2003034987) 01.05.2003 C07D 471/04 MERCK &CO., INC.
Compounds of structural formula (I) are disclosed as useful for modulating the androgen receptor (AR) in a tissue selective manner in a patient in need of such modulation, and in particular for antagonizing AR in the prostate of a male patient or in the uterus of a female patient and agonizing AR in bone and/or muscle tissue. These compounds are useful in the treating conditions caused by androgen deficiency or which can be ameliorated by androgen administration, including: osteoporosis, periodontal disease, bone fracture, bone damage following bone reconstructive surgery, sarcopenia, frailty, aging skin, male hypogonadism, female sexual dysfunction, post-menopausal symptoms in women, atherosclerosis, hypercholesterolemia, hyperlipidemia, a...
-- ------------------------------------------------------------------------------

COMPOSITION EXHIBITING ENHANCED FORMULATION STABILITY AND DELIVERY OF TOPICAL ACTIVE INGREDIENTS

(WO2003034979) 01.05.2003 A61Q 11/00 SOL-GEL TECHNOLOGIES LTD.
A therapeutic, cosmetic or cosmeceutic composition for topical application, capable of stabilizing an active ingredient and delivering the active ingredient, comprising a plurality of microcapsules having a core-shell structure. The microcapsules have a diameter of approximately 0.1 to 100 micron. The core of each microcapsule includes at least one active ingredient, and is encapsulated within a microcapsular shell. The shell is comprised of at least one inorganic polymer obtained by a sol-gel process, and the shell protects the active ingredient before topical application and is designed to release the active ingredient from the microcapsules following application. The composition is useful in encapsulating active ingredients, such as benz...
------------------------------------------ --------------------------------------

ESTERS OF AROMATIC ALKOXYLATED ALCOHOLS AND FATTY CARBOXYLIC ACIDS

(WO2003032919) 24.04.2003 A61K 8/39 CRODA, INC.
Esters of alkoxylated aromatic alcohol and fatty carboxylic acid are provided. The esters are especially suitable as additives for personal care and cosmetic products. Certain of the esters of alkoxylated aromatic alcohol and fatty carboxylic acid having certain skin spread factor or viscosity are also provided. A personal care or cosmetic product composition that includes from about 0.1% to about 99% of at least one ester of alkoxylated aromatic alcohol and fatty carboxylic acid, and from about 0.1% to 60% of at least one functional ingredient is provided. The functional ingredients in the composition 15 may include active ingredients and additional ingredients. Especially suitable active ingredients are sunscreen active ingredients and an...
------------------ --------------------------------------------------------------

ACTIVE AGENTS USING LIPOSOME BEADS

(WO2003030818) 17.04.2003 A61K 8/14 SUVANPRAKORN, Pichit
Compositions and methods for administration of active agents encapsulated within liposome beads to enable a wider range of delivery vehicles, to provide longer product shelf-life, to allow multiple active agents within the composition, to allow the controlled use of the active agents, to provide protected and designable release features and to provide visual inspection for damage and inconsistency.
---------------------------------------------------------- ----------------------

CULTIVATION OF DISPERSED MYCOBACTERIA

(WO2003029478) 10.04.2003 C12N 1/20 CHIRON BEHRING GMBH &CO.
The present invention relates to a culture medium for disperse mycobacteria comprising at least one detergent and an antifoam agent, whereby said antifoam agent is a member of the silicone family. In addition, the invention provides for methods for the activation of dipressed mycobacteria, for obtaining a standardized mycobyterial culture or for the production of (a), purified protein derivates(s) (PDD) which comprise the cultivation of mycobacteria in the active medium disclosed herein. Furthermore, the use of standardized mycobacterial cultures obtained by the method of the invention for the preparation of pharmaceutical or diagnostic compositions is described.
--------------------------------------------------------------------------------

ANDROSTANE 17-BETA-CARBOXAMIDES AS ANDROGEN RECEPTOR MODULATORS

(WO2003029268) 10.04.2003 A61K 31/56 MERCK &CO., INC.
Compounds of structural formula as herein defined are disclosed as useful in a method for modulating the androgen receptor in a tissue selective manner in a patient in need of such modulation, as well as in a method of activating the function of the androgen receptor in a patient, and in particular the method wherein the function of the androgen receptor is blocked in the prostate of a male patient or in the uterus of a female patient and activated in bone and/or muscle tissue. These compounds are useful in the treatment of conditions caused by androgen deficiency or which can be ameliorated by androgen administration, including osteoporosis, periodontal disease, bone fracture, bone damage following bone reconstructive surgery, sarcopen...
-- ------------------------------------------------------------------------------

METHOD AND TOPICAL FORMULATION FOR TREATING SKIN CONDITIONS ASSOCIATED WITH AGING

(WO2003026680) 03.04.2003 A61K 8/19 DERMATRENDS, INC.
A composition and method are provided for alleviating the dermatological signs of intrinsic and extrinsic aging. A topical formulation containing a cosmeceutically active base, wherein the formulation provides a pH in the range of about 8.0 to 13.0 at the skin surface, is applied to the skin in order to prevent or treat aging-related skin conditions such as wrinkles, dry skin, age spots, sun damage (particularly UV radiation-induced oxidative stress), blemishes, hyperpigmented skin, age spots, increased skin thickness, loss of skin elasticity and collagen content, dry skin, lentigines and melasmas. The cosmeceutically active base is either an inorganic base, such as an inorganic hydroxide, an inorganic oxide, or a metal salt of a weak acid,...
------------------------------------------ --------------------------------------

EMOLLIENT SKIN CONDITIONING CREAM AND METHOD

(WO2003026607) 03.04.2003 A61K 8/34 CRABTREE &EVELYN, LTD.
A cosmetic composition for use in cleansing and conditioning the skin of a human being that comprises (A) 35% to 80% by weight of emollient materiel; (B) a water- soluble surface active agent in a proportion selected from the range of 0.4% to 8.0% by weight; and (C) a water-insoluble C12-C18 monocarboxylic acid salt, the weight ratio of said emollient material to said carboxylic acid salt being in the range of about 7:1 to about 1:1.
------------------------------------------ --------------------------------------

TOPICAL APPLICATION OF CHROMOPHORES FOR HAIR REMOVAL

(WO2003026600) 03.04.2003 A61K 8/04 CERAMOPTEC INDUSTRIES, INC.
A device and method is disclosed for permanent or semi- permanent removal of hair through the activation of microparticles introduced into hair follicles. Microparticles are incorporated into a composition that is topically applied to the skin. These microparticles containing or consisting of chromophores or chemically activated molecules are of a variety of shapes and sizes. Microparticles are within a size range of 1 micron to 70 microns, and preferably between 10 and 50 microns. Microparticles of this size and variety of shapes enter hair follicles on all areas of the skin without entering other areas of the skin, such as the stratum corneum or sweat gland channels. Treatment of the skin with electromagnetic radiation, ultrasonic radiatio...
------------------ --------------------------------------------------------------

ANDROSTANES AS ANDROGEN RECEPTOR MODULATORS

(WO2003026568) 03.04.2003 A61K 31/568 MERCK &CO., INC.
Compounds of structural formula (I) as herein defined are disclosed as useful in a method for modulating a function of the androgen receptor in a tissue selective manner in a patient in need of such modulation, as well as in a method of activating the function of the androgen receptor in a patient, and in particular the method wherein the function of the androgen receptor is blocked in the prostate of a male patient or in the uterus of a female patient and activated in bone and/or muscle tissue. These compounds are useful in the treatment of conditions caused by androgen deficiency or which can be ameliorated by androgen administration, including osteopenia, osteoporosis, periodontal disease, bone fracture, bone damage following bone re...
-- ------------------------------------------------------------------------------

MICROSTRUCTURES FOR DELIVERING A COMPOSITION CUTANEOUSLY TO SKIN USING ROTATABLE STRUCTURES

(WO2003024518) 27.03.2003 A61B 17/00 THE PROCTER &GAMBLE COMPANY
An improved method and apparatus (600) is provided as a system to deliver a composition, preferably a medical or pharmaceutical composition or active, through the stratum corneum of skin, without introducing bleeding or damage to tissue, and absent pain or other trauma. The dimensions and shapes of the microelements (12) are controlled so as to control the penetration depth into the skin. The microelements can be 'hollow' such that passageways (626) are created therethrough to allow the composition to flow from a chamber (476), through the microelements, and into the skin. Alternatively, the microelements can be 'solid' (622), and the composition is applied directly to the skin just before or just after the microelements are applied to the ...
-------------------------- ------------------------------------------------------

ENAMEL MATRIX PROTEIN COMPOSITIONS FOR MODULATING IMMUNE RESPONSE

(WO2003024479) 27.03.2003 A61K 35/32 BIORA BIOEX AB
The present invention relates to the use of a preparation of an active enamel matrix substance, such as an amelogenin, for the manufacture of a pharmaceutical composition for modulating an immune response. The composition can be used in preventing and/or treating a condition or disease in a mammal that is characterised by said mammal presenting an imbalance in its native immune response to an internal and/or external stimuli, i.e. wherein at least a part of said mammal's immune system is stimulated non-discriminatingly, reacts hypersensitivity to said immunogen, or fails to react to said stimuli. Said condition can typically either be systematic or local, such as a systemic and/or post-traumatic whole-body inflammation or an autoimmune dise...
---------- ----------------------------------------------------------------------

USE OF GUAIOL FOR TREATING THE SKIN

(WO2003024417) 27.03.2003 A61K 8/34 CIBA SPECIALTY CHEMICALS HOLDING INC.
The use is described of compositions comprising (a) (-)-guaiol, (b) further skin-lightening active substance(s) and, optionally, (c) one or more UV-A and/or UV-B absorbers as melanogenesis inhibitors and for skin-lightening.
-------------------------- ------------------------------------------------------

HEMOCYANIN NUCLEIC ACIDS AND POLYPEPTIDES AND RELATED VECTORS, FUSION PROTEINS, CONJUGATES, CELLS AND METHODS OF USE

(WO2003023006) 20.03.2003 C07K 14/435 PIERCE BIOTECHNOLOGY, INC.
An isolated or purified nucleic acid molecule consisting essentially of a nucleotide sequence encoding KLH or a fragment thereof, as well as an isolated or purified nucleic acid molecule consisting essentially of a nucleotide sequence complementary thereto; a vector comprising such a nucleic acid, optionally as part of an encoded fusion protein when the nucleic acid encodes KLH or fragment thereof; a cell comprising and expressing an above-described nucleic acid, optionally in the form of a vector; an isolated or purified polypeptide molecule consisting essentially of an amino acid sequence encoding KLH-1, KLH-2, or a fragment of either of the foregoing, as well as a conjugate or fusion protein comprising the same and a therapeutically or p...
-------------------------- ------------------------------------------------------

TRANSDERMAL ADMINISTRATION OF AN ENALAPRIL ESTER

(WO2003022270) 20.03.2003 A61K 9/70 NOVEN PHARMACEUTICALS, INC.
Disclosed is a dermal composition comprising enalapril ethyl ester or another prodrug corresponding to a pharmaceutically active form of an ACE inhibitor in an amount corresponding to a therapeutically effective amount of enalaprilat (or other pharmaceutically active form of enalapri) or pharmaceutically active form of the ACE inhibitor in admixture with a pharmaceutically acceptable carrier. In a preferred embodiment, the carrier is a pressure-sensitive adhesive matrix comprising a polymer or polymer blend. The dermal composition is applied in a method of substantially increasing the flux of enalaprilat through the skin of a human or an animal by maintaining the dermal composition in contact with the skin.
---------------------------------- ----------------------------------------------

METHODS FOR STERILIZING PREPARATIONS CONTAINING ALBUMIN

(WO2003020325) 13.03.2003 A61K 38/38 CLEARANT, INC.
Methods are disclosed for sterilizing preparations containing albumin to reduce the level of one or more active biological contaminants or pathogens therein, such as viruses, bacteria (including inter- and intracellular bacteria, such as mycoplasmas, ureaplasmas, nanobacteria, chlamydia, rickettsias), yeasts, molds, fungi, prions or similar agents responsible, alone or in combination, for TSEs and/or single or multicellular parasites. These methods involve sterilizing preparations containing albumin, such as plasma protein fractions, with irradiation.
------------------------------------------ --------------------------------------

HYDROGENATED CASTOR OIL DISPERSED IN A LIPID FOR PHARMACEUTICALLY ELEGANT TOPICAL OINTMENTS

(WO2003020203) 13.03.2003 A61K 8/92 HEALTHPOINT, LTD.
A topical ointment pharmaceutical composition that uses a lipophilic base, a pharmaceutical active and, dispersed in the base, from about 1 % to about 50 % by weight of the total composition of hydrogenated non- melted castor oil in powder form. The result of using hydrogenated non-melted castor oil in powder form is a surprising pharmaceutical elegance perceived to be smoother in texture and more spreadable than an ointment made by melting the hydrogenated castor oil.
-------------------------------------------------- ------------------------------

MULTIVESICULAR EMULSION TOPICAL DELIVERY SYSTEMS

(WO2003020037) 13.03.2003 A61K 8/41 HEALTHPOINT, LTD.
A topical delivery composition which employs a multivesicular emulsion in combination with a pharmaceutically/pharmacologically active agent is disclosed. The multivesicular emulsion is formed from a quaternary amine salt emulsifier such as behentrimonium methosulfate. The emulsion is multi-lamellar which is a series of concentric spheres or vesiculars of oil and water phase that can be seen microscopically. As a result, the active is time released over a sustained period rather than spike released as is common with most topicals.
---------------------------------- ----------------------------------------------

COMPOSITIONS AND METHODS FOR TARGETING CEREBRAL CIRCULATION AND TREATMENT OF HEADACHE

(WO2003018023) 06.03.2003 A61K 9/00 FROME, Bruce
Methods and compositions for targeting cerebral circulation and treatment of headache include formulations comprising a pharmacologically active substance in a transdermal formulation, which is topically applied to an area of skin superficial to a carotid artery, a temporal artery, a vertebral artery, or to a tender spot associated with a headache. Particularly preferred formulations include a xanthine derivative (e.g., theophylline, caffeine, aminophylline), and may further comprise ketoprofen. Contemplated methods further include methods of advertising use of contemplated compositions.
---------- ----------------------------------------------------------------------

COMPOSITIONS AND METHODS FOR TARGETING CEREBRAL CIRCULATION AND TREATMENT OF HEADACHE

(WO2003017932) 06.03.2003 A61K 9/00 EPITOME PHARMACEUTICALS LIMITED
Methods and compositions for targeting cerebral circulation and treatment of headache include formulations comprising a pharmacologically active substance in a transdermal formulation, which is topically applied to an area of skin superficial to a carotid artery, a temporal artery, a vertebral artery, or to a tender spot associated with a headache. Particularly preferred formulations include a xanthine derivative (e.g., theophylline, caffeine, aminophylline), and may further comprise ketoprofen. Contemplated methods further include methods of advertising use of contemplated compositions.
-------------------------------------------------- ------------------------------

POLYMERIC URETHANE ESTER QUATS AND THEIR USE IN PERSONAL CARE COMPOSITIONS

(WO2003016247) 27.02.2003 A61K 8/87 ALZO INTERNATIONAL, INC.
The present invention relates to a composition and use of polymeric urethane esters quats as an active ingredient for skin and hair contacting personal care compositions and products related thereto. These compositions are generally produced by the reaction of a trialkanolamine with a hydroxy fatty acid to produce a trialkanolamine fatty acid ester, which is then polymerized with a diisocyanate and in preferred embodiments, further reacted with a quaternizing agent, to produce preferred quaternized compositions according to the present invention.
-------------------------------------------------- ------------------------------

ANDROGEN RECEPTOR MODULATORS AND METHODS OF USE THEREOF

(WO2003011302) 13.02.2003 A61K 31/435 MERCK &CO., INC.
Compounds of structural formula (I) as herein defined are disclosed as useful in a method for modulating the androgen receptor in a tissue selective manner in a patient in need of such modulation, as well as in a method of agonizing the androgen receptor in a patient, and in particular the method wherein the androgen receptor is antagonized in the prostate of a male patient or in the uterus of a female patient and agonized in bone and/or muscle tissue. These compounds are useful in the treatment of conditions caused by androgen deficiency or which can be ameliorated by androgen administration, including: osteoporosis, periodontal disease, bone fracture, bone damage following bone reconstructive surgery, sarcopenia, frailty, aging skin, male...
---------------------------------- ----------------------------------------------

STILBENE DERIVATIVES, A METHOD FOR PREPARATION THEREOF, AND ITS USE

(WO2003010121) 06.02.2003 A61K 8/02 PACIFIC CORPORATION
The present invention relates to stilbene derivatives ; a method of preparation therefor ; and a medicinal composition for treating hyperpigmentation and a cosmetic composition for whitening skin containing the stilbene derivatives as an active ingredient.
-------------------------- ------------------------------------------------------

TOPICAL PHARMACEUTICAL FORMULATION

(WO2003009877) 06.02.2003 A61L 26/00 ADVANCED BIOTECHNOLOGIES INTERNATIONAL
A composition comprising a non-volatile silicone fluid in admixture with fumed silica and a pharmaceutical active agent.
------------------------------------------------------------------ --------------

USE OF BIOLOGICALLY ACTIVE HIV-1 TAT, FRAGMENTS OR DERIVATES THEREOF, TO TARGET AND/OR TO ACTIVATE ANTIGEN-PRESENTING CELLS, AND/OR TO DELIVER CARGO MOLECULES FOR PREVENTIVE OR THERAPEUTIC VACCINATION AND/OR TO TREAT OTHER DISEASES

(WO2003009867) 06.02.2003 A61K 39/39 ISTITUTO SUPERIORE DI SANITA'
The present invention concerns a method for prophylactic and/or therapeutic vaccination and/or treatment and/or diagnosis of HIV/AIDS, other infectious diseases, inflammatory and angiogenic diseases and tumours which utilizes a biologically active HIV-1 Tat protein, fragments or derivates thereof, as a module with one or more of the following features: antigen, adjuvant and targeting- delivery system to specific antigen-presenting cells including dendritic cells, endothelial cells and macrophages. In particular, it is claimed that Tat can be used only in its biologically active form as an antigen combined with one or more other antigens, to prime or to boost protective immune responses against itself as well as other antigens and/or to selec...
---------------------------------- ----------------------------------------------

STABLE READY-TO-USE DOSAGE FORMS CONTAINING COLORING MATTER AND ACTIVE CHLORINE, METHODS OF MAKING AND USING

(WO2003009801) 06.02.2003 A01N 59/00 FREEDMAN, Shimon
A method of producing a disinfectant or sterilizing liquid, cream, ointment, paste, or gel by dissolving in a solvent a stable ready-to-use dosage form containing coloring matter and an organic chloroxidizer acting as a chlorine donor releasing active chlorine. The coloring matter is in its maximal level of oxidation. The chloroxidizer with coloring matter has a pH of 4 - 8 and is present in a sufficient quantity to disinfect or sterilize the surface, vessel, or tissue as required while the colored appearance of the liquid, cream, ointment, paste, or gel is stably maintained over a period of time which exceeds the period of time that the disinfectant would be normally used for that purpose.
------------------ --------------------------------------------------------------

ANTIVIRAL COMPOSITION AND TREATMENT METHOD

(WO2003003833) 16.01.2003 A61K 31/045 INTERNATIONAL FLORA TECHNOLOGIES, LTD.
Presented is a composition, and method thereof, that is useful for the treatment of various viral infections. The method may be carried out using compositions comprising alcohols of the general formula R lCH2-0H, wherein R ?1¿ comprises CH¿3?-(CH¿2?)¿7?-CH=CH-CH¿2?-CH¿2?)x -,and x is (6), (8), (10) and (12), or comparable compositions that may also include other physiologically active constituents that do not interfere with the efficacy of the primary composition of the present invention. The compositions according to the present invention may further comprise salts of long chain fatty acids and/or mixed chain esters and unreacted wax esters. The compositions may be obtained by the base catalyzed alcoholysis reaction between a wax este...
-- ------------------------------------------------------------------------------

ENHANCED DRUG DELIVERY IN TRANSDERMAL SYSTEMS

(WO2002102390) 27.12.2002 A61K 9/70 NOVEN PHARMACEUTICALS, INC.
A composition for transdermal administration resulting from an admixture includes: a therapeutically effective amount of a drug that includes a parent drug and a prodrug; and a pharmaceutically acceptable carrier, wherein the parent drug and prodrug are individually present in an amount sufficient for a pharmacological effect. In a preferred embodiment, the admixture includes: a therapeutically effective amount of a pharmaceutically active agent that includes a corresponding steroid and a steroid derivative; and a carrier for the pharmaceutically active agent. The steroid and the corresponding steroid derivative are present in a weight ratio of 10:1 to 1:10 steroid: corresponding steroid derivative. In a preferred embodiment ratio is 6:1 to...
---------- ----------------------------------------------------------------------

COMPOSITIONS FOR PREVENTION AND TREATMENT OF SKIN WRINKLE

(WO2002102349) 27.12.2002 A61K 8/49 LG HOUSEHOLD &HEALTH CARE LTD.
The present invention relates to a composition for preventing and treating skin aging, and particularly to a composition for preventing and treating skin aging comprising a procyanidin oligomer. The composition of the present invention is safe when applied to skin, has effects of wrinkle improvement, elasticity increase, skin reinformement, etc. by promoting collagen synthesis in skin to make collagen metabolism active, and it has superior effects for inhibiting and treating skin wrinkles.
---------- ----------------------------------------------------------------------

GUM RESIN AS A CARRIER FOR TOPICAL APPLICATION OF PHARMACOLOGICALLY ACTIVE AGENTS

(WO2002102304) 27.12.2002 A61K 8/49 BATTAGLIA, Alex
The invention provides a biological dressing for treatment of a dermatological disease comprised of a gum resin, a topically acceptable volatile solvent, and a pharmacologically active agent. The gum resin is present in a suitable amount that the composition, when the solvent evaporates, will dry to form a solid coating that sticks to the skin or mucosal membrane to which the composition is applied and maintain the pharmacologically active agent over a sustained period of time in contact with sites on the skin or mucosal membranes exhibiting symptoms of the disease. Methods are provided for treating symptoms of dermatological diseases with such a pharmacological composition. Biological dressings including tincture of benzoin and clotrimazol...
-------------------------------------------------- ------------------------------

TOPICAL COMPOSITIONS FOR VETERINARY USES

(WO2002098404) 12.12.2002 A61K 9/00 TENDSKIN COMPANY
A method of treating a non-human dermatological disorder, wherein the method comprises topically administering to a non-human dermatological disorder a therapeutically effective amount of a topical composition containing: (1) an active component comprising at least one salicylate derivative; and (2) at least one pharmaceutically acceptable solubilizer.
---------------------------------- ----------------------------------------------

METHOD OF USING OPTICALLY-ACTIVATED PARTICLES IN COSMETIC PREPARATIONS

(WO2002098349) 12.12.2002 A61K 8/11 LIPO CHEMICALS, INC.
Optically-activated fixed particles for use in cosmetic, toiletries, or pharmaceutical preparations. The optically-activated fixed particles include a plurality of substrate particles selected from the group consisting of polyamides, polyacrylates, polyesters, other plastic polymers, natural materials, starch, cellulose, regenerated cellulose, metals, salts, and minerals, and other insoluble solids; a fluorescent compound fixed to each of the plurality of substrate particles to form integral units in the form of optically- activated fixed particles for reducing the visual perception of skin imperfections, including cellulite, shadows, skin discolorations, wrinkles, and mild scars. Each of the optically-activated fixed particles are optionall...
------------------ --------------------------------------------------------------

TOPICAL COMPOSITION COMPRISING AN ACTIVATED, TRANS-STRUCTURED COSMETIC BONDING AGENT

(WO2002096372) 05.12.2002 A61K 8/31 THE PROCTER &GAMBLE COMPANY
The present invention relates to cosmetic compositions that comprise a safe and effective amount of a bonding agent comprising trans structure wherein X represents a cosmetic benefit agent, L represents an optional chemical linker between X and a remainder of the bonding agent; and either tethered to a chemical linker or not R represents an activating electron withdrawing group; and a cosmetically acceptable carrier for the bonding agent wherein the composition is administered topically to mammalian proteinaceous substrates and wherein the bonding agent reacts with a protein contained in the substrate such that the bonding agent, and thus the cosmetic benefit agent, is covalently attached to the substrate. The invention further relates to m...
-------------------------------------------------- ------------------------------

COSMETIC COMPOSITIONS CONTAINING ROSEMARY EXTRACT AND DHA

(WO2002096371) 05.12.2002 A61K 8/35 E-L MANAGEMENT CORP.
The present invention relates to a topical composition comprising a malodor-reducing effective amount of a rosemary extract, or active fraction thereof, in combination with a self-tanning effective amount of DHA. The invention also provides a method of reducing the potential for malodor generation of a DHA composition comprising adding to the composition an effective amount of rosemary extract or active fraction thereof.
------------------------------------------ --------------------------------------

POMEGRANATE PRODUCTS USEFUL IN IMPROVING HEALTH AND METHODS OF USE THEREOF

(WO2002094303) 28.11.2002 A61K 35/78 RIMONEST LTD.
A mixture of pomegranate seed oil product and a pomegranate juice product and a pharmaceutical composition containing same. The mixture, which is a cancer chemopreventive, includes a pomegranate seed oil product and pomegranate juice product. The pharmaceutical composition includes physiologically active amounts of pomegranate seed oil product, a pomegranate juice product and a pharmaceutically acceptable carrier. According to some disclosed embodiments, a pomegranate peel product is further included. Further disclosed is a selective estrogen receptor modulator and other biologically active compounds derived from pomegranates as well as methods of use thereof.
---------- ----------------------------------------------------------------------

LIPOTEICHOIC ACID FROM LACTIC ACID BACTERIA AND ITS USE TO MODULATE IMMUNE RESPONSES MEDIATED BY GRAM-NEGATIVE BACTERIA, POTENTIAL PATHOGENIC GRAM-POSITIVE BACTERIA

(WO2002094296) 28.11.2002 A23L 1/30 SOCIETE DES PRODUITS NESTLE S.A.
The invention relates to a composition for modulating the immune responses induced by Gram negative bacteria, potential pathogenic Gram positive bacteria and/or their derivatives, comprising lipoteichoic acid from lactic acid bacteria as an active ingredient. It also relates to the use of a lipoteichoic acid from lactic acid bacteria as an active ingredient and/or lactic acid bacteria producing it and/or its supernatant of culture, in the manufacture of a medicament, an oral or topical product for cosmetic, dermatological or ophtalmological applications, a food or petfood composition for modulating bacterial colonisation, immune responses and decreasing the inflammatory processes associated with bacterially-mediated disease and infection in...
---------------------------------------------------------- ----------------------

METHOD AND KIT FOR THE TREATMENT OF COSMETIC SKIN CONDITIONS

(WO2002092167) 21.11.2002 A61N 1/32 THE PROCTER &GAMBLE COMPANY
The present invention relates to a method for the treatment of a selected area of the skin and/or subcutaneous tissue, and in particular for the cosmetic treatment of skin conditions such as regional fat deposits including cellulite, comprising exposing the selected area to a static magnetic field having a field intensity in the range about 100 Gauss to about 2000 Gauss. The invention is further concerned with a kit for treating a selected area of skin and/or subcutaneous tissue, and in particular for the treatment of regional fat deposits including cellulite. The kit includes a device comprising a static magnetic field source which, in use, is applied to the selected area of the skin and/or subcutaneous tissue and a topical composition ada...
------------------ --------------------------------------------------------------

TOPICAL PRODUCT WITH VISUAL INDICATOR

(WO2002092040) 21.11.2002 A45D 40/16 THE GILLETTE COMPANY
A product for application to the skin includes a container and a composition within the container including a cosmetic or therapeutic active ingredient. Some time after first use, the aplication surface of the composition changes from a first visual appearance to a second visual appearance due to a change in the composition.
-------------------------- ------------------------------------------------------

USE OF ALPHA 1-ANTICHYMOTRYPSIN FOR THE MANUFACTURE OF A COMPOSITION FOR TREATMENT, PREVENTION OR DIAGNOSIS OF POORLY HEALING DIABETIC OR ARTERIAL WOUNDS

(WO2002088180) 07.11.2002 A61K 38/00 SWITCH BIOTECH AG
The invention relates to the use of alpha 1-antichymotrypsin (ACT) polypeptides according to SEQ ID No. 1 to SEQ ID No. 4 and/or nucleic acids encoding them, or an antibody or a fragment thereof directed against the polypeptide, or of a cell which is expressing the polypeptide or a nucleic acid encoding it, for diagnosis, treatment and/or prevention of diabetes- associated and/or arterial wounds which heal poorly and for identifying pharmacologically active substances which exert an influence on the expression or function, particularly the activity of ACT.
---------------------------------- ----------------------------------------------

METHOD, KIT AND DEVICE FOR THE TREATMENT OF COSMETIC SKIN CONDITIONS

(WO2002087700) 07.11.2002 A61F 7/00 THE PROCTER &GAMBLE COMPANY
The present invention concerns a method and a kit, for the treatment of a selected area of the skin and/or subcutaneous tissue, and in particular for the cosmetic treatment of skin conditions such as regional fat deposits including cellulite. The method comprises heating the selected area to a sustained skin temperature of about 32 to about 50°C for a desired period of time, using a device comprising either a heat source capable of conductively heating the selected area or, alternatively, an infra-red source for emitting infra-red with a wavelength from about 700 nm to about 15000 nm. The method also comprises administering, simultaneously or sequentially in either order, a composition containing an active agent selected from the group ...
-------------------------------------------------------------------------- ------

A METHOD AND APPARATUS FOR THE TREATMENT OF COSMETIC SKIN CONDITIOINS

(WO2002087692) 07.11.2002 A61N 1/10 THE PROCTER &GAMBLE COMPANY
The present invention relates to a method for the treatment of cosmetic skin conditions such as regional fat deposits, and in particular for the treatment of cellulite using an electrostatically discharged current. The method comprises treating a selected area of a cosmetic skin condition by the electrostatic application, from a storage medium, of a current between the storage medium and the selected area. The invention is further concerned with a kit for treating a selected area of cosmetic skin conditions such as regional fat deposits, and in particular for the treatment of cellulite. The kit includes a device comprising an electrostatic storage medium from which, in use, a current is electrostatically discharged between the device and th...
------------------------------------------------------------------ --------------

ANTIPERSPIRANT AND DEODORANT COMPOSITIONS CONTAINING A LOW MOLECULAR WEIGHT POLYETHYLENE GELLANT

(WO2002087521) 07.11.2002 A61K 8/26 THE GILLETTE COMPANY
The present invention embraces an anhydrous topical antiperspirant or deodorant composition comprising an antiperspirant or deodorant active, a dermatologically acceptable volatile silicone liquid carrier vehicle and a polyethylene homopolymer dissolved in the vehicle to serve as a thickening or solidifying agent, wherein the polyethylene homopolymer has a molecular weight of about 200 to about 800 daltons, preferably about 300 to about 600 daltons, most preferably about 400 to about 500 daltons. The composition should be substantially free of any other organic or natural waxes. The present invention also embraces a method of inhibiting or reducing perspiration or a method of inhibiting or reducing malodor by topically appealing an effectiv...
-- ------------------------------------------------------------------------------

SELF-FOAMING SHAVING LOTION

(WO2002087520) 07.11.2002 A61K 7/00 THE GILLETTE COMPANY
The present invention is directed to a self-foaming shaving composition in the form of a lotion. The shaving composition comprises water, a water dispersible surface active agent capable of forming a lather, a volatile self-foaming agent, and a water soluble thickening agent wherein the composition is in the form of a self-foaming lotion having an elastic modulus (G') of about 100 to about 1000 Pascals, preferably about 200 to about 900 Pa, most preferably about 400 to about 800 Pa (measured with a rheometer at frequency 1Hz, oscillatory stress range 0.01-1.0 Pa, temperature 5 °C, Gap 1000 $g(m)m). The present invention is also directed to an improved shaving method in which a shaving composition of the present invention is applied to an a...
---------------------------------- ----------------------------------------------

COMPOSITIONS & FORMULATIONS WITH A NON-GLUCOCORTICOID STEROID &/OR A UBIQUINONE & KIT FOR TREATMENT OF RESPIRATORY & LUNG DISEASE

(WO2002085297) 31.10.2002 A61K 31/122 EAST CAROLINA UNIVERSITY
A composition comprises as the active agent a Non-glucocorticoid steroid, analogue thereof, a ubiquinone, or their salts, in an amount effective for reducing levels of, or hypersensitivity to, adenosine, increasing levels of lung surfactant or ubiquinone, or for preventing or treating respiratory, lung and cancer diseases. The present treatment is useful for treating asthma, rhinitis, COPD, CF, RDS, pulmonary fibrosis, cancer and other diseases.
------------------------------------------------------------------ --------------

COMPOSITION, FORMULATIONS AND KIT FOR TREATMENT OF RESPIRATORY AND LUNG DISEASE WITH NON-GLUCOCORTICOID STEROIDS AND/OR UBIQUINONE AND A BRONCHODILATING AGENT

(WO2002085296) 31.10.2002 A61K 31/122 EPIGENESIS PHARMACEUTICALS, INC.
A pharmaceutical or veterinary composition, comprises a first active agent selected from a non-glucocorticoid steroid or analogues, a ubiquinone, or salts thereof, and a second active agent comprising a bronchodilator. The composition is provided in various formulations and in the form of a kit. The products of this patent are applied to the prophylaxis and treatment of respiratory, lung and malignant diseases.
-------------------------- ------------------------------------------------------

METHOD AND APPARATUS FOR DETECTING RESPONSE TO DAMAGE IN PLANTS

(WO2002084299) 24.10.2002 G01N 33/84 UNIVERSITY OF DURHAM
Method for detecting response to damage or disease in a plant or crop comprising detecting Active Oxygen Species (AOS), in a quantitative assay; diagnostic reagent comprising an extract of damaged or diseased plant or crop tissue, or active component thereof, or synthetic equivalent or derivative thereof; use of the method or reagent in detecting response to damage or disease in a plant or crop selected from potato (seed, processor or consumer), apple, lychee, peer, apricot, peach, orange (juice), banana, leaf or stem browning in cut flowers, lettuce, pomegranate, grape, mushroom, logan fruit, loquat fruit, blueberry, carambola, dog rose, rambutan, coconut, avocado, plantain, pineapple, walnut, artichoke, sugarbeet and onion; apparatus and ...
------------------ --------------------------------------------------------------

WATER-IN-STABLE KOJIC ACID DERIVATIVES AND METHOD FOR PREPARING THEREOF, AND WHITENING COSMETICS COMPOSITION CONTAINING THE SAME

(WO2002083092) 24.10.2002 A61K 8/34 AMOREPACIFIC CORPORATION
There are provided a water-in stable kojic acid derivative represented by the following formula 1, a method for preparing the same and a skin-whitening cosmetic composition containing the same as an active ingredient:
------------------------------------------------------------------ --------------

MATRIX PROTEIN COMPOSITIONS FOR GUIDED CONNECTIVE TISSUE GROWTH

(WO2002080994) 17.10.2002 A61L 27/36 BIORA BIOEX AB
The present invention relates to the use of enamel matrix, enamel matrix derivatives and/or enamel matrix proteins as therapeutic and/or cosmetic agents. Said substances are sued for the manufacture of a pharmaceutical and/or cosmetic composition for actively inducing guiding and/or stimulating connective tissue growth and thus to prevent connective tissue scaring and/or contraction in a wound cavity and/or tissue defect that is characterised by a substantial loss of tissue. Comprised in the invention is in particular the use of active enamel substances for guided connective soft tissue growth and resistance to contraction in deep cavity shaped wounds following loss or removal of significant volumes of tissue, such as e.g. after surgical re...
-------------------------------------------------- ------------------------------

PHARMACOLOGICALLY ACTIVE STRONG ACID SOLUTIONS

(WO2002080940) 17.10.2002 A61K 31/14 CYTOREX BIOSCIENCES, INC.
Composition of pharmacologically active strong acid solutions comprising a mixture of strong and weak acids, and therapeutic methods thereof.
------------------ --------------------------------------------------------------

A JASMONATE PHARMACEUTICAL COMPOSITION FOR TREATMENT OF CANCER

(WO2002080890) 17.10.2002 A61K 31/122 RAMOT UNIVERSITY AUTHORITY FOR APPLIED RESEARCH AND INDUSTRIAL DEVELOPMENT LTD.
A pharmaceutical composition useful for the treatment of cancer in mammals, comprising as the active ingredient a therapeutically effective amount of a jasmonate compound. The jasmonate compounds are useful in treating a wide variety of malignancies.
------------------------------------------ --------------------------------------

ANTI-STRETCH MARK PREPARATION AND METHOD THEREOF

(WO2002080880) 17.10.2002 A61K 8/35 PRISCILLA S.R.L. UNIPERSONALE
An anti-stretch preparation, comprising a composition of substances for local use aimed at reducing visibility and treating skin stretch marks, and an active principle having an half-permanent pigmenting capability.
--------------------------------------------------------------------------------

ANTIMICROBIAL FORMULATIONS

(WO2002080668) 17.10.2002 A01N 25/30 KIMBERLY-CLARK WORLDWIDE, INC.
Antimicrobial formulations, which may be essentially free of an antimicrobial active, comprising one or more proton donating agents and an alkyl phosphate anionic surfactant comprising a mono alkyl phosphate having the chemical structure: (I),wherein ?R1¿ is a saturated or unsaturated straight chain or branched alkyl group having from about 8 to about 22 carbon atoms, x is a number from 0 to about 20, and ?R2¿ and ?R3¿ are independently selected from hydrogen, an alkali metal, or an alkanol amine, are provided and described herein. The formulations may be incorporated into wet wipes or various other personal care items such as facial tissue, bathroom tissue or feminine care products, or may be incorporated into lotions or soaps which may...
---------- ----------------------------------------------------------------------

HUMAN MEDICAL TREATMENT BY APPLICATION OF IMMUNOGLOBULIN A

(WO2002076502) 03.10.2002 A61L 2/00 SIMON, Michael, R.
Pooled human plasma is processed by cold ethanol fractionation to produce purified immunoglobulin G antibodies for intravenous administration. Immunoglobulin A is an unwanted by-product since intravenous administration of immunoglobulin A-containing immunoglobulin G can cause life-threatening anaphylaxis in some people. The present invention is the topical application of immunoglobulin A coupled with recombinant J chain, and optionally coupled with recombinant secretory component in order to render the immunoglobulin A more physiologically active, for the prevention or treatment of ocular diseases including ocular immune deficiency and infections. Antigen-specific monoclonal immunoglobulin A may be used.
---------------------------------- ----------------------------------------------

DERMATOLOGICAL AGENT FOR THE TREATMENT OF SKIN TRAUMA, ESPECIALLY IN BURN CONDITIONS

(WO2002076411) 03.10.2002 A61K 47/36 OWOC, Dorian
Dermatological agent for the treatment of skin trauma, especially in burn conditions, containing known natural active ingredients forming a mixture with the inert base medium, in particular containing the standardized extract of propolis in 0.1-20.0 parts by weight, with flavonoid content, recalculated to quercetin, not less than 1%, a standardized extract of vegetable raw material in 1,0-20.0 parts by weight, with flavonoid content, recalculated to quercetin, not less than 1% and at least one of the known dermatological antibiotics in quantity of 0.1-5.0 parts by weight, uniformly dispersed in the inert base of vehicular type in total quantity complementing to 100 parts by weight.
-------------------------------------------------- ------------------------------

PATCH FOR TRANSCUTANEOUS IMMUNIZATION

(WO2002074325) 26.09.2002 A61K 9/00 IOMAI CORPORATION
A protein- in-adhesive patch for transcutaneous immunization is described with at least four different components: (i) backing layer; (ii) pressure-sensitive adhesive layer adhering to the backing layer; (iii) at least one immunologically-active protein of an immunogenic formulation applied to the pressure-sensitive adhesive layer opposite the backing layer and/or incorporated in the pressure-sensitive adhesive layer such that the at least one protein is in contact with adhesive; and (iv) stabilizer which maintains the immunological activity of the at least one protein under ambient conditions.
-------------------------------------------------- ------------------------------

INTERFERON-BETA POLYNUCLEOTIDE THERAPY FOR AUTOIMMUNE AND INFLAMMATORY DISEASES

(WO2002072019) 19.09.2002 A61K 38/21 VICAL INCORPORATED
The present invention relates to methods of treating an autoimmune disease or an inflammatory condition, and in particular multiple sclerosis, in a mammal comprising administering a therapeutically effective amount of a non-infectious, non-integrating polynucleotide construct encoding a $g(b) interferon or an active fragment or variant thereof, wherein said construct is not associated with transfection-facilitating viral particles, liposomal formulation, or charged lipids.
---------------------------------- ----------------------------------------------

A CREAM-T0-POWDER DERMATOLOGICAL COMPOSITION

(WO2002072018) 19.09.2002 A61K 8/19 R.F. TECHNOLOGY CONSULTANTS, INC.
A cream, comprising about 5 to 60 % of a non-swelling clay, a swelling clay, a natural or synthetic gum, a surfactant, a hydrophilic and/or hydrophobic solvent, wherein, after application to a surface, dries to a uniform, visible, substantive, abrasion-resistant powder. The cream/powder composition is useful for a protective skin covering for preventing conditions such as bed sores, diaper rash, poison ivy or soothing uncomfortable feet, or as a delivery vehicle for a therapeutically - active dermatological agent, such as acne or fungal treatments, or as the delivery vehicle for treating other types of conditions, such a sore muscles, sore joints or microbial infections. Methods of making and using the cream also are included.
------------------------------------------ --------------------------------------

GENERATION OF VIABLE CELL ACTIVE BIOMATERIAL PATTERNS BY LASER TRANSFER

(WO2002070593) 12.09.2002 B01J 19/00 THE UNITED STATES OF AMERICA, AS REPRESENTED BY THE SECRETARY OF THE NAVY
A method for depositing a transfer material onto a receiving substrate (18) uses a laser energy source (12), a receiving substrate (18), and a target substrate (17). The target substrate comprises a laser-transparent support (15) and a composite material (16) in contact with the support (15). The composite material (16) comprises a mixture of transfer material, to be deposited, and a matrix material that, when exposed to laser energy, desorbs from the support (15). The laser energy source (12) is directed through the laser-transparent support (15) to strike the composite material (16) at a defined target location. The receiving substrate (18) is positioned on the composite side of the target substrate (17), in a spaced relation. The laser e...
------------------------------------------ --------------------------------------

CHIMERIC POLYPEPTIDES OF SERUM ALBUMIN AND USES RELATED THERETO

(WO2002070549) 12.09.2002 A61K 38/00 GPC BIOTECH INC.
The present invention relates to chimeric polypeptides in which a serum albumin protein has been altered to include one or more biologically active heterologous peptide sequences. The chimeric polypeptides may exhibit therapeutic activity related to the heterologous peptide sequences coupled with the improved serum half-lives derived from the serum albumin protein fragments. Heterologous peptide sequences may be chosen to promote any biological effect, including angiogenesis inhibition, antitumor activity, and induction of apoptosis. The therapeutic effect may be achieved by direct administration of the chimeric polypeptide, or by transfecting cells with a vector including a nucleic acid encoding such a chimeric polypeptide.
---------------------------------- ----------------------------------------------

ANHYDROUS ANTIPERSPIRANT AND DEODORANT COMPOSITIONS CONTAINING A SOLID, WATER-SOLUBLE, SKIN ACTIVE AGENT AND GLYCERIN

(WO2002069923) 12.09.2002 A61K 8/02 THE PROCTER &GAMBLE COMPANY
Disclosed are anhydrous antiperspirant and deodorant compositions that comprise from about 0.1% to about 30% by weight of an antiperspirant or deodorant active; from about 0.1% to about 20% by weight of a water-soluble, skin active solid (e.g., solid, water-soluble vitamins or other nutrients) other than the antiperspirant or deodorant active; from about 0.1% to about 40% by weight of a suspending agent; from about 0.1% to about 2.0% by weight of glycerin; and from about 10% to about 99% by weight of an anhydrous carrier liquid other than glycerin. The anhydrous compositions have lower visible residue on the applied areas of the skin even though they also contain relatively high residue solids in the form of water-soluble skin active solids...
-------------------------- ------------------------------------------------------

ANHYDROUS ANTIPERSPIRANT AND DEODORANT COMPOSITIONS CONTAINING A SOLID, WATER-SOLUBLE, SKIN ACTIVE AGENT

(WO2002069916) 12.09.2002 A61K 8/02 THE PROCTER &GAMBLE COMPANY
Disclosed are anhydrous antiperspirant and deodorant compositions that comprise from about 0.1 % to about 30 % by weight of an antiperspirant or deodorant active; from about 0.1 % to about 20 % by weight of a water-soluble, skin active solid (e.g., solid, water-soluble vitamins or other nutrients) other than the antiperspirant or deodorant active; from about 0.1 % to about 40 % by weight of a suspending agent; and from about 10 % to about 99 % by weight of an anhydrous carrier liquid, wherein the composition is substantially free of nonvolatile organic liquids having a C log P value greater than about 7.0. The anhydrous compositions allow the water-soluble skin active solids to release into the sweat or other moisture on the skin more rapid...
---------------------------------- ----------------------------------------------

SKIN COMPOSITION

(WO2002067886) 06.09.2002 A61K 8/97 COLGATE-PALMOLIVE COMPANY
A composition comprising a cream or lotion base said base further comprising a. An active agent or mixture thereof which brings about skin lightening, and b. An active agent or mixture thereof which prevents skin from further darkening when exposed to ultraviolet light.
------------------------------------------ --------------------------------------

ANTIPERSPIRANT OR DEODORANT COMPOSITIONS

(WO2002065997) 29.08.2002 A61K 7/32 UNILEVER PLC
Deodorant and antiperspirant compositions comprising an aluminium or aluminium-zirconium active can suffer from perceived irritancy when applied topically, which is generally manifested as an itch sensation. This irritancy can be ameliorated or overcome by incorporating within the composition a cannabanoid receptor (CBR) activating agent, and especially an amount selected in the range of from 0.25 to 10 wt. %.
-- ------------------------------------------------------------------------------

BIMODAL DRY POWDER FORMULATION FOR INHALATION

(WO2002062317) 15.08.2002 A61K 31/167 INNOVATA BIOMED LIMITED
There is described a bimodal pharmaceutical composition comprising effective amounts of a first active ingredient which substantially comprises a coarse fraction and a second active ingredient which substantially comprise a fine fraction characterised in that the coarse fraction possesses a greater mass median aerodynamic diameter (MMDA) than the fine fraction. There is also described a method of a method of delivering a therapeutically effective amount of a substantially fine active ingredient to the lung of a patient by the co-administration with a substantially coarse active ingredient.
-- ------------------------------------------------------------------------------

WATERY SOLUTION OF COPPER AND ZINC CHELATES FOR THE TREATMENT OF ANIMALS

(WO2002060433) 08.08.2002 A61K 31/315 A.K.B. BEHEERMAATSCHAPPIJ B.V.
The present invention relates to an aqueous composition with a base of copper and zinc chelate for use as an active substance for the prevention and treatment of inflammations of the skin and the hooves of animals. The present invention furthermore relates to the use of such an aqueous composition.
---------- ----------------------------------------------------------------------

VETERINARY DERMATOLOGIC COMPOSITION

(WO2002060406) 08.08.2002 A61K 8/68 COSMOFERM B.V.
This invention relates to the use of an active compound selected from the group comprising a sphingoid base, a sphingoid base derivative or a mixture of two or more these compounds for manufacturing a cosmetic composition suitable for topical application with animals having an at least partly fur covered skin for maintaining and/or repairing the keratoseborrheaic condition of the skin and/or fur.
-------------------------------------------------- ------------------------------

CHEMOKINES

(WO2002059301) 01.08.2002 A61K 38/00 K.U. LEUVEN RESEARCH AND DEVELOPMENT
The interferon (IFN)- inducible chemokines, i.e. IFN-$g(g) inducible protein-10 (IP-10), monokine induced by IFN-$g(g) (Mig) and IFN-inducible T-cell $g(a)-chemoattractant (I-TAC), share a unique CXC chemokine receptor (CXCR3). Recently, a highly specific membrane-bound protease and lymphocyte surface marker CD26/dipeptidyl peptidase IV (DPP IV) was found to be responsible for posttranslational processing of chemokines. Removal of NH¿2?-terminal dipeptides by CD26/DPP IV alters chemokine receptor binding and signaling, and hence inflammatory and anti-HIV activities. CD26/DPP IV and CXCR3 are both markers for Th1 lymphocytes and, moreover, CD26/DPP IV is present in a soluble, active form in human plasma. Here we report that I-TAC was efficie...
--------------------------------------------------------------------------------

SKIN WHITENING COMPOSITION CONTAINING ARBUTIN AND GLUCOSIDASE AS ACTIVE INGREDIENTS

(WO2002055047) 18.07.2002 A61K 8/60 COTDE, INC.
The present invention relates to skin whitening and/or depigmenting composition containing arbutin and glucosidase as active ingredients. The glucosidase is an enzyme hydrolizing arbutin into hydroquinone and glucose. In the composition of this invention, arbutin and glucosidase are separated and mixed just before applying to the skin. Then arbutin hydrlyzes into hydroquinone and glucose and the whitening effects are achieved by the hydroquinone inhibiting melanogenesis. The composition of this invention showed the superiority in safety and stability.
---------- ----------------------------------------------------------------------

PH-SENSITIVE MUCOADHESIVE FILM-FORMING GELS AND WAX-FILM COMPOSITES

(WO2002051382) 04.07.2002 A61K 9/00 UNIVERSITY OF KENTUCKY RESEARCH FOUNDATION
The present invention relates to pH-sensitive mucoadhesive film-forming gels and wax-film comosites suitable for topical and mucosal delivery of molecules of interest, namely active pharmaceuticals. The gels comprise a pharmaceutically acceptable pH- sensitive polymer that responds to a lowering of pH by precipitating into films when in contact with the skin or mucosal surface. The films also comprise an adhesive polymer that allows the film to remain in contact with the tissue for an extended period of time. The wax-film composites comprise a bi-layer film having both the said pH-sensitive mucoadhesive layer to promote strong adherence to the skin and mucosal surfaces as well as a specially bonded wax layer intended to extend the adherence ...
-------------------------------------------------- ------------------------------

COSMETIC COMPOSITIONS FOR PREVENTING SKIN IRRITATION

(WO2002051358) 04.07.2002 A61K 8/31 UNILEVER PLC
A cosmetic composition is provided that includes petroleum jelly and an anti-irritant agent which achieves at least a 10% reduction of Interleukin-1 alpha in an EpiDerm?TM¿ Skin Culture Model. The agent may be a botanical active or a decoupling polymer. Particularly preferred botanicals are echinacea, yucca, green tea and willow herb.
---------------------------------------------------------- ----------------------

METHODS FOR THE PRODUCTION OF MULTIMERIC PROTEINS, AND RELATED COMPOSITIONS

(WO2002050289) 27.06.2002 C12N 15/82 SEMBIOSYS GENETICS, INC.
Improved methods for the production of multimeric-protein- complexes, such as redox proteins and immunoglobins, in association with oil bodies are described. The redox protein is enzymatically active when prepared in association with the oil bodies. Also provided are related nucleic acids, proteins, cells, plants, and compositions.
------------------------------------------ --------------------------------------

COMPOSITIONS FOR PREVENTION AND ALLEVIATION OF SKIN WRINKLES

(WO2002049603) 27.06.2002 A61K 8/36 LG HOUSEHOLD &HEALTH CARE LTD.
The present invention discloses a topical composition for prevention and alleviation of wrinkling which comprises one or two or more selected from the group consisting of Phenytoin, Valproic acid, Cyclosporin A, Nifedipine, Diltiazem, Verapamil HC1 and Amolldipine as an active ingredient having an effect of boosting collagen synthesis.
------------------------------------------ --------------------------------------

METHOD AND COMPOSITION FOR THE TREATMENT OF DIABETIC NEUROPATHY

(WO2002049575) 27.06.2002 A61K 31/07 THE QUIGLEY CORPORATION
Compositions and a method for the treatment of diabetic neuropathy are disclosed. The compositions comprise a mixture of a compound that promotes synthesis of nerve growth factor, an aldose reductase inhibitor and an antioxidant, optionally formulated in a pharmaceutically acceptable carrier. This combination of active agents provides significant, effective relief of the symptoms of diabetic neuropathy, as well as at least partial recovery of lost neurological function in some cases. In addition, the compositions of the present invention, when used in effective amounts to treat diabetic neuropathy, do not exhibit the severe side effects of many prior art compositions proposed for treatment of this ailment. In a second aspect, a method for t...
------------------------------------------------------------------ --------------

SURFACE-ACTIVE COMPOSITIONS

(WO2002048298) 20.06.2002 C11D 3/20 CIBA SPECIALTY CHEMICALS HOLDING INC.
A surface-active composition is described which comprises (a) from 0.01 to 90 % by weight of a mixture of a microbicidal active ingredient of (a¿1?) a diphenyl ether compound and (a¿2?) a phenol derivative, (b) from 0 to 50 % by weight of one or more hydrotropic agents, (c) from 0 to 80 % by weight of one or more synthetic detergents or of a soap or of combinations of the mentioned substances and/or of a salt of a saturated and/or unsaturated C¿8?-C¿22? fatty acid, (d) from 0 to 50 % by weight of an alcohol, (e) from 0 to 50 % by weight of typical ingredients for cleaning and disinfectant compositions and optionally (f) tap water or deionised water ad 10 %. The compositions are used for the antimicrobial treatment of human skin, and hai...
------------------------------------------------------------------ --------------

ANTIBIOTIC/BENZOYL PEROXIDE DISPENSER

(WO2002047662) 20.06.2002 A61K 8/02 IMAGINITIVE RESEARCH ASSOCIATES, INC.
Two separate compositions, one containing an antibiotic and one containing benzoyl peroxide are packaged within and dispensed from a common dispenser. More particularly, a dual dispenser contains i) a first composition that is substantially anhydrous and includes a polar solvent, an antibiotic and a thickening agent selected from the group consisting of acrylic acid polymers and polyacrylamides; and ii) a second composition containing benzoyl peroxide or, alternatively, a retinoid. By packaging these two anti-acne active ingredients in this manner, long shelflife and convenient dispensing and application are provided.
-------------------------- ------------------------------------------------------

USE OF ACTIVE COMPOUNDS CAPABLE OF MODULATING THE INTRACELLULAR PATHWAY TRIGGERED BY THE DP RECEPTOR IN LANGERHANS CELLS

(WO2002045718) 13.06.2002 A61K 31/00 INSTITUT PASTEUR DE LILLE
The invention relates to the use of active compounds capable of modulating the intracellular pathway triggered by the prostaglandin D¿2? receptor (DP receptor) in Langerhans cells and/or dendritic cells and the subsequent emigration of Langerhans cells and/or dendritic cells, in the preparation of a medicine for modulating the immune cutaneous response. In particular, the invention relates to pharmaceutical compositions for topical application comprising prostaglandin D¿2? (PGD¿2?), agonists or antagonists of the DP receptor. The invention is in the area of the topical treatments of a variety of pathologies induced by or associated with an immune response.
-------------------------- ------------------------------------------------------

SKIN CREAM STIMULATING THE SURFACE BLOODSTREAM

(WO2002043691) 06.06.2002 A61K 8/41 PROVINCIA ITALIANA DELLA CONGREGAZIONE DEI FIGLI DELL'IMMACOLATA CONCEZIONE - ISTITUTO DERMOPATICO DELL'IMMACOLATA
A formulation of a skin cream based on the synergical combination of three particular active principles - escin, bufenin and rutin- whose pharmacological action stimulating the venous and arterial branchings of the peripheral bloodstream and the perivasal tissues is further increased both by the presence of antioxidants and inhibitors of histidine decarboxylase and the high concentration in soya lecithin (3%) and sebum-similar oil (2-10 %) causing the active principles to penetrate the skin where the three active principles should perfom their action. Said cream finds therapeutical application in the treatment of cellulitis and disorders connected to the inefficiency of the surface bloodstream, phlebopathy, phlebothrombosis, surface periphl...
-------------------------- ------------------------------------------------------

WATER-IN- OIL INSECT REPELLENT COMPOSITION AND METHOD OF APPLICATION TO THE SKIN

(WO2002043656) 06.06.2002 A01N 25/24 AVON PRODUCTS, INC.
The present invention is an insect repellent water-in-oil emulsion having an internal aqueous phase and an external oil phase. It also has an amount of an insect repellent active effective to repel insects when the composition is applied to the skin. The insect repellent active is substantially present in the oil phase. Also disclosed is a method of repelling insects from the skin by applying to the skin the above composition.
-- ------------------------------------------------------------------------------

EXTENDED DURATION INSECT REPELLENT COMPOSITION AND METHOD OF APPLICATION TO THE SKIN

(WO2002043491) 06.06.2002 A01N 25/24 AVON PRODUCTS, INC.
Disclosed is an insect repellent composition. The composition has an amount of an insect repellent active effective to repel insects when the composition is applied to the skin, and an amount of a urethane polymer sufficient to form a film on the surface of the skin. The composition also has a cosmetically-acceptable vehicle. Also disclosed is a method of repelling insects from the skin by applying the composition to the skin.
-------------------------------------------------- ------------------------------

AEROSOL INSECT REPELLENT COMPOSITION HAVING LOW VOC CONTENT AND METHOD OF APPLYING SAME TO THE SKIN

(WO2002043483) 06.06.2002 A01N 25/06 AVON PRODUCTS, INC.
Disclosed is an aerosol insect repellent composition. The composition has (a) an amount of an insect repellent effective to repel insects when applied to the skin and (b) a cosmetically- acceptable vehicle in which to disperse and deliver the insect repellent active. The vehicle has (i) a VOC component capable of volatilizing upon exposure to a reduction in pressure for delivering the composition in an aerosol form, and (ii) a non-VOC component. The aerosol composition has a VOC content of not greater than about 55 wt. % based upon the weight of the aerosol composition. Further disclosed is a method of repelling insects from skin wherein the aerosol composition is applied to or sprayed on the skin.
------------------------------------------ --------------------------------------

ACTIVE MANAGEMENT AND STEERING OF STRUCTURAL VIBRATION ENERGY

(WO2002042854) 30.05.2002 F16F 15/00 QUALITY RESEARCH, DEVELOPMENT &CONSULTING, INC.
Vibration suppression, isolation, and control in machines, devices, and structures is provided using active vibration control by confinement (AVCC). Vibrational energy is confined to sepecified regions to reduce or amplify the energy. An active vibration energa management system is used to manage vibration in a member (100). Sensors (102) are coupled to the member (100) to obtain a member response to vibrations. These sensors can be non-contacting or embedded with the member. A signal processor (110) is coupled to the sensors to extract member displacements, temporal derivatives of the displacement and spatial derivatives of displacement. Actuators (104) are coupled to the member to apply feedback forces in response to the signal processor ...
-------------------------------------------------- ------------------------------

HOUTTUYNINUM COMPOSITIONS AND METHODS FOR INHIBITING THE ACTIVITY OF ERBB-2 BASED THEREON

(WO2002041828) 30.05.2002 A61K 31/10 YANG, Dajun
The present invention relates to methods and compositions for inhibiting the activity of erbB-2. The described methods and compositions are particularly useful for inhibiting cellular proliferative disorders, such as cancer, characterized by over-activity and/or inappropriate activity of erbB-2. More particularly, method for the treatment of a cellular proliferative disorder characterized by over-activity or inappropriate activity of erbB-2 is provided including the step of administering to a patient in need of such treatment a therapeutically effective amount of soluble extract of houttuynum, or a compound selected from the group consisting of houttuyninum, Houttuymia cordata, neo-houttuyninum (decanoyl acetaldehyde), analogs thereof, phar...
---------- ----------------------------------------------------------------------

COMBINATION OF CATECHIN AND QUERCETIN FOR PHARMACEUTICAL OR DIETARY USE

(WO2002034262) 02.05.2002 A23L 1/30 GIULIANI S.P.A.
The invention relates to a composition for pharmaceutical or dietary use that possesses antioxidant activity and characterized in that it contains as active principle a combination of catechin quercetin, which exert a synergistic action when combined in mutual molar ratios selected within a critical range, from 6:1 to 3:1 mol of catechin:quercetin.
--------------------------------------------------------------------------------

MULTI-COMPONENT ANTIOXIDANT COMPOUNDS, PHARMACEUTICAL COMPOSITIONS CONTAINING SAME AND THEIR USE FOR REDUCING OR PREVENTING OXIDATIVE STRESS

(WO2002034202) 02.05.2002 A61K 38/00 YISSUM RESEARCH DEVELOPMENT COMPANY OF THE HEBREW UNIVERSITY OF JERUSALEM
An antioxidant compound is disclosed. The compound is characterized by (a) a peptide including at least three amino acid residues of which at least two are cysteine residues, each having a readily oxidizable sulfhydryl group for effecting antioxidation; and at least two peptide bonds, each being cleavable by at least one intracellular peptidase; and (b) a first hydrophobic or non-charged moiety being attached to an amino terminal of the peptide via a first bond and a second hydrophobic or non-charged moiety being attached to a carboxy terminal of the peptide via a second bond, the first hydrophobic or non-charged moiety and the second hydrophobic or non-charged moiety are selected so as to provide the antioxidant compound with membrane misc...
--------------------------------------------------------------------------------

MICROSTRUCTURES FOR DELIVERING A COMPOSITION CUTANEOUSLY TO SKIN

(WO2002032480) 25.04.2002 A61B 17/00 THE PROCTER &GAMBLE COMPANY
An improved method and apparatus is provided as a system to deliver a composition, preferably a medical or pharmaceutical composition or active, through the stratum corneum of skin, without introducing bleeding or damage to tissue, and absent pain or other trauma. The dimensions and shapes of the microelements are controlled so as to control the penetration depth into the skin. The microelements can be 'hollow' such that passageways are created therethrough to allow the composition to flow from a chamber, through the microelements, and into the skin. Alternatively, the microelements can be 'solid,' and the composition is applied directly to the skin just before or just after the microelements are applied to the skin surface to create the op...
---------------------------------------------------------- ----------------------

SUSTAINED RELEASE DELIVERY SYSTEM AND USES THEREOF

(WO2002032395) 25.04.2002 A61K 9/107 ADVANCED DELIVERY SYSTEMS APS
The invention relates to a sustained release delivery system for the delivery of an active agent to a warm-blooded animal and to uses thereof. The delivery system comprises an aqueous bicellar matrix that is liquid at temperatures below ambient temperature and forms a biodegradable gel at body temperature of said animal and an active agent, and optionally further comprises pharmaceutically acceptable additive, carrier and/or diluent. The aqueous bicellar matrix is preferably a mixture of a lipid, preferably phospholipid, and a detergent in water.
-- ------------------------------------------------------------------------------

PACKAGED SCALP COSMETIC COMPOSITIONS

(WO2002032381) 25.04.2002 A61K 8/02 THE PROCTER &GAMBLE COMPANY
Disclosed are packaged leave-on cosmetic compositions for direct application to the scalp, comprising 1) a leave-on scalp cosmetic composition that is substantially free of cleansing surfactants and contains by weight of the leave-on scalp cosmetic composition i) from about 40% to about 99% by weight of a volatile liquid having a vapor pressure greater than 23.7mmHg as measured at 25°C , ii) from about 0.005% to about 20% by weight of a skin active agent, and iii) from about 0.1% to about 20% by weight of a moisturizing material, preferably a liquid humectant, and 2) a package within which the scalp cosmetic composition is contained, wherein the package has a plurality of openings through which the leave-on scalp cosmetic composition is ap...
-- ------------------------------------------------------------------------------

SCALP COSMETIC AND DERMATOLOGICAL COMPOSITIONS

(WO2002030367) 18.04.2002 A61K 7/06 THE PROCTER &GAMBLE COMPANY
Disclosed are topical leave-on cosmetic compositions, including packaged leave-on compositions, for direct application to the scalp, comprising a) from about 40 % to about 99 % by weight of a volatile liquid, b) from about 0.005 % to about 20 % by weight of a skin active agent, and c) from about 0.1 % to about 20 % by weight of a moisturizing material, preferably a liquid humectant. The composition is a leave-on formulation that is substantially free of cleansing surfactants and is applied directly to the scalp. Also disclosed are methods of treating the scalp by directly applying the topical composition to the scalp. It has been found that the compositions and methods of the present invention can provide improved scalp moisturization and i...
-- ------------------------------------------------------------------------------

COMPOSITIONS FOR CLEANSING SKIN AND TREATING ACNE

(WO2002028361) 11.04.2002 A61K 8/34 JOHNSON &JOHNSON CONSUMER COMPANIES, INC.
A skin cleansing composition comprising: from about 0.1 to about 5 percent by weight of at least one anti-acne active ingredient; from about 1 to about 25 percent by weight of at least one alcohol; from about 0.1 to about 15 percent by weight of at least one solubilizer; and water is disclosed. The composition is stable and dries quickly, but does not make the skin feel dry after use.
-------------------------- ------------------------------------------------------

COMPOSITIONS AND METHODS FOR DELAYING, PREVENTING, REJUVENATING OR REVERSING SENESCENCE IN CELLS

(WO2002026940) 04.04.2002 A61K 8/49 THE BETA PEPTIDE FOUNDATION PTY LTD
A method of altering the senescence of cells comprising applying to said cells an effective amount of a composition wherein said composition includes N- acetyl-carnosine as an active ingredient.
---------------------------------- ----------------------------------------------

COSMETIC FORMULATION

(WO2002026207) 04.04.2002 A61K 8/34 PROVINCIA ITALIANA DELLA CONGREGAZIONE DEI FIGLI DELL'IMMACOLATA CONCEZIONE - ISTITUTO DERMOPATICO DELL'IMMACOLATA
A cosmetic formulation, including active principles of strictly natural origin to protect skin against exogenous or endogenous harmful agents as well as to balance again the dermal homeostasis lipids altered by dermatosis and ageing, is characterized by a lipid composition which is close to the human sebum, has a pool of antioxidants similar to those present in sebum and skin, and has anti-inflammatory and anti-free-radical molecules capable of preventing histidine from being decarboxylated and then histamine to be formed.
--------------------------------------------------------------------------------

COSMETIC COMPOSITIONS

(WO2002022102) 21.03.2002 A61K 8/34 THE PROCTER &GAMBLE COMPANY
According to the present invention there is provided a cosmetic composition suitable for topical application to the skin or hair comprising: (a) from about 0.0001 % to about 10 %, by weight, of biologically active enzyme; (b) from about 0.1 % to about 20 %, by weight, of polyhydric alcohol; and (c) from about 0.1 % to about 20 %, by weight, of skin care active selected from a vitamin B3 component, panthenol, vitamin E, vitamin E acetate, retinol, retinyl propionate, retinyl palmitate, retinoic acid, vitamin C, theobromine, $g(a)-hydroxyacid, farnesol, phytantriol, salicylic acid, and mixtures thereof. The compositions of the invention display high moisturisation efficacy without the associated high levels of tack, as well as good rheologica...
-- ------------------------------------------------------------------------------

COSMETIC METHOD

(WO2002022100) 21.03.2002 A61K 8/34 THE PROCTER &GAMBLE COMPANY
According to the present invention there is provided a cosmetic method for providing improved skin hydration wherein the method comprises topically applying to the skin a protease enzyme, and simultaneously or sequentially, topically applying to the skin a skin care active selected from a vitamin B¿3? component, vitamin E acetate, panthenol and mixtures thereof. There is also provided a cosmetic method for providing improved skin hydration wherein the method comprises topically applying to the skin a skin care active selected from a vitamin B¿3? component, vitamin E acetate, panthenol and mixtures thereof, and simultaneously or sequentially, topically applying to the skin a protease enzyme. Furthermore there is provided a cosmetic method ...
-------------------------- ------------------------------------------------------

COSMETIC METHOD FOR TREATMENT OF SKIN AND/OR HAIR

(WO2002022099) 21.03.2002 A61K 8/66 THE PROCTER &GAMBLE COMPANY
There is provided for a cosmetic method for treating the skin and/or hair wherein the method comprise a treatment comprising one or more cycles wherein a single cycle comprises: (a) administering, as phase one, for a period of 1 to 365 days, one or more unit doses a primary topical cosmetic composition comprising a biologically active enzyme, said enzyme being stably formulated; followed by (b) administering, as phase 2, for a period of 1 to 365 days, one or more unit doses of a placebo topical cosmetic composition. This cosmetic treatment method is useful for enabling the manufacturer to control the level of consumer exposure to a biologically active compound and also for cosmetically treating the skin or hair to provide softness and smoot...
-- ------------------------------------------------------------------------------

COMBINATION COMPRISING AN AT1-RECEPTOR ANTAGONIST AND AN INSULIN SECRETION ENHANCER OR AN INSULIN SENSITISER

(WO2002015933) 28.02.2002 A61K 31/41 NOVARTIS AG
The present invention relates to a combination, especially a pharmaceutical composition, comprising as active ingredients (i) an AT¿1?-receptor antagonist or a pharmaceutically acceptable salt thereof; (ii) (a) an insulin secretion enhancer or a pharmaceutically acceptable salt thereof or (b) an insulin sensitizer or a pharmaceutically acceptable salt thereof; and, in case of a pharmaceutical composition, a pharmaceutically acceptable carrier.
-------------------------- ------------------------------------------------------

COMBINATION COMPRISING AN INSULIN SECRETION ENHANCER AND AN ACTIVE INGREDIENT SELECTED FROM HMG-CO-A REDUCTASE INHIBITORS AND ACE INHIBITORS

(WO2002015892) 28.02.2002 A61K 45/06 NOVARTIS AG
The present invention relates to a combination, especially a pharmaceutical composition, comprising (a) an insulin secretion enhancer or a pharmaceutically acceptable salt thereof and (b) at least one of the active ingredients selected from the group consisting of (i) HMG-Co-A reductase inhibitors or a pharmaceutically acceptable salt thereof; and (ii) ACE inhibitors or a pharmaceutically acceptable salt thereof; and, in case of a pharmaceutical composition, a pharmaceutically acceptable carrier.
-------------------------- ------------------------------------------------------

USE OF COLOSTRININ, CONSTITUENT PEPTIDES THEREOF, AND ANALOGS THEREOF AS OXIDATIVE STRESS REGULATORS

(WO2002013850) 21.02.2002 A61K 8/64 THE UNIVERSITY OF TEXAS SYSTEM
The present invention provides methods that utilize compositions containing colostrinin, an constituent peptide thereof, an active analog thereof, and combinations thereof, as an oxidative stress regulator.
------------------ --------------------------------------------------------------

SEAL-OIL-BASED PHARMACEUTICAL, COSMETIC, DERMO-COSMETIC, HYGIENE, ALIMENTARY AND PARA-ALIMENTARY (FOOD-SUPPLEMENTS) PRODUCTS; THEIR METHODS OF PREPARATION; THEIR USES AS PREVENTIVE AND/OR AS THERAPEUTIC AGENTS

(WO2002013838) 21.02.2002 A23L 1/30 FUNDAÇAO ESSPRIT-ICARUS (FUNDAÇAO EUROPEIA DE INVESTIGAÇAO MEDICA), NGO; IPSS.
This invention concerns Pharmaceutical, Cosmetic Dermo-Cosmetic, Hygiene, Alimentary and Para-Alimentary (Food Supplements) Compositions (or Products or Compounds), characteristically containing Seal-Oil, its Components or Derivatives, associated with Active Ingredients (synergyzing them or compensating clinical or sub-clinical deficiencies) which said Compositions (Products or Compounds) deliver to the human organism; It also concerns the process(es) of preparation of said Compositions (Products or Compounds), which normally consist in mixing the necessary ingredients, eventually under heating and/or cooling, extraction of water, etc. An example of these processes is the following composition, involving : (a) Seal-Oil - with or without fis...
---------- ----------------------------------------------------------------------

METHODS FOR TREATING INFLAMMATORY DISEASES

(WO2002013812) 21.02.2002 A61K 31/19 PERSHADSINGH, Harrihar, A.
The present invention describes methods for the use of PPAR ligands in the treatment inflammatory endocrine, dermatological, cardiovascular immunological, neurological, ophthalmic, neoplastic, pulmonary diseases, and age-related dysregulations. In addition, methods are provided for treating said conditions and diseases comprising the step of administering to a human or an animal in need thereof a therapeutic amount of pharmacological compositions comprising a pharmaceutically acceptable carrier, and a PPAR$g(g) agonist which cross-activates PPAR$g(a) or PPAR$g(d) or both, or a PPAR$g(g) partial agonist, or a PPAR$g(g)/RXR agonist, effective to reverse, slow, stop, or prevent the pathological inflammatory or degenerative process.
-- ------------------------------------------------------------------------------

METHOD OF PROVIDING IMPROVED DEODORANT APPLICATION TO THE UNDERARM

(WO2002013776) 21.02.2002 A61K 8/34 THE PROCTER &GAMBLE COMPANY
Disclosed is a method of treating or preventing underarm malodor by topical application of an aqueous gel deodorant composition comprising: (a) from about 0.01 % to about 60 %, by weight of a deodorant active; (b) from about 0.01 % to about 15 %, by weight of a soap gelling agent comprising salts of C¿12?-C¿40? fatty acids; (c) from about 0.01 % to about 10 % by weight of a fragrance; (d) from about 0.2 % to about 1 % by weight of a skin sensate solubilized in a solvent system wherein the solvent system comprises: (i) from about 1 % to about 90 % by weight of the composition of a non- aqueous liquid carrier; (ii) from about 1 % to about 90 %, by weight of the composition is water; said solvent system having a solubility parameter of from a...
------------------------------------------------------------------ --------------

METHODS OF PREVENTING OR TREATING DISEASES AND CONDITIONS USING COMPLEX CARBOHYDRATES

(WO2002009728) 07.02.2002 A61K 31/726 DERMAL RESEARCH LABORATORIES, INC.
The invention relates to a method of preventing and treating diseases and conditions associated with allergies, autoimmunity, the adhesion cascade, the metastatic cascade or the coronary cascade comprising administering (i) at least one complex carbohydrate as the sole active ingredient, or (ii) at least one pharmaceutical composition which comprises as an active ingredient a pharmacologically effective amount of at least one low purity or cosmetic grade complex carbohydrate selected from the group consisting of oligosaccharides, sialylated oligosaccharides, polysaccharides and glycosaminoglycans, and an effective amount of at least one transdermal or transmucosal carrier in an amount effective to deliver the complex carbohydrate into the b...
---------------------------------------------------------- ----------------------

METHODS AND PHARMACEUTICAL COMPOSITIONS FOR HEALING WOUNDS

(WO2002009639) 07.02.2002 A61K 35/12 BAR ILAN UNIVERSITY
A pharmaceutical composition and method for inducing or accelerating a healing process of a skin wound are described. The pharmaceutical composition contains, as an active ingredient, a therapeutically effective amount of an agent for either enhancing PKC production and/or enhancing PKC activation; and a pharmaceutically acceptable carrier. The method is effected by administering the composition to a wound.
------------------------------------------------------------------ --------------

TREATMENT FOR EPITHELIAL DISEASES

(WO2002007630) 31.01.2002 A61B 17/22 CERAMOPTEC INDUSTRIES, INC.
An apparatus and method for treating epithelial hyperproliferative diseases by application of an active composition over the diseased irregular tissue which is in the form of a viscous gel to carry the photosensitizer. The gel's viscosity allows it to adhere to the tissue for a sufficient time to transfer the photosensitizer or for a mechanical device such an expanding balloon to press the gel into the tissue. The photosensitizer within the gel is activated by the corresponding wavelenght of radiation. An extended multi-ballon system limits the area of treatment and localizes the spread of the gel. The apparatus, designed to be used with an endoscope, contains a catheter with at least two balloons, one to block drainage of the gel and one t...
-------------------------------------------------- ------------------------------

SYSTEM AND METHOD FOR OPTIMIZING TISSUE BARRIER TRANSFER OF COMPOUNDS

(WO2002006518) 24.01.2002 C12M 3/06 TRANSFORM PHARMACEUTICALS, INC.
The present invention relates to high-throughput systems (100) and methods to prepare a large number of component combinations, at varying concentrations and identities, at the same time, and high -throughput methods to test tissue barrier (120) transfer, such as transdermal transfer, of components in each combination. The methods of the present invention allow determination of the effects of inactive components, such as solvents, excipients, enhancers, adhesives and additives, on tissue barrier (120) transfer of active components, such as pharmaceuticals. The invention thus encompasses the high-throughput testing of pharmaceutical compositions or formulations in order to determine the overall optimal composition or formulation for improved ...
-- ------------------------------------------------------------------------------

METHOD OF INDUCING SOLIDIFICATION USING ULTRASOUND AND COSMETIC STICK PREPARED THEREBY

(WO2002005973) 24.01.2002 A23D 7/00 UNILEVER PLC
A method of inducing solidification in a fluid composition comprising a cosmetic active, a crystalline organic structurant and a carrier, comprising exposing the fluid composition to ultrasound or converting the composition to a soft solid. A cosmetic stick in the form of a soft solid or firm stick comprising a cosmetic active, a crystalline organic structurant and a carrier in which the organic structurant is present in domains that are deficient in the cosmetic active, such as in particular an antiperspirant or deodorant active.
---------------------------------- ----------------------------------------------

PHARMACEUTICAL COMBINATIONS FOR TREATMENT AND PREVENTION OF DIABETES MELLITUS

(WO2002005795) 24.01.2002 A61K 33/00 KÉRI PHARMA KFT.
Pharmaceutical combinations for treatment and/or prevention of all sorts, periods and complications of diabetes mellitus in mammals, thus including the pre-diabetic diseases and their complications, optionally including furthermore ischaemic heart disease comprising an effective dose of at least one enzymatic nitric oxide (NO) donor active ingredient and optionally comprising an effective dose of at least one antidiabetic active ingredient, and further optionally comprising usual pharmaceutically acceptable carriers and/or other auxiliaries. The combination may consist of more than one pharmaceutical compositions. The effective doses related to the new insulin-sensitizing effect are considerably lower than the usual doses related to the kno...
---------- ----------------------------------------------------------------------

USE OF MATRIX METALLOPROTEASE INHIBITORS FOR THE TREATMENT OF CANCER

(WO2002005792) 24.01.2002 A61K 31/00 SIMON, Christian
The invention relates to the use of an active agent, particularly an inhibitor, in treating cancer by influencing, preferably inhibiting the expression of matrix-metalloproteases. The targets for this active agent can especially related to downstream regulators of the matrix- metalloprotease 9 (MMP-9) signal transduction pathway. According to the invention, especially inhibitors of p38beta and p38gamma as also of mitogen-activated kinase kinase 6 (MKK6) and mitogen-activated kinase kinase 3 (MKK3) can be applied.
--------------------------------------------------------------------------------

SKIN CARE COMPOSITIONS CONTAINING SILICONE ELASTOMERS

(WO2002003952) 17.01.2002 A61K 8/06 THE PROCTER &GAMBLE COMPANY
The present invention relates to a topical skin care composition having improved aesthetics containing a skin care active wherein the skin care active is soluble in a tacky solvent and wherein the dermatologically acceptable delivery system contains a tacky solvent in combination with a silicone elastomer and a carrier for the elastomer. The present invention also relates to methods of using such compositions to regulate the condition of mammalian skin while retaining good aesthetics.
---------- ----------------------------------------------------------------------

ANTIPERSPIRANT COMPOSITIONS

(WO2002003939) 17.01.2002 A61K 8/63 UNILEVER PLC
A firm solid antiperspirant composition having a continuous phase comprising water- immiscible liquid containing i) one or more gelating structurant materials which form a network of fibres within the liquid, and ii) a polymeric thickener which has an organic polymer backbone containing at least five monomer repeat units, which polymer has the ability to increase the viscosity of the water-immiscible liquid in the absence of the gelating structurant materials; and iii) an antiperspirant active dispersed in the continuous phase, said composition being free from or containing less than 3 % by weight of a fatty alcohol that is solid at 20 °C.
--------------------------------------------------------------------------------

METHODS OF ENHANCING DELIVERY OF OIL-SOLUBLE SKIN CARE ACTIVES

(WO2002003930) 17.01.2002 A61K 8/06 THE PROCTER &GAMBLE COMPANY
Water-in-silicone emulsion compositions containing a silicone oil, a silicone elastomer, and an oil-soluble skin care active such as terpene alcohols, phytosterol, anti-acne actives, beta- hydroxy acids, vitamin B¿3? compounds, retinoids, anti-oxidants/radical scavengers, chelators, flavonoids, anti-inflammatory agents, anti-cellulite, topical anesthetics, and mixtures thereof. Methods of enhancing the delivery of oil-soluble skin care actives using silicone elastomers.
-------------------------- ------------------------------------------------------

SUNSCREEN COMPOSITION WITH ENHANCED SPF AND WATER RESISTANT PROPERTIES

(WO2002003929) 17.01.2002 A61K 8/35 COLLABORATIVE TECHNOLOGIES, INC.
The present invention relates to a sunscreen formulation which exhibits superior ultraviolet protection and water resistance than prior art sunscreen compositions. The sunscreen formulation comprises (a) a dispersion comprising a sunscreen active agent and (b) a base composition comprising a rheological modifying agent and water. The sunscreen formulation is bustantially free of surfactants. According to a preferred embodiment, the sunscreen active agent is ethylhexylmethoxycinnamate, butylmethoxydibenzoylmethane, or a combination thereof. The sunscreen formulation preferably comprises a phosphorylated starch derivative as a rheological modifying agent. Another embodiment of the present invention is a method of protecting skin or hair from ...
---------------------------------------------------------- ----------------------

COMPOSITIONS FOR TREATING BACTERIAL INFECTIONS CONTAINING OXAZOLIDINONE COMPOUND, SULBACTAM AND AN AMPICILLIN

(WO2002002095) 10.01.2002 A61K 31/43 PHARMACIA &UPJOHN COMPANY
A composition having antibacterial activity is disclosed. More particularly, a mixture of an oxazolidinone compound, sulbactam, and ampicillin active agents, demonstrating activity against resistant strains of bacteria is disclosed. Methods for using an oxazolidinone compound, sulbactam, and ampicillin to treat a bacterial infection are also described.
---------------------------------------------------------- ----------------------

MATRIX PROTEIN COMPOSITIONS FOR INHIBITION OF EPITHELIAL CELL GROWTH

(WO2001097835) 27.12.2001 A61K 35/32 BIORA BIOEX AB
The present invention relates to the use of an active enamel substance for the preparation of a pharmaceutical composition for application on a medical implant or device and/or on tissue in contact with said implant or device so as to inhibit attachement, proliferation and/or growth of epithelial cells thereon, or to inhibit epithelial downgrowth along the surface of said implant or device. The preparation is utilised to bio-engineer surfaces of medical implants and devices which are in contact with epithelial tissue in such a way that growth of epithelial cells on or along the surfaces of such implants or devices is substantially inhibited. Accordingly, the present invention relates to a method of inhibiting attachment, proliferation and/o...
-------------------------------------------------- ------------------------------

VIP-RELATED PEPTIDES FOR THE TREATMENT OF SKIN DISORDERS

(WO2001093889) 13.12.2001 A61K 38/22 YEDA RESEARCH AND DEVELOPMENT CO. LTD.
The present invention relates to pharmaceutical compositions for the treatment of skin disorders comprising as active ingredient VIP-related peptides. It has been shown by the present invention that the compositions disclosed and claimed induce cell apoptosis and therefore may be used particularly for the treatment of skin disorders associated with hyperproliferation of skin cells. The present invention also provides a method for the treatment of hyperproliferative skin disorders and/or for inducing cell apoptosis, the method involving administration to the skin area to be treated a therapeutically effective amount of the VIP-related peptide.
------------------------------------------ --------------------------------------

INHALATION THERAPY DECONGESTANT WITH FORAMINOUS CARRIER

(WO2001089475) 29.11.2001 A61K 9/00 LEC TEC CORPORATION
A vaporizable decongestant is supported and stabilized on a flexible foraminous carrier composed typically of open-cell plastic foam, cloth or other fibrous material such as nonwoven fabric. The term 'foraminous' herein is intended to refer to a substance or medium containing minute openings or perforated by many minute apertures. The decongestant is placed on the surfaces within the interstices and minute apertures or on fibers from which the foraminous carrier is formed. Vaporization of the inhalable decongestant is facilitated by providing the potential for greatly increasing its exposed surface area. Distributing the decongestant composition over the large, expanded surface within the foraminous carrier is beneficial in enhancing both t...
---------- ----------------------------------------------------------------------

PROTEIN MATRIX MATERIALS, DEVICES AND METHODS OF MAKING AND USING THEREOF

(WO2001087267) 22.11.2001 A61K 9/70 GEL-DEL TECHNOLOGIES, INC.
The present invention relates to protein matrix materials and devices and the methods of making and using protein matrix materials and devices. More specifically the present invention relates to protein matrix materials and devices that may be utilized for various medical applications including, but not limited to, drug delivery devices for the controlled release of pharmacologically active agents, encapsulated or coated stent devices, vessels, tubular grafts, vascular grafts, wound healing devices including protein matrix suture material and meshes, skin/bone/tissue grafts, biocompatible electricity conducting matrices, clear protein matrices, protein matrix adhesion prevention barriers, cell scaffolding and other biocompatible protein mat...
------------------------------------------ --------------------------------------

EXTERNAL APPLICATION FOR ENHANCING THE SKIN PERMEABILITY OF THE ACTIVE COMPONENTS THEREIN

(WO2001087255) 22.11.2001 A61K 8/49 PACIFIC CORPORATION
The present invention relates to a composition for external application enhancing the skin absorption of the active components infused in the composition, more specifically relates to an external application having enhanced skin permeability of the active components by using protease stabilized by $g(b)-1,3-glucan branched with $g(b)-1,6-linkage as an agent for enhancing the skin permeability to weaken the wall properties of the corneous layer.
------------------------------------------------------------------ --------------

SUSTAINED RELEASE COMPOSITION COMPRISING AN ACTIVE AGENT IN A PLASTIC CARRIER AND SHAPED ARTICLES MADE THEREFROM

(WO2001087065) 22.11.2001 A01K 13/00 RÓZSA, László
The invention relates to a sustained release composition containing an active agent in a plastic carrier, which comprises: (a) 1 - 30 % by weight of an insecticide, 0.1 - 20 % by weight of an insect repellent agent, and/or 0.1 - 20 % by weight of an agent for animal care, with the proviso that the total amount of component (a) does not exceed 30 % by weight; (b) 50 - 95 % by weight of a thermoplastic polymer, and (c) 1 - 22 % by weight of a liquid which is incompatible with component (b), components (a), (b) and (c) being selected so that the solubility of component (a) in component (c) is at least 10 times higher than the solubility of component (b) in component (c), component (a) is practically insoluble in component (b), and components (...
---------- ----------------------------------------------------------------------

SKIN CARE COMPOSITION

(WO2001085129) 15.11.2001 A61K 8/365 JOHNSON &JOHNSON CONSUMER COMPANIES, INC.
There are provided compositions which include a retinoid and preferably retinol; a dermatologically active acid; and a volatile base, such as ammonium hydroxide. Another embodiment of the invention includes compositions comprising a retinoid and preferably retinol; a dermatologically active acid; a volatile base; and a second neutralizing agent. There are also provided compositions which include a retinoid, a neutralized ammonium salt of a dermatologically active acid, and optionally a neutralized salt, other than ammonium salt, of an acid. Further provided are methods for reducing fine lines, wrinkles, skin roughness, and pore size and for increasing the clarity of a skin surface, cellular turnover, skin radiance, skin smoothness, skin per...
-- ------------------------------------------------------------------------------

SKIN PROTECTANT SPRAY COMPOSITIONS

(WO2001085128) 15.11.2001 A61K 8/04 PFIZER PRODUCTS INC.
A liquid, water-repellent, substantially anhydrous, spray-pumpable skin protectant composition is disclosed. The composition is designed for spraying directly onto skin, has suitable adherence to the skin, and resists running. The composition contains one or more actives, one or more rheology modifiers, and a carrier. The rheological modifiers can be waxes and/or associative thickeners such as some forms of silica. The carrier can be mineral oil or a mineral oil replacement (e.g., isohexadecane, cyclomethicone). Film-forming components also help the composition resist running. One indication for which the composition may be formulated is diaper rash. The active ingredient for diaper rash may be dimethicone and preferably also zinc oxide.
-------------------------- ------------------------------------------------------

COSMETIC COMPOSITIONS

(WO2001085119) 15.11.2001 A61K 8/37 UNILEVER PLC
The sensory attributes and/or visibility of deposits of wax-structured antiperspirant or deodorant sticks in the form of emulsions can vary significantly depending on the formulation employed. A particularly beneficial balance of attributes is obtained in emulsion sticks by employing a composition comprising a continuous phase which comprises from 10 to 35 % volatile silicone oil, and from 5 to 15 % non-volatile hydrophobic oil, from 40 to 75 % of ta disperse aqueous phase which contains from 1 to 35 % of an antiperspirant or deodorant active, from 7 to 25 % of a wax structurant, from 0.1 to 10 % of an emulsifier, and preferably contains up to 5 % insoluble particulate materials, %s being by weight based on the composition.
--------------------------------------------------------------------------------

DETERGENT BAR COMPOSITION WITH BENEFIT AGENTS

(WO2001082884) 08.11.2001 A61K 8/02 UNILEVER PLC
A detergent bar comprising 15-85% detergent active and 0.1-20 % of a skin lightening agent. Preferably, the skin lightening agent is incorporated into the detergent bar at a temperature of 20-60°C. The invention also provides a cosmetic method of lightening the skin comprising washing with a detergent bar according to the invention.
---------------------------------- ----------------------------------------------

COMPOSITION EXHIBITING ENHANCED FORMULATION STABILITY AND DELIVERY OF TROPICAL ACTIVE INGREDIENTS

(WO2001080823) 01.11.2001 A61K 8/11 SOL-GEL TECHNOLOGIES LTD.
A therapeutic or cosmetic composition for topical application, capable of stabilizing an active ingredient and delivering said ingredient, comprising a plurality of microcapsules having a core-shell structure. The microcapsules have a diameter of approximately 0.1 to 100 microns. The core of each microcapsule includes at least one active ingredient, and is encapsulated within a microcapsular shell, The shell is comprised of at least one inorganic polymer obtained by a sol-gel process, and the shell protects the active ingredient before topical application and releases the ingredient after topical application. This composition is useful to encapsulate active ingredients that are unstable in formulation, or are irritating to the skin. The pre...
------------------------------------------------------------------ --------------

ROLES OF JAK/STAT FAMILY MEMBERS IN TOLERANCE INDUCTION

(WO2001079555) 25.10.2001 A61K 39/395 MILLENNIUM PHARMACEUTICALS, INC.
The present invention relates to methods and compositions for reducing immune rejection, for example, transplant- or autoimmune disorder-related immune rejection. The present invention also relates to methods and compositions for monitoring transplant acceptance and for monitoring an autoimmune disorder in a subject mammal. The present invention still further relates to methods for identifying compounds that can reduce immune rejection. The present invention is based, in part, on the discovery, demonstrated herein, that immune rejection can be monitored by determining the amount of particular members of the Jak/Stat signal transduction pathway present within an affected tissue (that is, a transplant cell, tissue, organ, or organ system, or ...
---------------------------------- ----------------------------------------------

TUBERCULOSIS ANTIGENS AND METHODS OF USE THEREOF

(WO2001079274) 25.10.2001 A61K 38/00 STATENS SERUM INSTITUT
The present invention is based on the identification and characterization of a number of novel M. tuberculosis derived proteins and protein fragments. The invention is directed to the polypeptides and immunologically active fragments thereof, the genes encoding them, immunological compositions such as vaccines and skin test reagents containing the polypeptides.
---------- ----------------------------------------------------------------------

MEMBRANE DELIVERY SYSTEM

(WO2001078692) 25.10.2001 A61K 8/02 COLOR ACCESS, INC.
The present invention relates to a delivery system for topical application to the skin comprising a freeze-dried, partially cross-linked polymeric gel membrane which can be reversibly returned to a dissolvable gel form upon the application of a wetting agent. The membrane can be used to deliver biologically active agents to the skin.
-------------------------------------------------- ------------------------------

CHITOSAN FORMULATION WITH AZELAIC ACID AND OTHER ACTIVES FOR THE TREATMENT OF ACNE

(WO2001074165) 11.10.2001 A61K 31/194 COGNIS CORPORATION
A composition for treating acneiform eruption containing: (a) a chitosan having a molecular weight ranging from about 500,000 to about 5,000,000 g/mole and a degree of deacylation greater than 80 %; (b) an acid-form active ingredient for treating acne; and (c) water.
-- ------------------------------------------------------------------------------

PEPTIDES BINDING TO NON-ACETYLATED H3 AND H4 HISTONES FOR CANCER THERAPY

(WO2001072784) 04.10.2001 A61K 38/00 FILGEN BIOSCIENCES, INC.
The present invention describes a composition of matter comprising a conserved structural motif that allows the targeting and binding of a chromatin binding protein to non-acetylated histone H3 and H4 and prevents their acetylation. This invention is responsible for the anti-carcinogenic property of a chromatin binding peptide isolated from soybean seed. This structural motif is found in a highly conserved manner in other chromatin-binding proteins from different species. Modifications to this structural motif such as fusions to other proteins with functional motifs and amino acid substitutions have potential therapeutic applications and can be developed as an in vivo gene silencing technology for biological and medical research. In particu...
-------------------------- ------------------------------------------------------

COSMETIC AND DERMATOLOGICAL COMPOSITION FOR PSORIATIC SKIN, SCALP TREATMENT AND CARE

(WO2001066079) 13.09.2001 A61K 8/42 BODNÁR, Tibor
The invention relates to cosmetic and dermatological composition for psoriatic skin, scalp treatment and care which contains from about 0.1 to about 10 % by weight, preferably from about 0.1 to about 8 % by weight of aqueous-alcoholicglyceric extract of the mixture comprising nettle, chelidonia, oak bark, willow bark, calendula, dandelion roof, camomile, achillea, dill and parsley, from about 0.1 to about 5.0 % by weight thyme oil, lemon oil and tea-tree oil, from about 0.5 to about 8 % by weight maize germ oil, from about 0.2 to about 6 % by weigh salts of natural origin, preferably thermal salt from Sárvár, from about 0.3 to about 10 % by weight propolis extract and from about 0.1 to about 8 % by weight tocopherolacetate and d-panthenol...
-- ------------------------------------------------------------------------------

ANDROGENIC ACTIVITY OF EUCOMMIA ULMOIDES EXTRACTS

(WO2001064227) 07.09.2001 A61K 35/00 THE NATIONAL UNIVERSITY OF SINGAPORE
The present invention relates generally to a method for modulating steroidogenic activity and a composition useful for same. The present invention further relates to a composition comprising a steroidogenic modulator useful for modulating physiological processes mediated by the androgen receptor or an active form thereof or complex comprising same and/or for modulating physiological processes mediated by estrogen receptors. The composition of the present invention preferably comprises an extract of herbs or botanical or horticultural equivalents of the herbs or chemical or functional equivalents of one or more components of the herbal extract thereof.
-- ------------------------------------------------------------------------------

DUAL COMPOSITION COSMETIC PRODUCT WITH A CONCENTRATION SENSITIVE AND AN INCOMPATIBLE ACTIVE RESPECTIVELY PLACED WITHIN FIRST AND SECOND COMPOSITIONS

(WO2001064166) 07.09.2001 A61K 8/04 UNILEVER PLC
A cosmetic product is provided packaged in a dispenser with separate first and second storage areas. The first of the areas contains a first cosmetic composition containing a first dermal active agent, preferably selected from keratolytic skin agents. Particularly preferred are alpha- and beta-hydroxy carboxylic acids as first dermal active placed in a composition having a pH from about 1 to about 5.5. The second area contains a second cosmetic composition with a second dermal agent incompatible with the first composition. Particularly preferred second dermal agents are retinoids, vitamins, enzymes and anti-oxidants. Most preferred is retinol. The dispenser allows transfer of the first and second compositions through an exit nozzle in a res...
---------- ----------------------------------------------------------------------

STABILIZED EMULSION COMPOSITIONS

(WO2001062224) 30.08.2001 A61K 8/04 BLOCK DRUG COMPANY, INC.
A water-in-oil emulsion for the topical delivery of a therapeutically effective active agent comprises a first emulsion agent selected from the group consisting of wax containing fatty acids, higher fatty acid, glycerol fatty acid ester, sorbitan fatty acid ester, oil, fat, and mixtures thereof; and a second emulsion agent selected from the group consisting of polyvalent metal ion compounds and mixtures thereof, and wherein the ratio of the first emulsion agent to the second emulsion agent is about 10:1 to 50:1.
-- ------------------------------------------------------------------------------

COMPOSITIONS FOR TOPICAL DELIVERY OF A PHARMACEUTICALLY ACTIVE AGENT HAVING REDUCED SKIN IRRITATION

(WO2001060336) 23.08.2001 A61K 8/34 THE PROCTER &GAMBLE COMPANY
The present invention relates to compositions for the topical delivery of at least one pharmaceutically active agent comprising from about 1 % to about 50 % by weight of at least one phospholipid and from about 0.1 % to about 50 % by weight of at least one skin conditioning agent. The at least one skin conditioning agent prevents or reduces the drying, irritation, and/or itching of the skin of animals and/or humans caused by the continuous or repetitive application of topical compositions to the skin of animals and/or humans, which contain high levels of phospholipids.
---------------------------------- ----------------------------------------------

ANHYDROUS ANTIPERSPIRANT COMPOSITIONS CONTAINING WATER-REACTIVE MONOMERS AS ANTIPERSPIRANT ACTIVE

(WO2001054658) 02.08.2001 A61K 8/23 THE PROCTER &GAMBLE COMPANY
Disclosed are non-adhesive antiperspirant compositions comprising a water or sweat -reactive monomer as the antiperspirant active, an anhydrous carrier, and an optional polymerization inhibitor, wherein the compositions are applied topically to the underarm or other suitable area of the skin to inhibit or prevent perspiration. The applied compositions form a discontinuous polymer-containing antiperspirant active on the applied skin surface, wherein the polymer-containing active is derived from water-reactive monomers that reacts with sweat at the opening of the sweat ducts after application, to thereby polymerize and form the polymer-containing antiperspirant active over and within the affected sweat ducts. The antiperspirant compositions an...
---------------------------------- ----------------------------------------------

COMPOSITION CONSISTING OF AN ACTIVE INGREDIENT AND A THERAPEUTICALLY ACTIVE DELIVERY SYSTEM, ESPECIALLY IN THE TREATMENT OF ANGIOGENESIS

(WO2001052893) 26.07.2001 A61K 31/00 THERYTE LTD
Provided is a composition comprising: (a) an active component having a therapeutic and/or diagnostic activity; and (b) a delivery component for facilitating delivery of the active component, wherein the delivery component has a therapeutic and/or diagnostic activity.
------------------ --------------------------------------------------------------

DROSPIRENONE FOR HORMONE REPLACEMENT THERAPY

(WO2001052857) 26.07.2001 A61K 31/585 SCHERING AKTIENGESELLSCHAFT
A pharmaceutical composition comprising as a first active ingredient an estrogen, such as estradiol or estradiol valerate, in sufficient amounts to treat disorders and symptoms associated with deficient endogenous levels of estrogen in women, and as a second active ingredient 6$g(b), 7$g(b); 15$g(b); 16$g(b)-dimethylene-3-oxo-17$g(a)-preg-4-ene-21, 17- carbolactone (drospirenone, DRSP) in sufficient amounts to protect the endometrium from the adverse effects of estrogen is useful for, amongst others, treating peri- menopausal, menopausal and post-menopausal women. This composition may be used for hormone replacement therapy and may be administered as a multi-phased pharmaceutical preparation. This combination therapy may comprise continuous, ...
-------------------------------------------------------------------------- ------

AGENTS, SUCH AS NICOTINAMIDE OR cADPR FOR THE TREATMENT OF SKIN DISORDERS

(WO2001051051) 19.07.2001 A61K 8/60 HAREL, Avikam
The invention concerns pharmaceutical compositions for the treatment of hyperproliferative diseases of the epidermis such as cancers and psoriasis, as well as for the treatment of aging of the epidermis. The active ingredient can be nicotinamide (NA), cyclic adenosine diphosphate-ribose (cADPR) or a combination of the two.
--------------------------------------------------------------------------------

PHARMACEUTICAL AND COSMETIC CARRIER OR COMPOSITION FOR TOPICAL APPLICATION

(WO2001051014) 19.07.2001 A21D 2/14 EINI, Meir
A pharmaceutical or cosmetic carrier or composition for topical application characterized by rheological properties which render the carrier or composition semi-solid at rest and a liquid upon application of shear forces thereto. The composition or carrier are prepared by mixing 1-25 percent of a solidifying agent and 75-99 percent of a hydrophobic solvent, by weight, wherein at least one of them has therapeutic or cosmetic benefits, in the presence or absence of a biologically active substance.
------------------------------------------------------------------ --------------

A METHOD OF APPLYING TREATMENT CHEMICALS TO A FIBER-BASED PLANAR PRODUCT AND PRODUCTS OBTAINED BY SAID METHOD

(WO2001049933) 12.07.2001 D21H 23/70 SCA HYGIENE PRODUCTS GMBH
The present invention relates to a method of applying at least one treatment chemical to a fiber-based planar product, in particular tissue, said method comprising the steps of: a) applying water, an aqueous solution or aqueous dispersion to a first surface area (1) of the product, b) allowing the product to swell in the first surface area, c) then applying a treatment composition containing at least one treatment chemical to at least one second surface area (2) of the product, said second area lying within the first area (1), as well as a fiber-based planar product, in particular tissue, obtainable by this method. Uniform swelling within the first surface area, particularly over the entire surface of the planar fiber-based product, prevent...
---------- ----------------------------------------------------------------------

METHODS OF USING ELECTRON ACTIVE COMPOUNDS FOR MANAGING CANCER

(WO2001049301) 12.07.2001 A61K 8/02 MARANTECH HOLDING, LLC
The present invention provides methods for preventing, treating, and/or managing one or more cancerous conditions in a patient, such as a human. A multivalent metal oxide, such as Ag(I,III), Cu (I,III), Pr(III,IV), and Bi(III,V) oxides or a pharmaceutically acceptable derivative thereof, may be administered to the patient in an amount and for a period of time which is therapeutically effective to prevent, treat, and/or manage such condition(s). These cancerous conditions include systemic and external cancers, and may also include conditions and symptoms associated with cancer. The present invention also provides a pharmaceutical composition suitable for treating such cancerous conditions. The compositions of the invention may be adapted for ...
-------------------------------------------------------------------------- ------

TREATMENT OF ACNE USING LIPOIC ACID

(WO2001049250) 12.07.2001 A61K 31/385 PERRICONE, Nicholas, V.
Active acne and acneiform scars are treated by topical application of a composition containing lipoic acid and/or a lipoic acid derivative such as dihydrolipoic acid, a lipoic or dihydrolipoic acid ester, a lipoic or dihydrolipoic acid amide, a lipoic or dihydrolipoic acid salt, and mixtures of any of these to reduce erythema, pore size, and scarring. Topical application of lipoic acid and/or a lipoic acid derivative are advantageously used with at least one adjunct ingredient such as a retinoid, an antibiotic, or benzoyl peroxide conventionally used for acne, alone or in combination with dimethylaminoalcohol, an $g(a)-hydroxy acid such as glycolic acid, a tyrosine, tocotrienol, and/or a fatty acid ester of ascorbic acid. One preferred embo...
--------------------------------------------------------------------------------

FIBERS PROVIDING CONTROLLED ACTIVE AGENT DELIVERY

(WO2001047567) 05.07.2001 A61F 13/15 KIMBERLY-CLARK WORLDWIDE, INC.
An agend fiber composed of an active agent/positive dispensing carrier combination and a fiber forming component. As a fiber or nonwoven or textile fabric containing the fiber, the agend delivers the active agent at a desired rate under conditions of use. Product applications include personal care products such as diapers, training pants, swimwear, refastenable pants, absorbent underwear, feminine hygiene products, incontinent wear, wound dressings and cleansing wipes. The fibers may be formed as monocomponent fibers or multicomponent fibers of varying configurations. Active agents that can be dispensed include skin wellness agents, therapeutic agents, and cleaning agents, for example. In accordance with the invention, agend fibers provide ...
------------------------------------------------------------------ --------------

CHITOSAN BIOPOLYMER FOR THE TOPICAL DELIVERY OF ACTIVE AGENTS

(WO2001045645) 28.06.2001 A61K 8/73 IVREA, INC.
The present invention relates to a carrier base for the topical delivery of an active agent comprising a high viscosity chitosan biopolymer. The invention further relates to a method of controlling the release of an active agent from a carrier base, comprising as a carrier base a high viscosity chitosan; providing the active agent; and mixing the active agent and the chitosan. Preferably, the carrier base comprises a high viscosity chitosan having a molecular weight of at least about 100,000 Dalton, more preferably at least about 250,000 Dalton and most preferably at least about 300,000 Dalton. In other preferred embodiments the chitosan has a concentration of at least about 2 weight %.
---------------------------------- ----------------------------------------------

COMPOSITIONS FOR EFFICIENT RELEASE OF ACTIVE INGREDIENTS

(WO2001043717) 21.06.2001 A61L 15/34 THE PROCTER &GAMBLE COMPANY
The present invention relates to a novel composition for efficiently releasing hydrophilic or water-soluble skin care actives from an oleaginous composition. The substantially oleaginous composition of the present invention comprises: (1) at least one skin care active; (2) a release agent having an HLB of at least about 3; and (3) a hydrophobic barrier protectant. The novel release composition may be topically applied to skin using a dispensing means such as an absorbent article, a wipe, a bandage, a pad, a canister, a stick, an aerosol dispenser, a sprayer, and the like.
-------------------------- ------------------------------------------------------

COMPOSITIONS AND METHODS FOR INTRANASAL DELIVERY OF ACTIVE AGENTS TO THE BRAIN

(WO2001041732) 14.06.2001 A61K 9/00 GORE, Stanley, L.
The present invention relates to a method for delivering at least one active agent to the brain of a mammal. The method comprises administering the at least one active agent to the nasal mucosa of the mammal, wherein the at least one active agent is absorbed through at least one area of nasal epithelium to at least one group of nerve fibers and delivered along at least one neural pathway into the brain of the mammal. The at least one active agent is preferably administered in the form of a composition containing at least one pharmaceutically-acceptable carrier.
---------------------------------- ----------------------------------------------

TOPICAL ANESTHETIC FORMULATION

(WO2001041550) 14.06.2001 A61K 31/137 TRANSDERMATECH, INC.
The topical anesthetic formulation of the present invention is typically a solution that preferably includes lidocaine, USP as the active anesthetic ingredient with benzyl alcohol and isopropyl alcohol. This invention deals with problems commonly associated with topical application of local anesthetics such as: slow onset of action; need for occlusion; messiness of creams, ointments or gels; and rapid loss of effect due to rapid systemic dispersion. The invention permits enhanced penetration of the anesthetic and thereby allows for a lesser total dosage of pharmaceutically active ingredient. The use of a lesser total dosage also decreases systemic toxicity.
---------------------------------------------------------- ----------------------

TOPICAL ADMINISTRATION OF KETOTIFEN

(WO2001039774) 07.06.2001 A61K 9/12 KLEIN PHARMACEUTICALS
A method of treating has a step in which a pharmacological composition comprising Ketotifen is provided. In another step, a skin area of a patient is identified that is affected with itching, and the pharmacological composition is topically administered to the area of skin at a dosage effective to reduce the itching. Contemplated compositions may have various formulations and may further comprise pharmacologically active and/or inactive ingredients.
---------------------------------------------------------- ----------------------

USE OF TAUROLIDINE OR TAURULTAM FOR THE MANUFACTURE OF A MEDICAMENT FOR THE TREATMENT OF TUMORS OF THE CENTRAL NERVOUS SYSTEM

(WO2001039762) 07.06.2001 A61K 31/16 RHODE ISLAND HOSPITAL, A LIFESPAN PARTNER
The invention provides a method of inhibiting tumor growth in a mammal, by administering to the mammal composition containing taurolidine, taurultam, or a biologically active derivative thereof. The composition is administered to directly contact a tumor cell at a dose sufficient to induce cell death by apoptosis.
---------------------------------------------------------- ----------------------

A PROPELLANT FREE SPRAY-ON SKIN PATCH COMPOSITION FOR IMPROVING WOUND HEALING AND FOR DRUG ADMINISTRATION

(WO2001037890) 31.05.2001 A61K 9/12 EVER POWER HOLDING INC
Propellant-free spray-on skin patch composition comprising at least one substantially water insoluble film forming agent, at least one film plasticiser agent, at least one water soluble compound, at least one organic solvent and optionally a physiologically active ingredient or pro-drug thereof. The composition forms a flexible, porous and physiologically compatible skin patch when sprayed onto skin and allowed to dry. Also described are methods of improving wound healing using the above composition to form a protective film over the wound, and a spray patch transdermal drug delivery system for delivering to or through the skin a physiologically active ingredient or a prodrug thereof.
------------------------------------------------------------------ --------------

CELL PERMEABLE PEPTIDES FOR INHIBITION OF INFLAMMATORY REACTIONS AND METHODS OF USE

(WO2001037821) 31.05.2001 A61K 38/00 VANDERBILT UNIVERSITY
The present invention relates to the delivery of biologically active molecules, such as peptides, into the interior of cells by administering to the cells a complex comprising the molecule linked to an importation competent signal peptide. Such delivery can be utilized, for example, to treat and/or prevent inflammatory conditions, e.g., but not limited to, systemic inflammatory reactions such as endotoxic shock, localized inflammatory reactions such as inflammatory skin diseases and conditions, and inflammatory diseases such as autoimmune diseases.
-------------------------------------------------- ------------------------------

METHOD AND COMPOSITION FOR THE TREATMENT OF SCARS

(WO2001037782) 31.05.2001 A61K 9/70 THE SG LICENSING CORPORATION
A method and composition for treating hypertrophic scars so as to reduce the size and approve the appearance of scars comprises applying to the scar a composition comprising a film-forming carrier such as a collodion which contains one or more active ingredients such as a topical steroid, silicone gel and vitamin E. Novel compositions using the Collodion film-forming carrier are also useful to treat a variety of adverse skin disorders.
------------------------------------------ --------------------------------------

SURFACTANT ADJUVANTS USEFUL IN HERBICIDE COMPOSITIONS

(WO2001037661) 31.05.2001 A01N 25/30 HUNTSMAN PETROCHEMICAL CORPORATION
Surfactant adjuvants that are expected to further improve the bioefficacy of herbicides. The surfactant adjuvant comprises an amine- based surfactant, and a sulfosuccinate or sulfosuccinamate-based surfactant. The surfactant adjuvant of the present invention combines the known surfactancy, or wetting characteristics, of sulfosuccinate or sulfosuccinamate-based surfactants, with the proven bioefficacy characteristics of alkoxylated amine-based surfactants. The present invention also provides for herbicide compositions that contain the surfactant adjuvants of the present invention. The herbicide compositions comprise a herbicide active ingredient, a surfactant adjuvant of the present invention, and optionally, one or more formulation aids. The...
-------------------------- ------------------------------------------------------

THERAPEUTIC COMPOSITIONS AND METHODS OF USE THEREOF

(WO2001034165) 17.05.2001 A61K 31/167 HODOSH, Milton
A therapeutic composition and a method of using the composition are provided. The composition includes an osmotic agent and an active agent. The osmotic agent improves the delivery of the active agent to the targeted tissue site.
---------------------------------------------------------- ----------------------

ADHESIVE COMPOSITION OVER A BIOACTIVE POLYMERIZATION INITIATOR

(WO2001030408) 03.05.2001 A61L 24/00 CLOSURE MEDICAL CORPORATION
A composition comprising a polymerizable adhesive monomer is applied over a biologically active initiator or accelerator for polymerization of the monomer. The biologically active initiator or accelerator is a medicament that provides a desired medical or therapeutic activity as well as enhancing polymerization of the adhesive.
------------------------------------------ --------------------------------------

PHARMACEUTICAL FORMULATIONS COMPRISING RESVERATROL AND USE THEREOF

(WO2001030336) 03.05.2001 A61K 8/34 PHARMASCIENCE
A method is provided for preventing or treating skin conditions, disorders or diseases, such as may be associated with or caused by inflammation, sun damage or natural aging. The method involves administration, preferably topical administration, of an active agent selected from the group consisting of resveratrol, pharmacologically acceptable salts, esters, amides, prodrugs and analogs thereof, and combinations of any of the foregoing. Pharmaceutical formulations for use in conjunction with the aforementioned method are provided as well.
-------------------------------------------------- ------------------------------

METHOD AND COMPOSITION FOR THE TREATMENT OF DERMATOLOGIC DISEASES

(WO2001028491) 26.04.2001 A61K 8/92 SCHULTZ, Neal, B.
A topical composition for the treatment of a dermatologic disease includes a carrier, at least one essential oil and a dermatologic active ingredient having a therapeutic effect for the dermatologic disease and a method for treating a dermatologic disease wherein an effective amount of the composition for the disease is applied to a patient having the disease.
---------------------------------- ----------------------------------------------

COMPOSITION AND METHOD FOR PRODUCING LUBRICATING, GERMICIDE FOAM

(WO2001022975) 05.04.2001 A01N 25/16 RICKETTS, David, J.
A skin cleaning, bacterial control, foam solution is provided, which enables a user to wash without requiring prewaiting with water; this is followed by rinsing off the foam. The foam solution product is produced by mixing foaming and cleaning ingredients, active bacterial control ingredients, and water with a gas such as air, CO¿2?, nitrogen, propellant, etc., to make the foam. The foam solution and method enables an improved coverage, better penetration, less time, and the least amount of active ingredients for controlling microorganisms when used for personal care washing. The lubricate of the water enables an easier wash, without the prior application of water; the wash is then followed by rinsing. The method for producing a foam surfa...
---------- ----------------------------------------------------------------------

A STABLE PRODUCT OF ISOHEXYLNAPHTHAZARINS WITH PENTA- AND TETRA-CYCLIC TRITERPENES

(WO2001021212) 29.03.2001 A61K 9/00 PAPAGEORGIOU, Vassilios
A stable pharmaceutical preparation comprising of isohexylnaphtharazins with penta- and tetra-cyclic terpenes which are the ingredients of plant oleoresins and gums. A stable pharmaceutical preparation that is the analogue of isohexylnaphtharazin that contains as active ingredients isohexylnaphtharazins and/or esters analogues from the chain alcohol hydroxyl groups of chemical formula (I), with the addition of penta- and tetra-cyclic triterpenes or better embedded in thawed oleoresins and gums of the resin-producing varieties of the genus Pistacia. The isohexylnaphtharazins and their analogues are useful wound-healing medicines but do present sensitivity to heat, oxygen and especially to light. A stable preparation of isohexylnaphtharazins ...
------------------------------------------ --------------------------------------

PERSONAL-CARE COMPOSITIONS

(WO2001021141) 29.03.2001 A61K 8/02 THE PROCTER &GAMBLE COMPANY
The invention provides the use of a polymeric component capable of forming liquid crystals upon contact with water, and/or a polymeric component which is in the form of liquid crystals, each of these polymeric components comprising at least one polymeric compound, for the preparation of a composition for the reduction of the activity of hydrolytic enzymes, in particular lipase enzymes or the formation of fatty acids by lipase enzymes, the composition preferably being for reduction of skin irritation, acne, eye irritation, dandruff or for improvement of skin healing. The invention also provides specific personal-care compositions containing these polymeric components. The polymeric compound has preferably a cloud point of 35 °C or below, an...
---------------------------------------------------------- ----------------------

THE USE OF BACTERIAL PHAGE ASSOCIATED LYSING ENZYMES FOR THE PROPHYLACTIC AND THERAPEUTIC TREATMENT OF VARIOUS ILLNESSES

(WO2001019385) 22.03.2001 A61K 38/46 NEW HORIZONS DIAGNOSTICS, INC.
A method for the prophylactic and therapeutic treatment of bacterial infections is disclosed which comprises the treatment of an individual with an effective amount of a modified version of a lytic enzyme produced by a bacteria infected with a bacteriophage specific for said bacteria wherein said modified version of said at least one lytic enzyme is selected from the group consisting of shuffled lytic enzymes, chimeric lytic enzymes, wherein the lytic enzyme is in an environment having a pH which allows for activity of said lytic enzyme; and a carrier for delivering said lytic enzyme. Additionally, a holin enzyme for puncturing the membrane may be included in the composition. This method, and composition can be used for the treatment of upp...
------------------------------------------ --------------------------------------

PHARMACEUTICAL AND/OR COSMETICAL COMPOSITIONS

(WO2001019365) 22.03.2001 A61K 8/63 ROCHE CONSUMER HEALTH AG
The present invention relates to pharmaceutical and/or cosmetical compositions comprising from 0.5 to 1.5 wt % of one or more compounds selected from the group consisting of Titrated Extract of Centella Asiatica (TECA), asiaticoside, asiatic acid and madecassic acid, and from 4 to 6 wt % of pantothenic acid and/or its derivatives. The compositions according to the present invention show an important activity in the neosynthesis of collagens, in contrast to compositions containing separately the same amount of the two active compounds. They are suitable for treating dermatological disorders such as wound-healing, chronic venous insufficiency, skin aging, wrinkling, laxity, cellulite and photodamage.
--------------------------------------------------------------------------------

COMPOSITIONS AND METHODS FOR MODIFICATION OF SKIN LIPID CONTENT

(WO2001017523) 15.03.2001 A61K 8/14 APPLIED GENETICS INCORPORATED DERMATICS
The topical use of ursolic acid compounds to alter the lipid content of mammalian skin is disclosed. The compounds can be encapsulated in liposomes and administered in this form to the skin in, for example, a lotion or a gel. The compounds are effective in, among other things, reducing the effects of aging, photoaging, and skin atrophy, including skin atrophy resulting from the topical use of retinoids and/or steroids. Compositions comprising a ursolic acid compound in combination with another therapeutically active topical compounds, such as, a retinoid or a steroid, are also disclosed.
---------------------------------------------------------- ----------------------

EXTRACTS DERIVED FROM PUERARIA MIRIFICA, BUTEA SUPERBA AND/OR MUCUNA COLLETTII AND EXTRACTION THEREOF

(WO2001015718) 08.03.2001 A23L 1/212 CHEIL JEDANG CORPORATION
The present invention relates to extracts derived from Pueraria mirifica, Butea superba and/or Mucuna collettii and extraction thereof, foods, beverages, pharmaceutical products and/or cosmetics containing the extracts as an active ingredient and manufacturing thereof. The extracts isolated from the said plants contain higher concentration of isoflavones. The products produced from composition containing the extracts considerably increase a resilience and gloss of skin at its application in human body.
-- ------------------------------------------------------------------------------

CYCLODEXTRIN CONTAINING PRESSURE SENSITIVE ADHESIVES

(WO2001013968) 01.03.2001 A61L 15/58 AVERY DENNISON CORPORATION
Compositions are disclosed which are normally pressure sensitive adhesive at ambient temperature, which are also absorbent of fluids, especially body fluids, and which contain 0.1 to 65 wt.% of a cyclodextrin material. Such compositions have various uses in the medical field. Lower amounts of cyclodextrin, from 0.1 - 10 wt.%, can confer odour absorbing properties on the adhesive, useful in consumer and medical products. Small amounts of other active ingredients such as antimicrobial components, active drug ingredients, fragrances, etc. may advantageously be complexed within the cyclodextrin molecules. Such compositions are useful for example as antibacterial adhesives, or as adhesives that bleach the skin, prevent and diminish acne skin ble...
------------------------------------------------------------------ --------------

SKIN COSMETIC COMPOSITIONS FOR REDUCING SKIN IRRITATION FROM WEAK CARBOXYLIC ACIDS

(WO2001013876) 01.03.2001 A61K 8/04 UNILEVER PLC
Cosmetic skin compositions containing a weak carboxylic acid and a random copolymer of ethylene oxide and propylene oxide. The copolymer reduces skin irritation that is sometimes caused by the weak acid active without reducing delivery of weak acids to skin tissues. A method of reducing skin irritation that may be caused by the topical application of a weak carboxylic acid is also described.
---------------------------------------------------------- ----------------------

DEODORANT COMPOSITIONS CONTAINING ISOPROPYL GLYCEROL ETHER

(WO2001013868) 01.03.2001 A61K 7/32 THE PROCTER &GAMBLE COMPANY
The present invention is directed to deodorant compositions, and methods of using such compositions, wherein the compositions comprise from about 0.1 % to about 99.9 % by weight of a deodorant active, fragrance or combination thereof, and from about 0.1 % to about 99.9 % by weight of a carrier comprising isopropyl glycerol ether. The deodorant composition preferably further comprises a suitable gellant or structurant to provide the desired product form, including a deodorant gel solid stick. The isopropyl glycerol ether carrier is a highly effective coupling agent and is milder to the skin when applied topically to the axilla or other areas of the skin as compared to many other polyol-containing deodorant compositions. The present invention...
-------------------------------------------------- ------------------------------

USE OF COLOSTRININ, CONSTITUENT PEPTIDES THEREOF, AND ANALOGS THEREOF AS OXIDATIVE STRESS REGULATORS

(WO2001012650) 22.02.2001 A61K 38/07 THE UNIVERSITY OF TEXAS SYSTEM
The present invention provides methods that utilize compositions containing colostrinin, a constituent peptide thereof, an active analog thereof, and combinations thereof, as an oxidative stress regulator.
------------------------------------------ --------------------------------------

IMPROVED TOPICAL MEDICAMENTS AND METHODS FOR PHOTODYNAMIC TREATMENT OF DISEASE

(WO2001012181) 22.02.2001 A61K 41/00 PHOTOGEN, INC.
New photodynamic, topically-applicable medicaments and certain medical uses of such photodynamic medicaments for treatment of human or animal tissue are described, wherein a primary active component of such medicaments is a halogenated xanthene. The halogenated xanthenes constitute a family of potent photosensitizers that become photoactivated upon illumination of the treatment site with visible wavelengths of light. In preferred embodiments, such medicaments are used for treatment of a variety of conditions affecting the skin and related organs; the mouth and digestive tract and related organs; the urinary and reproductive tracts and related organs; the respiratory tract and related organs; various other internal or external tissue surface...
------------------ --------------------------------------------------------------

COSMETIC COMPOSITIONS WITH SELF-WARMING COMPONENT

(WO2001012133) 22.02.2001 A61K 7/48 UNILEVER PLC
The present invention provides self-warming composition comprising a skin conditioning agent, and a redox system based on iron powder and a high surface area catalyst. The system is activated with moisture and/or air.
------------------------------------------------------------------ --------------

PHOSPHATE ESTER-BASED SURFACTANT ADJUVANTS AND COMPOSITIONS THEREOF

(WO2001011958) 22.02.2001 A01N 25/30 HUNTSMAN PETROCHEMICAL CORPORATION
Surfactants that further improve the bioefficacy of herbicides. The surfactants comprise (i) phosphate monoesters of tallow amine ethoxylates, alone or in combination with phosphate diesters of tallow amine ethoxylates, or (ii) alkoxylated phosphate monoesters of tallow amine ethoxylates, alone or in combination with alkoxylated phosphate diesters of tallow amine ethoxylates. The present invention also provides for herbicide compositions that contain the surfactants of the present invention. The herbicide compositions comprise a herbicidal active ingredient, a surfactant of the present invention, and optionally, one or more formulation aids. The herbicide compositions of the present invention are expected to have a reduced tendency to cause...
---------- ----------------------------------------------------------------------

COMPOSITIONS CONTAINING MIMOSA PHENOLIC COMPOUNDS

(WO2001007008) 01.02.2001 A61K 8/49 E-L MANAGEMENT CORPORATION
The invention relates to topical cosmetic and pharmaceutical compositions for enhancing collagen levels in skin cells, the compositions comprising an effective amount of a biologically active phenolic compound-containing extract, or active fraction thereof, obtainable from Mimosa pudica.
---------------------------------------------------------- ----------------------

COSMETIC COMPOSITIONS COMPRISING A CONTINUOUS PHASE

(WO2001007007) 01.02.2001 A61K 8/02 UNILEVER PLC
Compositions for application to human skin have a continuous phase which contains water-immiscible oil structured by incorporation of a compound of formula (I) in which Y and Y?1¿ are each independently -CH¿2? or $m(g)CO Q and Q?1¿ are each independently a hydrocarbyl group of at least 6 carbon atoms and m is from 2 to 4. The composition may be an antiperspirant containing suspended particulate antiperspirant active or containing a dispersed phase in which antiperspirant active is dissolved in water or water-immiscible solvent.
------------------------------------------ --------------------------------------

HOPS ACID ANTIBACTERIAL COMPOSITIONS

(WO2001006877) 01.02.2001 A23L 3/3472 RHODIA INC.
An antibacterial composition of matter comprising: a) one or more hops acid or hops acid derivatives or hops resin or hops resin derivatives; and b) one or more food grade surfactants, surface active agents, chelating agents, antioxidants, and/or organic acids is provided.
------------------------------------------------------------------ --------------

CHIMERIC POLYPEPTIDES OF SERUM ALBUMIN AND USES RELATED THERETO

(WO2001005826) 25.01.2001 A61K 38/00 GPC BIOTECH INC.
The present invention relates to chimeric polypeptides in which a serum albumin protein has been altered to include one or more biologically active heterologous peptide sequences. The chimeric polypeptides may exhibit therapeutic activity related to the heterologous peptide sequences coupled with the improved serum half-lives derived from the serum albumin protein fragments. Heterologous peptide sequences may be chosen to promote any biological effect, including angiogenesis inhibition, antitumor activity, and induction of apoptosis. The therapeutic effect may be achieved by direct administration of the chimeric polypeptide, or by transfecting cells with a vector including a nucleic acid encoding such a chimeric polypeptide.
---------------------------------------------------------- ----------------------

PHARMACEUTICAL COMPOSITION FOR THE TREATMENT OF CALCIFICATION

(WO2001003774) 18.01.2001 A61K 31/125 DÁRDAI, Zoltán
The invention relates to a pharmaceutical (including veterinary) composition for the treatment of calcification. The composition according to the invention is (a) either a topically applicable composition, or (b) an injectable composition or an infusion, and comprises as active agent acetylsalicylic acid either as a free acid or as its pharmaceutically acceptable water-soluble salt or as its pharmaceutically acceptable water-soluble biologically labile ester, together with a carrier, a diluent and/or an other auxiliary agent conventionally used in such compositions.
---------------------------------------------------------- ----------------------

EXOTHERMIC TOPICAL DELIVERY DEVICE

(WO2001003619) 18.01.2001 A61B 18/06 JOHNSON &JOHNSON CONSUMER COMPANIES, INC.
The present invention relates to an exothermic device (500) for topically delivering an active agent comprising a liquid reservoir (220) comprising water, a heating element (210) comprising an oxidizable material, an oxygen-permeable outer-layer (250), an active agent, and a water-impermeable layer (130), wherein upon the rupturing of the liquid reservoir, the water contacts the heating element and the oxygen to create an exothermic reaction.
-------------------------------------------------- ------------------------------

COSMETIC COMPOSITIONS

(WO2001000161) 04.01.2001 A61K 8/14 THE PROCTER &GAMBLE COMPANY
According to the present invention there is provided a cosmetic composition comprising: (a) at least one quaternary ammonium agent; and (b) at least one sunscreen active. The compositions of the present invention give sun protection benefits with low tackiness or stickiness. Moreover, the compositions of the present invention can give good skin care benefits with low levels of negatives such as greasiness, stickiness or tack.
------------------------------------------------------------------ --------------

DELIVERY OF A SACRIFICIAL SUBSTRATE TO INHIBIT PROTEASE PERMEATION INTO SKIN

(WO2001000157) 04.01.2001 A61K 8/02 KIMBERLY-CLARK WORLDWIDE, INC.
The present invention relates to a topical delivery system effective in depositing a thin, tenacious and substantially continuous coating of a sacrificial substrate on skin by an aqueous emulsion mediated dissolution of protein from a sheet material with subsequent transfer and deposition onto the skin. Coatings of sacrificial substrate on skin resist removal, thereby providing a protective barrier against chemically- and biochemically-induced skin damage. The treatment composition also provides a vehicle for administering an effective dose of an active agent to the skin surface.
---------------------------------- ----------------------------------------------

SILK PROTEIN TREATMENT COMPOSITION AND TREATED SUBSTRATE FOR TRANSFER TO SKIN

(WO2001000155) 04.01.2001 A61K 8/02 KIMBERLY-CLARK WORLDWIDE, INC.
The present invention relates to a topical delivery system effective in depositing a thin, tenacious and substantially continuous coating of a silk protein on skin by an aqueous emulsion mediated dissolution of protein from a substrate with subsequent transfer and deposition onto the skin. Coatings of silk protein on skin resist removal, thereby providing a protective barrier against chemically- and biochemically-induced skin damage. The treatment composition also provides a vehicle for administering an effective dose of an active agent to the skin surface.
---------------------------------- ----------------------------------------------

TOPICAL FORMULATIONS COMPRISING SKIN PENETRATION AGENTS AND THE USE THEREOF

(WO2001000139) 04.01.2001 A61K 47/00 DURHAM PHARMACEUTICALS LTD.
Disclosed are topical pharmaceutical compositions comprising a pharmaceutically active agent such as a corticosteroid, a diol, cetyl alcohol, glyceryl monostearate, laurocapram, stearyl alcohol, sodium lauryl sulfate and water. Also disclosed is a method for the manufacture of the compositions and methods for treating inflammatory skin conditions with the compositions.
------------------------------------------ --------------------------------------



ANHYDROUS ANTIPERSPIRANT CREAM COMPOSITIONS HAVING IMPROVED PERFUME LONGEVITY

(WO2000076472) 21.12.2000 A45D 40/00 THE PROCTER &GAMBLE COMPANY
Disclosed are anhydrous antiperspirant cream compositions that have improved fragrance longevity. These compositions have a penetration force value of from about 75 gram-force to about 500 gram-force and comprise (a) antiperspirant active, and (b) a perfume/cyclodextrin inclusion complex. Also disclosed are packaged anhydrous antiperspirant cream compositions which comprise (a) antiperspirant active; (b) a perfume/cyclodextrin inclusion complex; and (c) a dispensing package containing the composition, wherein the dispensing package comprises (i) a container body having an interior chamber and a dispensing end, and (ii) a perforated dome attached to the dispensing end of the container body and having a plurality of openings extending through...
-------------------------------------------------- ------------------------------

ANTIPERSPIRANT COMPOSITIONS

(WO2000074640) 14.12.2000 A61K 8/37 UNILEVER PLC
Antiperspirant compositions herein comprise an antiperspirant active, together with a carrier and a structurant for the carrier which comprises an organic wax having a melting point of from 40 to 90 °C of which at least 60 % of the weight of the wax is provided by at least one aliphatic ester satisfying the formula:- CH¿3?-(CH¿2?)¿n?-O-CO-(CH¿2?)¿m?-CH¿3? in which n is from 9 to 39 and m is from 0 to 35 to form a solid or a soft solid. The compositions can be anhydrous, in the form of a suspension of antiperspirant active, or can comprise aqueous emulsions. The formulations structured by the selected waxes provide lower visible deposits on topical application compared with conventional wax-structured formulations and the waxes are ef...
---------------------------------- ----------------------------------------------

PHARMACEUTICAL TRANSDERMAL COMPOSITIONS

(WO2000072883) 07.12.2000 A61K 47/10 AVIANA BIOPHARM
The compositions described herein allow for the delivery of substances to the organs of the skin such as hair follicles and sebaceous glands, to the tissues under the skin such as muscles, joints and related tissues and to the systemic circulation. The compositions can be used to treat a variety of skin disorders as well as disorders of deeper tissue or disorder distant to the site of application through absorption through the skin. The formulations include pharmaceutical compositions with or without enhancers for delivery of active ingredients to the skin and organs of the skin to treat common disorders of the skin and its organs, as well as areas distant from the skin, i.e., regional or systemic delivery via transdermal administration. Pr...
------------------------------------------ --------------------------------------

TOPICAL COMPOSITIONS PROVIDING IMPROVED TREATMENT OF SKIN OR SCALP FUNGAL INFECTIONS

(WO2000072818) 07.12.2000 A61K 31/497 THE PROCTER &GAMBLE COMPANY
Disclosed are topical compositions for the treatment of fungal infections on the skin or scalp which comprise an active component consisting of itraconazole and methods for treating fungal infections using these compositions.
---------------------------------- ----------------------------------------------

SUNSCREEN COMPOSITION CONTAINING SOL-GEL MICROCAPSULES

(WO2000072806) 07.12.2000 A61K 8/11 SOL-GEL TECHNOLOGIES LTD
The present invention generally relates to safe and stable sunscreen compositions comprising at least one sunscreen active ingredient in the form of an inert sol-gel microcapsules encapsulating ultraviolet absorbing compounds in any acceptable cosmetic vehicle. The composition according to the present invention can comprise several ultraviolet absorbers that may be encapsulated in the same sol-gel microcapsule or in different capsules. The encapsulation of the ultraviolet absorbers reduces or even prevents the contact between the sunscreen compounds and the human tissue, thus reducing various adverse effects that are associated with the use of sunscreens. The encapsulation also reduces or even prevents cross reactivity between the suscreen ...
---------- ----------------------------------------------------------------------

ABSORBENT ARTICLE WITH SKIN CARE COMPOSITION

(WO2000069481) 23.11.2000 A61F 13/15 THE PROCTER &GAMBLE COMPANY
An absorbent article comprising a body contacting surface and an absorbent core is disclosed. At least a portion of the body contacting surface comprises an effective amount of a skin care composition which is solid or semisolid at 40 °C and which is transferable from the body contacting surface to the wearer's skin by contact, normal wearer motion and body heat at a level effective in providing a skin benefit to the wearer's skin. The skin care composition comprises a skin care active ingredient. The skin care composition has a viscosity of more than about 10?5¿ Poise under shear stress of less than about 3X10?4¿ dynes/cm?2¿, and viscosity of less than about 10?2¿ Poise under shear stress of more than about 10?6¿ dynes/cm?2¿, at 40 ...
---------- ----------------------------------------------------------------------

SOYBEAN PROTEIN NUTRACEUTICALS

(WO2000066625) 09.11.2000 A61K 38/12 THE REGENTS OF THE UNIVERSITY OF CALIFORNIA
The invention provides methods and compositions for delivering effective amounts of lunasin as a nutraceutical. The general formulation comprises a composition comprising an active unit dosage of a lunasin polypeptide and a pharmaceutically acceptable excipient. The formulations may be delivered or administered by oral ingestion, by topically contacting skin using well known techniques for dermal delivery, by introducing into a retained physiological fluids. The invention also provides methods for making the subject formulations by purifying lunasin polypeptides to the requisite purity, and combining said lunasin polypeptide with a pharmaceutically acceptable excipient in an orally active unit dosage. The lunasin source material may be soyb...
------------------------------------------------------------------ --------------

NON-AQUEOUS LIQUID SHAMPOO COMPOSITION

(WO2000066172) 09.11.2000 A61K 8/46 SOLTEC RESEARCH PTY. LTD.
This invention relates to compositions suited to use as hair shampoos, and particularly those developed with a view to the treatment of a hair borne infestation, or of a skin disease of the scalp in addition to the primary purpose of hair cleaning and conditioning. In a first aspect of the invention there is provided a substantially non-aqueous liquid shampoo composition comprising at least one detergent, at least one active agent incompatible with water, an organic bulking agent and shampoo excipients, said organic bulking agent being miscible with water and miscible with said at least one detergent and shampoo excipients. It has been surprisingly found that replacing an aqueous bulking agent such as water with an organic compound which is...
-- ------------------------------------------------------------------------------

PHARMACEUTICAL COMPOSITION

(WO2000064450) 02.11.2000 A61K 9/06 LEO PHARMACEUTICAL PRODUCTS LTD. A/S (LØVENS KEMISKE FABRIK PRODUKTIONSAKTIESELSKAB)
The present invention relates to a pharmaceutical composition for dermal use, said composition comprising a first pharmacologically active component A consisting of at least one vitamin D or vitamin D analogue and a second pharmacologically active component B consisting of at least one corticosteroid.
---------------------------------- ----------------------------------------------

SKIN CARE COMPOSITIONS CONTAINING COMBINATION OF SKIN CARE ACTIVES

(WO2000062743) 26.10.2000 A61K 8/29 THE PROCTER &GAMBLE COMPANY
The present invention relates to skin care compositions containing combinations of skin care actives and to methods of using such compositions to regulate the condition of skin. The compositions contain a safe and effective amount of amount of a peptide active selected from the group consisting of pentapeptides, derivatives of pentapeptides, and mixtures thereof; a safe and effective amount of at least one additional skin care active; and a dermatologically acceptable carrier.
---------------------------------- ----------------------------------------------

SYSTEMS AND METHODS FOR ELECTROSURGICAL REMOVAL OF THE STRATUM CORNEUM

(WO2000062685) 26.10.2000 A61B 17/00 ARTHROCARE CORPORATION
The present invention provides systems, apparatus and methods for removing the outer layer, or stratum corneum, of a patient's skin. In one aspect of the invention, a method includes positioning an active electrode (58) adjacent to or near a target site on a patient's outer skin, and applying a sufficient high frequency voltage to the active electrode to remove the stratum corneum without removing the entire epidermis layer. In this manner, the present invention removes dead and/or damaged skin cells on the surface of the skin which improves the overall appearance of the skin. In addition, this process helps to stimulate the bodies own rejuvenation process. In some embodiments, this rejuvenation process occurs by the actual removal of the s...
---------- ----------------------------------------------------------------------

DRY FORMULATION FOR TRANSCUTANEOUS IMMUNIZATION

(WO2000061184) 19.10.2000 A61K 39/39 GLENN, Gregory, M.
A transcutaneous immunization system delivers antigen to immune cells through the skin, and induces an immune response in an animal or human. For example, a skin-active adjuvant (e.g., an ADP- ribosylating exotoxin) can be used to induce an antigen-specific immune response (e.g., humoral and/or cellular effectors) after transcutaneous application of a dry formulation containing antigen and adjuvant to skin of the animal or human. The dry formulation may be a powder or a unit-dose patch. Use of adjuvant is not required if the antigen is sufficiently antigenic. Transcutaneous immunization may be induced with or without penetration enhancement.
-------------------------- ------------------------------------------------------

ANTIMICROBIAL

(WO2000061107) 19.10.2000 A61K 8/02 THE PROCTER &GAMBLE COMPANY
An antimicrobial wipe comprises a porous or absorbent sheet impregnated with an antimicrobial cleansing composition, wherein the antimicrobial cleansing composition comprises from about 0.001 % to about 5.0 %, by weight of the antimicrobial cleansing composition, of an antimicrobial active; from about 0.05 % to about 10 %, by weight of the antimicrobial cleansing composition, of an anionic surfactant; from about 0.1 % to about 10 %, by weight of the antimicrobial cleansing composition, of a proton donating agent; and from about 3 % to about 99.85 %, by weight of the antimicrobial cleansing composition, water; wherein the composition is adjusted to a pH of from about 3.0 to about 6.0; wherein the antimicrobial cleansing composition has a Gra...
-------------------------- ------------------------------------------------------

ANTIMICROBIAL WIPES WHICH PROVIDE IMPROVED IMMEDIATE GERM REDUCTION

(WO2000061106) 19.10.2000 A01N 31/16 THE PROCTER &GAMBLE COMPANY
The present invention relates to an antimicrobial wipe effective against Gram positive bacteria, Gram negative bacteria, fungi, yeasts, molds, and viruses comprising a porous or absorbent sheet impregnated with an antimicrobial cleansing composition, wherein the antimicrobial cleansing composition comprises from about 0.001 % to about 5.0 %, by weight of the antimicrobial cleansing composition, of an antimicrobial active; from about 0.05 % to about 10 %, by weight of the antimicrobial cleansing composition, of an anionic surfactant; from about 0.1 % to about 10 %, by weight of the antimicrobial cleansing composition, of a proton donating agent; and from about 3 % to about 99.85 %, by weight of the antimicrobial cleansing composition, water;...
-- ------------------------------------------------------------------------------

ANTIMICROBIAL WIPES

(WO2000061105) 19.10.2000 A61K 8/02 THE PROCTER &GAMBLE COMPANY
An antimicrobial wipe comprises a porous or absorbent sheet impregnated with an antimicrobial cleansing composition, wherein the antimicrobial cleansing composition comprises from about 0.001 % to about 5.0 %, by weight of the antimicrobial cleansing composition, of an antimicrobial active; from about 0.05 % to about 10 %, by weight of the antimicrobial cleansing composition, of an anionic surfactant; from about 0.1 % to about 10 %, by weight of the antimicrobial cleansing composition, of a proton donating agent; and from about 3 % to about 99.85 %, by weight of the antimicrobial cleansing composition, water; wherein the composition is adjusted to a pH of from about 3.0 to about 6.0; wherein the antimicrobial cleansing composition has a Gra...
-------------------------- ------------------------------------------------------

ANTIPERSPIRANT COMPOSITIONS

(WO2000061094) 19.10.2000 A61K 33/08 UNILEVER PLC
An antiperspirant composition is a structured emulsion of a continuous phase containing water-immiscible liquid carrier plus a structurant, and a disperse phase which is a solution of antiperspirant active in water or a mixture of water and water-soluble solvent. The structurant is a fully or partially esterified saccharide. The compositions give low visible residue when applied to skin or to clothing.
------------------------------------------------------------------ --------------

ANTIPERSPIRANT COMPOSITIONS

(WO2000061082) 19.10.2000 A61K 8/26 UNILEVER PLC
An antiperspirant composition is a structured emulsion of a continuous phase containing water-immiscible liquid carrier plus a structurant, and a disperse phase which is a solution of antiperspirant active in water or a mixture of water and water-soluble solvent. The composition has at least 1 % light transmittance at 580nm, measured through 1 cm at 22 °C. Preferably the structurant gels the continuous phase by forming a network of fibres which extend throughout this phase.
-------------------------------------------------- ------------------------------

STRUCTURED COSMETIC COMPOSITIONS

(WO2000061081) 19.10.2000 A61K 8/02 UNILEVER PLC
A cosmetic composition is a structured emulsion of a continuous phase containing water- immiscible liquid carrier plus a structurant, and a disperse phase which is a solution of antiperspirant active in a more polar, probably aqueous, solvent. The structurant is a material which forms a network of fibres in the continuous phase, thereby gelling it. The structurant has an enthalpy of gelation in the carrier liquid or a test liquid with a magnitude of at least 30 kJ/mole. This minimum enthalpy of gelation facilitates processing at conveniently accessible temperatures and promotes stability.
-------------------------------------------------- ------------------------------

SKIN COSMETIC COMPOSITION

(WO2000056270) 28.09.2000 A61K 8/73 UNILEVER PLC
Cosmetic skin compositions containing a dextran or maltodextrin and a weak carboxylic acid. Dextran enhances the anti-aging activity of the weak acids and reduces skin irritation that is sometimes caused by the weak acid active.
-------------------------------------------------- ------------------------------

SKIN CARE COMPOSITIONS

(WO2000051551) 08.09.2000 A61K 8/67 THE PROCTER &GAMBLE COMPANY
The present invention relates to topical compositions for effecting immediate improvements in the appearance and feel of skin, in addition to providing chronic improvements in skin appearance. The compositions comprise: a) from 0.1 % to 10 % of an organic particulate material having a refractive index of from 1.3 to 1.7, the particulate material being dispersed in the composition and having a volume average particle size in the range of from about 10 to about 30 $g(m)m; b) from about 0.05 % to about 2.5 % by weight of a green, platelet-type interference pigment material having a TiO¿2? layer thickness of from about 120 nm to about 160 nm or a whole number multiple thereof; c) from about 0 % to about 3 % of an inorganic matting agent; and d...
---------------------------------------------------------- ----------------------

INHIBITORS OF CELLULAR NIACINAMIDE MONONUCLEOTIDE FORMATION AND THEIR USE IN CANCER THERAPY

(WO2000050399) 31.08.2000 A61K 31/00 KLINGE PHARMA GMBH
New biologically active compounds are described which inhibit the cellular formation of niacinamide mononucleotide, an essential intermediate of the NAD(P) biosynthesis in the cell. These compounds can represent the active ingredient of a pharmaceutical composition for the treatment of cancers, leukaemias or for immunosuppression. Furthermore, screening methods are described as a tool for detecting the above active compounds, and for examination of a given cell type for its dependency on niacinamide as a precursor for NAD synthesis.
------------------------------------------------------------------ --------------

SYNERGISTIC ANTIMICROBIAL SKIN WASHING COMPOSITIONS

(WO2000048554) 24.08.2000 A61K 8/34 ECOLAB INC.
A synergistic composition and a synergistic system for use in treating the skin and hair of people and animals comprises separate treatment compositions (solution, dispersions, emulsions, suspensions or other liquid or liquefiable materials). One treatment with a first composition that may comprise at least 0.1 % by weight of antimicrobially active aliphatic phenol derivative and treatment with another composition being selected from the group consisting of: a) a solution comprising an antimicrobially active cationic species, like chlorhexidine gluconate; b) a solution comprising antimicrobially active aliphatic phenol derivative, preferably in a different weight percentage of antimicrobially active aliphatic phenol derivative than said one...
-------------------------------------------------- ------------------------------

ZINC CHLORIDE IN TREATING SKIN DISEASES

(WO2000048541) 24.08.2000 A61K 9/70 BROOKS, Norman, A.
An improved method for the treatment of melanoma and skin diseases which utilizes a zinc chloride fixative mixture is provided. The active ingredients of the fixative mixture include zinc chloride (a deeply penetrating, tissue killing histologic preservative), and the anti-cancer plant alkaloids sanguinarine and chelerythrine. Zinc chloride allows the surgeon to perform a complete conventional surgical excision around and below a melanomatous tumor through painless, bloodless dead tissue, and because the microscopic structures are fixed in place by the zinc chloride, the excised tissue can be examined by a pathologist to confirm complete excision and clearance of the melanoma. Although zinc chloride fixative paste has been shown to be an ef...
-------------------------------------------------- ------------------------------

ADDUCT HAVING AN ACIDIC SOLUTION OF SPARINGLY-SOLUBLE GROUP IIA COMPLEXES

(WO2000048469) 24.08.2000 A01N 59/06 MORNINGSTAR DIAGNOSTICS
An adduct that has an acidic solution of sparingly-soluble Group IIA complexes ('AGIIS') and at least one additive. The AGIIS can be prepared by mixing a mineral acid (such as sulfuric acid), and a Group IIA hydroxide (such as calcium hydroxide) or a Group IIA salt of a dibasic acid (such as calcium sulfate), or a mixture of the two Group IIA compounds, followed by removing the solid formed. The additives can be an alcohol, an organic acid or a surface active agent. The composition has various uses, including cleaning, food production, decontamination, bioremediation, agricultural application, medical application, and detoxification of substances.
-------------------------- ------------------------------------------------------

SOYA EXTRACT CONTAINING LIPIDS, PROCESS FOR ITS PRODUCTION, AND PHARMACEUTICAL AND COSMETIC COMPOSITION

(WO2000045828) 10.08.2000 A61K 31/685 INDENA S.P.A.
A soya extract having a more precisely defined ratio of sphingomyelins to phospholipids, and its production process are claimed. The latter involves the following stages: a) extraction of ripe whole soya beans or oil-free soya flour using aliphatic alcohols or a mixture of these alcohols with water; b) concentration of the extract from stage a); c) extraction of the concentrated extract from stage b) by treatment with aliphatic hydrocarbons; d) treatment with vegetable activated carbon and concentration of the extract from stage c) by evaporation; e) insolubilization of the active components using aliphatic ketones; f) filtration of the active components, and drying. Also claimed is a pharmaceutical and cosmetic composition containing said ...
------------------ --------------------------------------------------------------

PREPARATION FOR WARTS

(WO2000045808) 10.08.2000 A61K 31/19 AGHOLME, Astrid
Use of a preparation comprising formic acid as an active ingredient for the manufacture of a medicament for the treatment of skin warts caused by a papilloma virus in a mammal by topical administration on the affected area.
---------- ----------------------------------------------------------------------

ANTIPERSPIRANT COMPOSITION WITH A HIGH MELTING POINT WAX

(WO2000044339) 03.08.2000 A61K 7/32 UNILEVER PLC
Antiperspirant/deodorant stick compositions comprising: (a) a high melting point wax, (b) an emollient, and (c) a particulate antiperspirant active, are described.
---------------------------------- ----------------------------------------------

CLEANSING COMPOSITIONS

(WO2000042985) 27.07.2000 A61K 8/34 THE PROCTER &GAMBLE COMPANY
A rinse-off liquid personal cleansing composition comprising: (a) water; (b) from about 1 % to about 60 % by weight of a water soluble surfactant; (c) a water- insoluble oil selected from highly branched polyalphaolefins having formula (A) wherein R?1¿ is H or C¿1?-C¿20? alkyl, R?4¿ is C¿1?-C¿20? alkyl, R?2¿ is H or C¿1? -C¿20?, and R?3¿ is C¿3?-C¿20? preferably from C¿5?-C¿20?, n is an integer from 0 to 3 and m is an integer of from 1 to 1000 and having a number average molecular weight of from about 1000 to about 25,000; and (d) a hydrophobic skin active component selected from antimicrobial agents, sunscreens, vitamins, perfume oils, insect repellants, anti fungal agents, and mixtures thereof, wherein the hydrophobic skin act...
-------------------------------------------------- ------------------------------

CLEANSING COMPOSITIONS

(WO2000042984) 27.07.2000 A61K 8/34 THE PROCTER &GAMBLE COMPANY
A rinse-off liquid personal cleansing composition comprising (a) water; (b) from about 1% to about 60% by weight of a water-soluble surfactant, (c) a water-insoluble oil selected from highly branched polyalphaolefins having formula (1): wherein R?1¿ is H or C¿1?-C¿ 20? alkyl, R?4¿ is C¿1?-C¿20? alkyl, R?2¿ is H or C¿1?-C¿20?, and R?3¿ is C¿3?-C¿ 20? preferably from C¿5?-C¿20?, n is an integer from 0 to 3 and m is an integer of from 1 to about 1000 and having a number average molecular weight of from about 1000 to about 25,000; and (d) a hydrophobic skin active component selected from antimicrobial agents, sunscreens, vitamins, perfume oils insect repellants, anti- fungal agents, and mixtures thereof, wherein the hydrophobic skin ...
-- ------------------------------------------------------------------------------

IMPROVED CONTROLLED RELEASE COMPOSITIONS AND METHOD

(WO2000041528) 20.07.2000 A61K 8/04 AMCOL INTERNATIONAL CORPORATION
A controlled release composition comprising an adsorbent polymer, an active agent, and a release retardant is disclosed. The composition has an improved ability to release the active agent over an extended time period.
-------------------------------------------------- ------------------------------

CREAM COMPOSITION COMPRISING DEAD SEA MUD

(WO2000040255) 13.07.2000 A61K 8/27 DEAD SEA LABORATORIES LTD.
The present invention relates to a pharmaceutical cream composition for topical application for the treatment of skin disorders and skin diseases, comprising 1-6 wt.% Dead Sea Mud as an active ingredient. Said composition is for use in treating skin disorders and skin diseases such as psoriasis, saborrehic dermatitis, xerosis, atopic dermatitis, eczema, diaper rash, skin burns of state I and sensitive skin. Said cream composition is also for use as a leave-on cosmetic cream for beautifying and enhancing the skin appearance. In addition to Dead Sea Mud said composition comprises ingredients suitable for the preparation of cosmetic cream. Said cream can further comprise up to 4 wt.% Dead Sea water.
-------------------------- ------------------------------------------------------

LIPOSOMIC NIFLUMIC ACID - NEW TRANSDERMAL ANTI-INFLAMMATORY MEDICINE

(WO2000038681) 06.07.2000 A61K 9/127 P.N. GEROLYMATOS S.A.
The present invention is referred to the encapsulation of the drug Niflumic acid in liposomes with the purpose to create a new transdermal non-steroidal anti-flammatory formulation. The Niflumic acid as well as its ester derivates, have been encapsulated into liposomes with different lipid formulations in order to achieve the increased effectiveness of the active compound. The liposome suspension, with or without the encapsulated drug has been formulated as a cream and a stability study of the final formulation has followed.
------------------------------------------------------------------ --------------

MICROCELLULAR POLYMERS AS CELL GROWTH MEDIA AND NOVEL POLYMERS

(WO2000034454) 15.06.2000 A61L 27/16 NEWCASTLE UNIVERSITY VENTURES LIMITED
Microcellular polyhipe polymer scaffold suitable for growth of living matter for biomedical applications, obtainable by polymerising a high internal phase emulsion, comprising a homogeneous cross-linked open cellular material defined by a bulk polymer matrix having a surface and an interface with an internal phase, and having porosity greater than 75 % comprising emulsion derived pores of diameter in the range of 0.1 to 10,000 micron and emulsion derive pore interconnects of diameter in the range of up to 100 micron, wherein the scaffold comprises a plurality of discrete and/or interpenetrating zones: at the polymer surface; within its bulk matrix; at the interface between polymer and internal phase; and/or between adjacent but distinct por...
-------------------------- ------------------------------------------------------

COATING USEFUL AS A DISPENSER OF AN ACTIVE INGREDIENT ON DRESSINGS AND BANDAGES

(WO2000030694) 02.06.2000 A61F 13/02 JOHNSON &JOHNSON CONSUMER COMPANIES, INC.
The dressings of the invention comprise at least two components: an absorbent substrate having a first skin-facing surface and a second opposing surface; and a discontinuous coating of a semi-solid composition having an ointment-like feel overlying a portion of the first surface of said absorbent substrate. The absorbent substrate is useful as a passive dispenser of at least one active ingredient that may be contained therein. The discontinuous coating is essentially non-adherent to the skin and is useful as an active dispenser of at least one active ingredient that may be contained therein. In preferred embodiments the dressing of the invention contains at least one and more preferably at least two active ingredients intended to provide th...
-------------------------------------------------- ------------------------------

OIL BODIES AS TOPICAL DELIVERY VEHICLES FOR ACTIVE AGENTS

(WO2000030602) 02.06.2000 A61K 8/14 SEMBIOSYS GENETICS INC.
The present invention relates to the topical delivery of active agents, for example cosmetic compounds, to living organisms. In particular the present invention relates to the administration of therapeutically active agents in the presence of compositions obtainable from living cells known as oil bodies. The oil bodies of the present invention are especially suitable in applications where it is desired that the active agent is topically delivered. The oil bodies of the present invention are preferably obtained from oil seed plants.
---------- ----------------------------------------------------------------------

LOW-IRRITATION ANTIPERSPIRANT AND DEODORANT COMPOSITIONS

(WO2000030598) 02.06.2000 A61K 31/74 THE PROCTER &GAMBLE COMPANY
Disclosed are topical compositions which comprise from about 0.01 % to about 60 % by weight of an antiperspirant and/or deodorant active; from about 1 % to about 60 % by weight of a volatile, nonpolar hydrocarbon liquid having a solubility parameter of less than about 7.5 (cal/cm?3¿)?0.5¿ and a vapor pressure as measured at 25 °C of from about 0.01 mmHg to about 6.0 mmHg; and from about 1 % to about 60 % by weight of a skin irritation -mitigating material having a vapor pressure equal to or less than that of the volatile, nonpolar hydrocarbon liquid, preferably a silicone-containing liquid; wherein the weight ratio of the volatile, nonpolar hydrocarbon liquid to the mitigating material is from about 5:1 to about 1:50. It has been found th...
--------------------------------------------------------------------------------

PHARMACEUTICAL COMPOSITIONS COMPRISING SYNTHETIC PEPTIDE COPOLYMERS AND METHODS FOR PREVENTING AND TREATING GVHD AND HVGD

(WO2000027417) 18.05.2000 A61K 38/00 YEDA RESEARCH AND DEVELOPMENT CO. LTD.
Compositions and methods for treating and preventing host-versus-graft disease and graft-versus-host disease comprising as active ingredient random copolymers of amino acids comprising one amino acid from at least three of the following groups: (a) lysine and arginine; (b) glutamic acid and aspartic acid; (c) alanine and glycine; and (d) tyrosine and tryptophan; with the proviso that the random copolymer is not Copolymer 1 or D- Copolymer 1 when the disease being treated is graft-versus-host disease.
-- ------------------------------------------------------------------------------

CYSTINE DERIVATIVES AS THERAPEUTIC AGENTS FOR MATRIX METALLOPROTEASE RELATED DISEASES

(WO2000027378) 18.05.2000 A61K 31/165 ROCHE DIAGNOSTICS GMBH
Subject of the present invention are pharmaceutical compositions containing nonpeptidic cystine derivatives of general formula (I) wherein R¿1? and R¿3? may be the same or different and are selected from hydrogen, an aromatic or non-aromatic carbocyclic or heterocyclic ring or a linear or branched saturated or unsaturated alkyl group of 1 to 15 carbon atoms which can be interrupted by a hetero atom and which can be substituted by an aromatic or non-aromatic carbocyclic or heterocyclic ring. R¿2? and R¿4? may be the same or different and are selected from hydrogen, a linear or branched, saturated or unsaturated alkyl group of 1 to 15 carbon atoms which can be interrupted by a hetero atom and which can be substituted by an aromatic or non...
---------------------------------------------------------- ----------------------

SKIN CARE COMPOSITION

(WO2000027353) 18.05.2000 A61K 6/00 JOHNSON &JOHNSON CONSUMER COMPANIES, INC.
There are provided compositions which include a retinoid and preferably retinol; a dermatologically active acid; and a volatile base, such as ammonium hydroxide. Another embodiment of the invention includes compositions comprising a retinoid and preferably retinol; a dermatologically active acid; a volatile base; and a second neutralizing agent. There are also provided compositions which include a retinoid, a neutralized ammonium salt of a dermatologically active acid, and optionally a neutralized salt, other than ammonium salt, of an acid. Further provided are methods for reducing fine lines, wrinkles, skin roughness, and pore size and for increasing the clarity of a skin surface, cellular turnover, skin radiance, skin smoothness, skin per...
------------------------------------------------------------------ --------------

A COMPOSITION CONTAINING AN INSECT REPELLENT ACTIVE BLEND

(WO2000027197) 18.05.2000 A01N 27/00 THE PROCTER &GAMBLE COMPANY
Disclosed is an insect repellent composition comprising: a) an insect repellent active blend comprising a fragrance carbonyl compound, a fragrance alcohol, a fragrance ester, a nitrile compound, an epoxide, and an ether compound; and b) a cosmetically-acceptable carrier.
------------------------------------------ --------------------------------------

SKIN CARE COMPOSITIONS

(WO2000024372) 04.05.2000 A61K 8/04 THE PROCTER &GAMBLE COMPANY
The present invention relates to topical compositions for effecting an immediate improvement in the appearance and feel of skin, in addition to providing chronic improvements in skin appearance. The compositions comprise from 0.5 % to 25 % of a first particulate material having a refractive index of from 1.3 to 1.7, the particulate material being dispersed in the composition and having a median particle size of from 2 to 30 $g(m)m, and an active effective for chronically regulating skin condition selected from Vitamin B3 compounds, retinoids, and mixtures thereof. Preferred embodiments are oil in water emulsions further comprising a second particulate material having a larger particle size than the first.
------------------ --------------------------------------------------------------

SKIN CARE COMPOSITIONS

(WO2000024371) 04.05.2000 A61K 8/04 THE PROCTER &GAMBLE COMPANY
The present invention relates to topical compositions for effecting an immediate improvement in the appearance and feel of skin, in addition to providing chronic improvements in skin appearance. The compositions comprises from 0.5 % to 25 % of a first particulate material having a refractive index of from 1.3 to 1.7, the particulate material being dispersed in the composition and having a median particle size of from 2 to 30 $g(m)m, and an active effective for chronically regulating skin condition selected from Vitamin B3 compounds, retinoids, and mixtures thereof. Preferred embodiments are oil in water emulsions further comprising a second particulate material having a larger particle size than the first.
------------------------------------------------------------------ --------------

SOLAR RADIATION PROTECTION COMPOSITION

(WO2000024369) 04.05.2000 A61K 8/44 NOUVAB INC
The invention relates to sunscreen compositions for humans including naturally occurring sunscreen agents from plants, algae, cyanobacteria, fungi and bacteria that protect against exposure to solar radiation. The active sunscreen agents are compounds that naturally occur in plants, algae, cyanobacteria, fungi and bacteria and derivatives of these compounds.
------------------------------------------------------------------ --------------

PHARMACEUTICAL FORMULATIONS USEFUL TO TREAT INFLAMMATORY AND IMMUNE DISORDERS

(WO2000023071) 27.04.2000 A61K 31/341 LEUKOSITE, INC.
A pharmaceutical formulation is provided for the treatment of inflammatory and/or immune disorders, particularly those mediated by platelet activating factor ('PAF') or a product of 5-lipoxygenase. The formulation, in one embodiment, is an essentially anhydrous ointment containing an active agent selected from the group consisting of 2,5-diaryl tetrahydrofurans, 2,5-diaryl tetrahydrothiophenes, 2,4- diaryl tetrahydrofurans, 2,4-diaryl tetrahydrothiophenes, 1,3-diaryl cyclopentanes, 2,4-diaryl pyrrolidines, and 2,5-diaryl pyrrolidines, and an enhancer composition containing one or more C¿3-18? esters such as diethyl succinate, propylene carbonate, diisopropyl adipate and glyceryl triacetate. In another embodiment, the formulation is a cream,...
-------------------------------------------------- ------------------------------

ALKOXYLATED FATTY ALCOHOL DICARBOXYLIC ACID ESTERS

(WO2000019972) 13.04.2000 C07C 67/00 CRODA, INC.
Fatty alkoxylated esters consisting of diesters of aliphatic or aromatic dicarboxylic acids, formed by reacting the acid with a stoichiometric excess of one or more polyalkoxylated fatty alcohols. Non-aqueous compositions for topical application are also disclosed including one or more active ingredients, and an emollient agent of the fatty alkoxylated esters of the present invention.
-- ------------------------------------------------------------------------------

TOPICAL FORMULATION OF ALKYL-, PHENYL-PYRIDONE

(WO2000016775) 30.03.2000 A61K 31/4418 MEPHA AG
A pharmaceutically acceptable topical formulation for the treatment and/or prevention of skin ailments, more particularly of fibriotic nature such as fibriotic lesional tissues, contiguous warts, contact dermatitis, and keloids, and to assist the healing of burns after surgery, comprising as active ingredient a substituted pyridone of the formula: n-(R?1¿)-1- R?2¿-2-(1H)-pyridone or a pharmaceutically acceptable salt or ester thereof, where R?1¿ is selected from methyl, ethyl, propyl, carboxyl and a carboxymethyl or carboxyethyl ester group, R?2¿ is selected from phenyl, methylphenyl, ethylphenyl, propylphenyl, and a carboxyphenyl or carboxyethylphenyl ester group, and n is 3, 4 or 5, together with an excipient, characterized in that the...
---------- ----------------------------------------------------------------------

PERSONAL CARE COMPOSITIONS CONTAINING ACTIVE PROTEINS TETHERED TO A WATER INSOLUBLE SUBSTRATE

(WO2000016733) 30.03.2000 A61K 8/02 THE PROCTER &GAMBLE COMPANY
The present invention relates to personal care compositions comprising a water insoluble substrate, a plurality of active proteins, and a binding means, comprising a polymeric tether, permanently attaching each of the enzymes to the substrate wherein the personal care composition comprises from about 0.01 $g(m) g/cm?2¿ to about 1000 $g(m)g/cm?2¿ of the enzyme on the substrate.
---------- ----------------------------------------------------------------------

MOUSSE COMPOSITION

(WO2000015193) 23.03.2000 A61K 8/04 SOLTEC RESEARCH PTY LTD
A pharmaceutical aerosol foam composition including an effective amount of a pharmaceutically active ingredient; an occlusive agent; an aqueous solvent; and an organic cosolvent, the pharmaceutically active ingredient being insoluble in both water and the occlusive agent; the occlusive agent being present in an amount sufficient to form an occlusive layer on the skin, in use.
------------------ --------------------------------------------------------------

ANTIPERSPIRANT PRODUCT AND METHOD

(WO2000015185) 23.03.2000 A61K 8/26 UNILEVER PLC
An antiperspirant product for the human skin, comprising an antiperspirant active for topical application, and an effective amount of a compound which inhibits the acidification mechanism in the eccrine gland to elevate the pH of sweat.
-- ------------------------------------------------------------------------------

A COMPOSITION CONTAINING INSECT REPELLENT

(WO2000013658) 16.03.2000 A61K 7/40 THE PROCTER &GAMBLE COMPANY
Disclosed is a composition having insect repellent benefits containing: (a) an active compound having formula (I); (b) a water-soluble polymer; and (c) a hydrophilic liquid carrier, wherein R?1¿ and R?2¿ are independently selected from saturated, straight or branched alkyl group of from 1 to about 10 carbons. Preferred compositions include skin care composition in gel, lotion and liquid forms.
------------------------------------------ --------------------------------------

PHOSPHOGLYCOLIPID AND METHODS FOR ITS USE

(WO2000011010) 02.03.2000 A61K 31/739 CORIXA CORPORATION
The invention concerns a novel phosphoglycolipid compound. The compound of the subject invention is 2- Deoxy-6-$i(O)- [2-deoxy-4-$i(O) -phosphono-3-$i(O) -[($i(R))-3- tetradecanoyloxytetradecanoyl] -2-[($i(R))-3- octadecanoyloxytetradecanoylamino] - $g(b)-D-glucopyranosyl] -2-[($i(R))-3- hexadecanoyloxytetradecanoylamino] -D- glucopyranose and pharmaceutically acceptable salts thereof. The compound is not immunoreactive, not pyrogenic, not toxic but is active in ameliorating tissue damage due to ischemia/reperfusion injury. Methods for using the subject compound to protect against reversible and irreversible damage due to ischemia/reperfusion injury are also disclosed.
-------------------------------------------------- ------------------------------

TOPICAL DELIVERY SYSTEMS FOR ACTIVE AGENTS

(WO2000007627) 17.02.2000 A61K 8/19 JOHNSON &JOHNSON CONSUMER COMPANIES, INC.
This invention relates to a method for enhancing the transmembrane penetration of benefit agents using a certain non-ionic lipid/surfactant-containing formulation as an enhancing agent, and the compositions used therein. Various active agents, such as anti-dandruff agents, hair growth agents, hair inhibitor agents, anti-acne agents, anti-aging agents, depilatory agents, and depigmentation agents, may be effectively delivered into the skin, hair follicles and sebaceous glands using the compositions of the present invention.
------------------ --------------------------------------------------------------

END MODIFIED THERMAL RESPONSIVE HYDROGELS

(WO2000007603) 17.02.2000 A61K 9/00 MADASH LLP
A pharmaceutic composition includes a pharmaceutically acceptable carrier, comprising a reverse thermally viscosifying polymer. The polymer includes a linear block copolymer, wherein at least one block comprises a poloxamer; and at least one block comprises a biocompatible polymer or oligomer, in an aqueous medium. The composition also includes an active agent which imparts a pharmaceutic or cosmetic effect. The composition viscosifies in response to an environmental stimulus. The composition is suitable for administration of the pharmaceutical agent across dermal, otic, rectal, vaginal, ophthalmic, esophageal and nasal mucosal membranes.
------------------------------------------ --------------------------------------

STABILIZED ASCORBIC ACID, COMPOSITION, AND METHOD OF USE

(WO2000006155) 10.02.2000 A61K 47/06 SUNSMART, INC.
A dispersion for carrying at least one water-soluble material or water-dispersible material (especially ascorbic acid, Vitamin C) in a relatively stable form is described, the dispersion comprising an oil phase containing particles comprising water-soluble polymer, water-soluble material or water-dispersible material (ascorbic acid), and water. The dispersion preferably comprises particles which have number average diameter dimensions of less than 2 microns, more preferably less than 1 micron. The dispersion may comprise oil components such as, for example only, a mineral oil, silicone oil, or cosmetic oil. A method of forming a dispersion of solid particles which comprise water-soluble material or water- dispersible material (e.g., ascorbic...
---------------------------------- ----------------------------------------------

SUNSCREEN COMPOSITIONS

(WO2000006110) 10.02.2000 A61K 8/35 THE PROCTER &GAMBLE COMPANY
The present invention relates to compositions suitable for use as sunscreens which provide excellent stability, efficiency, and UV protection efficacy in a safe, economical and aesthetically appealing manner (on-skin transparency, low skin irritation). Methods of use for these compositions are also disclosed. The compositions comprise: a) a safe and effective amount of a UVA-absorbing dibenzoylmethane sunscreen active; b) a safe and effective amount of a stabilizing agent having formula (I) wherein R¿1? and R¿1'? are independently in the para or meta position and are independently a hydrogen atom or a straight- or branched chain C¿1?-C¿8? alkyl radical, R¿2? is a straight- or branched-chain C¿1?-C¿12? alkyl radical; and R¿3? is a hy...
------------------------------------------ --------------------------------------

TRANSDERMAL PATCH AND TOPICAL COMPOSITIONS COMPRISING PROPYLNORAPOMORPHINE

(WO2000003698) 27.01.2000 A61K 9/70 UNIHART CORPORATION
Pharmaceutical composition comprising R(-) -propylnorapomorphine hydrochloride or S(+)-propylnorapomorphine hydrochloride and/or derivatives thereof, together with antioxidants, solubilizers and permeation activators to facilitate the passage of the active principle through the skin. The pharmaceutical composition is used in matrix (3, 3', 3') of a transdermal patch (1, 1', 1'), for the treatment of disorders of the Central Nervous System and in particular for the treatment of sexual impotence, hemicrania, Parkinson's disease and psychotic disorders. The release of the active principle can be modified by varying the concentrations of the solubilizers or of the permeation activators, or by providing a permeable membrane (4).
---------------------------------- ----------------------------------------------

COSMETIC COMPOSITION

(WO2000001354) 13.01.2000 A61K 7/32 UNILEVER PLC
Composition comprising an active capable of selectively increasing the population of naturally occurring deodorising microorganisms on the surface of the skin.
---------- ----------------------------------------------------------------------

COMPOSITIONS FOR RAPID AND NON-IRRITATING TRANSDERMAL DELIVERY OF PHARMACEUTICALLY ACTIVE AGENTS AND METHODS FOR FORMULATING SUCH COMPOSITIONS AND DELIVERY THEREOF

(WO2000001351) 13.01.2000 A61K 47/10 TRANSDERMAL TECHNOLOGIES, INC.
Pharmaceutical compositions for the transdermal administration of a medicament or other active agent by topical application of the composition to the skin of humans or other animals are described. Methodology for formulating such compositions which provide for very rapid uptake of the medicament and transmigration into and through the skin to either fatty tissues or the vascular system, while minimizing irritation to the skin and/or immunological response, is based on a transdermal delivery system (TDS) wherein the medicament is modified to form a true solution in a complex formed from particular solvents and solvent and solute modifiers in combination with skin stabilizers. Uptake of the medicament is further facilitated and made more rapi...
-------------------------------------------------- ------------------------------

METHOD OF TREATING TOPICAL AILMENTS

(WO2000000186) 06.01.2000 A61K 8/36 AMERICAN MEDICAL RESEARCH, INC.
A composition capable of forming a film that ionically bonds to the skin comprising: one or more active agents; a nonionic or substantially nonionic first film forming component; one ore more cationic surfactants comprising one or more fatty moities that are soluble in the first film forming component; and a liquid carrier. Also provided are stable emulsions of such compositions, compositions that are especially adapted to topically deliver medicinal agents to the surface of the skin, burns, skin lesions, warts, and ulcers, and methods for preparing such compositions.
---------------------------------------------------------- ----------------------

ACID/IRRITANT NEUTRALIZATION OF SKIN

(WO2000000168) 06.01.2000 A61K 8/26 AKPHARMA INC.
Methods and compositions using calcium glycerophosphate for the deacidification of the skin and treatment of dermatological conditions, including body odor and dermatological discomfort, are provided. Body odors, such as odor associated with axillary, foot, facial, scalp, and anal-genital regions, may be treated by the application of calcium glycerophosphate to the affected area or to the materials in contact with the affected area. Dermatological discomfort, such as dermatological discomfort associated with acidic body fluids or with the application of cosmetics or therapeutic formulations, may also be treated by the application of calcium glycerophosphate. The calcium glycerophosphate may be used alone in powdered form, or in a liquid, so...
-------------------------------------------------- ------------------------------

USE OF A DIPEPTIDE FOR STIMULATING REPAIR PROCESSES

(WO1999066948) 29.12.1999 A61K 38/05 OBSCHESTVO S OGRANICHENNOI OTVETSTVENNOSTIJU ''KLINIKA INSTITUTA BIOREGULYATSII I GERONTOLOGII''
L- Lys-L-Glu dipeptide is proposed for use in medicine for preparation of a drug capable of stimulating processes. According to the invention, the pharmaceutical peptide preparation capable of stimulating regeneration consists of pharmaceutically admissible carrier and effective quantity of dipeptides as an active part, which is a combination of: L-lysil-L-gluthmine acid or its salts. The pharmaceutical peptide preparation is proposed for the parental, intranasal, oral and local application. According to the invention, the method stimulating regeneration consists of prophylactic and/or treatment injections of the drug in the dose of 0,01-100.$g(m)kg. per 1 kg of weight, at least once a day during a period necessary for obtaining a therapeuti...
-------------------------- ------------------------------------------------------

TOPICAL OINTMENT COMPOSITION FOR BURN TREATMENT

(WO1999065526) 23.12.1999 A61K 47/06 BAGOS, Alfred, Louis
Topical ointment composition for burn treatment for healing skin tissue, having the consistency of a paste or cream, for treating skin injuries caused by burning, providing speedy and efficient regeneration of the injured skin areas. The preferred embodiment comprises a mixture of: bactericidal, anaesthetic, keratolytic, hydrating, tissue regenerating, absorption and permeation activating and aromatizing active components.
-- ------------------------------------------------------------------------------

ANAESTHETIC COMPOSITIONS

(WO1999065477) 23.12.1999 A61K 31/045 THURSDAY PLANTATION LABORATORIES LIMITED
A method of anaesthetising skin or mucous membrane of a subject comprising administering to the skin or mucous membrane of the subject an anaesthetic composition comprising alpha-terpineol as active compound and a diluent or excipient; together with anaesthetic compositions containing alpha- terpineol as active compound.
------------------------------------------ --------------------------------------

COMPOSITION FOR KEEPING AWAY VERMIN

(WO1999065311) 23.12.1999 A01N 1/00 NOVARTIS AG
The invention describes essentially a non-therapeutical process for deterring vermin, which is based on the usage of the largely known compounds of formula (I), as defined herein. Furthermore, it describes the corresponding vermin-deterring compositions which contain these substances as the active ingredient, compounds of formula (I) for the preparation of vermin-deterring compositions, and the use of compounds of formula (I) in the defence against vermin. Thus, the invention describes how and in which form the compounds of formula (I) or their acid addition salts are used to deter vermin from materials, places or warm-blooded animals.
---------- ----------------------------------------------------------------------

COMPOSITION FOR KEEPING AWAY VERMIN

(WO1999065308) 23.12.1999 A01N 43/36 NOVARTIS AG
The invention describes essentially a non- therapeutical process for deterring vermin, which is based on the usage of the largely know compounds of formula (I), as defined herein before. Furthermore, it describes the corresponding vermin-deterring compositions which contain these substances as the active ingredient, compounds of formula (I) for the preparation of vermin-deterring compositions, and the use of compounds of formula (I) in the defence against vermin. Thus, the invention describes how and in which form the compounds of formula (I) or their acid addition salts are used to deter vermin from materials, places or warm-blooded animals.
---------------------------------- ----------------------------------------------

COMPOSITION AND METHOD FOR TREATING PENILE ERECTILE DYSFUNCTION

(WO1999065303) 23.12.1999 A61K 9/00 MACROCHEM CORPORATION
A composition for the topical transdermal administration to the penis is based on prostaglandin E¿1?. The composition is non -irritating and effective for relieving erectile impotence or other penile erectile dysfunction. A penetration enhancing effective amount of a dioxolane, dioxane, or acetal skin penetration enhancing compound in a pharmaceutically acceptable aqueous alcoholic carrier is used to facilitate the penetration of the prostaglandin E¿1? active ingredient through the skin. Phentolamine or prazosin may be used in combination with or in place of prostaglandin E¿1?.
-------------------------- ------------------------------------------------------

ANTIPERSPIRANT COMPOSITIONS CONTAINING SELECT COUPLING AGENTS

(WO1999063962) 16.12.1999 A61K 7/32 THE PROCTER &GAMBLE COMPANY
Disclosed are antiperspirant compositions which comprise (a) from about 3 % to about 40 % by weight of a coupling agent comprising a combination of hexylene glycol and a hydrocarbon oil wherein the weight ratio of hexylene glycol to hydrocarbon oil is from about 1:2 to about 1:20; from about 0.5 % to about 60 % by weight of an antiperspirant active; from about 1 % to about 15 % by weight of a gellant selected from the group consisting of fatty acids, fatty acid esters, fatty acid amides, n-acyl amino acid derivatives, and mixtures thereof; and from about 10 % to about 80 % by weight of a volatile liquid carrier. The use of a combination of hexylene glycol and a hydrocarbon oil provides for improved coupling benefits at lower coupler concent...
------------------------------------------------------------------ --------------

CORN EXTRACT CONTRACEPTIVE

(WO1999062532) 09.12.1999 A61K 35/78 BAYLOR COLLEGE OF MEDICINE
Novel compositions extracted from corn products provide contraceptive and anti-neoplastic activities. Using novel extraction procedures, compositions may be isolated from corn products. For example, $i(Zea mays) plant product is extracted in a first solvent to produce a solvent extract, the solvent extract is dried to produce an extracted solid, the extracted solid is solubilized in a second solvent, the solubilized extract is purified in a chromatographic process, and an active fraction is collected from the chromatographic process. Compositions may be applied to animal bedding or food, and are adaptable to any suitable method of administration. The contraceptive activity of these compostions is effective for both males and females.
---------- ----------------------------------------------------------------------

TOPICAL TRANSDERMAL TREATMENTS

(WO1999062451) 09.12.1999 A01N 25/00 VERBISCAR, Anthony, J.
Jojoba alcohol, an oily liquid at moderate ambient temperatures, is readily absorbed by human skin where it relieves irritation and inhibits the formation of lesions caused by viruses. The inhibitory action is applicable to enveloped viruses which express as sores at dermal surfaces in human. When applied topically to an incipient herpes episode, it will quickly penetrate the epidermis to the subdermal cells and suppress viral replication which leads to inflammation and the formation of blisters on the face, genital and other skin and mucosal areas. Compositions of low molecular weight organic acids in jojoba alcohol enhance antiviral activity. Jojoba alcohol is a transdermal delivery system for these virucidal acids and other pharmacologic...
------------------ --------------------------------------------------------------

MATTHIOLA SEED OIL, MIXTURES CONTAINING IT AND USE THEREOF

(WO1999062359) 09.12.1999 A23K 1/16 STATE OF ISRAEL MINISTRY OF AGRICULTURE AGRICULTURE RESEARCH ORGANIZATION THE VOLKANI CENTER
The present invention relates to Matthiola incana seeds oil as an active ingredient in dietary supplements, mixtures and products for industrial use (useful for painting and lubrication) and pharmaceutical and cosmetic compositions useful for preventing and treating arteriosclerosis, coronary artery disease, chronic inflammatory disease, diabetes, cancerous tumor growth, prevention of blood vessels from closing following vascular surgery, improvement of inflammatory diseases, relieving symptoms of psoriasis, ensuring healthy skin condition and preventing skin wrinkles. The present invention further relates to a method for obtaining oil from Matthiola incana seeds comprising pressing of the plant seeds, collecting the resulting oil and purif...
------------------ --------------------------------------------------------------

THE INDUCTION OF ANTIBIOTIC PEPTIDES BY LAIT (SCD14) PROTEIN

(WO1999061468) 02.12.1999 A61K 38/00 GEMMA BIOTECHNOLOGY LTD.
A method of ameliorating the symptoms of sepsis comprising directly exposing epithelial cells of a mammal in need thereof to soluble CD14, or active variants thereof. A method of obtaining CD14 from a stock solution containing protein of a mammary secretion is described. A method of directly activating B cells using a soluble polypeptide having the amino acid sequence selected from the group consisting of leu-leu-leu-leu-leu-leu-pro-ser, leu-leu-leu-leu-leu-leu-pro-leu; and leu-leu-leu-leu-leu-leu-val-his, and which is specifically recognized by the monoclonal antibody 3C10 and which activates B cells is described. Bovine CD14 genomic DNA is described.
-------------------------- ------------------------------------------------------

PROCESS OF PURIFYING ANGIOGENESIS INHIBITORS

(WO1999061464) 02.12.1999 A61K 38/00 KOREA GREEN CROSS CORPORATION
The present invention relates to process of purifying the angiogenesis inhibitor proteins expressed in $i(E. coli) and to the use of recombinant kringle 1-3 (; greenstatin) purified by the above process as a angiogenesis inhibitor and an anticancer agent. Particularly, according to the process of purifying the protein, the angiogenesis inhibitor proteins overexpressed are solubilized, refolded, and purified as a pure and active form. The greenstatin purified by the process specifically suppresses endothelial cell proliferation, angiogenesis, and the growth of lung cancer, skin cancer, and brain tumor. Therefore, the process of this invention is applicable to the mass-production of angiogenesis inhibitor proteins such as greenstatin which is...
---------- ----------------------------------------------------------------------

TOPICAL PHARMACEUTICAL COMPOSITIONS USEFUL FOR THE TREATMENT OF CUTANEOUS OR CIRCULATORY PATHOLOGIES ON INFLAMMATORY, IMMUNE, PROLIFERATIVE OR DEGENERATIVE BASIS

(WO1999059523) 25.11.1999 A61K 8/92 CODEX V S.R.L.
Topical pharmaceutical compositions, containing as active ingredient a mixture of pollen extracts and vegetable oil unsaponifiables, useful for the treatment of cutaneous or circulatory pathologies on inflammatory, immune, proliferative or degenerative basis.
------------------------------------------------------------------ --------------

THERAPEUTIC COMPOSITIONS

(WO1999058104) 18.11.1999 A61K 8/73 INTERHEALTH AB
The invention relates to a composition comprising, from 2 to 8 % squalane, from 1.5 to 8 % cyclodextrin, and from 1.5 to 8 % of a pharmaceutically and/or cosmetically acceptable acid selected from aliphatic mono-, di-and $g(a)-hydroxy carboxylic acids having from 2 to 10 carbon atoms, and the balance selected from other pharmaceutically and/or cosmetically acceptable compatible anti-acne active substances as well as pharmaceutically and/or cosmetically acceptable paste, ointment or cream bases and additives. The composition has therapeutic and cosmetic effect and can be used as a cosmetic as well as for the preparation of a drug for prophylactic and curative treatment of acne. A method for the preparation of the composition as well as a met...
-- ------------------------------------------------------------------------------

DEODORANT COMPOSITIONS CONTAINING 1,2-HEXANEDIOL

(WO1999056715) 11.11.1999 A61K 7/32 THE PROCTER &GAMBLE COMPANY
The present invention is directed to deodorant compositions, and methods of using such compositions, wherein the compositions comprise from about 0.1 % to about 99.9 % by weight of a deodorant active, fragrance or combination thereof, and from about 0.1 % to about 99.9 % by weight of a carrier comprising 1,2-hexanediol. The deodorant composition preferably further comprises a suitable gellant or structurant to provide the desired product form, including a deodorant gel solid stick. The 1,2-hexanediol carrier is a highly effective coupling agent and is milder to the skin when applied topically to the axilla or other areas of the skin as compared to many other polyol-containing deodorant compositions. The present invention also relates to the...
-- ------------------------------------------------------------------------------

USE OF AN ADHESIVE COMPOSITION OVER A BIOACTIVE POLYMERIZATION INITIATOR OR ACCELERATOR

(WO1999055374) 04.11.1999 A61K 9/70 CLOSURE MEDICAL CORPORATION
A composition comprising a polymerizable adhesive monomer is applied over a biologically active initiator or accelerator for polymerization of the monomer. The biologically active initiator or accelerator is a medicament that provides a desired medical or therapeutic activity as well as enhancing polymerization of the adhesive.
------------------------------------------------------------------ --------------

AQUEOUS COMPOSITION COMPRISING ACTIVE INGREDIENTS FOR THE DE-PIGMENTATION OF THE SKIN

(WO1999055308) 04.11.1999 A61K 8/14 UNIVERA PHARMACEUTICALS, INC.
The present invention discloses aqueous compositions comprising liposomes of phospholipids, and at least one competitive inhibitor of an enzyme for the synthesis of melanin, in combination with at least one non-competitive inhibitor of an enzyme for the synthesis of melanin. The invention also includes the use of the compositions of this invention for the de- pigmentation of skin.
-------------------------------------------------- ------------------------------

ULTRASOUND ENHANCEMENT OF PERCUTANEOUS DRUG ABSORPTION

(WO1999051296) 14.10.1999 A61M 31/00 McDANIEL, David, H.
A system for enhancing and improving the transcutaneous or transdermal delivery of topical chemicals or drugs. A disposable container contains a substantially sterile unit dose of an active agent adapted for a single use in a medical treatment. The unit dose is formulated to enhance transport of the active agent through mammalian skin when the active agent is applied to the skin and the skin is exposed to light and/or ultrasound defined by at least one specific parameter.
------------------------------------------------------------------ --------------

ULTRASOUND ENHANCEMENT OF PERCUTANEOUS DRUG ABSORPTION

(WO1999051295) 14.10.1999 A61M 31/00 MCDANIEL, David, H.
A system for enhancing and improving the transcutaneous or transdermal delivery of topical chemicals or drugs. A disposable container contains a substantially sterile unit dose of an active agent adapted for a single use in a medical treatment. The unit dose is formulated to enhance transport of the active agent through mammalian skin when the active agent is applied to the skin and the skin is exposed to light and/or ultrasound defined by at least one specific parameter.
---------- ----------------------------------------------------------------------

PROTON DONATING ACTIVES IN ABSORBENT ARTICLES

(WO1999045976) 16.09.1999 A61L 15/42 THE PROCTER &GAMBLE COMPANY
An absorbent article that helps maintain a wearer's skin pH in an acidic condition is described. The absorbent article has a body contacting surface with a skin care composition that is transferred from the body contacting surface to the wearer's skin by contact, normal wearer motion and/or body heat. The skin care composition contains at least one proton donating active. Preferred proton donating actives include: monomeric organic acids, polymeric acids, and inorganic acid salts. The absorbent article also includes a liquid impermeable backsheet and an absorbent core positioned between the body contacting surface and the backsheet.
------------------ --------------------------------------------------------------

TOPICAL FORMULATION OF OIL-IN-WATER TYPE AS A CARRIER FOR PROVIDING A REDUCED IRRITANT EFFECT

(WO1999044586) 10.09.1999 A61K 47/26 SCOTIA HOLDINGS PLC
The invention relates to the use of a topical formulation of the oil-in-water type comprising an oily material, an aqueous phase and an emulsifier, wherein the emulsifier is a galactolipid material, as a carrier for providing a reduced irritant effect of an incorporated active substance on the skin. New topical formulations are also described.
------------------------------------------ --------------------------------------

TOPICAL FORMULATION OF THE OIL-IN-WATER TYPE, COMPRISING GALACTOLIPID MATERIAL AS EMULSIFIER, WITH A PROLONGED EFFECT OF AN INCORPORATED ACTIVE SUBSTANCE

(WO1999044585) 10.09.1999 A61K 8/04 SCOTIA HOLDINGS PLC
The invention relates to the use of a topical formulation of the oil-in-water type comprising an oily material, an aqueous phase and an emulsifier, wherein the emulsifier is a galactolipid material, as a carrier for providing a prolonged effect of an incorporated active substance. New topical formulations are also described.
-------------------------- ------------------------------------------------------

MATRIX PROTEIN COMPOSITIONS FOR WOUND HEALING

(WO1999043344) 02.09.1999 A61K 8/19 BIORA BIOEX AB
Active enamel substances may be used for the preparation of a pharmaceutical or cosmetic composition for healing of a wound, improving healing of a wound, soft tissue regeneration or repair, or for preventing or treating infection of inflammation.
---------------------------------- ----------------------------------------------

USE OF RHAMNOLIPIDS IN WOUND HEALING, TREATING BURN SHOCK, ATHEROSCLEROSIS, ORGAN TRANSPLANTS, DEPRESSION, SCHIZOPHRENIA AND COSMETICS

(WO1999043334) 02.09.1999 A61K 9/06 PILJAC, Tatjana
Various methods are provided, including wound healing with reduced fibrosis, treatment of burn shock, treatment and prevention of atherosclerosis, prevention and treatment of organ transplant rejection, treatment of depression and schizophrenia and treatment of the signs of aging, such as wrinkles, each of which uses administration of a composition containing one or more rhamnolipids as an active ingredient.
---------------------------------- ----------------------------------------------

SPHINGOLIPID DERIVATIVES AND THEIR METHODS OF USE

(WO1999041266) 19.08.1999 C07F 9/09 EMORY UNIVERSITY
Derivatives of sphingolipids of formula (I) are provided wherein the substituents are as defined in the specification and wherein there is at least one R?2¿ substituent in the sphingolipid derivative. The compounds are useful in the treatment of abnormal cell proliferation, including benign and malignant tumors, the promotion of cell differentiation, the induction of apoptosis, the inhibition of protein kinase C, and the treatment of inflammatory conditions, psoriasis, inflammatory bowel disease as well as proliferation of smooth muscle cells in the course of development of plaques in vascular tissue. The invention also includes a method for triggering the release of cytochrome c from mitochondria that includes administering an effective a...
------------------ --------------------------------------------------------------

METHODS AND COMPOSITIONS FOR DETECTION AND DIAGNOSIS OF INFECTIOUS DISEASES

(WO1999039693) 12.08.1999 A61K 9/70 JAPAN BCG LABORATORY
Methods and compositions for the detection and diagnosis of infectious diseases are provided. In particular, efficient and sensitive methods and compositions for the detection of active mycobacterial disease are provided for distinguishing between individuals having active disease, and individuals who have been immunologically exposed, such as those infected with a mycobacterium but who are without active disease, or those who have been vaccinated with BCG. The methods comprise topical application of antigen compositions for transdermal delivery.
-------------------------- ------------------------------------------------------

DEODORANT COMPOSITION CONTAINING D-AMINO ACID

(WO1999038474) 05.08.1999 A61K 8/27 THE GILLETTE COMPANY
A deodorant composition is disclosed which comprises a body odor suppressing effective amount of an optically active bactericide comprising D-amino acid, e.g., at least one selected from the group consisting of $g(b)-chloro-D- alanine and D-cycloserine, in a dermatologically acceptable carrier. A method is also provided for inhibiting body odor by applying to the skin a body odor suppressing effective amount of the bactericide.
-------------------------- ------------------------------------------------------

METHOD AND COMPOSITION FOR SKIN TREATMENT

(WO1999037295) 29.07.1999 A61K 33/40 DEVILLEZ, Richard, L.
Compositions and processes for medicating human skin disorders using hydrogen peroxide as an active antimicrobial agent. The composition includes essentially hydrogen peroxide, a non-volatile carrier-solvent, and water. A predetermined final hydrogen peroxide concentration is achieved through evaporation of water. In this manner, hydrogen peroxide concentration may be controlled to avoid deleterious effects. Other therapeutic agents such as alpha hydroxy acids may also be added to the composition for treating various skin ailments.
-- ------------------------------------------------------------------------------

WATER DISPERSIBLE POLYSACCHARIDE PARTICLES

(WO1999037285) 29.07.1999 A61K 9/16 ISP INVESTMENTS INC.
This invention relates to a composition containing an active chemical and a particulate polysaccharide matrix having improved water dispersibility and dispersion stability in aqueous solutions by the incorporation of a copolymer of an N-vinyl lactam monomer and a hydrophobic comonomer. The improved properties of the matrix promotes its use as a dispersing agent in a wide variety of formulations where soil and skin substantivity or sustained release of the active chemical is required, as in pharmaceutical, pre- and post- emergent agrochemical and cosmetic formulations. The invention also pertains to the preparation and use of formulations based on the use of polysaccharide/copolymer matrix of this invention.
-------------------------- ------------------------------------------------------

DRY EMOLLIENT COMPOSITIONS

(WO1999037274) 29.07.1999 A61K 8/04 INTERNATIONAL FLORA TECHNOLOGIES, LTD.
Dry-feel emollient composition additives comprising jojoba oil based esters have use in personal care, cosmetic, cosmeceutical and pharmaceutical products. The composition is essentially solid at room temperature, can be provided in various shapes and sizes (especially as particulates such as spheres), and can be produced from combinations of fatty alcohols, isopropyl esters and wax esters obtained from the oil contained in the seed of the jojoba plant ($i (Simmondsia chinensis)), jojoba oil. These new compositions also increase the range of applications for cosmetic compositions through an emollient that is more polar and hydrophilic than is found in jojoba oils (which may also be referred to in the art as jojoba wax esters). The compositio...
-------------------------- ------------------------------------------------------

INHIBITORS OF $g(a)4 MEDIATED CELL ADHESION

(WO1999036393) 22.07.1999 C07C 31/44 TANABE SEIYAKU CO., LTD.
The present invention relates to a pharmaceutical composition comprising as an active ingredient a compound of formula (I), wherein Ring A is an aromatic or a heterocyclic ring; Q is a bond, carbonyl, lower alkylene, lower alkenylene, -O-(lower alkylene)-, etc.; n is 0, 1 or 2; Z is oxygen or sulfur; W is oxygen, sulfur, -CH=CH-, -NH- or -N=CH-; R?1¿, R?2¿ and R?3¿ are the same or different and are hydrogen, halogen, hydroxyl, a substituted or unsubstituted lower alkyl group, a substituted or unsubstituted lower alkoxy group, a substituted or unsubstituted amino group, etc.; R?4¿ is tetrazolyl, carboxyl group, amide or ester; R?5¿ is hydrogen, nitro, amino, hydroxyl, lower alkanoyl, lower alkyl, etc.; R?6¿ is selected from (a) a subst...
---------------------------------- ----------------------------------------------

A GEL COMPOSITION FOR SKIN CARE AND PROTECTION AND A METHOD FOR PREPARATION THEREOF

(WO1999033443) 08.07.1999 A61K 7/48 DEAD SEA LABORATORIES LTD.
The present invention relates to a gel composition useful for skin care and protection comprising up to 80 % w/w Dead Sea water, hydrophobic and/or hydrophilic active agents, solubilizers, gelling agents or viscosity modifiers and water to complete up to 100 %. Preferably, the composition is a clear liquid gel. In the composition of the present invention the hydrophobic active agents may be vegetable oils, free fatty acids or vitamins, or any combination thereof and the hydrophilic active agent may be humectants, $g(a)- hydroxy acids, anti irritant agents, plant extracts, moisturizing agents or hydrolyzed plant proteins or any combination thereof. The gel may further comprise antioxidants and fragrances. The present invention further relates...
-- ------------------------------------------------------------------------------

ANTIPERSPIRANT CREAM COMPOSITIONS HAVING IMPROVED WASH-OFF AND ANTIPERSPIRANT EFFICACY

(WO1999030678) 24.06.1999 A61K 7/32 THE PROCTER &GAMBLE COMPANY
Disclosed are anhydrous antiperspirant cream compositions that have improved wash-off performance and good antiperspirant efficacy, which compositions have a penetration force value of from about 75 gram.force to about 500 gram.force, a delta stress value of from about 300 dyne/cm?2¿ to about 8.000 dyne/cm?2¿ as measured after extrusion of the composition through a shear force delivery means, and a static yield stress value of at least about 1.000 dyne/cm?2¿ as measured after extrusion of the composition through a shear force delivery means. These compositions comprise from about 0.1 % to about 20 % by weight of a crystalline gellant, from about 10 % to about 80 % by weight of an anhydrous liquid carrier for the crystalline gellant where...
------------------------------------------ --------------------------------------

STEREOSPECIFIC DELIVERY OF A DRUG USING ELECTROTRANSPORT

(WO1999027990) 10.06.1999 A61N 1/30 ALZA CORPORATION
Drug delivery device suitable for preferential delivery, via electrotransport, of a preferred isomeric form of a pharmaceutically active chiral compound from a mixture of the isomeric forms of said compound is provided. The device is characterised by one of the following features: the size of the donor electrode, the concentration of drug in the formulation, the current provided by source of electrical power or the amount of the formulation applied, are less than those necessary to provide therapeutically effective levels of the drug, if the preferred and less preferred isomers are delivered transdermally at the same rate.
------------------ --------------------------------------------------------------

A METHOD FOR $i(IN VIVO) DNA DELIVERY USING A NEEDLE FREE APPARATUS

(WO1999026662) 03.06.1999 A61K 48/00 AVENTIS PASTEUR
The present invention relates to the use of a solution comprising a non-infectious DNA molecule able to express in a mammal, a physiologically active protein, for the manufacture of a medicament intended to be delivered mainly to the mammalian skin using a needle-free apparatus adapted to this effect. The physiologically active protein can be an antigen that is (i) specific for a microorganism able to induce an infection in a mammal or (ii) tumor -associated; in this case the medicament is for treating or preventing an infection or a tumor disorder. The protein can also be a mammalian protein able to treat a genetic defect $i(e.g.), factor XIII or IX; or a cytokine.
------------------ --------------------------------------------------------------

ANTIPERSPIRANT OR DEODORANT COMPOSITIONS

(WO1999026597) 03.06.1999 A61K 8/26 UNILEVER PLC
Deodorant and antiperspirant compositions can suffer from perceived irritancy when applied topically, which can be ameliorated or overcome by incorporating within the composition borage seed oil, and especially an amount selected in the range of from 0.5 to 10 wt.%. The compositions advantageously comprise an aluminium or aluminium-zirconium active.
---------- ----------------------------------------------------------------------

NUCLEIC ACID FRAGMENTS AND POLYPEPTIDE FRAGMENTS DERIVED FROM $i(M. TUBERCULOSIS)

(WO1999024577) 20.05.1999 A61K 38/00 STATENS SERUM INSTITUT
The present invention is based on the identification and characterization of a number of $i(M. tuberculosis) derived novel proteins and protein fragments (SEQ ID NOs: 175, 177, 179, 181, 183, and 185). The invention is directed to the polypeptides and immunologically active fragments thereof, the genes encoding them, immunological compositions such as vaccines and skin test reagents containing the polypeptides. Another part of the invention is based on the surprising discovery that CFP7A induces a high protective immune response.
------------------ --------------------------------------------------------------

SKIN PENETRATION ENHANCING COMPONENTS

(WO1999024036) 20.05.1999 A61K 31/436 ABERDEEN UNIVERSITY
The present invention relates to a topical formulation for the treatment of a dermatological condition which comprises a macrocyclic lactone antibiotic, immunosuppressive macrolide or a biologically active analogue, derivative or pro-drug thereof; characterized in that it further comprises a permeation modulator and the permeation modulator and the macrocyclic lactone or macrolide or the biologically active analogue, derivative or pro-drug thereof are present in relative amounts such that when a therapeutic amount is applied to the skin a minimal systemic effect is produced. The immunosuppressive macrolide may be sirolimus.
-------------------------------------------------- ------------------------------

SUN PROTECTIVE BODY CLEANSER COMPOSITION

(WO1999024008) 20.05.1999 A61K 8/27 KAUFMAN, Stacy, R.
Disclosed in a body cleansing composition providing upon a single application protection against sunburn measured by Sun Protection Factor (SPF) of at least 15 as applied and SPF of at least 4, and preferably at least 5, after rinsing, consisting essentially of water; at least one first sunscreen compound which is a paramethoxycinnamate ester, and at least one second sunscreen compound able to absorb at least 50 % of incident radiation at wavelengths from 290 to 320 nanometers; a combination of at least two surface active agents including a first anionic agent which can be an alkyl sulfate salt or an alkoxylated alkyl sulfate salt, and a second agent which can be nonionic, anionic or zwitterionic; at least one hydroxyethylated organic nitro...
---------------------------------- ----------------------------------------------

INTEGRAL SKIN FOAMS

(WO1999022682) 14.05.1999 C08G 18/66 INTERCOOL ENERGY CORPORATION
A composition for an integral skin foam which comprises an isocyanate component, a blended polyol component, a surface active agent and a blowing agent with a cell regulator is disclosed.
-------------------------------------------------- ------------------------------

NOVEL PHARMACEUTICAL ALPHA-KETO CARBOXYLIC ACID COMPOSITIONS, METHOD OF MAKING AND USE THEREOF

(WO1999021544) 06.05.1999 A61K 31/19 UNITED STATES GOVERNMENT, as represented by THE SECRETARY OF THE ARMY
A pharmaceutical composition comprising as an active phosphorylation potential enhancing substance and an alpha-keto carboxylic acid or a pharmaceutically-acceptable salt thereof, its use and products containing the same.
------------------------------------------------------------------ --------------

$g(b)-D GLUCAN TOPICAL COMPOSITION

(WO1999021531) 06.05.1999 A61K 8/73 BRENNEN MEDICAL, INC.
A topical composition for healing treatment of burns and wounds and scarring therefrom has as the active ingredient cereal- derived (1-3) (1-4) $g(b)-D-glucan at about 0.5-15 w/w percent. The composition may be formulated in various forms with creams and gels being preferred for application to the skin.
---------------------------------------------------------- ----------------------

STABLE COSMETIC COMPOSITIONS

(WO1999020229) 29.04.1999 A61K 8/06 UNILEVER PLC
The inventive compositions contain an oil- in-water and a water-in-oil emulsion, each buffered to a specific pH, so that the difference in pH values of the two emulsions is at least two units. The molecular mixing is minimized by selecting suitable oil and oil phase in a water-in-oil emulsion. The change in pH is further minimized by buffering each emulsion. The particular advantage of the inventive compositions is the ability to separate within a single composition, with minimal intermixing, active compounds which require different pH environments for stability and/or optimum efficacy.
-- ------------------------------------------------------------------------------

A TRANSDERMAL DRUG DELIVERY SYSTEM FOR ANTI-INFLAMMATORY ANALGESIC AGENT COMPRISING DICLOFENAC DIETHYLAMMONIUM SALT, AND THE MANUFACTURING METHOD THEREOF

(WO1999016434) 08.04.1999 A61K 9/70 SAM YANG CO., LTD.
The invention herein relates to a transdermal drug delivery system for anti- inflammatory analgesic agent comprising diclofenac diethylammonium salt, wherein a backing film (1), a matrix layer (2) containing active ingredients, a release liner (3) which is removed before application onto the skin are laminated therein. More particularly, the invention herein relates to a transdermal drug delivery system for anti-inflammatory analgesic agent comprising diclofenac diethylammonium salt, wherein the transdermal penetration and adhesion of the patch to the body are enhanced by means of a matrix layer which comprises a diclofenac diethylammonium salt as active ingredient in addition to acrylic polymer as adhesive constituent, non-ionic surfacant a...
-------------------------------------------------- ------------------------------

NON-IRRITATING COSMETIC AND PHARMACEUTICAL COMPOSITIONS

(WO1999016412) 08.04.1999 A61K 8/11 E-L MANAGEMENT CORP.
The present invention relates to a cosmetic or pharmaceutical emulsion for topical application to the skin comprising an irritating agent and at least one non-disruptive emulsifier. In a preferred embodiment the irritating agent is a retinoid. The invention also provides a method for decreasing the irritation on the skin caused by an irritating active agent in a topical cosmetic or pharmaceutical emulsion which comprises employing as an emulsifier at least one of an alkyl polyoside, a grafted water soluble protein on a hydrophobic backbone, and lecithin.
------------------------------------------------------------------ --------------

STABLE ANHYDROUS FORMULATION

(WO1999013859) 25.03.1999 A61K 8/67 E-L MANAGEMENT CORP.
The present invention is a cosmetic or pharmaceutical composition for topical application comprising a silicone gel and an effective amount of a biological active, especially a retinoid. The compositions permit stabilization of the biologically active agents.
------------------ --------------------------------------------------------------

METHOD FOR PREPARING PHARMACEUTICAL FORMULATIONS

(WO1999011239) 11.03.1999 A61K 9/00 CHAUVIN PHARMACEUTICALS LIMITED
A pharmaceutical formulation may be prepared by a method comprising providing the active ingredient in solution in a pharmacologically-acceptable base and mixing the resulting solution with a pharmacologically-acceptable acid in an amount such that the formulation attains a pH in the range of from about 3.5 to about 8.5 to thereby precipitate out the active ingredients, a viscosity-enhancing agent having been incorporated in the formulation prior to or during the mixing with acid. The formulation is suitable for administration of a pharmacologically active ingredient which is sparingly soluble in water at a pH acceptable for administration, for example to the eye of the patient.
---------------------------------------------------------- ----------------------

ANTIBACTERIAL DEODORIZING COMPOSITIONS

(WO1999011234) 11.03.1999 A61K 8/97 INNOSCENT LTD.
A deodorizing composition comprising as an antimicrobial agent an effective amount of an extract of $i(Lawsonia inermis), or of an antimicrobially active fraction thereof.
-------------------------- ------------------------------------------------------

TREATMENT OF CELL-MEDIATED IMMUNE DISEASES

(WO1999009969) 04.03.1999 A61K 31/203 F. HOFFMANN-LA ROCHE AG
9-cis retinoic acid and pharmaceutically acceptable salts and pharmaceutically acceptable hydrolyzable esters thereof, 9-cis retinal and pharmaceutically acceptable acetals thereof, and 9-cis retinol and pharmaceutically acceptable hydrolyzable esters thereof as well as metabolites of 9-cis retinoic acid have been found to be efficacious in treating T-helper cell type 1 mediated immune diseases in well tolerated doses. Preferably, the active ingredient is formulated as a medicament for oral or topical administration.
---------- ----------------------------------------------------------------------

COMPOSITIONS FOR VISUALLY IMPROVING SKIN

(WO1999007339) 18.02.1999 A61K 8/34 THE PROCTER &GAMBLE COMPANY
The subject invention relates to compositions which are useful for improving the visual appearance of skin, especially facial skin. The composition contains certain primary actives including at least one polar skin care active, at least one sulfhydryl compound and at least one zwitterionic surfactant. The subject invention further relates to methods of improving the visual appearance of skin.
---------------------------------- ----------------------------------------------

NOVEL POLYAMPHOTERIC PHOSPHATE ESTER SURFACTANTS

(WO1999002537) 21.01.1999 C07F 9/09 RHODIA INC.
A surfactant composition comprising formula (1): wherein X is (2): wherein R and R¿1? independently represent the same or different C¿1? to C¿36? straight or branched chain alkyl, alkylene, aryl, alkylaryl and arylalkyl, said R and R¿1? optionally further characterized as containing ether, thioether, polyalkylene oxide, amine or quaternary ammonium, amide or ester groups; or are substituted thereby with the open valence filled by R¿3? wherein R¿3? is hydrogen or R, n is a whole number from (2) to about (4), m is a number of from 1 to 10, v is 0 or 1, w is 0, 1, or 2 with the further stipulation that both w's cannot be 0 and x and y are whole number integers of from 1-50. More specifically, R and R¿1? can individually represent (3): w...
-------------------------- ------------------------------------------------------

SKIN CLEANING COMPOSITION

(WO1999002129) 21.01.1999 A61K 8/34 DIMITROV, Juraj
Skin cleaning composition consists of 1 to 60 % by weight of natural and/or synthetic polymers and of a solvent up to the total amount of 100 % by weight. As a solvent water is used, or possibly a mixture of water and a monobasic alcohol, wherein the ratio monobasic alcohol : water is from 1 : 6 to 3 : 1. The composition may further contain preserving additives, cosmetically active substances, tensides, or possibly aromatic compositions.
------------------------------------------ --------------------------------------

NATURAL INSECT AND ARTHROPOD REPELLENT

(WO1999000014) 07.01.1999 A01N 37/02 REIFENRATH, William, G.
A topical insect repellent with extended duration of protection was obtained from mixtures of molecules based on two or more volatile repellent organic molecular species occurring naturally on the human skin surfaces. The novel repellent comprises mixtures of lower, intermediate, and higher volatility organic molecules. Active ingredients for formulations are obtained from homologous series of carboxylic acids, alcohols, ketones and lactones which span a similar range of volatility and which occur naturally on the skin surface. Volatile silicone fluid imparts mildness and water repellency to the repellent formulations. The invention repellent exhibits longevity and repellency that is comparable to DEET. The invention repellent, formulated i...
---------------------------------- ----------------------------------------------

TOPICAL TREATMENT OF PSORIASIS USING NEUTRALIZING ANTIBODIES TO IL-8

(WO1998058671) 30.12.1998 A61K 38/00 YES BIOTECH LABORATORIES LTD.
A method for treatment of psoriasis and other inflammatory skin conditions, comprising applying topically a composition containing as active ingredient an antibody neutralizing human Interleukin-8 (IL-8) biological activity together with a pharmaceutically acceptable carrier. The invention also includes a pharmaceutical composition for treating inflammatory skin conditions. The pharmaceutical composition includes antibodies that neutralize human Interleukin-8 (IL-8) biological activity.
-------------------------- ------------------------------------------------------

COSMETIC COMPOSITION CONTAINING A WHITENING AGENT AND AN EXFOLIANT

(WO1998058628) 30.12.1998 A61K 8/26 MARY KAY INC.
The present invention is a stabilized cosmetic composition useful in the lightening or whitening of skin. The composition contains a stabilized active ingredient for whitening along with an alpha hydroxy acid. The present invention is also a method of improving skin tone, moisturization and skin firmness through the use of the stabilized cosmetic composition and a moisture source.
------------------------------------------------------------------ --------------

LOW RESIDUE ANTIPERSPIRANT GEL-SOLID STICK COMPOSITIONS CONTAINING VOLATILE NONPOLAR HYDROCARBON SOLVENTS

(WO1998058623) 30.12.1998 A61K 7/32 THE PROCTER &GAMBLE COMPANY
Disclosed are anhydrous antiperspirant gel-solid sticks which comprise from about 0.5 % to about 60 % by weight of antiperspirant active; from about 1 % to about 15 % by weight of a gellant; from about 1 % to about 50 % by weight of nonpolar volatile hydrocarbon solvent having a solubility parameter of less than 8 (cal/cm?3¿)?0.5¿, a vapor pressure of from about 0.01 mmHg to about 6 mmHg, and an average boiling point of less than about 250 °C; and from about 0.01 % to about 10 % by weight of a polar, water-miscible solvent having a solubility parameter of from 12.5 (cal/cm?3¿)?0.5¿ to about 25 (cal/cm?3¿)?0.5¿; wherein the composition has a visible residue index of from about 11 to about 30 L-value, a product hardness of from about 5...
-- ------------------------------------------------------------------------------

HYALURONIC ACID DERIVATIVE BASED CELL CULTURE AND BIODEGRADABLE THREE- DIMENSIONAL MATRIX

(WO1998056897) 17.12.1998 A61L 15/28 FIDIA ADVANCED BIOPOLYMERS S.R.L.
The present invention relates to a biological material comprising a matrix consisting of at least one derivative of hyaluronic acid on which endothelial cells, glandular cells such as islets of Langerhans and liver cells, skin adnexa, germinative cells of hair bulbs, and keratinocytes are grown, optionally in presence of a medium treated with fibroblasts or in a co-culture with fibroblasts. It is also described the process for the production of said biological material and its use for human and veterinary use, in cardiovascolar and oncological surgery, in transplants, to enhance the biological process of tissue vascularization and for aesthetic use, and also for the screening of medicaments or toxic substances and as a support gene transfec...
-------------------------- ------------------------------------------------------

LIQUID ANTIMICROBIAL CLEANSING COMPOSITIONS

(WO1998055099) 10.12.1998 A61K 6/00 THE PROCTER &GAMBLE COMPANY
The present invention relates to a rinse-off antimicrobial cleansing composition comprising from about 0.1 % to about 5 % of an antimicrobial active, from about 8 % to about 18 % of an anionic surfactant, from about 2 % to about 12 % of a proton donating agent; from about 1 % to about 30 % of a lipophilic skin moisturizing agent; from about 0.1 % to about 4 % of a stabilizer; and from about 35 % to about 88.8 % of water. At least about 67 % of the anionic surfactant comprises a mixture of Class A and Class C surfactant. The weight ratio of Class A surfactant to Class C surfactant ranges from about 5:1 to about 1:2. The composition is adjusted to a pH of from about 3.5 to about 4.5.
------------------------------------------------------------------ --------------

MILD, RINSE-OFF ANTIMICROBIAL LIQUID CLEANSING COMPOSITIONS CONTAINING ACIDIC SURFACTANTS

(WO1998055098) 10.12.1998 A01N 25/34 THE PROCTER &GAMBLE COMPANY
The present invention relates to a rinse-off antimicrobial cleansing composition comprising from about 0.1 % to about 5.0 % by weight of the cleansing composition, of an antimicrobial active; from about 4 % to about 18 % by weight of the cleansing composition, of an anionic surfactant, wherein at least about 67 % of the anionic surfactant is selected from the group consisting of Class A surfactants, Class C surfactants, and mitures thereof, wherein the ratio of Class A surfactant to Class C is from about 100:0 to about 1.5:1, from about 0.1 % to about 10 % , by weight of the cleansing composition, of a Class D acidic surfactants; from about 69.4 % to about 84.9 % by weight of the cleansing composition of water; wherein the composition is ad...
--------------------------------------------------------------------------------

MILD, RINSE-OFF ANTIMICROBIAL LIQUID CLEANSING COMPOSITIONS CONTAINING SALICYLIC ACID

(WO1998055097) 10.12.1998 C11D 1/02 THE PROCTER &GAMBLE COMPANY
The present invention relates to a rinse-off antimicrobial cleansing composition comprising from about 0.1 % to about 5.0 %, by weight of the cleansing composition, of an antimicrobial active; from about 6 % to about 16 %, by weight of the cleansing composition, of an anionic surfactant, wherein at least about 67 % of the anionic surfactant is selected from the group consisting of Class A surfactants, Class C surfactants, and mixtures thereof, wherein the ratio of Class A surfactant to Class C is from about 100:0 to about 1.5:1; from about 2 % to about 4 %, by weight of the cleansing composition, of a proton donating agent having a Biological Activity Index, Z, of greater than about 0.75, wherein from about 0.15 % to about 2 %, by weight of...
---------------------------------- ----------------------------------------------

ANTIMICROBIAL WIPES

(WO1998055096) 10.12.1998 A61K 8/02 THE PROCTER &GAMBLE COMPANY
The present invention relates to an antimicrobial wipe comprising a porous or absorbent sheet impregnated with an antimicrobial cleansing composition, wherein the antimicrobial cleansing composition comprises from about 0.001 % to about 5.0 % by weight of the antimicrobial cleansing composition, of an antimicrobial active; from about 0.05 % to about 10 % by weight of the antimicrobial cleansing composition, of an anionic surfactant; from about 0.1 % to about 10 % by weight of the antimicrobial cleansing composition, of a proton donating agent; and from about 3 % to about 99,85 % by weight of the antimicrobial cleansing composition, water; wherein the composition is adjusted to a pH of from about 3.0 to about 6.0. The invention also encompas...
-------------------------------------------------- ------------------------------

LIQUID ANTIMICROBIAL CLEANSING COMPOSITIONS WHICH PROVIDE RESIDUAL BENEFIT VERSUS GRAM NEGATIVE BACTERIA

(WO1998055095) 10.12.1998 C11D 1/02 THE PROCTER &GAMBLE COMPANY
The present invention relates to a rinse-off antimicrobial cleansing composition comprising from about 0.001 % to about 5 % of an antimicrobial active, from about 1 % to about 80 % of an anionic surfactant, from about 0.1 % to about 12 % of a proton donating agent; from about 0.1 % to about 30 % of a deposition aid; and from about 3 % to about 98.8 % of water, wherein the composition is adjusted to a pH of from about 3.0 to about 6.0, wherein the rinse-off antimicrobial cleansing composition has a Gram Negative Residual Effectiveness Index of greater than about 0.3, and wherein the rinse-off antimicrobial cleansing composition has a Mildness Index of greater than 0.3. The invention also encompasses methods for cleansing skin and providing r...
-- ------------------------------------------------------------------------------

MILD, ANTIMICROBIAL WIPES

(WO1998055094) 10.12.1998 A61K 8/02 THE PROCTER &GAMBLE COMPANY
The present invention relates to an antimicrobial wipe comprising a porous or absorbent sheet impregnated with an antimicrobial cleansing composition, wherein the antimicrobial cleansing composition comprises from 1.001 % to 5.0 % by weight of the antimicrobial cleansing composition, of an antimicrobial active; from 0.05 % to 10 % by weight of the antimicrobial cleansing composition, of an anionic surfactant; from 0.1 % to 10 %, by weight of the antimicrobial cleansing composition, of a proton donating agent; and from 3 % to 99.85 %, by weight of the antimicrobial cleansing composition, water; wherein the composition is adjusted to a pH of from 3.0 to 6.0; wherein the antimicrobial cleansing composition has a Gram Positive Residual Effectiv...
------------------------------------------ --------------------------------------

MILD, RINSE-OFF ANTIMICROBIAL LIQUID CLEANSING COMPOSITIONS

(WO1998055093) 10.12.1998 A61P 17/10 THE PROCTER &GAMBLE COMPANY
The present invention relates to a rinse-off antimicrobial cleansing composition characterized in that it comprises from 0.001 % to 5 % of an antimicrobial active, from 1 % to 80 % of an anionic surfactant, from 0.1 % to 12 % of a proton donating agent; and from 3 % to 98.899 % of water, wherein the composition is adjusted to a pH of from 3.0 to 6.0, wherein the rinse-off antimicrobial cleansing composition has a Gram Positive Residual Effectiveness Index of greater than 1.8, and wherein the rinse-off antimicrobial cleansing composition has a Mildness Index of greater than 0.3. The present invention also relates to a rinse-off antimicrobial cleansing composition which has a Gram Positive Residual Effectiveness Index of greater 1.8. The pres...
-- ------------------------------------------------------------------------------

MILD, RINSE-OFF ANTIMICROBIAL LIQUID CLEANSING COMPOSITIONS

(WO1998055092) 10.12.1998 C11D 1/37 THE PROCTER &GAMBLE COMPANY
The present invention relates to a rinse-off antimicrobial cleansing composition comprising from about 0.1 % to about 5.0 % by weight of the cleansing composition, of an antimicrobial active; from about 9 % to about 14 % by weight of the cleansing composition, of an anionic surfactant, wherein at least about 67 % of the anionic surfactant is selected from the group consisting of Class A surfactants, Class C surfactants, and mixtures thereof, wherein the ratio of Class A surfactant to Class C is from about 4:1 to about 1.5:1, and wherein the total anionic surfactant comprises less than about 50 % of the ammonium counter cation salt; from about 4 % to about 8 % by weight of the cleansing composition, of a proton donating agent having a Biolog...
-- ------------------------------------------------------------------------------

MILD, LEAVE-ON ANTIMICROBIAL COMPOSITIONS

(WO1998055081) 10.12.1998 A61K 7/50 THE PROCTER &GAMBLE COMPANY
The present invention relates to a leave-on antimicrobial composition characterized in that it comprises from 0.001 % to 5 % of an antimicrobial active; from 0.05 % to 10 % of an anionic surfactant; from 0.1 % to 10 % of a proton donating agent; and from 0 % to 99.85 % of water; wherein the composition is adjusted to a pH of from 3.0 to 6.0; wherein the leave- on antimicrobial composition has a Gram Positive Residual Effectiveness Index of greater than 0.5; and wherein the leave-on antimicrobial composition has a Mildness Index of greater than 0.3. The present invention also relates to a leave-on antimicrobial cleansing composition which has a Gram Positive Residual Effectiveness Index of greater than 0.5. It also relates to a leave-on antim...
--------------------------------------------------------------------------------

LEAVE-ON ANTIMICROBIAL COMPOSITIONS

(WO1998055080) 10.12.1998 A01N 25/34 THE PROCTER &GAMBLE COMPANY
The present invention relates to a leave-on antimicrobial composition comprising from about 0.001 % to about 5.0 %, by weight of the leave-on antimicrobial composition, of an antimicrobial active; from about 0.05 % to about 10 %, by weight of the leave-on antimicrobial composition, of an anionic surfactant; from about 0.1 % to about 10 %, by weight of the leave-on antimicrobial composition, of a proton donating agent; and from about 0 % to about 99.85 %, by weight of the leave-on antimicrobial composition, water; wherein the composition is adjusted to a pH of from about 3.0 to about 6.0. The invention also encompasses methods for moisturizing, reducing the number of germs on the skin, and decreasing the spread of transient Gram negative and...
------------------ --------------------------------------------------------------

COMPOSITION FOR TREATING SKIN CONDITIONS

(WO1998052927) 26.11.1998 A61K 8/67 SCIVOLETTO, Rosemarie
Compositions for skin treatment are disclosed and include nicotinamide, nicotinic acid, and nicotinic esters as active ingredients. The compositions are applied topically to the skin to treat skin conditions including acne, fine lines and age spots, itching and pain from insect bites, bee stings, fungi (including athletes foot and jock itch), flaking and/or scaly skin (including dandruff, sebouheir dermatitis, psoriasis and heat rash) and burns. Different compositions are presented for use as an acne treatment, a face and body wash, a dermatophyte (nail fungus) treatment, still another is intended for use in makeup, and another in lipstick.
---------------------------------- ----------------------------------------------

SKIN CARE COMPOSITIONS AND METHOD OF IMPROVING SKIN APPEARANCE

(WO1998052533) 26.11.1998 A61K 8/29 THE PROCTER &GAMBLE COMPANY
Disclosed are topical compositions which are useful for providing essentially immediate improvements in skin appearance, e.g., good coverage of skin imperfections, e.g., pores and uneven skin tone, in addition to chronic improvements in skin appearance, while retaining a natural skin appearance. The compositions contain a particulate material having a refractive index of at least about 2, e.g., TiO¿2?, and an active for regulating skin condition following multiple topical applications of the composition. Preferred actives include Vitamin B¿3? compounds and retinoids.
---------- ----------------------------------------------------------------------

USE OF BETULINIC ACID DERIVATIVES FOR THE TREATMENT AND PREVENTION OF MELANOMA

(WO1998051293) 19.11.1998 A61K 31/047 THE BOARD OF TRUSTEES OF THE UNIVERSITY OF ILLINOIS
A composition and method of preventing or inhibiting tumor growth, and of treating malignant melanoma, without toxic side effects are disclosed. Betulinic acid or a betulinic acid derivative is the active compound of the composition, which is topically applied to the situs of tumor.
--------------------------------------------------------------------------------

TOPICAL ADMINISTRATION OF CATECHOLAMINES AND RELATED COMPOUNDS TO SUBCUTANEOUS MUSCLE TISSUE USING PERCUTANEOUS PENETRATION ENHANCERS

(WO1998050014) 12.11.1998 A61K 8/67 PERRICONE, Nicholas, V.
Compositions for the topical treatment of sagging subcutaenous muscle and overlying cutaneous tissue contain an active ingredient exhibiting or producing catecholamine activity such as catecholamines and/or related compounds in a dermatologically acceptable carrier that contains at least one percutaneous penetration enhancer. Examplary catecholamines include adrenaline, norepinepherine, dopamine and their precursors; catecholamine precursors such as tyrosine and phenylalanine are preferred. Many embodiments, particularly those employing tyrosine and/or phenylalanine as a catecholamine precursor, further contain a neurotransmitter synthesis enhancer such as dimethylaminoethanol, and other co-factors such as vitamin B¿6? and pantothenic acid...
------------------------------------------------------------------ --------------

COMPOSITIONS FOR COSMETIC APPLICATIONS

(WO1998050005) 12.11.1998 A61K 8/02 MEDLOGIC GLOBAL CORPORATION
A cosmetic composition is described having a cosmetically acceptable carrier, comprising a reverse thermal viscosifying polymer network comprising at least one poloxamer component capable of aggregation in response to a change in temperature randomly bonded to at least one poly(acrylic acid) component; and a cosmetically active agent which imparts a preselected cosmetic effect, said carrier and said agent disposed within an aqueous-based medium.
-------------------------------------------------- ------------------------------

COSMETIC PARTICULATE GEL CARRIERS FOR TOPICALLY APPLIED ACTIVE AGENTS

(WO1998050000) 12.11.1998 A61K 8/73 KOBO PRODUCTS, INC.
Crushable gel beads (10) formed of an agar complex provide novel cosmetic, pharmaceutical, etc. delivery vehicles for topical delivery of biologically or cosmetically active agents. Preferred agar beads (10) are complexes of a continuous phase of agar gel (12) in a self-supporting solid or semi-solid form with a restraining polymer (14). Entrapped in and dispersed randomly throughout each agar bead (10) is a water-soluble, preferably polar, restraining polymer (14), preferably a quaternized cationic polymer, such as polyquaternium (24) or steardimonium hydroxyethylcellulose. Various active agents (16) may be bound to restraining polymer (14), for example ascorbic acid, lactic acid or papain. Methods of manufacture are also described.
-------------------------- ------------------------------------------------------

SERINE PROTEASE AND TOPICAL RETINOID COMPOSITIONS

(WO1998048775) 05.11.1998 A61K 8/14 JOHNSON &JOHNSON CONSUMER COMPANIES, INC.
This invention is related to methods for treating Acne Vulgaris and/or for producing anti-aging effects on the skin of a mammal, and compositions effective for the same. More specifically, the present invention is directed to the use of serine proteases, as the sole active in a composition effective for the treatment of Acne Vulgaris and/or for producing anti-aging effects on the skin of a mammal, or in combination with a retinoid compound in a composition effective for the same.
------------------ --------------------------------------------------------------

COMPOSITIONS FOR COSMETIC APPLICATIONS

(WO1998048768) 05.11.1998 A61K 8/02 MEDLOGIC GLOBAL CORPORATION
A cosmetic composition is described having a cosmetically acceptable carrier, comprising a reverse thermal viscosifying polymer network comprising at least one poloxamer component capable of aggregation in response to a change in temperature randomly bonded to at least one poly(acrylic acid) component; and a cosmetically active agent which imparts a preselected cosmetic effect, said carrier and said agent disposed within an aqueous-based medium.
------------------------------------------------------------------ --------------

A NOVEL BIOADHESIVE DRUG DELIVERY SYSTEM BASED ON LIQUID CRYSTALS

(WO1998047487) 29.10.1998 A61K 9/127 DUMEX-ALPHARMA A/S
A drug delivery system containing a liquid crystalline phase such as a cubic, a hexagonal, a reverse hexagonal, a lamellar, a micellar and a reverse micellar liquid crystalline phase. The compositions are unique in that they, as delivery system, contain A) a substance which is capable of generating a liquid crystalline phase and providing suitable biopharmaceutical properties like e.g. suitable release of the active substance and bioadhesive properties, and B) at least another substance which without having any substantially negative effect on the biopharmaceutical properties provided by the substance mentioned above under A) either takes part in the formation of a liquid crystalline phase or dilutes the proportion of liquid crystalline pha...
---------------------------------------------------------- ----------------------

NUCLEIC ACID FRAGMENTS AND POLYPEPTIDE FRAGMENTS DERIVED FROM $i(M. TUBERCULOSIS)

(WO1998044119) 08.10.1998 A61K 38/00 STATENS SERUM INSTITUT
The present invention is based on the identification and characterization of a number of $i(M. tuberculosis) derived novel proteins and protein fragments (SEQ ID NOs: 2, 4, 6, 8, 10, 12, 14, 16, 17- 23, 42, 48, 50, 52, 54, 56, 58, 60, 62, 64, 66, 68, 70, 72-86, 88, 90, 92, 94, 141, 143, 145, 147, 149, 151, 153, and 168-171). The invention is directed to the polypeptides and immunologically active fragments thereof, the genes encoding them, immunological compositions such as vaccines and skin test reagents containing the polypeptides. Another part of the invention is based on the surprising discovery that fusions between ESAT-6 and MPT59 are superior immunogens compared to each of the unfused proteins, respectively.
------------------------------------------ --------------------------------------

SOLVENT SYSTEM FOR ENHANCED PENETRATION OF PHARMACEUTICAL COMPOUNDS

(WO1998043673) 08.10.1998 A61K 31/496 JOHNSON &JOHNSON CONSUMER COMPANIES, INC.
A composition is described, consisting of a topically active pharmaceutical compound or drug and a buffered solvent system capable of enhancing the penetration of said drug. The buffered solvent system allows for a reduced amount of pharmaceutical compound in the composition without significantly altering the efficacy of said compound.
--------------------------------------------------------------------------------

TIMED-RELEASE LOCALISED DRUG DELIVERY BY PERCUTANEOUS ADMINISTRATION

(WO1998040118) 17.09.1998 A61B 17/34 ADVANCED RESEARCH &TECHNOLOGY INSTITUTE
Devices and methods are disclosed for the percutaneous administration of a composition to a desired $i(in vivo) location. The composition comprises a biologically active substance and a pharmaceutically acceptable carrier. The pharmaceutically acceptable carrier is preferably non-solid and a polymer, which is preferably capable of being transformed into a gel, thus allowing timed-released delivery of the substance. A preferred use for this invention is to provide local delivery of biologically active substances for the prevention of restenosis following angioplasty or other blood vessel injury.
---------- ----------------------------------------------------------------------

HIGH EFFICIENCY HEATING AGENTS

(WO1998038243) 03.09.1998 B29C 65/36 JOHNSON, Robert, Harlan, Jr.
A unique class of high efficiency heating agents consisting of fibers and in particular ferromagnetic fibers for use in alternating magnetic fields is disclosed which have remarkably and unexpectedly high heating efficiencies. The fibers operate efficiently at lower field intensities; at lower frequencies; and, with smaller diameters (related to skin depths) than prior art technologies. The heating agents may be formed from a variety of materials, for example fibers including ferromagnetic material selected from the group consisting of: iron, nickel, cobalt, chromium and alloys thereof; preferably, the fibers can be selected from the group consisting of: carbon steel fibers, magnetic stainless steel fibers, nickel fibers, ferromagnetic coat...
--------------------------------------------------------------------------------

ANTIPERSPIRANT COMPOSITION

(WO1998035648) 20.08.1998 A61K 8/04 UNILEVER PLC
An aerosol antiperspirant composition for topical application to the human skin, comprising an antiperspirant active and a propellant, characterized in that the propellant comprises pentane.
---------- ----------------------------------------------------------------------

PHARMACEUTICAL COMPOSITION FOR TREATMENT OF SYNAPTIC DYSFUNCTION COMPRISING AN OXIME

(WO1998034615) 13.08.1998 A61K 31/44 SYNAPSE PHARMACEUTICALS INTERNATIONAL, INC.
A pharmaceutical composition is provided for treatment of chronic symptoms of synaptic dysfunction and related disease disorders comprising an effective amount of a pharmaceutically acceptable oxime which is physiologically active such as an acetylcholine esterase reactivator optionally in association with an additional pharmacologically active agent. The pharmaceutical composition has wide-ranging applicability in the treatment of withdrawal symptoms due to the cessation of tobacco use, respiratory disease, drug and alcohol addiction, disorders of the central and peripheral nervous systems, treatment of antineoplastic disease as well as the reduction of adverse effects of antineoplastic disease treatment, cardiac disorders and circulatory ...
-- ------------------------------------------------------------------------------

QUINAZOLINONE-CONTAINING PHARMACEUTICAL COMPOSITIONS FOR PREVENTION OF NEOVASCULARIZATION AND FOR TREATING MALIGNANCIES

(WO1998034613) 13.08.1998 A61K 31/517 AGRICULTURAL RESEARCH ORGANIZATION
The invention provides a composition for attenuating neovascularization and treating malignancies, including a pharmaceutically effective amount of a coupound having a formula (I) wherein: R¿ 1? is a member of the group consisting of hydrogen, halogen, nitro, benzo, lower alkyl, phenyl and lower alkoxy; R¿2? is a member of the group consisting of hydroxy, acetoxy, and lower alkoxy, and R¿3? is a member of the group consisting of hydrogen and lower alkenoxy carbonyl; and pharmaceutically acceptable salts thereof; as active ingredient therein, in combination with a pharmaceutically acceptable carrier.
---------------------------------------------------------- ----------------------

THERAPEUTIC TREATMENT AND PREVENTION OF INFECTIONS WITH A BIOACTIVE MATERIAL ENCAPSULATED WITHIN A BIODEGRADABLE- BIOCOMPATIBLE POLYMERIC MATRIX

(WO1998032427) 30.07.1998 A61K 9/16 UNITED STATES GOVERNMENT as represented by THE SECRETARY OF THE ARMY
Novel burst-free, sustained release biocompatible and biodegradable microcapsules which can be programmed to release their active core for variable durations ranging from 1-100 days in an aqueous physiological environment. The microcapsules are comprised of a core of polypeptide or other biologically active agent encapsulated in a matrix of poly(lactide/glycolide) copolymer, which may contain a pharmaceutically acceptable adjuvant, as a blend of upcapped free carboxyl end group and end-capped forms ranging in ratios from 100/0 to 1/99.
---------------------------------- ----------------------------------------------

SCREENING METHOD FOR COMPOUNDS ACTIVE IN TREATING MYOPIA AND HYPERMETROPIA

(WO1998030900) 16.07.1998 A61K 31/00 KLAUS TRIER APS
The invention relates to a method for identification of substances which are applicable for treatment or prevention of an insufficient longitudinal growth of the eye (hypermetropia) or for treatment or prevention of an excessive longitudinal growth of the eye (myopia); substances identified by the method for treating or preventing conditions related to the longitudinal growth of the eye; substances and mixtures of substances for the preparation of a pharmaceutical composition for the treatment or prevention of abnormal growth of the axial length of the eye. The identification involves measuring the effect of the substances on the retinal pigment epithelium of the eye, e.g. by detecting the metabolic effect of the substance on the retinal ep...
------------------------------------------------------------------ --------------

ANTISEBUM AND ANTIOXIDANT COMPOSITIONS

(WO1998030199) 16.07.1998 A61K 8/92 UNILEVER PLC
Gugulipid (a lipophilic ethyl acetate extract from C. mukul or C. wightii) or an alcoholic fraction of gugulipid or a low molecular weight fraction of gugulipid as an antisebum and/or antioxidant active in cosmetic skin care compositions and methods are described. Gugulipid from C. mukul and its alcoholic and low molecular weight fractions are capable of delivering dual benefit to the skin: controlling or preventing sebum secretion (oily skin conditions) and protecting the skin from free radical damage.
---------- ----------------------------------------------------------------------

SKIN PRODUCT HAVING CONTINUING ANTIMICROBIAL, ANTIVIRAL, ANTISEPTIC, AND HEALING PROPERTIES

(WO1998029085) 09.07.1998 A61K 8/92 AMERICAN MEDICAL RESEARCH, L.L.C.
A composition capable of forming a film that ionically bonds to the skin comprising: one or more active agents; a nonionic or substantially nonionic first film forming component; one or more cationic surfactants comprising one or more fatty moieties that are soluble in the first film forming component; and a liquid carrier. Also provided are stable emulsions of such compositions, compositions that are especially adapted to delivering medicinal agents to the surface of the skin, and methods for preparing such compositions.
-------------------------- ------------------------------------------------------

A NITROIMIDAZOLE GEL COMPOSITION

(WO1998027960) 02.07.1998 A61K 31/4164 BIOGLAN IRELAND (R &D) LIMITED
A viscous hydrogel composition, for use in a topical treatment of a skin condition involving dry or inflammed skin, comprising an antimicrobially active nitroimidazole drug, a water miscible alkylene glycol, a hydroxyalkyl cellulose gelling agent and water, buffered to have a physiologically acceptable pH and a method of making the same.
------------------------------------------ --------------------------------------

ANTIPERSPIRANT GEL-SOLID STICK COMPOSITIONS

(WO1998027955) 02.07.1998 A61K 8/34 THE PROCTER &GAMBLE COMPANY
Disclosed are anhydrous antiperspirant gel-solid stick compositions which comprise a particulate antiperspirant active; a solid non-polymeric gellant that is substantially free of dibenzylidene alditol, n-acyl amino acid derivatives, organic polymeric gellants, and inorganic thickening agents; and an anhydrous liquid carrier having an average solubility parameter of from about 3 to about 13 (cal/cm?3¿)?0.5¿, wherein the composition has a visible residue index of from about 11 to about 30 L-value, a product hardness of from about 500 gram.force to about 5,000 gram.force, a ratio of an elastic to viscous moduli of from about 0.1 to about 100. The refractive indices of the particulate antiperspirant active, solid non-polymeric gellant, and a...
------------------------------------------ --------------------------------------

LOW RESIDUE ANTIPERSPIRANT GEL-SOLID STICK COMPOSITIONS CONTAINING SELECT GELLANTS

(WO1998027953) 02.07.1998 A61K 7/32 THE PROCTER &GAMBLE COMPANY
Disclosed are anhydrous antiperspirant gel-solid stick compositions which comprise a particulate antiperspirant active; a solid non-polymeric gellant selected from the group consisting of 12-hydroxystearic acid, esters of 12-hydroxystearic acid, amides of 12-hydroxystearic acid, and combinations thereof, and an anhydrous liquid carrier having an average solubility parameter of from about 3 to about 13 (cal/cm?3¿)?0.5 ¿, wherein the composition has a visible residue index of from about 11 to about 30 L-value, a product hardness of from about 500 gram.force to about 5,000 gram.force, a ratio of an elastic to viscous moduli of from about 0,1 to about 100. The refractive indices of the particulate antiperspirant active, solid non-polymeric gel...
------------------------------------------------------------------ --------------

ANTIPERSPIRANT GEL-SOLID STICK COMPOSITIONS SUBSTANTIALLY FREE OF SELECT POLAR SOLVENTS

(WO1998027951) 02.07.1998 A61K 8/28 THE PROCTER &GAMBLE COMPANY
Disclosed are anhydrous antiperspirant gel-solid sticks which comprise particulate antiperspirant active; a solid non-polymeric gellant that is substantially free of dibenzylidene alditol, inorganic thickening agents, organic polymeric gellants, n-acyl amino acid derivatives, or combinations thereof; an anhydrous liquid carrier that is substantially free of polar, water-immiscible, organic solvents, wherein the composition has a visible residue index of from about 11 to about 30 L-value, a product hardness of from about 500 to about 5,000 gram-force, a rheology profile defined by a ratio of an elastic modulus (G') to a viscous modulus (G'') of from about 0.1 to about 100. The refractive indices of the particulate antiperspirant active, the ...
---------------------------------------------------------- ----------------------

ANTIPERSPIRANT GEL-SOLID STICK COMPOSITIONS

(WO1998027950) 02.07.1998 A61K 8/42 THE PROCTER &GAMBLE COMPANY
Disclosed are anhydrous antiperspirant gel-solid sticks which comprise particulate antiperspirant active; a solid non-polymeric gellant that is substantially free of dibenzylidene alditol, inorganic thickening agents, organic polymeric gellants, n- acyl amino acid derivatives, or combinations thereof; an anhydrous liquid carrier containing polyalkylsiloxanes, polyalkyarylsiloxanes, polyestersiloxanes, polyethersiloxane copolymers, polyfluorosiloxanes, polyaminosyloxanes, or combinations thereof. The composition has a visible residue index of from about 11 to about 30 L-value, a product hardness of from about 500 to about 5,000 gram.force, a rheology profile defined by a ratio of an elastic modulus (G') to a viscous modulus (G'') of from abou...
---------------------------------- ----------------------------------------------

ANTIPERSPIRANT GEL -SOLID STICK COMPOSITIONS

(WO1998027949) 02.07.1998 A61K 7/32 THE PROCTER &GAMBLE COMPANY
Disclosed are cosmetic gel-solid stick compositions comprising particulate antiperspirant active, a fatty acid gellant having a select dimer-to- monomer ratio and an optional secondary gellant, and an anhydrous liquid carrier. The select dimer-to-monomer ratio of the fatty acid gellant helps provide the composition with improved hardness, low residue performance and efficacy, especially when used in combination with a secondary gellant.
---------- ----------------------------------------------------------------------

ANTIPERSPIRANT OR DEODORANT COMPOSITION

(WO1998027947) 02.07.1998 A61K 7/32 UNILEVER PLC
A substantially anhydrous stick antiperspirant or deodorant composition comprising an antiperspirant or deodorant active, a carrier for the active and a moisturising cream comprising one or more humectants, which comprise at least one hydroxyl group and a perfume carrier material.
-- ------------------------------------------------------------------------------

ANTIPERSPIRANT OR DEODORANT COMPOSITIONS

(WO1998027946) 02.07.1998 H02K 15/00 UNILEVER PLC
An antiperspirant or deodorant cosmetic aerosol composition suitable for topical application to the human skin, comprising: i) an antiperspirant or deodorant active; ii) a moisturising cream; and optionally iii) a carrier for the antiperspirant or deodorant active.
-------------------------- ------------------------------------------------------

ANTIPERSPIRANT COSMETIC COMPOSITION

(WO1998025583) 18.06.1998 A61K 7/32 UNILEVER PLC
A suspension antiperspirant composition for topical application to the human skin comprising a solid particulate antiperspirant active suspended in a cosmetic base, characterised in that the antiperspirant active comprises a blend of relatively small particles with a volume average particle size in the range 0.5 to 8 $g(m)m and relatively large particles having a volume average particle size in the range greater than 12 to less than 50 $g(m)m.
---------------------------------- ----------------------------------------------

SHAVING COMPOSITION AND METHOD FOR PREVENTING PSEUDOFOLLICULITIS BARBAE

(WO1998025581) 18.06.1998 A61K 7/15 WILLIS, Isaac
A topically applied shaving composition for use by a human subject suffering from or prone to development of pseudofolliculitis barbae is disclosed. The composition comprises as its active ingredient about 0.01-5 % by weight of a bacteriostatic/hemostyptic agent, and an aqueous or water-miscible solvent, a volatile silicone and a thickening agent. A method of removing hair from a hairy skin area of such a subject comprising the application of a topical shaving composition containing about 0.01-5 % by weight of a bacteriostatic/hemostypic agent prior to removal of the hair by shaving, tweezing or waxing, is also disclosed.
------------------------------------------------------------------ --------------

ANTIPERSPIRANT COMPOSITION IN STICK FORM

(WO1998024404) 11.06.1998 A61K 7/32 UNILEVER PLC
An emulsion antiperspirant composition suitable for topical application to the human skin in a stick form, comprising an antiperspirant active material, water, a hydrophobic phase, and an emulsifier, characterised in that it additionally comprises at least 10 % by weight of the composition of ethanol.
-------------------------------------------------- ------------------------------

PERCUTANEOUS DELIVERY SYSTEM

(WO1998023291) 04.06.1998 A61K 9/70 SOLTEC RESEARCH PTY. LTD.
The invention relates to a substantially homogenous liquid composition capable of percutaneous delivery of one or more physiologically active agents, the composition including a rate modulating polymer, a volatile solvent and at least one physiologically active agent, said rate modulating polymer being selected to enable modulation of the rate of delivery of said physiologically active agent. Methods of percutaneous delivery of active agents and of prophylactic or therapeutic antimicrobial, antifungal or antiviral treatment using the compositions of the invention are also described.
-- ------------------------------------------------------------------------------

THERAPEUTIC AND COSMETIC COMPOSITIONS, THEIR USE AND METHOD FOR THE PREPARATION THEREOF

(WO1998022083) 28.05.1998 A61K 8/31 INTERHEALTH AB
A composition comprising as active ingredients (i) one or several components derived from an extract of crude shark liver oil, selected from the group comprising refined shark liver oil or a fraction thereof, squalane, squalene and alkylglycerols, and/or the synthetic equivalents of these; (ii) one or several carbohydrates forming inclusion and/or chelate complex with (i); and optionally (iii) one or several non-shark liver oil derived therapeutically or cosmetically active agents. A method of preparing the composition, as well as the use of the composition for the preparation of a pharmaceutical or cosmetic.
---------- ----------------------------------------------------------------------

TOPICAL FORMULATIONS CONTAINING AS A THERAPEUTIC ACTIVE AGENT FATTY ACIDS OR FATTY ALCOHOLS OR MONOGLYCERIDE DERIVATIVES THEREOF FOR TREATING OF MUCOSA INFECTIONS

(WO1998020872) 22.05.1998 A61K 9/00 THORMAR, Halldor
The present invention relates to a method for counteracting infections caused by bacteria, fungi or virus such as Herpes Simplex Virus in skin or mucosal membranes, in particular genital membranes, of a mammal. The method comprises topically administering to the skin or mucosal membrane an effective amount of a formulation comprising a) at least one microbicidal lipid, b) at least one solubilizing agent which keeps the lipid dissolved in the formulation, and optionally c) a gel-forming agent. The formulation used in the method may suitably be in the form of a hydrogel. The microbicidal lipid is preferably a C¿6-18? fatty acid, such as e.g. lauric acid, or a derivative thereof, e.g. a monoglyceride such as capric acid 1- monoglyceride. The s...
-------------------------------------------------- ------------------------------

NON-CHEMICAL SUNSCREEN COMPOSITION

(WO1998019651) 14.05.1998 A61K 8/29 E-L MANAGEMENT CORPORATION
The present invention relates to non-chemical sunscreen composition comprising as its active components, in synergistically effective amounts, a plant extract containing at least about 50 % by weight of proanthocyanidins, $g(g)-oryzanol, ferulic acid and/or an ester thereof, titanium dioxide and optionally, $i(Scutellaria) extract.
------------------------------------------------------------------ --------------

FATTY ACID ESTERS OF LACTIC ACID SALTS AS PERMEATION ENHANCERS

(WO1998018417) 07.05.1998 A61K 9/70 THERATECH, INC.
A transdermal drug delivery system which enhances the delivery of the drug comprises a composition containing, as an enhancer, one or more C¿5? to C¿21? fatty acid esters of a lactic acid salt. These compositions are made up of a safe and effective amount of an active pharmaceutical permeant contained in a penetration- enhancing vehicle comprising 0.25 to 50% w. of the fatty acid ester of a lactic acid salt enhancer in a suitable pressure sensitive adhesive carrier vehicle formed from an aqueous emulsion based pressure sensitive adhesive.
------------------ --------------------------------------------------------------

FATTY ACID ESTERS OF GLYCOLIC ACID AND ITS SALTS AS PERMEATION ENHANCERS

(WO1998018416) 07.05.1998 A61K 9/70 THERATECH, INC.
A transdermal drug delivery system which enhances the delivery of the drug comprises a composition containing, as an enhancer, one or more C¿5? to C¿21? fatty acid esters of glycolic acid and its salts. These compositions are made up of a safe and effective amount of an active pharmaceutical permeant contained in a penetration-enhancing vehicle comprising 0.25 to 50 wt.% of the fatty acid glycolic acid ester enhancer in a suitable carrier vehicle. These fatty acid glycolic acid ester enhancers may be used in various carrier vehicles to enhance the transdermal delivery of active permeants in either free form or used in an occlusive device, particularly in a transdermal patch in matrix or reservoir form. When used in matrix patch form, the ...
-- ------------------------------------------------------------------------------

POTENT TRANSDERMAL PENETRATION ENHANCERS

(WO1998017316) 30.04.1998 A61K 47/10 CELLEGY PHARMACEUTICALS INC.
The epidermal permeability barrier to systemically and/or topically active agents or compositions designed for topical administration is enhanced to an unexpected degree of certain combinations of known penetration enhancing excipients. One group of combinations comprise a glycol and an alcohol at a weight ratio within the range of 1:0.1 to 1:10 with one or more further additives, selected from the excipient groups of branched-chain esters of fatty acids, surfactants, and membrane fluidizers. Another group of combinations comprise an alcohol of four or more carbon atoms, and one or more further additives selected from the excipient groups of glycols and surfactants.
---------- ----------------------------------------------------------------------

USE OF GINKGO BILOBA EXTRACTS FOR THE PREPARATION OF PHARMACEUTICAL COMPOSITIONS, AND METHOD OF COSMETIC TREATMENT USING A GINKGO BILOBA EXTRACT

(WO1998017295) 30.04.1998 A61K 8/97 ROC
The invention relates to the use of at least one active ingredient capable of being obtained by extraction from Ginkgo biloba for the preparation of a composition with immunomodulatory activity. The invention also relates to a method for the cosmetic treatment of sensitive skins.
---------- ----------------------------------------------------------------------

PESTICIDAL METHODS, COMPOSITIONS AND DEVICES

(WO1998016106) 23.04.1998 A01N 25/16 GLOBOL CHEMICALS (UK) LIMITED
Novel methods, compositions and devices are described, whereby pests such as insects may be controlled by applying to the pests or their locus a foamed pesticidal composition including an effective amount of at least one pesticidally active agent. The application is conveniently achieved via a pressurised can device which discharges the foam via a nozzle under the effect of a lower alkane propellant. Compositions comprising the pesticidally active agent entrained in a predominently aqueous carrier are also described, both in the foamed condition and the preliminary, unfoamed, condition.
---------- ----------------------------------------------------------------------

AEROSOL ANTIPERSPIRANT COMPOSITION

(WO1998013014) 02.04.1998 A61K 7/32 UNILEVER PLC
Transparent aerosol antiperspirant compositions comprising an active antiperspirant salt, a carrier capable of solubilizing the active antiperspirant salt and having an effective solubility parameter of 11 to 13, and a liquified hydrocarbon gas propellant are disclosed.
---------- ----------------------------------------------------------------------

ANTIVIRAL COMPOSITIONS

(WO1998010768) 19.03.1998 A61K 31/52 GLAXO GROUP LIMITED
This invention relates to a topical pharmaceutical formulation suitable for use in treating virus infections of the skin and mucosa, and in particular it relates to topical formulations containing compounds having antiviral activity, particularly those active against Herpes Simplex Virus, with the exeption of aciclovir. The formulations are oil-in-water topical pharmaceutical formulations comprising a dispersed oil phase and a continuous aqueous phase comprising water, solubilised antiviral compound and at least 10 % of diethylene glycol monoethyl ether by weight of the formulation.
------------------------------------------ --------------------------------------

SOLID COSMETIC COMPOSITION WITH HEXANEDIOL-BEHENYL BEESWAX

(WO1998009612) 12.03.1998 A61K 8/26 COLGATE-PALMOLIVE COMPANY
Disclosed is a solid (e.g., cream, such as semi-solid or soft solid) cosmetic composition containing an active cosmetic material (e.g., a deodorant active, an antiperspirant active, a sunscreen, an insect repellent and/or an anti-fungal agent), volatile (e.g., cyclomethicone) and linear chain (e.g., dimethicone and/or phenyl trimethicone) silicone materials, and at least one gelling agent. The at least one gelling agent includes hexanediol-behenyl beeswax, and is included in the composition in an amount sufficient to provide the solid composition. By incorporating the hexanediol-behenyl beeswax as a gelling agent, conventional gelling agents such as fatty alcohols and hydrogenated castor oil need not be incorporated in the composition. When...
-------------------------- ------------------------------------------------------

COMPOSITION FOR PHARMACEUTICAL APPLICATIONS

(WO1998006438) 19.02.1998 A61K 9/00 MEDLOGIC GLOBAL CORPORATION
A pharmaceutic composition includes a pharmaceutically acceptable carrier, comprising a reverse thermally viscosifying polymer network. The polymer network includes at least one responsive polymer component, said responsive component capable of aggregation in solution in response to an environmental stimulus and at least one structural component, said structural component exhibiting self-repulsive interactions over use conditions. The responsive component is randomly bonded to said structural component and the polymer network characterized in that it viscosifies in response to said environmental stimulus. The composition further includes a pharmaceutically active agent which imparts a pharmaceutic effect, said carrier and said agent dispose...
------------------ --------------------------------------------------------------

SHAMPOO COMPOSITIONS

(WO1998004237) 05.02.1998 C11D 3/33 THE PROCTER &GAMBLE COMPANY
A shampoo composition comprising: (a) from about 1 % to about 60 % by weight of water-soluble surfactant selected from anionic surfactant, nonionic, amphoteric and cationic surfactants and mixtures thereof; (b) from about 0.001 % to about 10 % by weight of cosmetic agent and/or pharmaceutical active; (c) from about 0.001 % to about 10 % by weight of diamine dipolyacid component and/or salts thereof; and (d) water. The shampoo compositions of the invention are valuable for the provision of improved hair feel, hair shine and hair volume attributes as well as improved rinsibility and excellent lather volume, cleansing and hair conditioning characteristics.
------------------------------------------ --------------------------------------

METHOD FOR TREATMENT OF SYSTEMIC SCLEROSIS AND RELATED FIBROTIC DISEASES

(WO1998002173) 22.01.1998 A61K 38/39 THE UNIVERSITY OF TENNESSEE RESEARCH CORPORATION
The present invention is directed to a method and pharmaceutical formulations for the treatment of systemic sclerosis in mammals, by oral administration of collagen, including type (I) collagen, or biologically active peptide fragments thereof.
-- ------------------------------------------------------------------------------

LIQUID ANTISEPTIC SOAP FOR SKIN CARE

(WO1998002139) 22.01.1998 C11D 3/48 INDÚSTRIA E COMÉRCIO DE COSMÉTICOS NATURA LTDA.
The present invention provides an antiseptic, liquid, mild action composition, with the specific function of skin impurities removal and excessive oiliness fight in order to avoid, specially, the sebaceous follicle inflammation and infection. This is obtained through active components association, constituted of mild surfactant agents, for skin cleansing, together with a specific keratolytic agent, being this d-tartaric acid, and two antiseptic agents, being them predominantly triclosan, and thymol, as cooperative. This set of active components is dissolved and/or dispersed in an aqueous vehicle, which also contains adjuvant components, chosen between preserving agents, thickeners, solutizers, humectant and refreshing agents and perfumes us...
---------------------------------------------------------- ----------------------

DESICCANT COMPOSITION, IN EMULSION FORM, FOR THE SKIN

(WO1998002138) 22.01.1998 A61K 8/26 INDÚSTRIA E COMÉRCIO DE COSMÉTICOS NATURA LTDA.
Desiccant composition, in emulsion form, for the skin, which comprises a new set of active agents with proven effectiveness to collaborate in the reconstitution of the skin affected by excessive skin secretions, turning it dryer until it acquires the characteristics of normal skin, associated to the reduction of local irritations and inflammations incidence, observed mainly in cases of acne. The referred active agents set is constituted by the association of two inorganic desiccant agents, kaolin and titanium dioxide, with several organic components, namely: a skin renovating agent, allantoin; a moisturizing agent, panthenol; a cicatrizant agent, calendula extract; an antiseptic agent, benzalconial chloride; an anti-inflammatory agent, bisa...
------------------ --------------------------------------------------------------

COMPOSITION IN GEL FORM FOR SKIN OILINESS BALANCING

(WO1998002137) 22.01.1998 A61K 8/34 INDÚSTRIA E COMÉRCIO DE COSMÉTICOS NATURA LTDA.
The present invention provides a fluid gel for skin care, exhibiting antiseptic action, of keratolytic action, which promotes gentle refreshing sensation when applied to the skin. It is constituted of a new active substances set, each one of them providing a specific action, namely: a renovating agent, allantoin, a moisturizing agent, sodium PCA, a skin restoring agent, $i(Aloe vera) extract, a keratolytic agent, salicylic acid, an antiseptic agent, triclosan, two skin oiliness regulation agents, Hawthorn extract and $i(Cytobiol iris) extract, which cooperate in skin oiliness regulation, controlling secretion excess and, or sebaceous glands or follicle obstruction, avoiding skin irritations. These active substances are formulated with usual...
-------------------------------------------------- ------------------------------

SKIN MOISTURIZING AND PROTECTIVE COSMETIC COMPOSITIONS

(WO1998001107) 15.01.1998 A61K 8/29 INDÚSTRIA E COMÉRCIO DE COSMÉTICOS NATURA LTDA.
The present invention refers to skin moisturizing and protective cosmetic compositions against ultraviolet and infrared radiation, comprising a new active components association, formulated with vehicles and additives already known by themselves. Specifically, these compositions contain an active components set comprising: (a) a physical filter, constituted of coated titanium dioxide and/or titanium dioxide and mica, in a general ratio varying between 0,500 % to 6,000 % by weight; (b) a chemical filter, constituted of at least one component of the group constituted of octyl metoxycinnamate, butyl metoxy dibenzoyl methane, benzophenone 3, in a general ratio varying between 2,700 % to 20,000 % by weight; (c) an antiradicals agent, being this ...
---------- ----------------------------------------------------------------------

ANTIPERSPIRANT/DEODORANT FLUID COMPOSITION

(WO1998000097) 08.01.1998 A61K 8/31 UNILEVER PLC
A fluid arm treatment composition is provided including a deodorant and/or antiperspirant active, a cross-linked non-emulsifying siloxane elastomer and a volatile siloxane. The compositions were found not to leak. They also have improved efficacy, faster absorption, anti-whitening and other properties.
------------------------------------------------------------------ --------------

DEVICE FOR TOPICAL TREATMENT OF ACNE AND ITS METHOD OF MANUFACTURE

(WO1997048387) 24.12.1997 A61K 8/02 LAVIPHARM S.A. FOTINOS, Spiros
The invention provides a device in the form of a patch for the topical application of an anti-acne formulation, comprising a synthetic pressure-sensitive adhesive used as a carrier or associated with a carrier, said carrier having the anti-acne formulation uniformly distributed therein, characterized in that said anti-acne formulation comprises effective amounts of at least two active ingredients from at least two different groups of active ingredients and in that said at least two different groups are selected from the group comprising keratolytic agents, anti- irritant agents, antiseptic agents, antimicrobial agents, hormones, hormone- agonists, hormone-antagonists and other agents suitable for treating acne.
-- ------------------------------------------------------------------------------

SKIN WASH COMPOSITIONS COMPRISING TRICLOCARBAN AND SURFACTANTS

(WO1997048377) 24.12.1997 C11D 1/66 SMITHKLINE BEECHAM PLC CHARLTON, Lynda, Rosemary McGILLYCUDDY, Juliet, Teresa
A skin wash composition for topical application to water- wetted skin comprising triclocarban as an active antibacterial agent formulated in a mild and non-irritant detergent base consisting of a mixture of a non-ionic alkylpolyglucoside surfactant and an amphoteric surfactant in the absence of an anionic surfactant.
---------------------------------------------------------- ----------------------

COSMETIC COMPOSITION CONTAINING AN ANTIPERSPIRANT OR DEODORANT AND A MOISTURISING CREAM

(WO1997048373) 24.12.1997 A61K 07/32 UNILEVER PLC UNILEVER NV
An antiperspirant or deodorant cosmetic composition suitable for topical application to the human skin, comprising: i) an antiperspirant or deodorant active; ii) a moisturising cream; and optionally iii) a carrier for the antiperspirant or deodorant active.
-------------------------- ------------------------------------------------------

METHOD AND COMPOSITION FOR SKIN LIGHTENING

(WO1997047280) 18.12.1997 A61K 8/06 UNILEVER PLC UNILEVER N.V.
A method and composition is provided for treating skin to achieve lightening by employing an active of structure (I), wherein R is selected from the group consisting of hydrogen, hydroxy and C1-C30 alkyl or aryl groups radicals; and R1 is selected from the group consisting of hydrogen and C1-C30 alkyl or aryl radicals.
------------------------------------------------------------------ --------------

COMPOSITION

(WO1997047171) 18.12.1997 A61K 9/08 SMITHKLINE BEECHAM PLC CHARLTON, Lynda, Rosemary MCGILLYCUDDY, Juliet, Teresa OWEN, Sharon
A skin wash composition intended for topical application to water-wetted skin comprising an 'alpha'-hydroxy acid active ingredient formulated in a mild and non-irritant detergent base consisting of a mixture of a non-ionic alkylpolyglucoside surfactant and an amphoteric surfactant.
------------------ --------------------------------------------------------------

COSMETIC COMPOSITIONS

(WO1997044049) 27.11.1997 A61K 8/06 THE PROCTER &GAMBLE COMPANY LANGLOIS, Anne WALLBANKS, Yasmin, Tina
A cosmetic composition in the form of a water-in-oil emulsion comprising: (a) continuous oil phase and; (b) discontinuous aqueous phase comprising (i) water; (ii) acidic skin care active which is insoluble in said aqueous phase; and (iii) nonionic surfactant selected from polyoxyethylene-polyoxypropylene ethers of C4-C22 alcohols, and mixtures thereof. The compositions of the invention provide increased product stability and improved acidic skin care active solubility.
-------------------------- ------------------------------------------------------

NEW MEDICAMENTS CONTAINING GELATIN CROSS-LINKED WITH OXIDIZED POLYSACCHARIDES

(WO1997041899) 13.11.1997 A61K 9/70 INNOGENETICS N.V. SCHACHT, Etienne DRAYE, Jean-Pierre DELAEY, Bernard
The present invention relates to a medicament comprising a biopolymer matrix comprising gelatin cross-linked with an oxidized polysaccharide. Preferably said oxidized polysaccharide comprises an oxidized dextran or an oxidized xanthan. Preferably said medicament is a wound dressing. Preferably said matrix is in the form of a hydrated film, a hydrated or dry foam, dry fibres which may be fabricated into a woven or non-woven tissue, hydrated or dry micro beads, dry powder; or said matrix is covered with a semipermeable film, so as to control the humidity of the wound covered with the dressing, with the permeability chosen so as to maintain this humidity within a therapeutically optimal window. The invention also relates to a controlled releas...
-------------------------- ------------------------------------------------------

REPARATION AND PREVENTION OF FIBROTIC LESIONS

(WO1997041830) 13.11.1997 A61K 31/4412 MARGOLIN, Solomon, B.
In a preferred embodiment, drugs having pharmacological properties which are useful in the medicinal therapy of fibrotic disease for the reparation and prevention of fibrotic lesional tissues, such drugs including as active ingredient (s) one or more N-substituted 2-(1H) pyridone(s) and/or N-substituted 3-(1H) pyridones. The composition of this invention is novel as an anti-fibrotic drug, namely, as an agent for the reparation and prevention of fibrotic lesions.
-- ------------------------------------------------------------------------------

BIOLOGICALLY ACTIVE COMPOSITION

(WO1997040818) 06.11.1997 A61K 9/06 BIOGLAN AB LINDAHL, Åke BRYLAND, Rickard
A biologically active stick composition comprising a biologically active agent dissolved in a carrier system including an unsaturated fatty acid alcohol in mutual dissolution with an alkylene glycol as a solvent for said biologically active agent and a stiffening agent therefor, said stiffening agent imparting stick consistency to the composition, said alkylene glycol preferably being present in an amount of more than 12%. The composition can be prepared by dissolving the active agent in the solvent, combining the solution with the stiffening agent and shaping the formulation into a stick. The composition is especially intended for use as a medicament, preferably in the treatment of dermatological conditions, where it has been found to poss...
------------------------------------------------------------------ --------------

TOPICAL COMPOSITIONS COMPRISING DISPERSED SURFACTANT COMPLEX

(WO1997040817) 06.11.1997 A61K 8/40 THE PROCTER &GAMBLE COMPANY
Disclosed are topical skin care compositions which comprise from about 0.1 % to about 20 % by weight of an amine oxide surfactant, from about 0.1 % to about 20 % by weight of an anionic surfactant, from about 0.001 % to about 20 % by weight of a skin active agent, from about 40 % to about 99 % by weight of water, and dispersed surfactant complex formed prior to or during formulation of the composition, which complex comprises from about 25 % to about 100 % of the cationic surfactant of the composition and from about 25 % to about 100 % of the anionic surfactant of the composition. The skin care compositions are useful for clarifying the skin and reducing pore size, while providing improved deposition or efficacy of skin active agents onto t...
---------------------------------------------------------- ----------------------

TOPICAL COMPOSITIONS COMPRISING DISPERSED SURFACTANT COMPLEX

(WO1997040816) 06.11.1997 C11D 1/62 THE PROCTER &GAMBLE COMPANY
Disclosed are topical skin care compositions which comprise from about 0.1 % to about 20 % by weight of a cationic surfactant, from about 0.1 % to about 20 % by weight of an anionic surfactant, from about 0.001 % to about 20 % by weight of a skin active agent, from about 40 % to about 99 % by weight of water, and dispersed surfactant complex formed prior to or during formulation of the composition, which complex comprises from about 25 % to about 100 % of the cationic surfactant of the composition and from about 25 % to about 100 % of the anionic surfactant of the composition. The skin care compositions are useful for clarifying the skin and reducing pore size, while providing improved deposition or efficacy of skin active agents onto the s...
-------------------------------------------------- ------------------------------

METHODS OF REGULATING SKIN CONDITION WITH CENTELLA ASIATICA EXTRACT

(WO1997039734) 30.10.1997 A61K 8/63 THE PROCTER &GAMBLE COMPANY
The present invention relates to the topical use of Centella asiatica for regulating the condition of mammalian skin, especially for regulating tactile and/or visible signs of skin aging, e.g., ameliorating lines and wrinkles and prophylactically treating loss of elasticity. The present invention also relates to a method for prophylactically treating tactile and/or visible signs of loss of skin elasticity, including loss of elasticity associated with skin aging, involving the topical application of a composition containing substantially pure asiatic acid as the active agent for said regulation. In a preferred embodiment, the active consists essentially of substantially pure asiatic acid, more preferably the active consists of substantially ...
---------------------------------------------------------- ----------------------

HERBAL TREATMENTS FOR IMPROVING SKIN APPEARANCE

(WO1997036568) 09.10.1997 A61K 8/97 SMITH, Walter, P.
The invention provides herbal treatments for aged skin employing valerian extracts and other active herbal agents that are effective as relaxants. Surprisingly, mere ingestion of valerian tea on a daily basis is effective to reduce deep wrinkles. The treatments are particularly effective on persons afflicted by stress and are shown by clinical tests to reduce wrinkles and acne lesions and to improve skin texture and skin color without an increase in puffiness such as might be expected from mere hydration of the skin. The herbal agents can be administered either in a tea or a topical composition, and a combination of the two treatments is particularly effective. A preferred herbal agent is an aqueous valerian root extract. Other herbal agent...
------------------------------------------ --------------------------------------

LOW RESIDUE ANTIPERSPIRANT STICK COMPOSITION

(WO1997034577) 25.09.1997 A61K 07/32 COLGATE-PALMOLIVE COMPANY
Disclosed are antiperspirant stick compositions that exhibit substantially no visible residue (whitening) upon application to the skin or after drying. The compositions include both emollients that are silicone materials and emollients that are not silicone materials, these materials having a refractive index of at least 1.4460, in addition to including a vehicle (for example, cyclomethicone), a gelling agent (for example, stearyl alcohol and hydrogenated castor oil) and the active antiperspirant material (for example, particulate antiperspirant metal salts). These compositions reduce the necessity of using expensive silicone materials, while still achieving antiperspirant compositions with substantially no visible residue.
---------------------------------------------------------- ----------------------

METHODS OF USING EMU OIL AND ACTIVE FRACTIONS THEREOF AS AN INSECT REPELLENT

(WO1997033594) 18.09.1997 A01N 37/06 AGRAQUEST, INC. THE PERKIN ELMER CORPORATION MANKER, Denise, C. MARRONE, Pamela, Gail JUDD, Stephen
This invention provides a method for repelling biting insects such as mosquitoes by topically applying to the skin of a subject emu oil, fractions of emu oil obtained by flash chromatography or a composition comprising emu oil and citronella. Also provided are methods for repelling biting insects by topically applying diluted fractions of emu oil. The invention also provides a compound useful in repelling biting insects having the NMR spectrum of Figure 3, that is ultraviolet light sensitive and is reactive to vanillin/sulfuric acid. Also provided are compounds useful in repelling biting insects having the NMR spectrum of Figure 4, that is not ultraviolet light sensitive and is not reactive to vanillin/sulfuric acid. A composition for repel...
------------------ --------------------------------------------------------------

CLEANSING AND MOISTURIZING SURFACTANT COMPOSITIONS

(WO1997033561) 18.09.1997 C11D 1/62 JOHNSON &JOHNSON CONSUMER PRODUCTS, INC.
Cleansing surfactant compositions are provided which cleanse, condition and moisturize the skin and hair and which exhibit a low degree of irritation to the eyes. These cleansing compositions preferably contain the following components: (a) a surfactant portion containing: 1. a non-ionic surfactant; 2. an amphoteric surfactant; and 3. an anionic surfactant; the total concentration of said non-ionic, amphoteric and anionic surfactants being present in the composition in an amount from about 5 to about 20 percent by weight of said cleansing composition; and (b) a substantive humectant present in the composition in an amount from about 0.01 to about 3 percent by weight of said cleansing composition. The substantive humectants used in the prese...
---------------------------------------------------------- ----------------------

9-CIS-RETINOIC ACID ESTERS AND AMIDES AND USES THEREOF

(WO1997032839) 12.09.1997 A61K 31/165 MOLECULAR DESIGN INTERNATIONAL, INC.
Esters and amides of 9-cis-retinoic acid are synthesized, formulated into pharmaceutically acceptable carriers and administered for the treatment of acne vulgaris, cystic acne, hyperpigmentation, hypopigmentation, psoriasis, dermal and epidermal hypoplasia and kerotoses, the reduction of wrinkling of the skin as an incident of aging and actinic damage, normalization of the production of sebum, the reduction of enlarged pores, promoting the rate of wound healing, limiting of scar tissue formation during healing and the like. They are additionally useful for treatment or amelioration of the same additional classes of skin disorders as is retinoic acid itself and other retinoids. These disorders include ichthyoses (e.g., ichthyosis hystrix, ep...
---------- ----------------------------------------------------------------------

SKIN TREATMENT WITH SALICYLIC ACID ESTERS AND RETINOIDS

(WO1997030691) 28.08.1997 A61K 8/06 UNILEVER PLC UNILEVER N.V.
A cosmetic method and composition are provided for treating skin conditions including those arising from dermatologic disorders, chronoaging and environmental abuse. Non-ring esterified C11-C30 alkyl or alkenyl esters of salicylic acid in combination with retinol or a C18-C30 fatty acid ester thereof used as the active components are applied to the skin in a pharmaceutically acceptable carrier. Most preferred as the salicylate ester is tridecyl salicylate and as the retinol fatty acid ester is retinyl linoleate.
--------------------------------------------------------------------------------

MAKE-UP REMOVING COMPOSITIONS COMPRISING STARCH AND A SURFACE ACTIVE AGENT

(WO1997028780) 14.08.1997 A61K 8/73 UNILEVER PLC UNILEVER N.V.
A cosmetic composition comprising a surface active agent and 5 to 40 wt.% particulate starch can be used to remove make-up. It has sensory properties comparable to cold creams and a foaming capacity comparable to a typical facial wash product on addition of water.
---------------------------------------------------------- ----------------------

PERSONAL CARE COMPOSITION

(WO1997027835) 07.08.1997 A61K 8/34 UNILEVER PLC UNILEVER N.V.
A personal care composition in the form of an aqueous liquid comprises: (i) a lipid composition comprising two components D and E, where D is a molecule having one long hydrocarbon chain and a hydrophillic head group and E is a material which comprises at least one of a compound selected from 3'beta'-sterol; squalane; squalene; saponins or sapogenins of the plant steroid or triterpenoid type; di and tri terpenes such as phytol, retinol and amyrin; and mixtures thereof, wherein D and E are respectively present at levels within the range 0.1 to 10 wt.% and 0.2 to 12 wt.% based on the total composition; (ii) a surface active agent selected from anionic, nonionic, cationic, zwitterionic, amphoteric surface active agents, soap and mixtures there...
-- ------------------------------------------------------------------------------

USE OF FLUVASTATIN DERIVATIVES IN SKIN DISEASE AND TOPICAL COMPOSITIONS CONTAINING THEM

(WO1997026874) 31.07.1997 A61K 31/404 NOVARTIS AG KRIWET, Katrin RYDER, Neil, Stewart WERNER, Andreas
The invention concerns topical aqueous, lower alkanol-free pharmaceutical compositions containing the compound of formula (I) in racemic or optically active form, in free acid form or in the form of a physiologically-hydrolysable and -acceptable ester or a 'delta'-lactone (internal ester) thereof or in salt form, e.g. emulsion gels; it further concerns the use of that compound in the preparation of a medicament for the treatment of acne, and a method of topical treatment with that compound of a skin condition using a 2- compartment applicator.
-------------------------------------------------- ------------------------------

COSMETIC COMPOSITIONS

(WO1997020540) 12.06.1997 A61K 8/06 THE PROCTER &GAMBLE COMPANY GOLDSWORTHY, Maxine, Jane JAKUBOVIC, David, Andrew JAMES, Martin, Ian SCALLY, James, Joseph WATSON, Andrew, David
A cosmetic composition in the form of a water-in-oil emulsion comprising: (a) discontinuous aqueous phase comprising an aqueous or hydroalcoholic solution of acidic skin care active; (b) continuous oil phase; and (c) pigment which has been coated with organosilicon component selected from a polyorganosiloxane and a silane, and mixtures thereof; characterised in that the aqueous phase has a pH of less than about 6 and the coated pigment has a hydrogen potential of less than about 2.0 ml H2/g of coated pigment. The compositions of the invention provide benefits in terms of reducing hydrogen gas generation and improving product stability.
------------------------------------------ --------------------------------------

ANTIPERSPIRANT CREAM COMPOSITIONS HAVING IMPROVED RHEOLOGY

(WO1997017942) 22.05.1997 A61Q 5/10 THE PROCTER &GAMBLE COMPANY
Disclosed are anhydrous antiperspirant cream compositions that are substantially free of polymeric or inorganic thickening, and have improved product stability and spreading performance. These compositions have a rheology profile characterized by select product hardness (from about 75 gram force to about 500 gram force), delta stress (from about 300 dyne/cm2 to about 8,000 dyne/cm2) and static yield stress (at least about 1,000 dyne/cm2) values. The new rheology profile is preferably applied to antiperspirant cream compositions comprising from about 0.1 % to about 20 % by weight of a crystalline gellant, from about 10 % to about 80 % by weight of an anhydrous liquid carrier for the crystalline gellant having a solubility parameter of from a...
---------------------------------------------------------- ----------------------

PHARMACEUTICAL COMPOSITION FOR TOPICAL APPLICATION

(WO1997017062) 15.05.1997 A61K 9/08 RECKITT &COLMAN PRODUCTS LIMITED POILE, Steven HARRISON, Julian, Earle
A pharmaceutical composition for topical application comprising: i) a pharmaceutically active agent, and ii) a pharmaceutically acceptable vehicle, the pharmaceutical composition having a pH of 7 to 12 or a pH of 2 to 4, characterised in that the pharmaceutically active agent is dissolved at or below its saturation concentration and that the composition becomes supersaturated when the pH is changed to below 7 or greater than 4.
-- ------------------------------------------------------------------------------

TOPICAL COMPOSITIONS FOR REGULATING THE OILY/SHINY APPEARANCE OF SKIN

(WO1997017060) 15.05.1997 A61K 8/42 THE PROCTER &GAMBLE COMPANY
Disclosed are topical compositions for regulating the oily and/or shiny appearance of skin. The compositions contain: (a) an active for regulating the oily and/or shiny appearance of skin, said active consisting essentially of one or more compounds selected from the group consisting of niacinamide, pyridoxine, panthenol, and pantothenic acid, in an amount that is safe and effective for regulating the oily and/or shiny appearance of the skin; and (b) a cosmetically acceptable carrier for said active. Also disclosed are methods of regulating the oily and/or shiny appearance of skin by topical application of such compositions.
-------------------------- ------------------------------------------------------

EXTRACTS OF SHARK CARTILAGE

(WO1997016197) 09.05.1997 A61K 35/60 LES LABORATOIRES AETERNA INC.
The present invention relates to cartilage extracts and to a method of producing the same. Shark cartilage extracts having anti-angiogenic, anti-tumoral, anti- inflammatory and anti-collagenolytic activites have been obtained by an improved process. The process comprises the steps of obtaining a homogenate of cartilage in an aqueous solution, this homogenate being separated in a solid fraction (SOLID EXTRACT) and a liquid fraction which was further fractionated to obtain a LIQUID EXTRACT having molecules of a molecular weight comprised between 0 to 500 kDa. The composition of the liquid extract has then been investigated by different ways. Further fractionation of this extract led to the preliminary characterization of some of its active com...
-------------------------------------------------- ------------------------------

PERSONAL CLEANSING COMPOSITION

(WO1997016168) 09.05.1997 A61K 8/31 COLGATE-PALMOLIVE COMPANY
A personal cleansing composition which comprises (a) a skin cleansing effective amount of a surfactant or mixture of surfactants, (b) a hydrophobic active component in quantities which bring about a perceived effect on the skin, said effect selected from the group consisting of skin conditioning, skin protection from irritants and antibacterial agents, (c) a hydrocarbon containing component, and (d) a cationic polymer, the quantities of (c) and (d) selected so that the effect on the skin by component (b) is enhanced over the additive effects of (c) and (d) alone.
------------------ --------------------------------------------------------------

NON-POLYMERIC SUSTAINED RELEASE DELIVERY SYSTEM

(WO1997015285) 01.05.1997 A61K 9/00 ATRIX LABORATORIES, INC. DUNN, Richard, L.
The invention relates to a method and composition for forming an implant in situ within a body using non-polymeric materials, and the use of such implants as medical devices and drug delivery systems. The composition can be applied to an animal to treat periodontal disease or other tissue defect, enhance compatibility and performance of an implantable article, and deliver a biologically active agent.
---------- ----------------------------------------------------------------------

TOPICALLY APPLIED, STRUCTURAL CELLULITE TREATMENTS

(WO1997014412) 24.04.1997 A61K 8/365 MARY KAY INC.
New topically applied treatments for cellulite are shown by comparative data to effect structural improvements in cellulite-afflicted thigh area tissues including skin-thickening, thigh-firming and thigh-reduction. The disclosed treatments disrupt the skin's water barrier and elevate trans- epidermal water loss (TEWL) for extended periods of weeks or months and include methods of mechanical or solvent action, for example, tape stripping, or acetone washes. Preferred treatments use creams with active ingredients such as lactic acid to elevate TEWL, a retinoid, preferably vitamin A palmitate to disrupt barrier rebuilding and prolong elevation of TEWL levels, and a cerebroside to inhibit lipid synthesis and intensify the TEWL elevation. Diureti...
------------------ --------------------------------------------------------------

BARRIER DISRUPTION TREATMENTS FOR STRUCTURALLY DETERIORATED SKIN

(WO1997014403) 24.04.1997 A61K 8/67 MARY KAY INC.
New topically applied treatments for structurally deteriorated or otherwise aged skin are shown by comparative data to effect structural improvements in the deteriorated skin, as shown by skin-thickening data. The disclosed treatments dirsupt the skin's water barrier and elevate trans- epidermal moisture loss (TEML) for extended periods of weeks or months and include methods of mechanical or solvent action, for example, tape stripping, or acetone washes. Preferred treatments use cosmetic creams or gels with active ingredients such as lactic acid as a primary, water-soluble barrier disruption agent, a retinoid, for example vitamin A palmitate as a lipid-soluble barrier disruption agent and a particular cerebroside to inhibit barrier repair. S...
---------- ----------------------------------------------------------------------

LIQUID CRYSTAL COSMETIC COMPOSITION

(WO1997014394) 24.04.1997 A61K 8/02 UNILEVER PLC UNILEVER N.V.
A process for reversibly applying a cosmetic composition to the skin or hair comprises: a) contacting the skin or hair with the cosmetic composition, the composition comprising at least one amphiphilic material which is capable of forming a water-insoluble liquid crystal phase of greater than one-dimensional periodicity and a cosmetic agent; and b) when desired, removing the cosmetic composition by applying to the skin or hair a cleansing composition comprising a surface active agent and a hydrotrope capable of destroying the liquid crystal phase formed in step a). An advantage of such a system is that the cosmetic agent is strongly adhered to the skin or hair when applied and can be effectively removed therefrom when desired.
---------- ----------------------------------------------------------------------

A PHARMACEUTICAL COMPOSITION FOR ADMINISTRATION OF AN ACTIVE SUBSTANCE TO OR THROUGH A SKIN OR MUCOSAL SURFACE

(WO1997013528) 17.04.1997 A61K 9/127 DUMEX-ALPHARMA A/S NIELSEN, Lise, Sylvest HANSEN, Jens
Pharmaceutical compositions for administration of an active substance to or through a damaged or undamaged skin or mucosal surface or to the oral cavity including the teeth of an animal such as a human. The composition has advantageous properties with respect to release of the active substance from the composition and, furthermore, the composition is bioadhesive. The composition comprises the active substance and an effective amount of a fatty acid ester which, together with a liquid phase, is capable of generating a liquid crystalline phase in which the constituents of the composition are enclosed, the active substance having a solubility in the liquid crystalline phase of at most 20 mg/g at 20 °C, and a solubility in water of at most 10 ...
---------------------------------- ----------------------------------------------

ANTIPERSPIRANT AND DEODORANT COMPOSITIONS CONTAINING POLY(ETHENYLFORMAMIDE) THICKENER

(WO1997013496) 17.04.1997 A61K 8/02 THE MENNEN COMPANY
Disclosed is a cosmetic composition (solid or liquid, for example, including sticks and gels) containing an antiperspirant active aluminum-containing material, such as aluminum chlorohydrate, in a solvent therefor, and also containing poly(ethenylformamide) as a thickening agent of the composition. This composition can be an antiperspirant composition, where it contains an antiperspirant effective amount of the antiperspirant active aluminum- containing material, and can be applied to axillary regions of a human to reduce perspiration therefrom. Ammonium acetate can also be incorporated in the composition, to firm up the composition. The composition can be in the form of a gel, dispensed by extruding the gel through pores or slots in the top...
-- ------------------------------------------------------------------------------

MOLECULAR TRANSDERMAL TRANSPORT SYSTEM

(WO1997013482) 17.04.1997 A61K 9/70 MASIZ, John, J.
An efficient transdermal delivery system for delivering an active ingredient to the blood supply of a living body, comprising a vasodilator and/or topical counter irritant, an active ingredient, a permeation enhancer for the active ingredient, and a water soluble gum for binding the foregoing. A non-breathable layer also can be used for controlling the microenvironment at the transport site. Compression can be used to further enhance the blood supply at the transport site.
---------------------------------- ----------------------------------------------

PERIPHERALLY ACTIVE ANTI-HYPERALGESIC OPIATES

(WO1997009973) 20.03.1997 A61K 31/00 THE REGENTS OF THE UNIVERSITY OF CALIFORNIA ADOLOR CORPORATION YAKSH, Tony, L. FARRAR, John, J. MAYCOCK, Alan, L. LEWIS, Michael, E. DOW, Gordon, J.
Compositions and methods using the compositions for treatment of peripheral hyperalgesia are provided. The compositions contain an anti-hyperalgesia effective amount of one or more compounds that directly or indirectly interact with peripheral opiate receptors, but that do not, upon topical or local administration, elicit substantial central nervous system effects. The anti-diarrheal compound 4-(p- chlorophenyl)-4-hydroxy-N-N-dimethyl-'alpha','alpha'-diphenyl-1- piperidinebutyramide hydrochloride is preferred for use in the compositions and methods.
------------------------------------------------------------------ --------------

A NON-IRRITATING SKIN AND HAIR REJUVENATING COMPOSITION HAVING A pH BETWEEN 1 AND 6.5

(WO1997009965) 20.03.1997 A61K 8/04 ISP INVESTMENTS INC.
This invention relates to an acidic non- irritating lotion, cream or ointment for rejuvenating skin and hair which comprises a micronized, homogenized hydrogen of a cross-linked N-vinyl lactam polymer and an organic rejuvenating agent selected from the group consisting of pyruvic acid, a mono- or poly- carboxylated C1 to C20 hydrocarbon optionally substituted with from 1 to 3 hydroxy groups and ammonium and alkali metal salts of said acids and mixtures thereof including mixtures of the acids and/or said salts. The invention also relates to a cross-linked N-vinyl lactam polymer in the form of a stable, homogenized flowable hydrogel having microparticles which can be passed through a screen of between about 40 and about 350 mesh size and to th...
---------- ----------------------------------------------------------------------

PROTECTION FROM ULTRAVIOLET (UV) RADIATION-INDUCED SKIN DAMAGE BY TOPICAL TREATMENT WITH MELATONIN (N-ACETYL-5-METROXYTRYPTAMINE)

(WO1997006779) 27.02.1997 A61K 8/49 KISTLER, Gonzague, S.
The invention relates to a cosmetic topical composition for the protection of the skin of persons exposing themselves to the sun. Its active principle consists of at least one compound of formula (I), in which n is 1 or 2; R1 and R2 are identical or different from each other and are H, NH2, COOH, OH or acyl comprising from 1-4 carbon atoms or alkoxy comprising from 1 to 4 carbon atoms; R3 and R4 are, indenpendently from each other, H, F, Fr, Cl, I; X is OH or alkoxy comprising from 1-4 carbon atoms; Y is H, OH or NH2.
-- ------------------------------------------------------------------------------

COSMETIC GEL COMPOSITION HAVING REDUCED SKIN IRRITATION

(WO1997006778) 27.02.1997 A61K 07/32 THE MENNEN COMPANY
Disclosed is a glycol-containing base gel composition having reduced skin irritation potential, in which a cosmetically active agent (e.g., deodorant active agent, sunscreen, antiperspirant active agent, etc.) can be incorporated to provide a cosmetic gel (e.g., soft gel or stick) composition. The gelling agent for the gel composition can be a soap. The base gel composition includes at least one glycol having a structure of the formula H (OC3H6)nOH, where n represents the number of repeating propylene oxide groups and ranges from 1-80, with the provisos that: (1) more than zero, and up to 100 % by weight, of the glycol component, has n=3 or 4; (2) less than 20 % by weight of the glycol component has n=1; (3) not more than 90 % by weight of t...
---------- ----------------------------------------------------------------------

TRANSDERMAL NITRATE FORMULATION

(WO1997004757) 13.02.1997 A61K 9/70 CAL INTERNATIONAL LIMITED BYRNE, William McCAFFERTY, Dermot
A transdermal patch comprises a backing, an adhesive for applying the patch and a liner which is released to apply the patch. The adhesive contains an isosorbide mononitrate aspirinate as a pharmaceutically active product to achieve antianginal and platelet washing properties.
------------------------------------------ --------------------------------------

APPARATUS AND METHODS FOR IMPROVED NONINVASIVE DERMAL ADMINISTRATION OF PHARMACEUTICALS

(WO1997004728) 13.02.1997 A61F 13/00 ZHANG, Jie ZHANG, Hao
An apparatus, product formulation, and method for improved dermal permeation of pharmaceuticals wherein the apparatus includes a thin drug formulation reservoir and a heat-generating chamber separated by a first non-permeable wall, wherein the reservoir and chamber are formed in or supported by a housing. The drug formulation reservoir houses or is capable of housing a predetermined amount of a formulation containing pharmaceutically-active agent(s). The heat-generating/temperature-regulating chamber includes a medium for generating controlled heat, preferably a chemical composition made of carbon, iron, water and/or salt which is activated upon contact with air (oxygen). The function of the heat-generating/temperature-regulating element is...
------------------ --------------------------------------------------------------

COMPOSITIONS FOR TOPICAL DELIVERY OF ACTIVE INGREDIENTS

(WO1997003648) 06.02.1997 A61K 31/00 THE PROCTER &GAMBLE COMPANY
The compositions of the present invention are useful for the topical delivery of a wide variety of active ingredients. These compositions are particularly useful for treating conditions such as acne and its attendant skin lesions, blemisches, and other imperfections. These compositions are nonirritating to the skin and also provide skin feel benefits. These compositions can be in the form of leave-on products and products that are rinsed or wiped from the skin after use.
-------------------------- ------------------------------------------------------

STABLE TOPICAL COMPOSITIONS

(WO1997001326) 16.01.1997 A61K 9/107 THE PROCTER &GAMBLE COMPANY
The present invention relates to leave on, skin care compositions, comprising: (A) from about 0.001 % to about 20 % of an active ingredient, (B) from about 1 % to about 20 % of a stable, hydrophobic, structuring agent selected from the group consisting of saturated C16 to C30 fatty alcohols, saturated C16 to C30 fatty alcohols containing from about 1 to about 5 moles of ethylene oxide, saturated C16 to C30 diols, saturated C16 to C30 monoglycerol ethers, saturated C16 to C30 hydroxy fatty acids, and mixtures thereof, having a melting point of at least about 45 °C; and (C) from about 0.05 % to about 10 % of a hydrophilic surfactant selected from the group consisting of anionic surfactants, cationic surfactants, zwitterionic surfactants, and...
-------------------------- ------------------------------------------------------

A COMPOSITION COMPRISING AN ACTIVE AGENT DISSOLVED IN A GLASS-FORMING CARRIER AND A PROCESS FOR THE PREPARATION THEREOF

(WO1997000670) 09.01.1997 A61K 9/02 BIOGLAN AB LINDAHL, Åke
A biologically active composition comprising a solution of an active agent dissolved in a glass-forming carrier, which carrier comprises a glass-forming substance (A) containing a plasticizer (B), the amount of plasticizer preferably being selected so that the composition has a non-solid consistency. The composition can be prepared by dissolving the active agent in a melted mixture of the glass- forming substance and the plasticizer at a temperature below the decomposition temperature of said active agent. Use of the glass-forming carrier for dissolving a biologically active agent.
-------------------------------------------------- ------------------------------

METHODS AND ARTICLES OF MANUFACTURE FOR DIAGNOSIS OF MYCOBACTERIAL INFECTION

(WO1996041171) 19.12.1996 A61K 39/04 DYNAGEN, INC.
This invention relates to the use of purified single protein antigens as challenge antigens for eliciting a cell mediated immune response as a means of detecting mycobacterial infection in humans or animals. A cell mediated immune response is manifest in the subject as a delayed type hypersensitivity (DTH) skin reaction upon introduction by intradermal injection of purified single protein tuberculin antigens. The use of a combination of two or more single protein antigens with different species specificities permits the differential diagnosis of tuberculosis infection from infections due to atypical mycobacteria such as Mycobacterium avium, Mycobacterium intracellulare of Mycobacterium kansasii, and also permits classification of infected s...
-- ------------------------------------------------------------------------------

COMPOSITIONS AND METHODS FOR TOPICAL ADMINISTRATION OF PHARMACEUTICALLY ACTIVE AGENTS

(WO1996040086) 19.12.1996 A61K 9/00 NOVEN PHARMACEUTICALS, INC. KANIOS, David, P. GENTILE, Joseph, A. MANTELLE, Juan, A. SABLOTSKY, Steven
Compositions for topical application comprising a therapeutically effective amount of a pharmaceutical agent(s), a pharmaceutically acceptable bioadhesive carrier, a solvent for the pharmaceutical agent(s) in the carrier and a clay, and methods of administering the pharmaceutical agents to a mammal are disclosed.
---------- ----------------------------------------------------------------------

FRAGRANCES AND FLAVORANTS

(WO1996040070) 19.12.1996 A23L 1/22 EMISPHERE TECHNOLOGIES, INC. MILSTEIN, Sam, J.
Compositions useful in the delivery of fragrances and flavorant active agents, and particularly vaporous fragrances and flavorants, are provided. These compositions include a microsphere which includes: (a) the active agent; and (b) (i) a proteinoid, (ii) a modified hydrolyzed vegetable protein wherein the protein is modified with an amino reactive agent, or (iii) a combination thereof. Also contemplated is a method for preparing these compositions wherein the active agent is mixed with the proteinoid of hydrolyzed vegetable protein solution and the proteinoid or modified hydrolyzed vegetable protein is precipitated out of the solution, thereby forming a microsphere containing the active agent. In a further embodiment, the active agent is a...
--------------------------------------------------------------------------------

NOVEL USES FOR THYROID HORMONES OR THYROID HORMONE-LIKE COMPOUNDS

(WO1996040048) 19.12.1996 A61K 8/64 KARO BIO AB LAVIN, Thomas, N. VAHLQUIST, Anders, B.
This invention relates to the use of topically applied thyroid hormones and thyroid hormone-like compounds which are receptor binding ligands, either agonists or antagonists, to improve the appearance of the skin and underlying subcutaneous fat and improve certain medical conditions when applied topically. These compounds can be used to treat skin conditions such as stria, cellulite, roughened skin, actinic skin damage, intrinsically aged skin, photodamaged skin, lichen planus, ichthyosis, acne, psoriasis, wrinkled skin, and to diminish the size and improve the appearance of skin scarring from surgical or naturally occurring wounds, and to reduce the incidence of hyperkeratotic scarring. These hormones or hormone analogs will also increase ...
------------------ --------------------------------------------------------------

TREATMENT REGIME FOR SKIN

(WO1996037420) 28.11.1996 A61K 8/02 UNILEVER PLC UNILEVER N.V.
A method for a skin treatment regime and a respective product is provided which cosmetically improves human skin. The product includes a first composition containing at least one active and functioning to impart a first benefit to the skin. A second composition is provided which includes a second different active and imparts a second benefit to the skin. The first and second compositions are stored in respective separate containers, which nevertheless are joined together for reminding a consumer to use the compositions in tandem and to facilitate in one sale all necessary elements of a suggested regime. Packaging suitable for this purposes can be a series of stackable jars releasably lockable together through a threaded screw arrangement on...
-------------------------- ------------------------------------------------------

TOPICAL TREATMENT AND/OR PREVENTION OF SAGGING SUBCUTANEOUS MUSCLE AND OVERLYING CUTANEOUS TISSUE USING ACETYLCHOLINE PRECURSORS AND CATECHOLAMINES

(WO1996033709) 31.10.1996 A61K 31/131 PERRICONE, Nicholas, V.
Compositions for the topical treatment of sagging subcutaneous muscle and overlying cutaneous tissue containing catecholamines and/or acetylcholine precursors in a dermatologically acceptable carrier. Catecholamines include adrenaline, norepinepherine, dopamine and their precursors; catecholamine precursors such as tyrosine and phenylalanine are preferred. Acetylcholine precursors include dimethylaminoethanol, monoaminoethanol, choline, serine, and mixtures thereof. Preferred embodiments further contain at least one other ingredient that enhances skin penetration. In these and other embodiments, particularly those employing tyrosine and/or phenylalanine as a catecholamine precursor, other cofactors such as vitamin B6 and pantothenic acid or...
------------------------------------------------------------------ --------------

COMPOSITIONS AND METHODS FOR INDUCING DERMAL ANALGESIA

(WO1996033706) 31.10.1996 A61K 31/167 PHARMETRIX, INC.
Compositions and methods for the topical delivery of anesthetic agents to subjects in need thereof. The compositions are emulsified creams which contain at least one, and preferably two or more anesthetic agents, a cell envelope disordering compound, a lipophilic permeation enhancer, a polyoxyethylene ether, a solubilizing agent, a self-emulsifying agent and water. These multi-component systems effectively allow the penetration of the active agents to produce both a rapid onset and longer duration of anesthesia for the tissue to which the composition is applied, preferably under occlusion.
-------------------------------------------------- ------------------------------

GEL DEODORANT COMPOSITIONS

(WO1996032091) 17.10.1996 A61K 07/32 THE PROCTER &GAMBLE COMPANY
The present invention relates to a gel deodorant composition comprising: (a) from about 0.001 % to about 50 %, by weight of the composition, of deodorant active, fragrance, or combination thereof; (b) from about 0.01 % to about 15 %, by weight of the composition, of a soap gelling agent selected from the group consisting of salts of C12-C40 fatty acids, and combinations thereof; (c) from about 3 % to about 50 %, by weight of the composition, of glycerol, a polymer of glycerol, wherein said polymer has a weight average molecular weight of about 800 or less, or combinations therof; (d) from about 5 % to about 70 %, by weight of the composition, of one or more low molecular weight polyoxyethylene compounds having a structure according to Formu...
-- ------------------------------------------------------------------------------

LOW pH SKIN-TREATMENT COMPOSITION

(WO1996032089) 17.10.1996 A61K 31/01 THE ANDREW JERGENS COMPANY
A low pH skin-treatment composition employs cationic surfactants generally known to be skin irritants and a fatty acid, together with a hydrocarbon component in an oil-in-water emulsion. The addition of fatty acid to the cationic surfactant appears to form a complex which prevents the cationic surfactant from irritating the skin and at the same time substantially reduces pH of the composition. The resulting composition is not skin irritating, and reflects a pH of about 2-4. The composition may be used to restore pH of skin after exposure to alkaline compositions, and as a vehicle for the administration of active agents having an acidic pH.
------------------------------------------ --------------------------------------

SKIN CARE COMPOSITIONS CONTAINING RETINOIDS AND LIPOSOMES

(WO1996031194) 10.10.1996 A61K 8/67 JOHNSON &JOHNSON CONSUMER PRODUCTS, INC. WANG, Jonas, C., T. YUSUF, Mohammed LIU, Jue-Chen
This invention relates to a skin care composition containing a retinoid compound as an active ingredient, which is encapsulated in non-phospholipid liposomes and is chemically stable over a long period of time.
-------------------------- ------------------------------------------------------

DEODORANT COMPOSITIONS

(WO1996031189) 10.10.1996 A61K 8/04 UNILEVER PLC UNILEVER N.V.
A propellant driven deodorant composition for topical application to the human skin, comprising a deodorant active material comprising a cosmetically acceptable polyhexamethylene biguanide salt, a cosmetically suitable vehicle comprising a short chain monohydric alcohol, and a non polar propellant composition having a Hildebrand Solubility Parameter of less than 14.5 MPa1/2, characterized in that the composition additionally comprises an effective amount of water.
---------- ----------------------------------------------------------------------

CONTROLLED RELEASE OF MOLECULAR COMPONENTS COMPRISING THE USE OF FRAGMENTING AND EXPANDING MOLECULES

(WO1996030002) 03.10.1996 A61K 9/00 SANDIA CORPORATION
A method for releasing molecules (guest molecules) from the matrix formed by the structure of another molecule (host molecule) in a controllable manner has been invented. This method has many applications in science and industry. In addition, applications based on such molecular systems may revolutionize significant areas of medicine, in particular the treatment of cancer and of viral infection. Similar effects can also be obtained by controlled fragmentation of a source molecule, where the molecular fragments form the active principle.
------------------------------------------------------------------ --------------

TOPICAL FORMULATION FOR LOCAL DELIVERY OF A PHARMACEUTICALLY ACTIVE AGENT

(WO1996029988) 03.10.1996 A61K 9/06 ROENTSCH, George, Elmer SNYDER, William, Scott, II
This invention relates to a composition useful in the delivery of pharmaceutically active agents through the skin. In one embodiment of the invention, the composition is formulated with a non-steroidal anti-inflammatory agent, such as ibuprofen or ketoprofen. Such formulation is rapidly absorbed through the skin to provide local relief from pain. In another embodiment of the invention, the composition is formulated with an antineoplastic agent. Such formulation is rapidly absorbed through the skin to provide local delivery to subcutaneous tumors. The composition is useful for transcutaneous delivery of other pharmaceutically-active compounds.
------------------ --------------------------------------------------------------

POLY(HYDROXY ACID)/POLYMER CONJUGATES FOR SKIN APPLICATIONS

(WO1996029080) 26.09.1996 A61K 8/72 FOCAL, INC.
A method for alleviating the symptoms of a cosmetic or dermatologic skin condition is described. An effective amount of a poly(hydroxy acid)/polymer conjugate in a pharmaceutically or cosmetically acceptable vehicle is provided. Topical compositions of the conjugates with another cosmetic or dermatological agent, and compounds of the conjugates having attached physiologically active functional groups, are also provided.
---------- ----------------------------------------------------------------------

COMPOSITION FOR TREATING SKIN CONDITIONS COMPRISING AN INHIBITOR OF SKIN ISO-PHOSPHODIESTERASE

(WO1996027384) 12.09.1996 A61K 8/60 PARFUMS CHRISTIAN DIOR
The present invention relates to a composition for improving skin conditions containing as active ingredient a specific inhibitor of human skin iso PDE and a dermatological acceptable carrier. It also relates to a method for improving skin conditions comprising the application of this composition.
-- ------------------------------------------------------------------------------

CORTICOSTEROID-CONTAINING PHARMACEUTICAL COMPOSITION

(WO1996027376) 12.09.1996 A61K 9/12 MEDEVA PLC JONES, Julie, Irene BAKER, Anthony, Richard HALLS, Neil, Graham WATMOUGH, Peter MARRIOTT, Peter
The present invention provides a foamable pharmaceutical composition comprising a corticosteroid active substance, a quick-break foaming agent, a propellant and a buffering agent. The quick-break foaming agent typically comprises an aliphatic alcohol, water, a fatty alcohol and surface active agent. The compositions of the invention can be used to treat various skin disease, and in particular scalp psoriasis.
------------------ --------------------------------------------------------------

ANTI-TRANSFORMING GROWTH FACTOR-'beta' GENE THERAPY

(WO1996025178) 22.08.1996 A61K 38/00 THE UNIVERSITY OF UTAH
The present invention provides methods for reducing a pathology in a subject characterized by a deleterious accumulation of TGF-'beta'-induced extracellular matrix in a tissue by introducing a nucleic acid encoding a TGF-'beta'-specific inhibitory agent or active fragment thereof into a cell in the subject. In one embodiment, the nucleic acid encoding the TGF-'beta'- specific inhibitory agent is introduced into a cell in vivo by injection, for example, in skeletal muscle. In another embodiment, the nucleic acid encoding the TGF-'beta'-specific inhibitory agent is transfected into a cell ex vivo to obtain a cell expressing the agent, and the cell is then administered into the subject to be treated. TGF-'beta'-specific inhibitory agents of the...
------------------ --------------------------------------------------------------

A METHOD FOR THE TREATMENT OF HYPERPROLIFERATIVE EPITHELIAL SKIN DISEASES BY TOPICAL APPLICATION OF HYDROXYLATED AROMATIC PROTEIN CROSS-LINKING COMPOUNDS

(WO1996025159) 22.08.1996 A61K 31/165 THE GOVERNMENT OF THE UNITED STATES OF AMERICA, represented by THE SECRETARY, DEPARTMENT OF HEALTH AND HUMAN SERVICES
The present invention relates to a method of treating hyperproliferative epithelial lesions by topical administration. The method prevents growth and actively cross-links these aberrant cells, thereby killing the cells. The present invention is useful in control and prevention of hyperproliferative epithelial disorders, such as HPV- infected cell lesions, actinic keratosis, melanomas, and malignant and pre- malignant carcinomas.
-------------------------------------------------- ------------------------------

IMPROVED TOPICAL APPLICATION EMULSIONS

(WO1996024325) 15.08.1996 A61K 8/67 R.P. SCHERER CORPORATION PUNTO, Louis POTINI, Chim DUQUE, Pilar GOULD, Eva
The present invention relates in general to products for topical application to the skin, and more particularly to improved stable emulsions for containing water-soluble active ingredients, such as Vitamin C, glycolic acid, etc., which may nonetheless be packaged with gelatin capsules, and which have demonstrated improved stability. In particular, the invention relates to a novel polyethylene glycol-in-oil emulsion that is compatible with gelatin capsules.
-------------------------------------------------- ------------------------------

EXTRACTS OF SHARK CARTILAGE, PROCESS OF PRODUCTION AND USES THEREOF

(WO1996023512) 08.08.1996 A61K 35/60 LES LABORATOIRES AETERNA INC.
The present invention relates to cartilage extracts and to a method of producing the same. Shark cartilage extracts having anti-angiogenic, direct anti-tumor proliferating, anti-inflammatory and anti-collagenolytic activities have been obtained by an improved process. The process comprises the steps of obtaining a homogenate of cartilage in an aqueous solution, this homogenate being centrifuged and further fractionated to obtain a total extract having molecules of a molecular weight comprised between 0 to 500 KDa. The composition of the liquid extract has then been investigated by different ways. Further fractionation of this extract led to the preliminary characterization of some of its active components. Due to the multiplicity of biologi...
-- ------------------------------------------------------------------------------

REGULATING GENE EXPRESSION USING RETINOIDS WITH CH2OH OR RELATED GROUPS AT THE SIDE CHAIN TERMINAL POSITION

(WO1996021438) 18.07.1996 A61K 31/07 CORNELL RESEARCH FOUNDATION, INC. THE TRUSTEES OF COLUMBIA UNIVERSITY IN THE CITY OF NEW YORK
For the first time, certain retinoids with a side chain terminal CH2OH group or ester or ether thereof or aldehyde rather than a side chain terminal COOH group and substitution at the 4-position have been indicated to bind to nuclear receptors and to be biologically active in inducing cell differentiation of normal and tumor cells. These compounds activate gene expression through binding to nuclear receptor proteins. These compounds induce differentiation in normal and cancer cells and are useful for treating leukemias, and lymphomas, squamous cell carcinomas, deep (cystic) acne, psoriasis and photodamaged or aging skin. These compounds have stability and in vitro half-life advantages over and solubility differences from all-trans-retinoic ...
-------------------------------------------------- ------------------------------

ANHYDROUS COSMETIC COMPOSITIONS WITH DERMATOLOGICALLY ACTIVE AGENTS

(WO1996021422) 18.07.1996 A61K 07/48 MARY KAY INC.
Novel cosmetic compositions containing topical delivery systems for polar dermatologically active agents are disclosed. Active agents, for example, skin revitalizing alpha hydroxy acids are absorbed or adsorbed on to preferably porous carrier particles with the assistance of a viscous polar solvent such as glycerin, if necessary, and dispersed in an anhydrous cosmetic base along with a film-forming system. Such compositions can be formulated into a variety of different cosmetic products, for example eye shadows, eye treatment primers and lip treatments, each providing significant immediate cosmetic benefits and longer term dermatologic activity.
------------------------------------------------------------------ --------------

TRANSDERMAL DELIVERY SYSTEM WITH ADHESIVE OVERLAY AND PEEL SEAL DISC

(WO1996019205) 27.06.1996 A61K 9/70 THERATECH, INC.
A device (10) for administering an active agent to the skin or mucosa of an individual comprising a laminated composite of an adhesive overlay (26), a backing layer (14) underlying the central portion of the adhesive overlay, an active agent-permeable membrane (16), the backing layer and membrane defining a reservoir (12) that contains a formulation of the active agent, a peel seal disc (20) underlying the active agent-permeable membrane, a heat seal (22) about the periphery of the peel seal disc, the active agent-permeable membrane and the backing layer and a removable release liner (24) underlying the exposed overlay and peel seal disc. The adhesive layer is above and peripheral to the path of the active agent to the skin or mucosa and is...
---------------------------------------------------------- ----------------------

PERMANENT HAIR GROWTH-BREAKER

(WO1996017585) 13.06.1996 A61K 8/19 AL-RAMADHANI, Nabeel DAHAM, Sultan
A permanent hair growth-breaker composition (two active ingredients combined together in a single formulation) effective to prevent re-growth of unwanted hair from an area of skin from which said unwanted hair is removed by plucking from its roots comprises the following constituents in the stated proportions: zinc (elemental or as salt) 0.0001 to 10 g/100 ml, copper (elemental or as salt) 0.0001 to 10 g/100 ml, with excipient to a total volume of 100 ml. The composition may be formulated as a solution, lotion, cream, ointment, gel or similar which enables it to be kept at the site of application for a predetermined period. Optional constituents include viscosity builders for thickening; emollients/humectants to enhance skin feel; stabilise...
---------------------------------------------------------- ----------------------

SKIN CARE COMPOSITIONS AND METHODS

(WO1996014822) 23.05.1996 A61K 8/02 OSMOTICS CORPORATION
Skin care compositions and methods are provided for improving the appearance of skin affected by aging, photodamage and/or oxidative stress. Specifically, adhesive materials containing cosmetically active ingredients, e.g., one or more antioxidants such as Vitamins A, C and/or E, or moisturizers are applied to target areas including the frowline area of the forehead, the front of the neck, the crows-feet area near the eyes, the upper lip and the nasolabial area.
-------------------------------------------------- ------------------------------

METHODS AND DEVICES FOR IMMUNIZING A HOST TO TUMOR-ASSOCIATED ANTIGENS THROUGH ADMINISTRATION OF NAKED POLYNUCLEOTIDES WHICH ENCODE TUMOR-ASSOCIATED ANTIGENIC PEPTIDES

(WO1996014074) 17.05.1996 A61K 39/00 THE REGENTS OF THE UNIVERSITY OF CALIFORNIA
The invention is directed to methods for introducing biologically active peptides into a host administration of polynucleotides which operatively encode for the peptide of interest. In a preferred embodiment of the invention, a host who has been identified as having a tumor bearing at least one tumor-associated antigen is the recipient of a polynucleotide which operatively encodes for a foreign mimic of the tumor-associated antigen or a mutation of the self-antigen. The antigen-encoding polynucleotides are administered to host tissues which have a high concentration of antigen presenting cells in them relative to other host tissues. The method is particularly useful in treating cancer through induction of antigen-specific cytotoxic T lympho...
-------------------------------------------------- ------------------------------

SPRAYABLE COMPOSITIONS CONTAINING DISPERSED POWDERS AND METHODS FOR USING THE SAME

(WO1996014051) 17.05.1996 A61K 8/04 ESTEE LAUDER, INC.
Stable, sprayable compositions suitable for topical application to human skin or hair are provided, along with a method for their preparation. The compositions comprise water-in-oil emulsions and a variety of substantially insoluble dispersed powder. The compositions are useful for applying color to human skin or hair, for protecting human skin from ultraviolet radiation, and for treating human skin or hair with a dermatologically active agent. The compositions have unique suspending power, stability and dispersibility for water-in-oil emulsions.
-------------------------------------------------- ------------------------------

METHODS AND DEVICES FOR IMMUNIZING A HOST THROUGH ADMINISTRATION OF NAKED POLYNUCLEOTIDES WHICH ENCODE ANTIGENIC PEPTIDES

(WO1996013277) 09.05.1996 A61B 17/20 THE REGENTS OF THE UNIVERSITY OF CALIFORNIA
The invention is directed to methods for introducing biologically active peptides into a host by administration of polynucleotides which operatively encode for the peptide of interest. In a preferred embodiment of the invention, a mammal is desensitized to an antigen, in particular an allergen, through administration to the mammal of polynucleotides which operatively encode the antigen. The antigen-encoding polynucleotides are administered to host tissues which have a high concentration of antigen presenting cells in them relative to other host tissues. The method is particularly useful in treating allergies because the allergen-encoding polynucleotides of the invention to induce tolerance while suppressing IgE antibody formation. Devices a...
-------------------------- ------------------------------------------------------

PERSONAL CARE COMPOSITION

(WO1996012469) 02.05.1996 A61K 8/14 UNILEVER PLC UNILEVER N.V.
A personal care composition in the form of an aqueous liquid comprises: i) a lipid composition comprising three components A, B and C, where A is a molecule having at least two hydrocarbon chains and a polar head group for which: (a); B is molecule having one long chain and a polar head group; and C comprises a compound capable of assisting the formation of lipid bilayers and stabilising any lipid bilayers formed in the lipid composition; and the molar ratio of A:B:C is 1.0:1.5 to 6.0:1.1 to 8.0; ii) a surface active agent selected from anionic, nonionic, cationic, zwitterionic, amphoteric surface active agents, soap and mixtures thereof; and iii) a deposition aid. The composition may be in the form of for example a shower gel or facial cle...
---------------------------------------------------------- ----------------------

FORMULATIONS COMPRISING THERAPEUTICALLY- ACTIVE PROTEINS OR POLYPEPTIDES

(WO1996011705) 25.04.1996 A61K 9/70 PHARMADERM RESEARCH &DEVELOPMENT LTD. GERTNER, Avi RUBINSTEIN, Yosef
A pharmaceutical formulation, adapted particularly for transdermal administration, comprises an aqueous emulsion or dispersion including, in addition to the aqueous phase: (a) as active ingredient, at least one therapeutically active protein or polypeptide; (b) at least one pharmaceutically acceptable emulsifier; and optionally (c) an oil phase of at least one ester of a C1-12 aliphatic hydroxy compound with 1-4 alcoholic hydroxy groups with a C8-24 aliphatic carboxylic acid with 1-3 carboxylic acid groups. As regards (a), its presence or therapeutic effect is detectable in the bloodstream within <2 hours after commencing transdermal administration, and when (a) is insulin, this is desirably pretreated to increase its activity.
-- ------------------------------------------------------------------------------

IONTOPHORETIC DRUG DELIVERY SYSTEM, INCLUDING DISPOSABLE PATCH AND REUSABLE, REMOVABLE CONTROLLER

(WO1996010441) 11.04.1996 A61N 1/30 BECTON DICKINSON AND COMPANY
An iontophoretic drug delivery system (10) of the present invention includes a disposable patch, a reusable controller (14), a power source (16) and an electrode assembly (20) in electrical contact with at least two reservoirs, with at least one of the reservoirs containing an active formulation to be delivered to an applied area of a patient. The patch, power source (16) and electrode assembly (20) are for a single use and/or disposable, with the controller (14) being removably engageable with the patch for frequent reuse. In addition, the controller (14) may include a second power source for delivering sufficient energy to the controller for controlling and monitoring the electrical energy delivered by the electrode assembly (20). In an a...
-------------------------------------------------- ------------------------------

PHOSPHOLIPID- AND CHOLESTEROL-FREE AQUEOUS COMPOSITION FOR TOPICAL APPLICATION TO THE SKIN

(WO1996009812) 04.04.1996 A61K 8/14 YAMANOUCHI EUROPE B.V. RIJKSUNIVERSITEIT LEIDEN BOUWSTRA, Johanna, Aaltje
The invention relates to a phospholipid- and cholesterol-free aqueous composition for topical application to the skin comprising a pharmaceutically active principle and a vector system for the controlled and in- depth transport and release of said active principle through skin layers, said vector system consisting of at least one first, non-ionic surfactant, forming vesicles upon dispersion in water and a lamellar phase upon concentrating said vesicles, and at least one second, non-ionic, hydrophilic surfactant, the ratio of said at least one first, non-ionic surfactant and said at least one second, non- ionic surfactant being such that the vector system consists of flexible vesicles.
------------------------------------------------------------------ --------------

NEW USE OF PROSTAGLANDINS

(WO1996009055) 28.03.1996 A61K 31/5575 PHARMACIA AB STJERNSCHANTZ, Johan RESUL, Bahram
Composition comprising a therapeutically active and physiologically acceptable amount of prostaglandin A or prostaglandin J or a derivative of any one of these in a carrier, for treatment of psoriasis.
---------------------------------- ----------------------------------------------

SURFACE-ACTIVE FORMULATIONS

(WO1996006153) 29.02.1996 C11D 3/00 CIBA-GEIGY AG MOLDOVANYI, Laszlo
The invention relates to surface-active soap formulations, comprising: (a) 0.01 to 5 % by weight of a microbicidal active substance selected from the group consisting of (a1) phenol derivatives (a2) diphenyl compounds (a3) benzyl alcohols (a4) chlorohexidine (a5) C12-C14alkylbetaines and C8-C18fatty acid amidoalkylbetaines (a6) amphoteric surfactants and (a7) trihalocarbanilides; (b) 0.1 to 25 % by weight of one or more than one hydrotropic agent; (c) 0 to 10 % by weight of one or more than one synthetic surface-active substance or of a soap or of combinations of the cited substances; (d) 0 to 8 % by weight of a salt of a saturated and/or unsaturated C8-C22fatty acid; (e) 0 to 50 % by weight of a dihydric alcohol; (f) 0 to 70 % by weight of...
-------------------------------------------------- ------------------------------

SURFACE-ACTIVE FORMULATIONS

(WO1996006152) 29.02.1996 C11D 3/00 CIBA-GEIGY AG MOLDOVANYI, Laszlo
The invention relates to surface-active soap formulations, comprising (a) 0.01 to 0.2 % by weight of a microbicidal active substance, (b) 0.1 to 7.5 % by weight of one or more than one hydrotropic agent, (c) 0 to 2 % by weight of one or more than one synthetic surface-active substance or of a soap or of combinations of the cited substances and/or of a salt of a saturated and/or unsaturated C8-C22fatty acid, (d) 0 to 10 % by weight of a dihydric alcohol, (e) 0 to 70 % by weight of a monohydric alcohol, and (f) mains water or deionised water to make up 100 %. The formulation is used for the disinfection and cleansing of the human skin and hands and of hard objects.
------------------------------------------------------------------ --------------

COMPOSITION FOR TREATMENT OF SKIN BLISTERS

(WO1996005805) 29.02.1996 A61K 31/045 KAMME, Carl
A cream composition for treatment of or prophylaxis against skin blisters, such as blisters developing after sun-bathing, in solar dermatitis or in connexion with an infection by Herpes simplex virus comprises one member each straight chain primary aliphatic alcohols, preferably C12-C22 straight chain alcohols, branched chain primary aliphatic alcohols, preferably C12-C24 branched chain alcohols, and polyglycol ethers of primary aliphatic alcohols, preferably of C12-C22 primary alcohols. The composition is free from pharmacologically active agents in amounts that are therapeutically effective in man. Methods of treatment, a process for manufacture of the composition and the use of the composition for the manufacture of a medicament are also...
-- ------------------------------------------------------------------------------

A TOPICAL PREPARATION FOR THE PREVENTION AND TREATMENT OF LESIONS AND SORES ASSOCIATED WITH A HERPES VIRUS

(WO1996002244) 01.02.1996 A61K 31/194 AGIS INDUSTRIES (1983) LTD. WHALLEY, Kevin
The invention provides a topical pharmaceutical composition for the prevention and treatment of lesions and sores of the skin or mucosa associated with a herpes virus, comprising a carboxylic or dicarboxylic acid or a salt thereof as active ingredient therein, in combination with a pharmaceutically or cosmetically acceptable carrier.
------------------ --------------------------------------------------------------

DETERGENT COMPOSITION

(WO1996002230) 01.02.1996 C11D 3/16 UNILEVER PLC UNILEVER NV
An aqueous liquid cleansing and moisturising composition comprising a surface active agent and a benefit agent in which the surface active agent and benefit agent are separate but combinedly dispensable from a single packaging means in a predetermined ratio as discrete domains. Separating the benefit agent from the surface active agent results in improved deposition of the benefit agent.
-- ------------------------------------------------------------------------------

SOAP COMPOSITION

(WO1996002229) 01.02.1996 A61K 31/00 UNILEVER PLC UNILEVER N.V.
An aqueous cleansing and moisturising composition comprising 5-35 wt % C8 to C22 fatty acid; up to 10 wt % of a surface active agent, a benefit agent having a weight average particle size in the range 15 to 500 microns and structurant. The structurant is a material which causes the composition to adopt the lamellar phase or a material which structures the continuous liquid phase or a mixture thereof. The composition is substantially free of insoluble solid fatty acid or fatty acid soap.
---------------------------------- ----------------------------------------------

DETERGENT COMPOSITION

(WO1996002224) 01.02.1996 A61K 8/36 UNILEVER PLC UNILEVER N.V.
An aqueous liquid cleansing and moisturising composition comprisign a surface active agent, a skin benefit agent having a weight average particle size in the range 50 to 500 microns and a structurant. The composition is substantially free of insoluble fatty acid soap and has a viscosity of at least 5000 Pas at a shear stress of 0.01 Pa at 25 °C.
-------------------------------------------------- ------------------------------

TOPICAL COMPOSITIONS COMPRISING N- ACETYL-L-CYSTEINE

(WO1996000060) 04.01.1996 A61K 31/198 THE PROCTER &GAMBLE COMPANY
Compositions comprising (i) an active comprising NAC and (ii) a nonformaldehyde forming preservative and that are substantially free of formaldehyde and formaldehyde forming components. The compositions have higher efficacy and stability than corresponding compositions that do contain formaldehyde or formaldehyde forming components.
------------------------------------------ --------------------------------------

COMPOSITIONS FOR APPLYING ACTIVE SUBSTANCES TO OR THROUGH THE SKIN

(WO1995035095) 28.12.1995 A61K 8/14 YISSUM RESEARCH DEVELOPMENT COMPANY OF THE HEBREW UNIVERSITY OF JERUSALEM TOUITOU, Elka
A cosmetic or medical composition of topical application to the skin. It results in the transdermal passage of an active ingredient, or in the introduction of such agent into the skin. The essential components of such compositions are a phospholipid, a lower aliphatic alcohol of two to four carbon atoms, optionally with propylene glycol, water and a compatible active ingredient. The alcohol content is generally from 20 to 50 %, and when glycol is present, the combined percentage of alcohol and glycol being up to about 70 %. The compositions are suitable for the topical application of a wide variety of cosmetic and pharmaceutical compounds.
-------------------------------------------------- ------------------------------

STABLE GEL FORMULATION FOR TOPICAL TREATMENT OF SKIN CONDITIONS

(WO1995033489) 14.12.1995 A61K 8/67 ALLERGAN, INC.
The present invention provides a stable gel formulation for topical treatment of skin conditions in humans. The stable gel formulation includes an active agent, having activity for treatment of acne and psoriasis, which is insoluble in water and a plurality of nonaqueous vehicles for both solubilizing said active agent and forming a gel therewith enabling topical application of the gel to a skin condition. The plurality of vehicles are each present in amounts, and in combination, to control release of the active agent from the gel to the skin condition.
------------------------------------------------------------------ --------------

A MEDICATED WIPE

(WO1995031189) 23.11.1995 A61K 9/70 BIOGLAN LABORATORIES LTD. GOODMAN, Michael
A wipe, comprising an absorbent woven or non-woven fabric, cloth or tissue substrate, impregnated with a pharmaceutically active agent, wherein the agent is a substance effective in stimulating melanocytes to produce melanin and/or is effective in a topical treatment of a skin condition in combination with electromagnetic radiation falling in the range of 220-700nm.
-------------------------------------------------- ------------------------------

TRANSDERMAL DEVICE FOR ADMINISTRATION THROUGH DE-EPITHELIALIZED SKIN

(WO1995030410) 16.11.1995 A61K 9/70 SVEDMAN, Pal
A transdermal device is described suitable for delivery of a pharmaceutical to the systemic circulation through de-epithelialized skin. In its various embodiments the device includes means to prevent the attack of any protein or polypeptide active agent included therein by proteolytic enzymes which exude from the lesion, means to prevent the ingress of bacteria and other cellular debris from the lesion and means to ensure that substantially all said active agent is directed to the de-epithelialized lesion.
------------------ --------------------------------------------------------------

TREATMENT OF WARTS USING ANTHRALINS AND OCCLUSION

(WO1995028136) 26.10.1995 A61F 13/00 TOWSEND, Marvin, S. BLOOM, Leonard ROBINSON, Howard, N. MARTIN, Neil, F.
A method of treating a patient having one or more warts includes the steps of: applying to the wart an amount of a composition consisting essentially of an anthralin active ingredient and a pharmaceutical carrier; covering the wart and skin areas peripheral to the wart with an adhesive tape (20), such that the adhesive tape adheres to peripheral skin areas, whereby the adhesive tape (20) provides an occluding environment for the wart treated with the composition. The occluding environment is maintained for a desired period of time, and the adhesive tape (20) is removed. For a number of times as desired, a fresh amount of anthralin-containing compositions is applied, and a fresh piece of adhesive tape (20) is applied to recreate the occludin...
---------------------------------- ----------------------------------------------

PEPTIDES

(WO1995027728) 19.10.1995 A23L 3/3463 LUMINIS PTY. LIMITED BOWIE, John, Hamilton TYLER, Michael, James
Novel, biologically active peptides, known as Tryptophyllins L, Rubellidins, Dynastins, Uperins, Eucnemins and Frenatins, and also a new series of Caerin peptides, are extractable from the skin or glands of frogs. These peptides generally have the formula: W-X-Trp-Y-Z, pGlu-X-Trp-Y-Z, W-X-Phe-Phe-Y-Z, W-Gly- Leu-Y-Z, W-Ala-Gly-Y-Z, or W-Gly-Y-Z, wherein W is hydrogen, X and Y are peptide sequences, and Z is hydroxyl or amino. Some of the present peptides have potent physiological activity, e.g. as neurotransmitters, neuromodulators, wide spectrum antibiotics, antiviral agents and nematocidal agents. The peptides may also be used for food preservation.
-------------------------------------------------- ------------------------------

NOVEL PHARMACEUTICAL COMPOSITION FOR SKIN DISEASES

(WO1995025523) 28.09.1995 A61K 35/16 YUNGJIN PHARMACEUTICAL CO., LTD. CHUNG, Kae, Jong CHANG, Man, Sik CHUN, Jong, Ok CHUN, Jae, Kwang CHOI, Wahn, Soo KIM, Sung, Chul
The present invention relates to novel pharmaceutical composition for skin diseases, in particular to novel pharmaceutical composition useful for treatment of skin diseases; e.g. burns, wounds, general operative wounds, pernio, decubitus, folliculitis, impetigo, intertrigo, radiation ulcer, acne vulgaris or infectious eczematous dermatitis comprising deproteinized dialysate of calf's blood with tissue regenerative activity and aminoglycoside antibiotic with bacterial infection inhibitory activity as active ingredients.
--------------------------------------------------------------------------------

TOPICAL THALIDOMIDE COMPOSITIONS FOR SURFACE OR MUCOSAL WOUNDS, ULCERATIONS, AND LESIONS

(WO1995024891) 21.09.1995 A61K 31/445 PIACQUADIO, Daniel, J.
Surface wounds, ulcerations and lesions are treated with a solubilized topical composition containing as its active thalidomide or a pro drug, analog or biologically active salt form thereof.
---------------------------------- ----------------------------------------------

DEODORANT AND ANTIPERSPIRANT COMPOSITIONS

(WO1995024887) 21.09.1995 A61K 8/88 THE MENNEN COMPANY
Disclosed is a gel or stick composition for reduction of body malodor, containing active deodorant and/or antiperspirant ingredients, a polyamide gelling agent and a solvent system for the polyamide gelling agent. The polyamide gelling agent has good stability, even in the presence of acidic antiperspirant metal salts, and can provide a clear deodorant or antiperspirant gel or stick. The composition has good pay-off characteristics and application properties, and good structural integrity. Moreover, the composition can be formulated so as not to leave any undesirable residue, such as a white residue left after applying conventional antiperspirant sticks.
------------------------------------------ --------------------------------------

VETERINARY FORMULATION

(WO1995024219) 14.09.1995 A01N 25/02 COMMONWEALTH SCIENTIFIC AND INDUSTRIAL RESEARCH ORGANISATION AUSTRALIAN WOOL RESEARCH &PROMOTION ORGANISATION HENNESSY, Desmond, Ronald DARWISH, Alan MAXWELL, Colin, Arthur RUSSELL, Ian, Maxwell
A wool grease fraction having a substantially neutral oxidation profile and a formulation for topical application to wool producing animals, said formulation comprising a light stable active agent in a vehicle comprising a wool grease fraction having a substantially neutral profile. A formulation for topical application to wool producing animals, said formulation comprising a light stable active agent in a vehicle comprising at least one of a sterol ester, a wax ester, a triterpene ester containing substantially unoxidised isocholesterols or an analogue thereof. Processes for manufacturing the fractions and formulations and methods of controlling pests employing the formulations.
-------------------------------------------------- ------------------------------

LOW pH, HYDROLYTICALLY STABLE, COSMETIC COMPOSITIONS CONTAINING ACIDIC ACTIVES

(WO1995024179) 14.09.1995 A61K 8/06 THE PROCTER &GAMBLE COMPANY
The present invention relates to leave on, oil-in-water, skin care compositions, comprising: (A) from about 0.05 % to about 20 % of an acidic active ingredient, preferably having a solubility parameter from about 6 to about 12; (B) from about 0.1 % to about 25 % of alkoxylated alcohols, alkoxylated polyols, and mixtures thereof; (C) from about 1 % to about 20 % of an acid stable, hydrophobic, structuring agent selected from the group consisting of saturated C16 to C30 fatty alcohols, saturated C16 to C30 fatty alcohols containing from about 1 to about 5 moles of ethylene oxide, saturated C16 to C30 diols, saturated C16 to C30 monoglycerol ethers, saturated C16 to C30 hydroxy fatty acids, and mixtures thereof, having a melting point of at le...
--------------------------------------------------------------------------------

SKIN LIGHTENING COMPOSITIONS

(WO1995023780) 08.09.1995 A61K 8/34 THE PROCTER &GAMBLE COMPANY
This invention relates to compositions, compounds and methods for lightening skin, using active compounds having the structure (I) or (II) wherein: (i) each X is, independently, selected from the group consisting of halo, alkyl, substituted alkyl, aryl, OR, OCOR, COR, CONRR, COOR, CN, SR, SOR, SO2R, SO3R and NRR, wherein X is other than hydroxy, amino and thio, if this X is attached ortho to the phenol hydroxy; (ii) m is an integer from 0 to 4; (iii) each R' and R'' is, independently, selected from the group consisting of hydrogen, halo, alkyl, substituted alkyl, aryl, OR, OCOR, OCRROR, COR, CR(OR)OR, CONRR, COOR, CRROR, CN, SR, and NRR; wherein halo, when it appears, is other than geminal to a hydroxy, NH2, or SH; (iv) R''' is alkyl or sub...
------------------------------------------------------------------ --------------

CELL GROWTH STIMULATING COMPOSITIONS CONTAINING ALOESIN

(WO1995023604) 08.09.1995 A61K 31/70 NAMYANG ALOE CO., LTD. KIM, Kyeong, Ho PARK, Jeong, Hill SUNG, Chung, Ki KIM, Jin, Woong CHOI, Jae, Sue LEE, Seung, Ki KIM, Yeong, Shik SON, Byeong, Hwa CHUNG, Myung, Hee PARK, Young, In KIM, Kyu, Won LEE, Chong, Kil
The present invention relates to a cell growth stimulating composition containing aloesin as an active ingredient. More specifically, the present invention relates to a composition for stimulating cell growth, especially for stimulating epidermal cells and hepatic cells, which contains aloesin as an active ingredient. Aloesin is a component of Aloe vera, for which an effect for blocking ultraviolet ray from skin and an activity as mushroom tyrosinase inhibitor have been disclosed in the prior art. However, accordint to the present invention, it has now been identified that aloesin has the novel pharmacological use as a cell growth stimulating agent which has never been disclosed in the prior art.
-- ------------------------------------------------------------------------------

METHOD AND COMPOSITION FOR TOPICAL TREATMENT OF DAMAGED TISSUE USING HISTAMINE PHOSPHATE AS ACTIVE INGREDIENT

(WO1995023601) 08.09.1995 A61K 9/00 PROFESSIONAL PHARMACEUTICAL, INC.
A pharmaceutical composition of water, water soluble vinyl polymer gel, amine alcohol dispersant and IEP is used topically to treat herpes labialis and aphthous stomatitis lesions, and also to treat herpes genitalis, chicken pox, allergic conjunctivitis, giant papillary conjunctivitis, stomatitis secondary to chemotherapy, thermal burn, sunburn, decubitus ulcers and shingles.
------------------------------------------ --------------------------------------

METHOD FOR DELIPIDATION OF SKIN AND CERUMEN REMOVAL

(WO1995019108) 20.07.1995 A61K 31/715 SANCHEZ, Robert, A. HENDLER, Sheldon, S.
The invention relates to the field of skin and hair care products. Uncomplexed or loosely complexed cyclodextrin is the active ingredient of a composition which may be used to remove cerumen from the ear canal, or to cleanse the skin or hair.
------------------------------------------ --------------------------------------

TRANSDERMAL DRUG DELIVERY SYSTEM

(WO1995017866) 06.07.1995 A61K 9/70 ROYDS, Robert, B. LIM, John ROSEN, Joel, D.
In a transdermal drug delivery system (10), encapsulation material used to coat drug granules (24) controls the release of an active ingredient. The active ingredient is released into a water retaining matrix (20), which acts as a reservoir, and transdermal drug penetration is driven by the resulting concentration gradient. The delivery system is enclosed in a patch comprising a composite shell (12), which acts as an occlusive covering when attached to skin, thus enhancing the hydration of the skin area and fostering absorption of the drug. Visible change indicators (28) incorporated into the system provide indicators at significant "landmarks" in the lifetime of the patch. Microcapsules used for the indicator may be formulated so that the ...
---------------------------------- ----------------------------------------------

ETHANOL SUBSTITUTES

(WO1995017156) 29.06.1995 A61K 9/00 THE PROCTER &GAMBLE COMPANY
A composition providing the physiologic sensations of ethanol, comprising an alkoxy glycol ether and preferably further comprising a cooling agent and an oral care or pharmaceutical active.
-------------------------------------------------- ------------------------------

GAS MICROSPHERES FOR TOPICAL AND SUBCUTANEOUS APPLICATION

(WO1995015118) 08.06.1995 A61K 8/14 UNGER, Evan, C. MATSUNAGA, Terry YELLOWHAIR, David
Gas and gaseous precursor filled microspheres (1), and foams thereof, provide novel topical and subcutaneous delivery vehicles for various active ingredients, including drugs and cosmetics (2).
------------------------------------------------------------------ --------------

COSMETIC METHOD FOR TREATMENT OF SKIN

(WO1995013792) 26.05.1995 A61K 8/67 UNILEVER PLC UNILEVER N.V.
A method is provided for improving skin condition through a system whose steps include applying to the skin separately on a plurality of days a first composition that incorporates a retinoid which is either retinol or retinoic acid in a pharmaceutically acceptable carrier. Once the skin has acclimated to any irritation induced by the first composition, a second composition is applied to the skin daily for a subsequent period of time. The second composition will also include retinoid but at a level at least 10 % higher than that employed in the first composition. Once the skin has acclimated to the second composition, subsequent progressive increases of the active retinoid can be applied over subsequent periods of time. Finally, a maintenanc...
-- ------------------------------------------------------------------------------

NON-IRRITATING COSMETIC COMPOSITIONS

(WO1995013790) 26.05.1995 A61K 31/19 UNILEVER PLC UNILEVER N.V.
A cosmetic composition is provided which includes as an active ingredient a C2-C28 'alpha'-hydroxy carboxylic acid within a non-stinging ester base formula comprising a C7-C60 neoalkanol ester and a C12-C40 fatty acid ester alkoxylated with from 1 to 100 moles alkylene oxide per mole of glyceride.
---------------------------------------------------------- ----------------------

COSMETIC METHOD FOR TREATMENT OF SKIN

(WO1995013789) 26.05.1995 A61K 31/19 UNILEVER PLC UNILEVER N.V.
A method is provided for improving skin condition through a system whose steps include applying to the skin separately on a plurality of days a first composition that incorporates a C2-C28 'alpha'- or 'beta'-hydroxy carboxylic acid in a pharmaceutically acceptable carrier. Once the skin has acclimated to any irritation induced by the first composition, a second composition is applied to the skin daily for a subsequent period of time. The second composition will also include hydroxy carboxylic acid but at a level at least 10 % higher than that employed in the first composition. Once the skin has acclimated to the second composition, subsequent progressive increases of the active hydroxy carboxylic acid can be applied over subsequent periods ...
------------------------------------------------------------------ --------------

VISCOELASTIC COMPOSITIONS OF FLUORINATED ORGANIC COMPOUNDS

(WO1995009606) 13.04.1995 A61K 8/70 S.A.ATTA APPLICATIONS ET TRANSFERTS DE TECHNOLOGIES AVANCEES
Compositions for topical application in gel form comprising a fluorocarbon or perfluorocarbon compound or mixtures thereof at a concentration of at least about 75 % v/v, a minor quantity of a surface active agent and an aqueous phase. The compositions provide a storage-stable high concentration fluorocarbon gel that is prepared without the use of thickeners or additional stabilizing agents. The gels are useful in formulations for pharmaceutical, cosmetic purposes and for other products as well.
---------- ----------------------------------------------------------------------

SKIN CARE METHOD AND COMPOSITION

(WO1995007688) 23.03.1995 A61K 8/66 UNILEVER PLC UNILEVER N.V.
A composition for topical application to the skin for alleviation or prevention of dry flaky skin conditions, dandruff or acne comprising one or more stratum corneum trypsin-like enzymes. The composition may further comprise an additional enzyme selected from glycosidases, other proteases, lipases and mixtures thereof. Optional additional active ingredients include sunscreens, lipids, hydroxy carboxylic acids and ketocarboxylic acids.
------------------------------------------------------------------ --------------

SKIN CARE METHOD AND COMPOSITION

(WO1995007687) 23.03.1995 A61K 8/66 UNILEVER PLC UNILEVER N.V.
A composition for topical application to the skin for alleviation or prevention of dry flaky skin conditions, dandruff or acne comprising one or more stratum corneum cathepsin-D-like enzymes. The composition may further comprise an additional enzyme selected from glycosidases, other proteases, lipases and mixtures thereof. Optional additional active ingredients include sunscreens, lipids, hydroxy carboxylic acids and ketocarboxylic acids.
-------------------------------------------------- ------------------------------

SKIN CARE COMPOSITION COMPRISING THIOL PROTEASES FROM THE STRATUM CORNEUM

(WO1995007686) 23.03.1995 A61K 8/66 UNILEVER PLC UNILEVER NV
A composition for topical application to the skin for alleviation or prevention of dry flaky skin condition, dandruff or acne comprising one or more stratum corneum thiol proteases. The composition may further comprise a mild reducing agent and/or an additional enzyme selected from glycosidases, other proteases, lipases and mixtures thereof. Optional additional active ingredients include sunscreens, lipids, hydroxy carboxylic acids and ketocarboxylic acids.
-------------------------------------------------- ------------------------------

BACTERIOCINS FROM STREPTOCOCCUS THERMOPHILUS

(WO1995006736) 09.03.1995 A23C 9/123 SOCIETE DES PRODUITS NESTLE S.A. GERMOND, Jacques-Edouard MARCISET, Olivier MOLLET, Beat
The invention relates to two new Streptococcus thermophilus bacteriocins having the amino acid sequences SEQ ID NO:1 and SEQ ID NO:2, the signal peptides of these two bacteriocins, the nucleotide sequences encoding these bacteriocins especially an operon encoding the said bacteriocins having the sequence SEQ ID NO:3, the strains producing at least one of these bacteriocins especially the strain CNCM I-1351, a method for producing a supernatant extract comprising at least one of these two bacteriocins, and use of these bacteriocins in the preparation of food products, especially cheeses and acidified milks, and cosmetic products as active agent against pathogens.
---------------------------------------------------------- ----------------------

METHODS OF SUPPRESSING GRAFT REJECTION

(WO1995006717) 09.03.1995 A61K 35/28 VIAGENE, INC.
Tissue cells of an animal transformed with a recombinant vector construct which (a) directs the expression of a protein or active portion thereof; (b) transcribes an antisense message; or (c) transcribes a ribozyme capable of inhibiting MHC antigen presentation are provided. In a related aspect, the cells are transformed with two or more of such proteins, antisense or ribozymes, or combinations thereof. The tissue cells are particularly useful within methods for suppressing graft rejection. Pharmaceutical compositions comprising such transformed tissue cells are also provided.
-------------------------- ------------------------------------------------------

SILICONE GRAFTED THERMOPLASTIC ELASTOMERIC COPOLYMERS AND HAIR AND SKIN CARE COMPOSITIONS CONTAINING THE SAME

(WO1995006079) 02.03.1995 A61K 8/896 THE PROCTER &GAMBLE COMPANY
The present invention relates to water or alcohol soluble or dispersible silicone grafted thermoplastic elastomeric copolymers and to cosmetic and pharmaceutical compositions containing these copolymers. This invention especially relates to copolymers useful for hair styling purposes, and to hair styling compositions containing these copolymers. This invention further relates to copolymers useful for providing cosmetic and pharmaceutical compositions for topical application to the skin. These topical skin care compositions are useful for delivering and/or transdermally transporting active ingredients to or through the skin.
-- ------------------------------------------------------------------------------

SILICONE GRAFTED THERMOPLASTIC ELASTOMERIC COPOLYMERS AND HAIR AND SKIN CARE COMPOSITIONS CONTAINING THE SAME

(WO1995006078) 02.03.1995 A61K 8/896 THE PROCTER &GAMBLE COMPANY
The present invention relates to water or alcohol soluble or dispersible silicone grafted thermoplastic elastomeric copolymers and to cosmetic and pharmaceutical compositions containing these copolymers. This invention especially relates to copolymers useful for hair styling purposes, and to hair styling compositions containing these copolymers. This invention further relates to copolymers useful for providing cosmetic and pharmaceutical compositions for topical application to the skin. These topical skin care compositions are useful for delivering and/or transdermally transporting active ingredients to or through the skin.
---------------------------------- ----------------------------------------------

METHOD, COMPOSITIONS AND DEVICES FOR ADMINISTRATION OF NAKED POLYNUCLEOTIDES WHICH ENCODE BIOLOGICALLY ACTIVE PEPTIDES

(WO1995005853) 02.03.1995 A61B 17/20 THE REGENTS OF THE UNIVERSITY OF CALIFORNIA CARSON, Dennis, A. RAZ, Eyal HOWELL, Meredith, L.
The invention encompasses methods of introducing biologically active peptides into a host (particularly for vaccination or transitory expression of a therapeutic peptide) by administration of polynucleotides which operatively encode for the peptide. In most embodiments, the polynucleotides are naked in the sense that they are neither complexed to colloidal preparations such as liposomes or associated with a genomic integrating vector. In one embodiment, the naked polynucleotides are administered to host tissues which have a high concentration of antigen presenting cells in them relative to other host tissues. It is believed that the polynucleotides are taken up and expressed locally, systemically and/or at locations remote from their point ...
---------------------------------- ----------------------------------------------

QUATERNARY SALTS OF PARA-DIALKYLAMINO BENZAMIDE DERIVATIVES

(WO1995005797) 02.03.1995 C07C 237/34 ISP VAN DYK INC.
This invention relates to non-hydrolyzable, non-irritating, hair, skin and textile substantive quaternary ammonium salts of a para-dialkylamino benzamide having formula (I) wherein R' and R'' are each selected from the group of C1 to C2 alkyl; n is an integer having a value of from 2 to 6; R is an alkyl radical having from 1 to 30 carbon atoms; R1 and R2 are each selected from the group of C1 to C4 alkyl, hydrogen and, alternatively, R1 and R2, together with the attached cationic nitrogen atom can form a 5 to 6-membered heterocyclic ring selected from the group (a, b, c, d, e, f and g) and X is an anion. These benzamide derivatives are active sunscreening agents which are usefully employed at a concentration of from about 0.5 to about 10 wt...
-------------------------- ------------------------------------------------------

COSMETIC COMPOSITIONS

(WO1995004537) 16.02.1995 A61K 31/19 THE PROCTER &GAMBLE COMPANY BRIGGS, Gillian, Scott CROOK, Teresa-Barbara FISH, Karen DECKNER, George, Endel
A cosmetic composition in the form of an emulsion, gel or lotion comprising an aqueous/alcoholic solution of an acidic anti-acne active and a pyrrolidone-based complexing agent therefor, wherein the aqueous/alcoholic solution has a pH of less than pKa + 1, where pKa is the logarithmic acidity constant for the fully protonated anti-acne active. The cosmetic composition exhibits anti-acne effectiveness and product and colour stability.
-------------------------- ------------------------------------------------------

COSMETIC COMPOSITIONS

(WO1995004517) 16.02.1995 A61K 8/362 THE PROCTER &GAMBLE COMPANY BRIGGS, Gillian, Scott CROOK, Teresa, Barbara FISH, Karen DECKNER, George, Endel
A make-up composition in the form of a water-in-oil or oil-in-water emulsion comprising an acidic anti-acne active dissolved in the aqueous phase and a pigment or mixture of pigments dispersed in the oil phase. The make-up composition exhibits anti-acne effectiveness and product and colour stability.
------------------ --------------------------------------------------------------

PERSONAL CLEANSING COMPOSITIONS

(WO1995003781) 09.02.1995 A61K 8/06 THE PROCTER &GAMBLE COMPANY
The present invention relates to oil-in-water emulsion compositions that are useful for personal cleansing and for depositing an active ingredient upon the skin surface. The active ingredient in these compositions has a solubility parameter from about 7 to about 13. A preferred active ingredient is salicylic acid.
------------------------------------------------------------------ --------------

COSMETIC, SKIN-RENEWAL STIMULATING COMPOSITION WITH LONG-TERM IRRITATION CONTROL

(WO1995003028) 02.02.1995 A61K 07/00 HERSTEIN, Morris
A cosmetic skin-renewal stimulating composition suitable for daily use by consumers and providing anti-aging benefits with control of delayed irritation. The invention adds small quantities of a naturally occuring small-molecule, biologically active, aliphatic aminodiol lipid, for example sphingosine, to cosmetics incorporating a skin-renewal stimulating acid, for example lactic, hydroxybenzoic or retinoic acid, to provide control of deferred hyperproliferative allergenicity induced by the skin-renewal stimulating acid. Comparative data show a beneficial control of long- term irritation induced by several weeks of daily use of a variety of skin-renewal stimulating acids. The novel activity is displayed by sphingosine alone among several clas...
---------------------------------------------------------- ----------------------

MONOLITHIC MATRIX TRANSDERMAL DELIVERY SYSTEM

(WO1995001767) 19.01.1995 A61K 9/70 CYGNUS THERAPEUTIC SYSTEMS WONG, Ooi NGUYEN, Thuytien, N.
Monolithic matrix formulations for transdermal administration of an active agent, include in combination as a copolymer 2- ethylhexyl acrylate, 2-hydroxyethyl methacrylate, and methacrylic acid. Transdermal delivery devices having a monolithic matrix (4) made using such a formulation in combination with an active agent and a vehicle or vehicle formulation are capable of delivering the active agent at skin flux rates suitable for transdermal administration of the active agent.
------------------------------------------ --------------------------------------

THERMOPLASTIC ELASTOMERIC COPOLYMERS AND HAIR AND SKIN CARE COMPOSITIONS CONTAINING THE SAME

(WO1995001384) 12.01.1995 A61K 8/73 THE PROCTER &GAMBLE COMPANY
The present invention relates to water or alcohol soluble or dispersible thermoplastic elastomeric copolymers and to cosmetic and pharmaceutical compositions containing these copolymers. This invention especially relates to copolymers useful for hair styling purposes, and to hair styling compositions containing these copolymers. This invention further relates to copolymers useful for providing cosmetic and pharmaceutical compositions for topical application to the skin. These topical skin care compositions are useful for delivering and/or transdermally transporting active ingredients to or through the skin.
---------------------------------------------------------- ----------------------

THERMOPLASTIC ELASTOMERIC COPOLYMERS AND HAIR AND SKIN CARE, COMPOSITIONS CONTAINING THE SAME

(WO1995001383) 12.01.1995 A61K 8/73 THE PROCTER &GAMBLE COMPANY
The present invention relates to water or alcohol soluble or dispersible thermoplastic elastomeric copolymers and to cosmetic and pharmaceutical compositions containing these copolymers. This invention especially relates to copolymers useful for hair styling purposes, and the hair styling compositions containing these copolymers. This invention further relates to copolymers useful for providing cosmetic and pharmaceutical compositions for topical application to the skin. These topical skin care compositions are useful for delivering and/or transdermally transporting active ingredients to or through the skin.
---------------------------------------------------------- ----------------------

NEW PHARMACEUTICAL PREPARATIONS, CONTAINING 8-CHLORO-3(betaDIETHYLAMINOETHYL)-4-METHYL-7-ETHOXYCARBONYLMETHOXY COUMARIN AND THE SALTS THEREOF, IN THE TREATMENT OF PATHOLOGICAL CONDITIONS INVOLVING HIGH RELEASE OF NITRIC OXIDE

(WO1995000142) 05.01.1995 A61K 31/37 FIDIA S.P.A. DI ROSA, Massimo CIRILLO, Rocco HORNBY, Edward, Joseph PROSDOCIMI, Marco
A pharmaceutical composition which comprises as an active ingredient, an effective amount of 8- chloro-3(beta-diethylaminoethyl)-4-methyl-7-ethoxycarbonylmethoxy coumarin or a pharmaceutically acceptable salt thereof, for the treatment of pathological conditions involving high release of nitric oxide (NO).
------------------ --------------------------------------------------------------

MOLECULAR TRANSDERMAL TRANSPORT SYSTEM

(WO1995000088) 05.01.1995 A61K 9/70 MASIZ, John, J.
An efficient transdermal delivery system for delivering an active ingredient to the blood supply of a living body, comprising a vasodilator and/or topical counter irritant, an active ingredient, a permeation enhancer for the active ingredient, and a water soluble gum for binding the foregoing. A non-breathable layer also can be used for controlling the microenvironment at the transport site. Compression can be used to further enhance the blood supply at the transport site.
---------------------------------- ----------------------------------------------

SKIN TREATMENT METHOD UTILIZING A COMPOSITION AND A PAD

(WO1994027569) 08.12.1994 A61K 8/02 DERMATOLOGY HOME PRODUCTS, INC. PHARMAGEN, INC.
A method employing a novel combination of a skin care composition and cosmetic applicator pad is provided for at-home skin degreasing, peeling and/or exfoliating and moisturizing, which is gentle in that the concentrations of the active skin peeling and/or degreasing, exfoliating and moisturizing ingredient, principally an alpha hydroxy acid, or a mixture of alpha hydroxy acids, preferably including acetone, is far lower than that routinely used for professional use in the offices of professional dermatologists, aestheticians and/or cosmetologists. The composition of the present invention is provided in a suitable pharmaceutical vehicle and is presaturated into a convenient cosmetic applicator pad.
---------------------------------- ----------------------------------------------

INTRAORAL- PROCEDURES ELECTRODE

(WO1994027491) 08.12.1994 A61B 18/16 MINNESOTA MINING AND MANUFACTURING COMPANY
Intraoral-procedures TENS electrodes (10, 30, 40, 50, 60, 70, 80) are disclosed. Intraoral electrodes (60, 70, 80, 170) include active electrodes and return electrodes having a common carrier with a field of pressure sensitive adhesive for adhering the electrode to a hand (finger or thumb) of the practitioner or an applicator. Extraoral electrodes (10, 30, 40, 50) adhere to facial skin of mammals and provide TENS treatment for intraoral-procedures. The electrodes can be dual channel to combine active electrodes and return electrodes on one electrode. Optionally, a dual channel electrode is used in combination with an elongated applicator (140) having a bifurcated end in order to facilitate guiding a syringe needle toward a desired injection...
------------------ --------------------------------------------------------------

TOILET SOAP BARS

(WO1994026865) 24.11.1994 C11D 9/00 UNILEVER PLC UNILEVER N.V.
The invention relates to toilet soap bars, particularly to mild toilet soap bars comprising blends of soap with one or more co-actives. There is a need for mild bars which do not have the processing problems associated with the use of superfatting agents and co-actives, which can be made without difficulty on conventional soap production lines without substantial modification of the lines and yet provide a product with reduced harshness while maintaining lathering and structural properties. Moreover, it is desirable that soap bars should not suffer from the defect of grittiness and it is also desirable that these bars have a composition which contains relatively low levels of the significantly more expensive lauric fats. We have determined ...
-------------------------- ------------------------------------------------------

COMPOSITIONS AND METHODS FOR REPARATION AND PREVENTION OF FIBROTIC LESIONS

(WO1994026249) 24.11.1994 A61K 31/4412 MARGOLIN, Solomon, B.
In a preferred embodiment, drugs having pharmacological properties which are useful in the medicinal therapy of fibrotic disease for the reparation and prevention of fibrotic lesional tissues, such drugs including as active ingredient(s) one or more N-substituted 2-(1H) pyridone(s) and/or N-substituted 3-(1H) pyridones. The composition of this invention is novel as an anti-fibrotic drug, namely, as an agent for treating fibrosis. Any existing compounds have not been shown to be effective for the reparation and prevention of fibrotic lesions. The figure is a graphic representation of a response to a dosage of pirfenidone as shown in Table 3.
--------------------------------------------------------------------------------

POUR-ON FORMULATIONS CONTAININNG POLYMERIC MATERIAL, GLYCOLS AND GLYCERIDES

(WO1994026113) 24.11.1994 A01N 43/90 MERCK &CO., INC. CHOI, Hoo-Kyun WILLIAMS, James, B.
There is disclosed a topical formulation containing glycols, glycerides, or their derivatives, an avermectin compound (active ingredient) and optionally a polymeric material which has been discovered to provide superior efficacy against endoparasites and ectoparasites when compared to conventional formulations and to maintain the concentration of the active compound in the milk of dairy animals below a safe concentration for human consumption. The formulation contains the avermectin active ingredient and at least 50 % of the glycol or glyceride or polymeric material.
---------------------------------- ----------------------------------------------

ANTIPERSPIRANT COMPOSITIONS

(WO1994024993) 10.11.1994 A61K 07/32 UNILEVER PLC UNILEVER NV
An antiperspirant composition suitable for topical application to human skin comprising an antiperspirant active which comprises at least one amphiphilic material, the antiperspirant active being one which forms, upon contact with perspiration, a water-insoluble liquid crystal phase of greater than one- dimensional periodicity, in a cosmetic vehicle comprising volatile silicone and containing low levels of a short chain monohydric alcohol.
------------------ --------------------------------------------------------------

SKIN CARE COMPOSITION

(WO1994021225) 29.09.1994 A61K 8/67 WADSTEIN, Jan SAMUELSSON, Mats
A skin care composition is disclosed, comprising as an active ingredient a conjugate of a vitamin A derivative and beta-cyclodextrin, and pharmaceutically acceptable carriers and/or fillers. There is also disclosed the use of a conjugate of a vitamin A derivative and beta-cyclodextrin and, optionally, colostrum for preparing a composition for therapeutic or prophylactic treatment of ageing symptoms in skin.
-------------------------------------------------- ------------------------------

GLYCOSYLATION OF LIPIDS AND LIPID- CONTAINING PARTICLES, AND DIAGNOSTIC AND THERAPEUTIC METHODS AND MATERIALS DERIVED THEREFROM

(WO1994020083) 15.09.1994 A61K 31/00 THE PICOWER INSTITUTE FOR MEDICAL RESEARCH
The in vivo oxidation of lipids and lipid-containing molecules has been discovered to be initiated by the concurrent reaction of such lipid materials with reducing sugars such as glucose, advanced glycosylation endproducts such as AGE-peptides, or a compound which forms advanced glycosylation endproducts, to form materials or particles known as AGE-lipids. AGE-lipids have been implicated in the aging process, the abnormal formation of lipofuscin and invarious disease states such as diabetes and atherosclerosis. Diagnostic methods are contemplated, extending in utility from the detection of the onset and course of conditions in which variations in lipid oxidation, AGE-lipid levels, LDL levels, apolipoprotein levels, apolipoprotein receptor b...
---------------------------------- ----------------------------------------------

METHODS AND DIAGNOSTIC KITS UTILIZING MAMMALIAN STRESS PROMOTERS TO DETERMINE TOXICITY OF A COMPOUND

(WO1994017208) 04.08.1994 C12Q 1/68 XENOMETRIX, INC. FARR, Spencer, B. MARQUE, Todd, D.
This invention provides methods and diagnostic kits for identifying and characterizing toxic compounds. These methods and diagnostic kits measure transcription or translation levels from genes linked to native eukaryotic stress promoters, especially those of mammals. The kits and methods of this invention utilize at least one stress promoter from each of the following groups: redox stress, DNA stress, protein stress and energy/ionic stress. The invention also provides methods and diagnostic kits for identifying and characterizing compounds that are toxic to specific organs, such as skin and the eye, as well as for each of the individual stresses indicated above. The methods and diagnostic kits of this invention yield information concerning ...
------------------ --------------------------------------------------------------

DEODORANT COMPOSITIONS

(WO1994014409) 07.07.1994 A61K 07/36 UNILEVER PLC UNILEVER N.V. FRANKLIN, Kevin, Ronald WIGHT, Gordon, Robert
Deodorant compositions for topical application to human skin, e.g. underarm, contain as active agent a layered double hydroxide of the general formula: [Zn(1-x) Alx (OH) 2]x+ By-x/y . zH2O where B is an interlayer anion or mixture of anions, y is the charge on the anion, x is 0.1 to 0.5, z is 0 to 100.
------------------ --------------------------------------------------------------

DEODORANT COMPOSITION

(WO1994014408) 07.07.1994 A61K 07/32 UNILEVER PLC UNILEVER N.V.
Deodorant compositions for topical applications to human skin, e.g. underarm, contain as active agent a layered hydroxide which contains copper and at least one other metal, and has the crystal structure of spangolite. Such a material may comply with a general formula: CuxZnyTi(OH)12R2.nH2O, where R is one or a mixture of divalent anions, the sum of x and y is 6 and n ranges from 1 to 6.
------------------------------------------------------------------ --------------

MELANOGENIC INHIBITOR, AND METHODS OF PRODUCING AND USING THE SAME

(WO1994012534) 09.06.1994 A61K 38/00 UNIVERSITY OF CINCINNATI NORDLUND, James, J. FAROOQUI, Jamal, Z.
A purified, naturally derived melanogenic inhibitor protein capable of inhibiting melanogenesis in pigmentary cells has an amino acid sequence SEQ ID NO:4. A method of producing melanogenic inhibitor protein comprises grafting mammalian skin onto a live host, permitting the mammalian skin to remain on the host for a predetermined period of time, removing the mammalian skin, and extracting the protein from the skin. Methods of controlling melanogenesis in pigmentary cells or selectively destroying melanoma cells comprise the steps of mixing an effective amount of melanogenic inhibitor protein, or an active segment, derivative, or analog thereof, with a suitable carrier, and applying this mixture to the pigmentary or melanoma cells.
-- ------------------------------------------------------------------------------

RECTAL FLUNISOLIDE COMPOSITIONS FOR TREATING INFLAMMATORY INTESTINAL DISORDERS

(WO1994012187) 09.06.1994 A61K 9/00 VALEAS S.P.A. INDUSTRIA CHIMICA E FARMACEUTICA BERNAREGGI, Virgilio FANO, Maurizio GAGNONI, Alessandro
Topical rectal therapeutic composition containing, as the active ingredient, flunisolide and/or one or more ester derivatives of same, in combination with suitable excipients and/or diluents, for the treatment of inflammatory intestinal disorders.
------------------------------------------------------------------ --------------

TRANSDERMAL DELIVERY OF KETOROLAC

(WO1994010986) 26.05.1994 A61K 9/70 PHARMETRIX CORPORATION
A patch for the transdermal delivery of ketorolac is described. The patch is capable of delivering therapeutically effective levels of ketorolac through a patient's skin for a period of 12 hours or more. The patch may be an adhesive matrix, a monolithic matrix, or a liquid reservoir type transdermal patch. Also described is the transdermal delivery of (-) ketorolac, the active enantiomer of ketorolac, at therapeutically effective levels for a period of 12 hours or more.
------------------------------------------ --------------------------------------

SYNTHETIC DETERGENT BARS AND THE METHOD OF MAKING THE SAME

(WO1994007988) 14.04.1994 C11D 1/12 MONA INDUSTRIES, INC.
There is provided a mild detergent toilet bar (syndet bar) composition containing from at least 25 percent up to about 65 percent by weight of synthetic surface active agents, which lathers, foams and wears well, exhibits minimal slushing and curd-forming properties in all types of water, possesses good plasticity and tactile properties while also being mild and non-injurious to the user's skin and readily processed with conventional soap-making equipment. The syndet bar compositions contain a) from about 15 to 35 percent by weight of water soluble acyl esters of isethionic acid salts; b) at least one sulfosuccinate in an amount from about 10 to about 30 percent by weight wherein the weight ratio of said acyl isethionate esters to sulfosucc...
---------------------------------- ----------------------------------------------

PHARMACEUTICAL COMPOSITION FOR TOPICAL USE CONTAINING A CROSSLINKED CATIONIC POLYMER AND AN ALKOXYLATED ETHER

(WO1994002176) 03.02.1994 A61K 8/35 THE PROCTER &GAMBLE COMPANY
The present invention relates to pharmaceutical compositions for topical application comprising a safe and effective amount of a pharmaceutical active, from about 0.1 % to about 10.0 % of a high molecular weight cationic polymer, from about 0.05 % to about 5 % of a high HLB non-ionic surfactant, and from about 0.1 % to about 25 % of an alkoxylated ether. In further embodiments, these compositions also comprise from about 0.01 % to about 5 % of a low HLB non-toxic surfactant.
---------- ----------------------------------------------------------------------

SKIN REGENERATING COSMETIC COMPOSITION

(WO1994002118) 03.02.1994 A61K 8/97 BIOGAL GYOGYSZERGYAR RT SZALOKI, Erzsébet SZABO, Éva HEGEDÜS, Éva JACSO, Erika HANGACSI, Irén KEREK, Kßlmßn BERECZKI, Erzsébet SAS, Erzsébet SZABO, Tünde KARANCSI, Erika FABIAN, Agnes AGNI, Zsolt PAPP, Gabriella KOVACS, Anik¾ NAGY, Ilona JAKAB, Tünde DEMK
The invention relates to skin regenerating cosmetic compositions comprising as active ingredient the extract of the drug of chickweed (Stellaria media) and pansy (Viola tricolor) in a quantity of 3-60% by weight together with one or more cosmetically acceptable vehicle and/or excipient and/or supplementary material in a quantity of 97-40% by weight.
------------------ --------------------------------------------------------------

ANHYDROUS FORMULATIONS FOR ADMINISTERING LIPOPHILIC AGENTS

(WO1993023083) 25.11.1993 A61K 9/06 AGOURON PHARMACEUTICALS, INC.
Anhydrous formulations useful for administering lipophilic, pharmaceutically active agents to hosts in need of such treatment, processes for preparing these formulations, pharmaceutical compositions based upon these formulations, and the use of these formulations to administer lipophilic, pharmaceutically active agents to a host. The lipophilic agent to be administered is solubilized in a hydrophilic vehicle which makes up at least part of the anhydrous formulation. Preferably, the lipophilic agent is present in the hydrophilic vehicle in a supersaturated or near saturated amount. Preferred pharmaceutical compositions based upon the formulations according to the present invention are useful in treating skin dermatoses such as psoriasis.
---------- ----------------------------------------------------------------------

TRANSDERMAL DRUG DELIVERY SYSTEMS AND RELATED COMPOSITIONS AND METHODS OF USE

(WO1993023019) 25.11.1993 A61K 9/70 SRI INTERNATIONAL
Transdermal drug delivery systems are provided in which a release rate-controlling means limits the flux of drug out of the device but not the flux of skin permeation enhancer. The devices contain an enhancer composition of a lower aliphatic ester of a lower aliphatic carboxylic acid, a lower alkanol, and, optionally, additional permeation enhancing components. Methods for using the transdermal systems for administering pharmacologically active agents are provided as well.
------------------------------------------ --------------------------------------

ANTIPERSPIRANT GEL STICK COMPOSITION

(WO1993023008) 25.11.1993 A61K 07/32 THE PROCTER &GAMBLE COMPANY
The present invention discloses antiperspirant gel stick compositions made from a n- acyl amino acid amides, a liquid base material, and an antiperspirant active. The above combination provides gel stick antiperspirant compositions having excellent efficacy, stability, low residue, low skin irritation and aesthetic advantages over compositions disclosed in the art. These compositions are easily prepared by conventional techniques.
-------------------------------------------------- ------------------------------

BIOADHESIVE SOLID MINERAL OIL EMULSION

(WO1993021905) 11.11.1993 A61K 9/00 BERLEX BIOSCIENCES DIVISION OF BERLEX LABORATORIES, INC.
A viscous, film-forming, bioadhesive solid aqueous mineral oil emulsion ointment composition which is readily spreadable and adapted for topical application, which comprises water, mineral oil, an amount of a non-ionic surfactant effective to stabilize the emulsion, a polyethylene glycol, and a hydrophilic substituted cellulose and which optionally contains a pharmaceutically active agent, for example, a growth factor, e.g., TGFalpha, has wound healing promoting activity, particularly of wounds of the inside of the mouth.
-- ------------------------------------------------------------------------------

AQUEOUS PERSONAL OR COSMETIC DETERGENT COMPOSITIONS COMPRISING VEGETABLE OIL ADDUCTS

(WO1993021293) 28.10.1993 A61K 8/14 THE PROCTER &GAMBLE COMPANY GIRET, Michel, Joseph LANGLOIS, Anne DUKE, Roland, Philip JEDLA, Emil
A detergent, personnal cleansing or cosmetic composition comprising: a) one or more surfactants selected from anionic, nonionic, amphoteric, zwitterionic, and cationic surfactants and mixtures thereof, and which comprises at least one surfactant having a structure incorporating one or more amido, amino or ammonio moieties (hereinafter N-surfactant), b) an adduct prepared from vegetable oils containing non-conjugated polyunsaturated fatty acid esters which are conjugated and elaidinized and then modified via Dies-Alder addition with a member of the group consisting of acrylic acid, fumaric acid and maleic anhydride; and c) water, and wherein the vegetable oil adduct is in the form of a solution or dispersion having an average particle size o...
------------------------------------------ --------------------------------------

LINSEED MUCILAGE

(WO1993016707) 02.09.1993 A61K 8/73 SMITHKLINE BEECHAM PLC O'MULLANE, John, Edward HAYTER, Ian, Peter
Compositions of matter comprising linseed mucilage and purified forms thereof having therapeutic and cosmetic utility for topical applications to the skin and/or mucous membranes of the body. Linseed mucilage compositions have mucoadherent properties; they may be used as an artificial mucus or lubricant and may be combined with active treating substances.
-------------------------- ------------------------------------------------------

METHODS OF TREATING INFLAMMATORY DERMATOSES

(WO1993015740) 19.08.1993 A61K 31/57 KLIGMAN, Albert, M.
Inflammatory dermatoses are controlled and cleared by topical application to the affected areas of the skin of a composition containing both a corticosteroid and a retinoid. The combined therapy is more effective than either active ingredient alone and is particularly effective for chronic dermatoses which are or have become resistant to corticosteroid treatment alone. After clearing has been obtained with once or twice daily applications of the corticosteroid-retinoid composition, usually after several weeks, clearance can be maintained by less frequent application or lower concentrations of the composition or by application of only one of the corticosteroid or retinoid, less potent corticosteroids, or other non-steroidal therapies, depend...
---------------------------------- ----------------------------------------------

AMINO ACIDS USEFUL AS INHIBITORS OF THE ADVANCED GLYCOSYLATION OF PROTEINS

(WO1993014750) 05.08.1993 A61K 31/155 THE ROCKEFELLER UNIVERSITY ALTEON INC.
The present invention relates to compositions and methods for inhibiting protein aging. Accordingly, a composition is disclosed which comprises an agent or compound capable of inhibiting the formation of advanced glycosylation end products of target proteins by reacting with the carbonyl moiety of the early glycosylation product of such target proteins formed by their initial glycosylation. Suitable agents are amino acids and their derivatives which contain an active nitrogen-containing group. Particular agents comprise lysine and mixtures thereof. The method comprises contacting the target protein with the composition. Both industrial and therapeutic applications for the invention are envisioned, as food spoilage and animal protein aging c...
-- ------------------------------------------------------------------------------

VEGETABLE OIL-BASED SKIN PERMEATION ENHANCER COMPOSITIONS, AND ASSOCIATED METHODS AND SYSTEMS

(WO1993012744) 08.07.1993 A61K 47/44 CYGNUS THERAPEUTIC SYSTEMS
Methods and compositions are provided which increase the permeability of skin to transdermally administered pharmacologically active agents. The compositions are formulated with one or more vegetable oils as skin permeation enhancers; a preferred composition contains both coconut oil and soybean oil. Drug delivery systems for administering drugs transdermally in combination with the vegetable oil-based enhancer compositions are provided as well.
------------------ --------------------------------------------------------------

IMPROVED FORMULATIONS WITH HYDROPHOBIC PERMEATION ENHANCERS

(WO1993011798) 24.06.1993 A61K 47/12 ALZA CORPORATION
This invention is directed to a novel formulation for effectively utilizing hydrophobic permeation enhancers for the increased permeability of active agents through the skin or mucosa along with reduction of the lag time between application of the active agent and attainment of a therapeutically effective agent flux, with little or no irritation to the host. The invention is directed to compositions containing a hydrophobic permeation enhancer, which permeation enhancer has been micronized and stabilized in an inert carrier such as water. These compositions can be combined with a biologically active agent to provide enhanced permeability of the active agent to the skin or mucosa.
-- ------------------------------------------------------------------------------

TRANSDERMAL ESTRADIOL DELIVERY SYSTEM

(WO1993010772) 10.06.1993 A61K 9/70 ROTTA RESEARCH LABORATORIUM S.P.A. ROVATI, Luigi ROVATI, Lucio MAKOVEC, Francesco CORDES, Günter FISCHER, Wilfried
The invention is represented by a transdermal medicated patch for the extended release of 17beta-estradiol to the skin. The transdermal patch is formed by an outer covering, a matrix containing from 1 % to 5 % (w/w) 17beta-estradiol, and a protective liner which is removed before use. The matrix is formed of pressure sensitive adhesive acrylic copolymers, in which the active ingredient is dissolved or dispersed. The acrylic copolymers are obtained by radical polymerization of 2-ethylhexyl acrylate, methyl acrylate, acrylic acid, vinyl acetate, hydroxyethyl acrylate or a mixture thereof. Optionally quantities of less than 0.5 % (w/w) of other substances may be added.
-- ------------------------------------------------------------------------------

USE OF SALICYLIC ACID FOR REGULATING SKIN WRINKLES AND/OR SKIN ATROPHY

(WO1993010756) 10.06.1993 A61K 8/35 RICHARDSON-VICKS, INC.
The present invention relates to a method for regulating wrinkles and/or atrophy in mammalian skin comprising treating the skin with a safe and effective amount of salicylic acid and/or additional active component.
---------------------------------------------------------- ----------------------

COMPOSITIONS FOR REGULATING SKIN WRINKLES AND/OR SKIN ATROPHY

(WO1993010755) 10.06.1993 A61K 8/02 RICHARDSON-VICKS, INC.
The present invention relates to a composition for regulating wrinkles and/or atrophy in mammalian skin comprising treating the skin with a safe and effective amount of salicylic acid and/or additional active component.
-------------------------- ------------------------------------------------------

COMPOSITION AND SKIN TREATMENT METHOD THEREWITH FOR MITIGATING ACNE AND MALE-PATTERN BALDNESS

(WO1993010750) 10.06.1993 A61K 8/19 ALT, John, P.
A topical application composition for mitigating male pattern baldness and testosterone- induced acne contains, as essential active, androgen-reducing components (a) a testosterone-reducing amount of an ionizable sodium salt, and (b) an association of compounds for forming, androgen segregating cellular proliferation phospholipids. The association includes lecithin, soy oil, phosphoric acid, choline chloride and optionally inositol and a nonionic surfactant in an amount for solubilizing and/or dispersing components (a) and (b) in a cosmetically-compatible vehicle for topical application.
---------------------------------------------------------- ----------------------

DRUG DELIVERY DEVICE

(WO1993009842) 27.05.1993 A61N 1/30 ELAN CORPORATION, PLC CORISH, John CORRIGAN, Owen, Ignatius
A transdermal device for the controlled administration of a drug to the skin comprises a reservoir (12) for the drug and an electric circuit which includes an electrode system (13, 14) which is operable to actively transport the drug in a controlled manner from the reservoir (12) towards the skin for transport therethrough, the skin not being part of the electric circuit, and the drug passing through an electrode (13) of said electrode system (13, 14) during the active transport to the skin. The electrode (13) is disposed between the reservoir (12) for the drug and an optional transit chamber (15). The electrode (13) can be permeable to the drug or the electrode can function as a gate, being permeable to the drug in the open condition and l...
---------------------------------- ----------------------------------------------

PHARMACEUTICAL LYSINE-CONTAINING POLYPEPTIDE COMPOSITIONS AND METHODS OF USE THEREOF

(WO1993008816) 13.05.1993 A61K 38/00 CYTOVEN
Pharmaceutical compositions and methods are provided for the therapy of immunodeficient, immunodepressed or hyperactive immune states and for the prevention and treatment of opportunistic infections in such states comprising administering to a subject a pharmaceutically acceptable composition comprising as an active ingredient peptides having the formula: R'-L- Glx-L-Glx-L-Lys-R'' and/or their pharmaceutically acceptable salts; wherein Glx is Gln or Glu.
------------------------------------------------------------------ --------------

PHARMACEUTICAL DIPEPTIDE COMPOSITIONS AND METHODS OF USE THEREOF

(WO1993008815) 13.05.1993 A61K 38/00 CYTOVEN
Methods are provided for the therapy of immunodeficient, immunodepressed or hyperactive immune states and for the prevention and treatment of opportunistic infections in such states comprising administering to a subject a pharmaceutically acceptable composition comprising as an active ingredient the dipeptide L-Glu-L-Trp, the cyclic monomer thereof, polymers thereof of the formula H2N - [L-Glu-L-Trp]n - CO2H; cyclic polymers thereof of formula (I) and their pharmaceutically acceptable salts thereof, wherein n and m are independently 2.
-------------------------- ------------------------------------------------------

MEDICAL APPARATUS FIXATION AND INFECTION CONTROL DEVICE

(WO1993007928) 29.04.1993 A61M 25/02 BIODERM, INC.
A device (3) and composition securely affixes an invasive medical apparatus to an entrance site and controls infections associated with the infiltration of microbes along the external walls of such apparatus. Provided in sterile form, the device takes various shapes and sizes and is configured for use with various sizes and types of invasive medical apparatus. The device can incorporate a hydrocolloid composition which, by virtue of its adhesive properties, holds that device in place at a skin entrance site. Alternatively, fixation is effected by adhesive provided on mating surfaces of the device or by thin-film, adhesive leaves. The device achieves a mechanically occlusive seal, a constant presence of medically active substances such as an...
---------- ----------------------------------------------------------------------

ENHANCED SKIN PENETRATION SYSTEM FOR IMPROVED TOPICAL DELIVERY OF DRUGS

(WO1993007903) 29.04.1993 A61K 47/32 RICHARDSON-VICKS, INC.
The invention relates to pharmaceutical compositions for topical application comprising a safe and effective amount of a pharmaceutical active, and from about 0.1 % to about 10.0 % of a high molecular weight cationic polymer. These compositions provide enhanceed penetration of the pharmaceutical active.
------------------------------------------ --------------------------------------

ENHANCED SKIN PENETRATION SYSTEM FOR IMPROVED TOPICAL DELIVERY OF DRUGS

(WO1993007902) 29.04.1993 A61K 8/35 RICHARDSON-VICKS, INC.
The invention involves pharmaceutical compositions for topical application comprising: (a) a safe and effective amount of a pharmaceutical active; and (b) from about 0.05 % to about 5 % of a non-ionic polyacrylamide having a molecular weight of from about 1,000,000 to about 30,000,000.
------------------------------------------------------------------ --------------

LOW pH AQUEOUS COSMETIC GEL CONTAINING NON-IONIC POLYACRYLAMIDE DERIVATIVES

(WO1993007856) 29.04.1993 A61K 8/81 RICHARDSON-VICKS, INC.
A skin care composition in the form of a low pH aqueous gel. The compositions provide improved skinfeel and residue characteristics together with excellent moisturizing, emolliency, rub-in and absorption characteristics. The gel comprises 0.05 % to 20 % of a non-ionic polyacrylamide having a molecular weight from 1,000,000 to 30,000,000, a humectant, an emollient and possibly pharmaceutically or cosmetically active compound (drugs, anti-acne, tanning or sunscreen agent).
---------------------------------------------------------- ----------------------

METHODS AND COMPOSITIONS FOR TREATING SUNBURNS

(WO1993003720) 04.03.1993 A61K 31/07 TREVITHICK, John, R.
A method of treating sunburn in human or animal skin comprises applying to the sunburned area a topical composition containing as active ingredient a tocopherol ester such as tocophero acetate or tocopherol polyethylene glycol succinate.
---------- ----------------------------------------------------------------------

CONVERTIBLE MICROEMULSION FORMULATIONS

(WO1992018147) 29.10.1992 A61K 9/107 AFFINITY BIOTECH, INC.
There is provided a water-in-oil (w/o) microemulsion which readily converts to an oil-in-water (o/w) emulsion by the addition of aqueous fluid to the w/o microemulsion, whereby any water-soluble biologically-active material in the aqueous phase is released for absorption by the body. The w/o microemulsion is particularly useful for storing proteins and the like for long periods of time at room temperature and above until they are ready for use, at which time the addition of aqueous fluid converts the microemulsion to an o/w emulsion and releases the protein.
---------------------------------- ----------------------------------------------

PHARMACEUTICAL DIPEPTIDE COMPOSITIONS AND METHODS OF USE THEREOF

(WO1992017191) 15.10.1992 A61K 38/00 CYTOVEN KHAVINSON, Vladimir Khatskelevich MOROZOV, Vyacheslav Grigorievich YAKOVLEV, German Mikhailovich SERY, Sergey Vladimirovich
Methods are provided for the therapy of immunodeficient, immunodepressed or hyperactive immune states and for the prevention and treatment of opportunistic infections in such states comprising administering to a subject a pharmaceutically acceptable composition comprising as an active ingredient the dipeptide L-Glu-L-Trp and/or its pharmaceutically acceptable salts.
-------------------------- ------------------------------------------------------

COMPOSITIONS AND METHOD COMPRISING AMINOALCOHOL DERIVATIVES AS MEMBRANE PENETRATION ENHANCERS

(WO1992016236) 01.10.1992 A61K 47/18 RAJADHYAKSHA, Vithal, J.
A method and compositions for enhancing absorption of topically administered physiologically active agents through the skin and mucous membranes of humans and animals in a transdermal device or formulation for local of systemic use, comprising a therapeutically effective amount of a pharmaceutically active agent and a non-toxic, effective amount of penetration enhancing agent of formula (I), wherein R is selected from H, and an aliphatic hydrocarbon group with from about 1 to about 20 carbon atoms, optionally containing a heteroatom in the hydrocarbon chain; R1 is selected from H, OH or O-CO-R5, where R5 is an aliphatic hydrocarbon group with from about 1 to 18 carbon atoms; R2 is selected from H, a lower aliphatic hydrocarbon group, acyl, ...
---------------------------------- ----------------------------------------------

COSMETIC COMPOSITIONS CONTAINING HYDROPHOBICALLY MODIFIED NONIONIC POLYMER AND UNSATURATED QUATERNARY AMMONIUM SURFACTANT

(WO1992016187) 01.10.1992 A61K 8/41 THE PROCTER &GAMBLE COMPANY
Disclosed is a vehicle system having a thickening system which comprises a nonionic long-chain alkylated water-soluble polymer and a specific cationic quaternary ammonium surfactant component dispersed in a compatible solvent. The quaternary surfactant component has an iodine value of at least about 15. The quaternary surfactant component is characterized by having a sufficient level of unsaturated C¿14?-C¿22? alkyl or C¿14?-C¿22? alkyl amido C¿2?-C¿6? alkylene radicals such that the average iodine value is at least about 15. These vehicle systems are useful in cosmetic compositions which are used to deliver an active component to the hair or skin. The vehicle systems are particularly useful in hair care compositions, especially rinse...
-------------------------- ------------------------------------------------------

COMPOSITIONS AND METHODS FOR TOPICAL ADMINISTRATION OF PHARMACEUTICALLY ACTIVE AGENTS

(WO1992015289) 17.09.1992 A61K 9/00 NOVEN PHARMACEUTICALS, INC.
A composition for topical application comprising a therapeutically effective amount of a pharmaceutical agent(s), a flexible, finite, pharmaceutically acceptable, adhesive, and a solvent for the pharmaceutical agent(s) in the adhesive and a method of administering the pharmaceutical agent to a mammal are disclosed.
-- ------------------------------------------------------------------------------

THERAPEUTIC AND COSMETIC COMPOSITIONS FOR TREATMENT OF SKIN

(WO1992015276) 17.09.1992 A61K 8/98 McGINNIS, Michael
An active ingredient for a therapeutic or cosmetic comosition is obtained from live gastropoda (e.g., snails) which are physically stimulated (e.g., by centrifuging) to cause secretion of a fluid which is then centrifuged and filtered. Preferably the gastropoda are fasted prior to the physical stimulation. The therapeutic or cosmetic compositions contain about 0.1-30 % of the active ingredient which is a mixture of amino acids and atoxic substances, an effective amount of an excipient preferred for use with biologically active ingredients, and other conventional ingredients provided they do not affect the stability and/or the activity. The therapeutic composition, in the form of a topical cream, can be used to treat various types of burns, ...
---------- ----------------------------------------------------------------------

COMPOSITION FOR USE IN TRANSDERMAL ADMINISTRATION

(WO1992014442) 03.09.1992 A61K 9/10 COMMONWEALTH SCIENTIFIC AND INDUSTRIAL RESEARCH ORGANISATION
The invention provides a composition for transdermal administration of a biologically active agent comprising said biologically active agent and a pharmaceutically acceptable carrier wherein said biologically active agent is present at a concentration above its solubility limit in said carrier at ambient conditions and wherein there are sufficient fine solid particles of said agent dispersed through said carrier to substantially facilitate the transdermal transfer of said composition. The invention also provides a method of preparation of such compositions.
---------------------------------------------------------- ----------------------

PRESSURE-SENSITIVE ADHESIVE COMPOSITIONS SUITABLE FOR MEDICAL USES

(WO1992013906) 20.08.1992 A61L 15/58 BIOINTERFACE TECHNOLOGIES, INC.
A dermatologically-acceptable, moisture vapor-permeable, pressure-sensitive adhesive composition that is a single-phase solid at ambient temperature and resists dissolution when exposed to water, comprises a polymer adhesive which is the product of a process cmprising the steps of chain extending a water-soluble derivatized capped prepolymer which comprises a first terminal group and a low-temperature curable group, until the resultant polymer attains a determined level of tackiness, and then subjecting the polymer to low-temperature curing. The adhesive is used to advantage in medical products like adhesive bandages, plasters, dressings and surgical drapes, and can dissolve water-soluble bio-active additives.
-------------------------------------------------- ------------------------------

METHOD AND SYSTEMS FOR ADMINISTERING DRUGS TRANSDERMALLY USING SORBITAN ESTERS AS SKIN PERMEATION ENHANCERS

(WO1992010154) 25.06.1992 A61K 9/70 THERATECH, INC.
Skin permeation enhancer compositions are provided which increase the permeability of skin to transdermally administered pharmacologically active agents. The compositions contain a sorbitan ester in addition to the selected pharmacologically active agent and may also contain C¿1?-C¿4? aliphatic alcohol. Methods and drug delivery systems are provided which systems have a laminated matrix or a drug reservoir. In the drug reservoir type of Figure 1, designated (10) there is provided a backing layer (12), a drug reservoir (14) and a two piece release liner (16a) and (16b). In the laminated type, designated (18) in Figure 2, there is provided a backing film (20), a reservoir (22), a ring shaped layer (24) of an adhesive, a membrane layer (26) ...
------------------------------------------ --------------------------------------

A GEL-FORMING LIQUID CARRIER COMPOSITION

(WO1992009307) 11.06.1992 A61K 8/73 KABI PHARMACIA AB CARLSSON, Anders BOGENTOFT, Conny
A carrier composition which is a liquid at or below room temperature and forms a high viscosity layer or gel at body temperature, which comprises a water-soluble, nonionic cellulose ether having a cloud point not higher than 40 °C, preferably 35 °C, a charged surfactant and optional additives in water. Said carrier composition can be used for oral or local administration of a pharmacologically active substance to the skin, mucous membrane, the eye or a body cavity.
------------------------------------------------------------------ --------------

THE DELAY, PREVENTION AND/OR REVERSAL OF CELL SENESCENCE

(WO1992009298) 11.06.1992 A61K 38/04 PEPTIDE TECHNOLOGY LTD.
The present invention provides a method for the delay, prevention and/or reversal of cell senescence. The method of the present invention comprises administering to the cells a composition including a compound having chemical properties similar to carnosine, the active compound being present in a concentration of greater than 10mM. In preferred forms of the invention the compound is carnosine or homocarnosine and the cells are preferably human fibroblast cells. The invention also provides an improved cell culture medium which includes carnosine or a carnosine like compound.
-------------------------------------------------- ------------------------------

METHODS AND COMPOSITIONS FOR AMELIORATION OF SKIN WRINKLES

(WO1992007587) 14.05.1992 A61K 8/65 NARHEX LIMITED
There are disclosed compositions for the amelioration of wrinkles of the skin, an methods for their use. The compositions comprise, as active substance, elastin, at least some of which has a molecular weight of less than 10,000. The compositions may further comprise an agent for reducing corneocyte cohesion of the lower levels of the hyperkeratotic stratum of the skin, such agent being typically an alpha- hydroxy acid. The methods of use of the compositions of the invention may comprise topical application or subcutaneous injection.
-------------------------- ------------------------------------------------------

COMPOSITION FOR THE TOPICAL TREATMENT OF PSORIASIS

(WO1992003142) 05.03.1992 A61K 31/20 BIOGAL GYOGYSZERGYAR RT. KÉRI, Tibor JANCSO, Sßndor KRISTOF, Ilona PAL, Veronika SZABO, Erzsébet BECKER, LÝvia
The invention relates to a pharmaceutical composition suitable for the topical treatment of psoriasis comprising an aqueous and/or pharmaceutically acceptable organic solvent, preferably ethanolic extract of young corn-crops and/or corn-beard and/or nodulous corn-stalk and/or corn-cob and gamma-linolic acid as active ingredient admixed with one or more solid and/or liquid carriers and/or other additives.
---------- ----------------------------------------------------------------------

CONTROLLED RELEASE FORMULATIONS AND METHOD

(WO1992003124) 05.03.1992 A61K 8/73 ORAMED, INC.
A polymeric complex composition comprising a reaction complex formed by the interaction of a polycarbophil component with alginic acid or a salt thereof, said interaction being performed in the presence of a divalent cation and in the presence of an active agent selected from the group consisting of medicinal agents and cosmetic agents. Also disclosed is a polymeric delivery system which is formed by a polycarbophil type composition with an active agent, optionally in the presence of water and/or other cosolvent. There is also described a method of controlled release treatment comprising the steps of providing such a polymeric complex and an effective amount of an active agent selected from the group consisting of medicinal agents and cosme...
---------- ----------------------------------------------------------------------

IMPROVED IONTOPHORETIC ADMINISTRATION OF DRUGS

(WO1991016103) 31.10.1991 A61K 9/00 GENSIA PHARMACEUTICALS, INC.
Methods, formulations, and a system for improved iontophoretic administration of a drug, by, preferably, topical administration of a formulation containing an active vasodilator, rubefacient, or counterirritant agent such as capsaicin on the skin at the electrode site, or, iontophoretic administration of a vasodilator formulation or alpha blocker prior to iontophoretic administration of the drug.
---------------------------------- ----------------------------------------------

COMPOSITION AND TREATMENT WITH BIOLOGICALLY ACTIVE PEPTIDES AND TOXIC CATIONS

(WO1991016066) 31.10.1991 A61K 38/00 MAGAININ SCIENCES INC. BERKOWITZ, Barry JACOB, Leonard
A composition comprising a biologically active amphiphilic ion channel-forming peptide or ion channel forming protein and a toxic cation, such as a silver cation. Such compositions may be employed as pharmaceuticals, particularly for the treatment and prevention of eye infections.
---------------------------------- ----------------------------------------------

CATIONIC LIPIDS FOR INTRACELLULAR DELIVERY OF BIOLOGICALLY ACTIVE MOLECULES

(WO1991016024) 31.10.1991 A61K 9/127 VICAL, INC.
Disclosed are cationic lipids capable of facilitating transport of biologically active agents into cells, including the transfection of cells by therapeutic polynucleotides, the delivery of antiviral drugs, and the introduction of immunogenic peptides. The cationic lipids, comprising an ammonium group, have general structure (I). Also disclosed are adducts of these compounds comprising additional cationic sites that enhance the transfective or transport activity. Structure-activity correlations provide for the selection of preferred compounds to be synthesized for this purpose. Compositions disclosed for use of these cationic lipids include formulations for in vitro transfection and pharmaceutical formulations for parenteral and topical adm...
--------------------------------------------------------------------------------

FILM-FORMING PROTEINACEOUS EMULSION

(WO1991015117) 17.10.1991 A01N 25/04 BASIC BIO SYSTEMS, INC.
A proteinaceous emulsion and method for making a proteinaceous emulsion comprising a lipophilic phase, an aqueous phase and a protein emulsifier; which is capable of forming a thin film and has the capability of carrying active ingredients contained in either or both the aqueous phase and the lipophilic phase of the emulsion.
-------------------------- ------------------------------------------------------

PROCESS AND COMPOSITION FOR THE TREATING OF INJURIES CAUSED BY THE RADIATION OF HEAT AND LIGHT

(WO1991012798) 05.09.1991 A61K 31/195 CHINOIN GYOGYSZER- ÉS VEGYÉSZETI TERMÉKEK GYARA RT. SZO"CSIK, Katalin SZÜTS, Tamßs VIRAG, Sßndor Z.SZABO, Anna BENDEFFY, Erzsébet O"RI, Jßnos SEBESTYÉN, Gyula GERGELY, Vera KOVACS, Mßria HIDASI, György JUHASZ, Istvßn DOBOZY, Attila
The invention relates to a process for the preparation of medicines, medical cosmetics or cosmetical products containing as active ingredient gamma-L-glutamyl taurine of formula (I) which comprises admixing a compound of formula (I) with pharmaceutically and/or cosmetically acceptable inert, non-toxic carriers and/or additives, and preparing a composition suitable for the prevention and/or treating of skin injuries and/or autoimmune diseases caused by the radiation of heat and light.
---------- ----------------------------------------------------------------------

AN ANTIVIRAL AGENT DERIVED FROM THE HULL OF THE KUKUI NUT

(WO1991012012) 22.08.1991 A61P 31/12 MANIKAS, John
The use of the active ingredient present in the juice obtained from the green hull of the kukui nut for use as an antiviral pharmaceutical agent. This active ingredient is particularly useful in the topical treatment of viral infections, such as herpes simplex, genital herpes, genital warts, herpes zoster and chickenpox. The raw liquid juice, or the juice formulated in a pharmaceutically acceptable carrier, is topically administered to the surface lesion caused by the virus. Some components present of the active ingredient in the kukui nut hull juice include methyl esters of long chain fatty acids and their isomers.
------------------------------------------------------------------ --------------

NON-AQUEOUS EMULSION OF SILICONE OIL AND STEARINE

(WO1991010771) 25.07.1991 D06M 13/02 STULTS, Jerry, F. GREENE, George, H. PHILLIPS, James, C.
A non-aqueous emulsion comprises a stearine, a silicone, and, optionally, a diluent such as a glyceride, and a silicone emulsifier. The stearine is present in an amount sufficient to provide a non-aqueous emulsion when the components are melted together and mixed until the emulsion is set. The silicone oil is preferably a dimethyl silicone which can be optionally endblocked while the preferred stearine comprises hydrogenated rapeseed stearine or hydrogenated castor stearine. The non-aqueous emulsion can be employed as a lubricant for natural or synthetic fibers. In addition, the non-aqueous emulsion can be employed within a cream or ointment composition with at least one active ingredient.
------------------------------------------------------------------ --------------

METHODS OF ENHANCING WOUND HEALING AND TISSUE REPAIR

(WO1991010437) 25.07.1991 A61K 9/70 NEW YORK SOCIETY FOR THE RELIEF OF THE RUPTURED AND CRIPPLED, MAINTAINING THE HOSPITAL FOR SPECIAL SURGERY BOCKMAN, Richard GUIDON, Peter
Skin, connective and support tissue repair is enhanced and augmented by administering pharmaceutically acceptable gallium- containing compounds in amounts sufficient to provide therapeutic levels of elemental gallium. Gallium-containing compounds mimic the effects of endogenous growth factors to induce cells within these tissues to produce new matrix by increasing the formation of critical structural matrix proteins responsible for skin, support and connective tissue repair, maintenance and augmentation. Gallium- containing coumpounds are suitable for a variety of applications in wound healing, including dermatologic and cosmetic skin repair, bone fracture repair and successful bonding of implanted tissue grafts and connective and support tis...
--------------------------------------------------------------------------------

USE OF CAFFEINE IN THE TREATMENT OF HERPES SIMPLEX VIRUS INFECTIONS

(WO1991007969) 13.06.1991 A61K 31/52 SURTECH INTERNATIONAL LTD. POTTS, Michael
Pharmaceutical compositions are provided for topical application having anti-viral effect against herpes simplex virus (HSV). The pharmaceutical compositions according to the invention comprise caffeine at active concentrations with suitable excipients to form e.g. gels, lip-salves and lip-sticks.
-- ------------------------------------------------------------------------------

DRUG DELIVERY SYSTEMS AND MATRIX THEREFOR

(WO1991005529) 02.05.1991 A61F 13/00 WATSON LABORATORIES, INC.
A drug delivery system that contains an active ingredient-containing adhesive matrix coextensive with a backing layer is described. The adhesive matrix contains an anhydrous, hydratable pressure -sensitive adhesive, a non-aromatic terpene alcohol or an ester thereof, an absorption promoter and a drug, such as a steroid, capable of transdermal or transcutaneous administration. The non-aromatic terpen alcohol preferably is alpha -terpineol. A dosage form such as a transdermal patch is disclosed, as well as a method for long-term administration of a drug to a mammal.
------------------ --------------------------------------------------------------

SURFACES HAVING DESIRABLE CELL ADHESIVE EFFECTS

(WO1991005036) 18.04.1991 A61L 17/14 BOARD OF REGENTS, THE UNIVERSITY OF TEXAS SYSTEM
An absorbed protein-independent cell-adhesive surface is disclosed. The treated surface comprises a chemically derivatized material to which small peptides, having less than 12 amino acid residues and including YIGSR, RGD or REDV amino acid sequence are covalently linked to. The peptides of the present invention include a terminal glycine amino acid. Tresyl chloride activation of surface hydroxyl moieties provides the active surface sites by which a terminal glycine arm of a selected peptide attaches to form covalent bonds between the substrate and peptide. By way of example, surfaces which may be used in conjunction with the present invention include polymer, metal, and ceramic surfaces. The present methods also include a pretreatment meth...
-------------------------------------------------- ------------------------------

TOPICAL ANTIINFLAMMATORY COMPOSITIONS WITH MINIMAL SYSTEMIC ABSORPTION

(WO1991003227) 21.03.1991 A61K 47/10 E.I. DU PONT DE NEMOURS AND COMPANY
Topical polyethylene glycol based formulations for the delivery of 2-substituted-1-naphthols and indoles and particularly, 2-phenylmethyl-1-naphthol are provided. Said topical formulations exert excellent localized antiinflammatory activity while demonstrating low levels of skin penetration in vitro and in vivo thereby reducing unwanted side effects and reducing systemic toxicity associated with the active drug compounds.
-- ------------------------------------------------------------------------------

TOPICAL COMPOSITIONS CONTAINING LYCD AND OTHER TOPICALLY ACTIVE MEDICINAL INGREDIENTS

(WO1991002533) 07.03.1991 A61K 8/49 LEVIN, Robert, H.
A topical composition comprising LYCD together with known topically active useful medicinal agents such as anti-wrinkling, antibiotic, anticancer, antifungal, antiinflammatory such as anti-acne, antiviral, wound healing, and hair-growing agents. The LYCD works together with the other active agents to achieve a synergistic result more effective than can be obtained from the topical agents individually, and more effective than could be predicted from the mere addition of the known efficacies of the individual ingredients.
-------------------------------------------------- ------------------------------

VASODILATORY AND IMMUNE SUPPRESSANT PEPTIDES

(WO1991000293) 10.01.1991 A61K 38/00 THE PRESIDENT AND FELLOWS OF HARVARD COLLEGE LERNER, Ethan, A. REMOLD, Heinz, G. RIBEIRO, Jose, M., C. TITUS, Richard, G.
Disclosed are proteins derived from the sand fly Lutzomyia longipalpis capable of inducing vasodilation in mammals, and data characterizing the proteins and nucleic acid encoding the proteins. Also disclosed is a method for temporarily inactivating the immune system in a mammal comprising administering to the mammal the Lutzomyia protein, CGRP, calcitonin, or active immune suppressing analogs thereof.
------------------------------------------------------------------ --------------

INSECTICIDAL AND REPELLENT COMPOSITION

(WO1990015533) 27.12.1990 A01N 43/26 HERMAN, Stephen
Insecticidal and repellent compositions comprising ozonides of hydrocarbons are disclosed. Hydrocarbons which are believed to be active when prepared in accordance with the present invention include terpenes and unsaturated fatty acids derived from plant and animal sources. Other examples of suitable unsaturated hydrocarbons include natural and synthetic steroids, alkenes and their substituted derivatives, and other naturally or synthetically unsaturated hydrocarbons derived primarily from petroleum. Methods of use for the compositions are also disclosed.
-------------------------- ------------------------------------------------------

SLOW RELEASE VEHICLES FOR MINIMIZING SKIN IRRITANCY OF TOPICAL COMPOSITIONS

(WO1990014833) 13.12.1990 A61K 8/67 BAZZANO, Gail, S.
Stable, aqueous gel vehicles are provided for the topical application to the skin of irritating active ingredients such as retinoids, particularly tretinoin, with slow release of the active ingredient and minimal irritancy to the skin. The vehicles include a gelling agent effective to form a gel and hold the active ingredient in the aqueous medium for slow release on the skin, and an effective amount of an antioxidant to retard decomposition of the active ingredient. The vehicles and formulations are preferably aqueous emulsions which contain a solubilizing agent for the generally non-water soluble active ingredients, as well as usually an emulsifying agent and/or surfactant. Chelating agents, emollients, preservatives and other adjuvants a...
------------------------------------------------------------------ --------------

WATER-SOLUBLE VITAMIN A PREPARATIONS FOR APPLICATION TO THE SKIN

(WO1990014093) 29.11.1990 A61K 8/67 IOWA STATE UNIVERSITY RESEARCH FOUNDATION, INC.
A non-irritating topical medicament is provided which contains retinoic acid glucuronide as the active ingredient. The medicament may be applied to the skin for treatement of acne or skin aging.
---------- ----------------------------------------------------------------------

AQUEOUS BASED PERSONAL WASHING CLEANSER

(WO1990013283) 15.11.1990 C11D 1/12 UNILEVER PLC
An aqueous based personal washing product is disclosed which when used has good cleaning ability and is particularly mild to the skin. The free flowing liquid product is particularly adapted for facial washing and contains acyl ester of isethionic acid salt, long fatty acids and moisturizer component, and preferably a co-active surfactant.
-------------------------- ------------------------------------------------------

ACYL ISETHIONATE SKIN CLEANSING COMPOSITIONS

(WO1990012860) 01.11.1990 C11D 1/10 UNILEVER PLC UNILEVER NV
A skin cleansing composition is provided that includes a combination of C16-C18 acyl isethionate ester salts having no more than 25 % C14 or lower acyl groups with at least one co-active surfactant. The weight ratio of acyl isethionate to co-active will range from about 20:1 to about 1:1. Soap is present in an amount no higher than 10 % by weight of the composition. The compositions are mild and in bar form can have improved lather and mush properties.
------------------------------------------------------------------ --------------

DEVICE FOR ADMINISTERING AN ACTIVE AGENT TO THE SKIN OR MUCOSA

(WO1990011065) 04.10.1990 A61K 9/70 THERATECH, INC.
A transdermal drug delivery device (11) comprising a drug formulation-containing reservoir (13) defined by a backing layer (12) and a drug-permeable membrane layer (16), a peelable inner liner (20) that underlies the reservoir and a portion of the backing/membrane outwardly of the reservoir periphery, an adhesive layer (15) that underlies the inner liner and outwardly extending portions of the membrane/backing layers, and a peelable release liner layer (17) that underlies the adhesive layer with a first permanent heat seal (18) between the backing and the membrane about the perimeter of the reservoir and another peelable (impermanent) heat seal (19) between the membrane and the inner liner underlying the first permanent heat seal, the heat ...
---------------------------------------------------------- ----------------------

SKIN PERMEATION ENHANCER COMPOSITIONS

(WO1990011064) 04.10.1990 A61K 9/70 CYGNUS RESEARCH CORPORATION
Skin permeation enhancer compositions are provided which increase the permeability of skin to transdermally administered pharmacologically active agents. The composition contains diethylene glycol monoethyl or monomethyl ether in addition to an ester component such as propylene glycol monolaurate, methyl laurate or the like. The compositions are particularly useful in conjunction with the transdermal administration of steroid drugs such as progestogens and estrogens. Methods and drug delivery systems for using the enhancer compositions are provided as well.
------------------ --------------------------------------------------------------

DIAGNOSIS AND TREATMENT OF INSULIN DEPENDENT DIABETES MELLITUS

(WO1990010449) 20.09.1990 A61K 35/14 COHEN, Irun, R.
A 65 KD heat shock protein, proteins cross-reactive therewith, antibodies thereto or T cells specific thereto can be used for detecting in humans the existence of, a tendency to develop, or the initiation of a process leading to insulin dependent diabetes mellitus. Antibodies to hsp65 can be used to detect the hsp65 molecule in blood or urine. The hsp65 molecule of any species, or any other substance immunologically cross-reactive therewith, when administered with a tolerogenic carrier, can be used for the prevention or treatment of IDDM prior to development of clinical symptoms thereof. T cells, active fragments thereof or the receptor peptide thereof can also be used for prevention or treatment of IDDM.
---------------------------------------------------------- ----------------------

COMPOSITION FOR REPARATION AND PREVENTION OF FIBROTIC LESIONS

(WO1990009176) 23.08.1990 A61K 31/44 MARGOLIN, Solomon, B.
In a preferred embodiment, drugs having heretofore unknown pharmacological properties which are useful in the medicinal therapy of fibrotic disease for the reparation and prevention of fibrotic lesional tissues, such drugs including as the active ingredient 5-methyl-1-phenyl-2-(1H)-pyridone. The composition of this invention is novel as an antifibrotic drug, namely, as an agent for treating fibrosis. Any existing compounds have not been shown to be effective for the reparation and prevention of fibrotic lesions.
------------------------------------------ --------------------------------------

STABILIZED MICROPOROUS MATERIALS AND HYDROGEL MATERIALS

(WO1990007545) 12.07.1990 A61F 2/14 ANDERSON, David, M.
A stabilized, highly regular, biocompatible microporous material having a highly regular pore system, arising from the polymerisation of an equilibrium cubic phase and incorporating a plurality of biologically active agents in the pore system. Alternatively, a stabilized hydrogel material comprising a microporous hydrogel matrix containing a fixed, highly connected network of macropores, a process for preparing such hydrogel and its application in contact lenses, catheters, prostheses, plastic surgery, etc.
-------------------------- ------------------------------------------------------

POLYPEPTIDE-POLYMER CONJUGATES ACTIVE IN WOUND HEALING

(WO1990006767) 28.06.1990 A61K 38/00 LA JOLLA CANCER RESEARCH FOUNDATION
A conjugate of a synthetic polypeptide containing RGD or (dR)GD and a biodegradable polymer, such as hyaluronic acid or chondroitin sulfate is disclosed. Methods of making the conjugate and using it to aid wound healing by providing a temporary matrix is disclosed.
------------------------------------------------------------------ --------------

THREE-DIMENSIONAL CELL AND TISSUE CULTURE SYSTEM

(WO1990002796) 22.03.1990 A61K 35/12 MARROW-TECH INCORPORATED
The present invention relates to a three-dimensional cell culture system which can be used to culture a variety of different cells and tissues in vitro for prolonged periods of time. In accordance with the invention, cells derived from a desired tissue are inoculated and grown on a pre-established stromal support matrix. The stromal support matrix comprises stromal cells, such as fibroblasts actively growing on a three-dimensional matrix. Stromal cells may also include other cells found in loose connective tissue such as endothelial cells, macrophages/monocytes, adipocytes, pericytes, reticular cells found in bone marrow stroma, etc. The stromal matrix provides the support, growth factors, and regulatory factors necessary to sustain long-te...
------------------------------------------ --------------------------------------

INSECT REPELLANT

(WO1990000859) 08.02.1990 C11D 3/48 NELSON &ROBERTSON PTY. LTD.
Insect repellant active ingredients can be formulated with ordinary soap when particular fillers are incorporated in the composition. The invention provides an insect repellant soap composition comprising (a) from 60 % to 75 % by weight of toilet soap base; (b) from 10 % to 15 % by weight of a filler capable of absorbing moisture; (c) from 18 % to 20 % by weight of an insect repellant; (d) 0 % to 0.3 % by weight of terpinol; (e) 0.2 % to 0.3 % by weight of a binding agent; (f) 0.25 % to 2 % by weight of an insecticide; and (g) when the filler is full cream milk powder or skim milk powder, 0.05 % to 0.3 % by weight of a preservative. All percentages by weight being based on the total weight of the composition.
World  Patents Published  in 2007
   
...or use our Search Engine
to search for patent
documents by number.
Search for anything.
Simply type the words in
the box..
Clck to enlarge and view details
WORLD PATENTS IN ACTIVES FOR SKIN CARE GRANTED FROM 1990 TO 2006
This list includes patent documents published by the World Intellectual Property Organization (WIPO). The list was retrieved by searching the claims section of all patent applications
published. Salient search terms include skin care active ingredients having properties such as anti-ageing, anti-wrinkle, antioxidant, acne control benefits, skin whitening or lightening,
blemish removal, etc. This category includes technology related to the synthesis and delivery of actives such as peptides, exfoliants, α-hydroxy acids, herbals, free radical scavenger, "green"
derived molecules, etc.